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Abstract 
Background 
Kidney function reduces with age, increasing the risk of harm and hospital admission 
from medicines. This project aimed to investigate the extent to which 
recommendations for prescribing drugs are applied for older people with reduced 
kidney function in primary care, and what needs to change to improve patient safety.   
Research design and methods 
A pragmatic sequential mixed methods design was used: 
1. Cross-sectional case-note review.  
2. Scoping literature review. 
3. Primary Care Trust (PCT) wide cross-sectional survey of prescribing data.  
4. GP interview study using the Theoretical Domains Framework. 
5. Expert and stakeholder consensus group study. 
Results 
For 8 study drugs across a large PCT, a kidney function too low for recommended use 
was found for 3.5-39.6% in ≥65 year olds, and 24.2-79.5% in ≥85 years. The Cockcroft 
Gault equation provides a more accurate estimate of kidney function when prescribing 
for older people; 68.9-95.3% of patient drug events where kidney function was too low 
would have been missed if an estimated glomerular filtration rate had been used. 
GPs expressed a lack of awareness and knowledge about prescribing when kidney 
function is reduced. Although they monitored kidney function, it was not thought of 
when prescribing. Not having warnings and prompts at medication review was a 
particular barrier identified by GPs, and that the British National Formulary information 
on prescribing in renal impairment information needs to be clarified. 
The priorities for intervention and research agreed were to increase awareness of the 
need to assess kidney function in the prescribing process for older people, and to 
provide patient and drug specific warnings and prompts at medication review as well 
as initiation. 
Conclusion 
Many older people were taking medication that needed altering, or stopping, because 
of their reduced kidney function. This research has mapped the prevalence of 
inappropriate prescribing, and explored the behaviour determinants of GP prescribing, 
in reduced kidney function in primary care, identified what needs to change in practice, 
policy, and further research required, to improve patient safety. 
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MRSA  methicillin-resistant staphylococcus aureus 
NHS  National Health Service (UK) 
NICE  National Institute for Health and Clinical Excellence 
NOAC  new/ novel oral anticoagulant 
NPSA  National Patient Safety Agency 
NSAID  non-steroidal anti-inflammatory drug 
NSF  National Service Framework 
OCEBM Oxford Centre for Evidence-Based Medicine 
OR  odds ratios 
PCT  Primary Care Trust 
RCCT  randomised cluster controlled trial 
RCP  Royal College of Physicians 
RCT  randomised controlled trial  
RKF  reduced kidney function 
SIGN  Scottish Intercollegiate Guidelines Network 
SPC  summary of product characteristics (drug licence data sheet) 
SrCr  serum creatinine 
TDF  Theoretical Domains Framework 
TPB  Theory of Planned Behaviour 
U&Es  urea and electrolytes 
UK  United Kingdom 
UKMRC United Kingdom Medical Research Council 
USA  United States of America 
UTI  urinary tract infection 
WHO  World Health Organisation 
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Kidney function estimation terms and abbreviations 
A table of the kidney function estimation abbreviations used throughout the thesis are 
presented in Table 1. A full explanation of the terms is given in Chapter 1 (1.2.3), but a 
brief explanation is included in the table below to provide a simple reminder that is 
easily accessible.  
 
Table 1: Summary table of kidney function terms and their abbreviations. 
  
Kidney function estimation terms and abbreviations 
Creatinine clearance (CrCl) – historically used for drug and dosing prescribing 
decisions, and used for the dosing studies of most available drugs. 
 CG - Cockcroft Gault equation 
 CrCl-CG - creatinine clearance calculated using the CG equation. 
CrCl-CG AW - creatinine clearance calculated using the CG equation  
and actual body weight in the equation. 
CrCl-CG IBW - creatinine clearance calculated using the CG equation 
and ideal body weight (or actual if lower) in the equation. 
 
Estimated glomerular filtration rate (eGFR), reported by pathology 
laboratories across the UK with kidney function blood test results, and used to 
stage kidney disease, but not designed for prescribing decisions. 
 MDRD - eGFR calculated using the Modification of Diet in Renal  
Disease equation (used by pathology laboratories at the time of 
this research).  
CKD-EPI - eGFR calculated using the Chronic Kidney Disease 
Epidemiology Collaboration Equation (a revised version of the 
MDRD equation and begun to be introduced into primary care in 
2016).          
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“The pen is mightier than the scalpel in terms of the damage that you can do to a 
patient by writing the wrong drug and the wrong dose” 
Participant C1, renal physician with a national role (2015) 
 
1 Chapter 1: Background 
 
1.1 Introduction 
Reducing the risk of medication for older people has been a focus for most of my 
career as a pharmacist. On the Elderly Care wards at Leeds General Infirmary, I 
worked on ensuring parameters such as kidney function were assessed in relation to 
prescribing, as there are changes with aging, and many clinicians did not seem to be 
aware that doses might need reducing or alternative drugs used. For the last fifteen 
years I have worked in Bradford primary care. In that time there has been an 
increased awareness of kidney disease with the introduction of the National Institute 
for Health and Care Excellence (NICE) guidelines for chronic kidney disease (NICE 
CG73, 2008; CG182, 2014) and acute kidney injury (NICE CG169, 2013), and a 
National Service Framework (NSF) for Renal Services (NSF, 2005). However, my 
professional experience working in GP practices led me to believe that kidney function 
was still not routinely assessed in relation to prescribing. 
Another concern was that the NICE guidelines introduced a different kidney function 
estimation equation to assess risk to the kidney, presented as the ‘estimation of 
glomerular filtration rate (eGFR)’. This new equation was giving very different results to 
the Cockcroft Gault equation (Cockcroft and Gault, 1976) I had always used for 
decisions on drug use and dosing, when used for assessing the kidney function in 
older people.  
When raising the issue with clinicians they would ask whether it was really a problem. 
An Elderly Care consultant and researcher, unconvinced that there was an issue, 
suggested that I should do a study in my workplace that could provide the basis for 
research if required. So, as a pilot study to prove the concept before applying to do a 
PhD, I undertook a case-note review at the GP practices where I am a practice 
pharmacist in Bradford. The results of this study are presented in this chapter as it 
formed the background for the future research, and supported my application to read 
for a PhD. The case-note review also started me thinking about prescribing behaviour, 
and how that might be changed to get prescribing recommendations in reduced kidney 
function (RKF) applied in practice. 
24 
 
1.2 Context 
 Risk of harm from drugs 
Paracelcus (1493-1541) is credited as first recognising that ‘no thing is without poison; 
the dosage makes it either a poison or a remedy.’ The toxic potency of a chemical is 
ultimately defined by the dose (the amount) that will produce an adverse reaction in a 
biological system (Hodgson, 2010). 
Minimising risk, to ensure medicines use is as safe as possible, is a key aim of 
prescribing (Barber, 1995), and one of the four guiding principles of medicines 
optimisation (Royal Pharmaceutical Society, 2013). However, ‘An Organisation with a 
Memory’ (Department of Health, 2000) reported that every year thousands of people 
are reported to have experienced serious adverse events related to medicines. The 
Audit Commission report ‘A Spoonful of Sugar’ (2001) suggested that medication 
errors account for about one-fifth of deaths due to all types of adverse events in 
hospital and are an increasingly common stimulus to litigation.  
Over half a million medication incidents were reported to the National Patient Safety 
Agency (NPSA) between 2005 and 2010, with 16% involving actual patient harm 
(Cousins et al, 2012). There are reports of potential harm for all healthcare sectors: 
Hospital inpatients: the General Medical Council’s EQUIP study has demonstrated a 
prescribing error rate of almost 9% (Dornan et al, 2009).  
Hospital admissions: adverse drug reactions (ADRs) have been found to account for 
6.5% of all hospital admissions (Pirmohamed et al, 2004), with over half judged to be 
preventable (Howard et al, 2007). 
Primary care: an estimated 1.7 million serious prescribing errors occurred in 2010 
(Avery et al, 2012).Two recent studies found 13.9% of vulnerable patients were 
prescribed one or more high risk drugs (Guthrie et al, 2011), and Stocks et al (2015) 
found the prevalence, of different types of potentially hazardous prescribing, varied 
between practices from almost zero to 10.2%.  
Care homes: over two thirds of residents were exposed to one or more medication 
errors (Barber et al, 2009). 
Adverse drug reactions result in high costs for the healthcare systems, as well as for 
patients. A systematic review (Wiffen et al, 2002) estimated the overall ADR impact on 
England to be 4 out of 100 hospital bed-days at a cost of about £380 million a year to 
the NHS in England. Factors associated with increased incidence of ADR were 
increasing age, especially over 70 years, increasing number of medicines, and 
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particular classes of medicine. Non-steroidal anti-inflammatories (NSAIDs) were found 
to be responsible for between 60% and 70% of all ADRs leading to hospital admission, 
or causing ADRs within a hospital episode. A recent report commissioned by the 
Department of Health, ‘Exploring the costs of unsafe care in the NHS’, showed that 
hospital admissions for ADRs, and harm related to medicine given during inpatient 
stays, cost £770 million in 2007, and that £5m was spent on litigation for drug-related 
medical errors between 1995 and 2007 (Frontier Economics, 2014). 
Elimination of drugs via the kidney is a process where there is the potential for patient 
harm if the kidneys are not functioning normally. Hydrophilic drugs and metabolites are 
removed from the body more slowly when kidney function is reduced and blood levels 
rise, increasing the risk of harm (Ashley, 2008). The importance of following 
recommendations for medicines use in RKF is illustrated by the ‘new oral anti-
coagulant’ (NOAC), dabigatran, where the documented lower dose schedule in renal 
impairment was not followed leading to a number of cases of serious and fatal 
haemorrhage reported in elderly patients in Japan (MHRA, 2011). 
 
 Drug elimination and reduced kidney function 
Elimination from the body of hydrophilic drugs and metabolites via the kidney is by 
glomerular filtration, renal tubular secretion, and resorption (Matzke and Frye, 1997). 
Where kidney function is impaired, reduced glomerular filtration and tubular secretion 
results in higher plasma levels of the drug, and the reduction in resorption causes a 
higher concentration of drug in the urine. The extent to which drugs are affected 
depends on the percentage of active drug and/or metabolites that would normally be 
excreted by the kidney (Ashley and Morlidge, 2008). The Renal Drug Handbook 3rd 
Edition (Ashley and Currie (Eds), 2009) states that the use of drugs in patients with 
RKF can give rise to other problems for several reasons: 
 Altered pharmacokinetics of some drugs that are variable and complex. 
 For many drugs, some or all altered pharmacokinetic parameters are not 
known. 
 Sensitivity to some drugs is increased. 
 Many side-effects are particularly poorly tolerated by renally impaired patients. 
 Some drugs are ineffective when kidney function is reduced. 
 Kidney function generally declines with age. 
There are recommendations for use of drugs in RKF in the ‘Summaries of Product 
Characteristics’ (SPCs), the Medicines and Healthcare products Regulatory Agency 
(MHRA) approved and regulated prescribing information for licensed medicines. The 
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SPC also has a ‘pharmacokinetics’ section which may give more detail on the 
elimination of the drug. An example of the effect of kidney function on blood levels is 
shown in the pharmacokinetic section of the SPC for enalapril which states that “at a 
creatinine clearance of <30ml/min the ‘AUC’ [area under the plasma concentration-
time curve] is 8 times that at normal kidney function”. AUC is an indicator of the 
amount of drug that reaches the body over time. Giving a dose of 5mg daily to a 
person with a kidney function <30ml/min would be giving the equivalent of 8 times the 
dose i.e. 40mg/day. 
The reduction in kidney function affects the pharmacological effects of many drugs, 
including those of toxic or active metabolites that are excreted by the kidney. 
 
 Assessment of kidney function 
Kidney function needs to be assessed to inform prescribing decisions, as well as to 
give a marker of kidney disease and an indication of risk to the kidney. Assessment 
involves a measurement of glomerular filtration rate which is estimated from the 
clearance of a solute present in a stable concentration in the plasma and freely filtered 
by the kidney. A naturally occurring solute used is creatinine, a product of muscle 
breakdown, which is currently the one used in practice (Ashley and Morlidge, 2008). 
Twenty-four hour urine collection gives a direct measurement of the clearance of 
creatinine, but is not usually practical. Kidney function is normally estimated using the 
serum creatinine level and a calculation using a standard equation, which introduces 
limitations; for example the terms for age, sex, and race only capture some of the 
determinants of creatinine concentration in blood plasma, and the coefficients 
represent average effects observed in the population used to develop the equations. 
The kidney function estimation equations, and their limitations, are discussed in more 
detail in the following sections (1.2.3.1, 1.2.3.2). Table 2 provides a summary of the 
equations with the abbreviations used throughout the thesis. This table is reproduced 
at the end of the abbreviations list (Page 22, Table 1) to provide an easily accessible 
reference. 
Up until the first CKD UK guidelines were introduced in 2005 (Joint Specialty 
Committee for Renal disease of the Royal College of Physicians of London and the 
Renal Association, 2005), the most widely used equation to estimate kidney function 
was the Cockcroft Gault equation (Cockcroft and Gault, 1976). However, the new 
guidelines introduced the use of ‘estimated glomerular filtration rate’ (eGFR) calculated 
using the Modification of Diet in Renal Disease (MDRD) equation (Levey et al, 1999), 
and in the recently updated NICE guidelines (NICE CG182, 2014) the ‘Chronic Kidney 
27 
 
Disease Epidemiology Collaboration’ (CKD-EPI) equation has been introduced to 
estimate glomerular filtration rate of creatinine.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Summary table of kidney function terms and their abbreviations 
(reproduced on Page 22 with the abbreviations table). 
 
Recent publications on use of the ‘new oral anticoagulants’ (NOACs) have illustrated 
the difficulty of applying the recommendations for use in RKF because of the different 
equations used for estimating kidney function, concluding that CrCl calculated using 
Cockcroft Gault should be used to reduce the risk of overdose and bleeding, and not 
eGFR (Heidbuchel et al, 2013; Wood et al, 2013).  
The complexity and limitations with using the kidney function estimation equations is 
initially explored in the following sections. The uncertainty in using each equation this 
engenders suggested the need for a scoping review of the available evidence for 
Kidney function estimation terms and abbreviations 
Creatinine clearance (CrCl) – historically used for drug and dosing prescribing 
decisions, and used for the dosing studies of most available drugs. 
 CG - Cockcroft Gault equation 
 CrCl-CG - creatinine clearance calculated using the CG equation. 
CrCl-CG AW - creatinine clearance calculated using the CG equation  
and actual body weight in the equation. 
CrCl-CG IBW - creatinine clearance calculated using the CG equation 
and ideal body weight (or actual if lower) in the equation. 
 
Estimated glomerular filtration rate (eGFR), reported by pathology 
laboratories across the UK with kidney function blood test results, and used to 
stage kidney disease, but not designed for prescribing decisions. 
 MDRD - eGFR calculated using the Modification of Diet in Renal  
Disease equation (used by pathology laboratories at the time of 
this research).  
CKD-EPI - eGFR calculated using the Chronic Kidney Disease 
Epidemiology Collaboration Equation (a revised version of the 
MDRD equation and begun to be introduced into primary care in 
2016).          
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assessing kidney function when prescribing for older people, and is explored in more 
depth in the literature review (Chapter 2, 2.6). 
1.2.3.1 Creatinine clearance (CrCl) 
CrCl calculated using the Cockcroft Gault equation 
Creatinine clearance is the originally used estimate of kidney function, calculated by 
the Cockcroft Gault equation (Cockcroft and Gault, 1976). It has been used historically 
in drug company dosing studies and the SPCs quote recommendations for dosing in 
renal impairment as CrCl. The BNF states that ‘published information on the effects of 
renal impairment on drug elimination is usually stated in terms of creatinine clearance’. 
Some SPCs emphasise the need to use the Cockcroft Gault equation by writing it out 
in full, for example for gabapentin, pregabalin and edoxaban. The Cockcroft Gault 
equation is shown in Figure 1. Where creatinine clearance has been estimated using 
the Cockcroft Gault equation, rather than, for example, directly measured, the 
abbreviation ‘CrCl-CG’ has been used throughout the thesis. 
 
Figure 1: The Cockcroft Gault equation for kidney function estimation. 
 
Limitations 
The Cockcroft Gault equation has been criticised as it was developed using only a 
small sample of Caucasian men (Cockcroft and Gault, 1976) and so would have 
limitations in being generalised to other populations such as women, older people, and 
different ethnic groups. Helou (2010) comments that the success of the Cockcroft 
Gault equation is not due to the original study, but to its validation in several later 
studies for different populations, including for older people, compared to both 
measured CrCl values and reference glomerular filtration rate measurement methods,. 
The Cockcroft Gault equation includes a weight factor. Creatinine is formed from 
muscle turnover and so the weight element needs to give an indication of muscle 
mass, and not excess body fat; for this reason, ideal body weight (IBW) is 
The Cockcroft Gault equation (Cockcroft and Gault, 1976) 
Creatinine clearance (CrCl-CG) ml/min = F x (140 – age) x IBW (kg) 
                                Serum creatinine (micromol/l) 
Where  F = 1.23 for males or 1.04 for females 
IBW = ideal body weight (or actual body weight if lower)). 
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recommended in the British National Formulary (BNF70, 2015). The need for a weight 
to calculate CrCl-CG was suggested to reduce the feasibility of reporting in primary 
care. Patients may not have a weight on the record, and pathology laboratories would 
not have access to a patient’s weight to be able to report CrCl-CG with kidney function 
monitoring results. 
Primary care patient record systems do not all have a calculator to help prescribers 
calculate CrCl-CG. Even where there is a calculator, such as on the ‘SystmOne’ ‘renal 
calculator’, the prescriber would need to know where to find it and when to use it as 
there are no prompts or sign-posts to its use.  
Hellou’s review (2010) found that, although there were major limitations in the original 
Cockcroft Gault equation development study, later studies have validated its use, 
including for older people. Hudson & Nyman (2011) state that, as dosing regimens for 
most currently available drugs are based on pharmacokinetic studies that have used 
CrCl-CG as the measure of kidney function, it is the most appropriate estimate to use 
when making prescribing decisions. 
1.2.3.2 Estimated glomerular filtration rate (eGFR) 
a) eGFR calculated using the MDRD  
In 2008 the NICE guidelines for chronic kidney disease (CKD) (NICE CG73, 2008) 
established the term ‘estimated glomerular filtration rate’ (eGFR) calculated using the 
4 variable MDRD equation (Figure 2). The guidelines recommend use of MDRD as 
this equation does not require a value for patient weight and can therefore be easily 
calculated using clinical laboratory instrument software. The eGFR is now reported by 
pathology laboratories across the UK with kidney function blood test results, and is 
used to stage kidney disease. 
 Figure 2: The MDRD equation for kidney function estimation. 
 
 
 
The Modification of Diet in Renal Disease equation (Levey et al, 1999) 
eGFR ml/min/1.73m2 = 175 x [serum creatinine (micromol/l)]-1.154 x age (years)-0.203 
                                                                   88.4 
x 0.742 if female 
x 1.21 if African American or African Caribbean 
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Limitations 
The MDRD equation was not designed to give a kidney function estimation for drug 
dosing decisions. It was developed to give an indication of risk to the kidney and allow 
staging of kidney function to guide monitoring and treatment of CKD. For drug 
prescribing it is not important whether the reduced kidney function is a factor of 
senescence, kidney disease or acute kidney injury. Section 1.2.4 discusses further the 
effect of old age on kidney function and that a reduced kidney function is not 
necessarily as a result of disease. Even for assessment of kidney disease, the 
validation studies for eGFR did not include people aged over 65 years (Spruill, 2008).  
Across the UK eGFR is now reported from pathology laboratories with all kidney 
function blood tests (urea and electrolytes (U&Es) including serum creatinine) making 
it readily available on the patient record to give an indication of kidney function level. 
One problem with its use highlighted by the ‘Kidney Disease: Improving Global 
Outcomes Foundation’ (KDIGO) is that the eGFR is reported per body surface area 
(BSA) of 1.73m2 but the figure is never adjusted in practice for individuals where BSA 
is different, which could lead to error. For example, a male patient with a BSA of 
2.28m2 has a larger body surface area and so should have the eGFR adjusted: a 
reported eGFR of 70 ml/min/1.73m2 should be adjusted for the BSA to 53.1 ml/min. A 
threshold for CKD is 60 ml/min and whether the BSA had been accounted for or not 
would alter the assessed stage of kidney disease for this patient, and the consequent 
management. 
Since 2010, the British National Formulary (from BNF59, 2010) has quoted renal 
impairment recommendations as ‘eGFR’ but the figures are taken from the drug SPCs, 
where exactly the same figures are CrCl-CG. The BNF states that, although CrCl and 
eGFR are not interchangeable, for most patients the eGFR is an adequate 
approximation of CrCl, but that calculation with the Cockcroft Gault equation should be 
used for ‘potentially toxic drugs with a small safety margin’, and the Cockcroft Gault 
equation is provided in the ‘Prescribing in Renal Impairment’ section.  
As the abbreviation ‘eGFR’ is used widely where the calculation has been with the 
MDRD equation, eGFR will be used in the rest of this thesis to mean estimated 
glomerular filtration rate calculated using the MDRD equation (see Summary  
Table 1 and 2). 
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b) eGFR calculated using the Chronic Kidney Disease Epidemiology 
Collaboration equation (CKD-EPI) 
The most recent NICE guidance for chronic kidney disease (NICE CG182, 2014) has 
introduced the change that clinical laboratories should use the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) equation to estimate the glomerular filtration 
rate of creatinine (Figure 3).  
CKD-EPI is based on the same four variables as the MDRD Study equation, but uses 
a different model for the relationship between estimated glomerular filtration rate and 
serum creatinine, and an altered relationship for age, sex and race. It has been 
reported to ‘perform better’, and with less bias, than the MDRD Study equation, 
especially in patients with higher glomerular filtration rate, which results in reduced 
misclassification of CKD (Levey et al, 2009).  
 
Figure 3: The CKD-EPI equation for kidney function estimation 
 
Limitations 
CKD-EPI has similar limitations to MDRD in relation to use for drug prescribing 
decisions. It has been developed, and declared to ‘perform better’, for classification of 
kidney disease and assessment of risk to the kidney, not for prescribing decisions. It 
does not have a weight element to the equation, and is also reported as ml/min/1.73m2 
so it is also unlikely to be adjusted to body surface area. Like MDRD, the validation 
studies did not assess performance for older people.  
Since the recent change in NICE recommendation (NICE CG182, 2014), reporting of 
eGFR using CKD-EPI is not yet widespread in routine use. For the duration of this 
research MDRD was the equation used by pathology laboratories, and in this thesis 
The Chronic Kidney Disease Epidemiology Collaboration equation (Levey et 
al, 2009) 
eGFR ml/min/1.73m2 = 141 × min (Scr /κ, 1)α × max(Scr /κ, 1)-1.209 × 0.993Age × 
1.018 [if female] × 1.159 [if black] 
where:Scr is serum creatinine in mg/dL, 
κ is 0.7 for females and 0.9 for males, 
α is -0.329 for females and -0.411 for males, 
min indicates the minimum of Scr /κ or 1, and 
max indicates the maximum of Scr /κ or 1. 
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the abbreviation ‘eGFR’ will mean that the MDRD equation has been used (see 
Summary Table 1 and 2). 
 
 Kidney function and prescribing for older people 
1.2.4.1 Kidney function reduces with age 
Glomerular filtration rate slowly decreases with aging as a normal biological 
phenomenon linked to cellular and organ senescence (Beers and Berkaw, 2000; 
Grimley-Evans et al, 2000; Glassock and Winearis, 2009). On average the decline has 
been found to be approximately 0.9-1ml/min annually after the age of 30 years, and 
decreases more rapidly after 65 years (Lindeman et al, 1985). Confounding factors 
such as hypertension, coronary heart disease, congestive heart failure, the use of 
nephrotoxic drugs, and super-imposed kidney disease contribute to the rate and 
magnitude of the kidney function decline (Ponticelli et al, 2015). The Renal Drug 
Handbook states that many older people have a glomerular filtration rate of <50ml/min 
which because of reduced muscle mass, may not be reflected by an elevated 
creatinine. Both muscle mass and creatinine turnover reduce at a similar rate with 
increasing age leading to serum creatinine levels tending to remain normal and not 
reflecting a decline in kidney function for older people (Ashley and Currie, 2014). 
Although they state that ‘mild renal impairment can be assumed for the elderly’, the 
complexity of natural decline, and the effects of disease and drugs, means that an 
assessment of kidney function needs to be made in order to make decisions on doses 
of drugs excreted by the kidney (Ashley and Morlidge, 2008). 
Glassock and Winearis (2009) argue that the ‘new paradigm’ introduced in the last 15 
years of ‘eGFR’ calculated using the MDRD equation is unadjusted for the effects of 
age. The combination of eGFR and the introduction of the new classification for 
diagnosis and staging of CKD used in the NICE guideline (National Kidney 
Foundation, 2002) has led to the unintended consequence of misclassification of many 
older people, often females, as having CKD when they are within a normal range for 
their age. The fact that the MDRD equation is unadjusted for the effects of age would 
also affect assessment of the level of kidney function for drug prescribing decisions, 
irrespective of whether it is a factor of senescence or disease. 
1.2.4.2 Risk of harm for older people 
Older people are therefore more at risk from drugs that are affected by renal 
impairment because of a naturally reduced kidney function as age increases. The 
effects of chronic conditions can have an added effect. Older people are more likely to 
be taking regular medications, with around 75% of those aged 60 years and older, and 
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over 90% in the over 70s taking at least one prescribed medicine (Petty et al, 2014). 
The mean number of medicines per patient on repeat prescriptions is over 5 for the 
60-69 year olds, and up to 7.1 for the over 80s (Petty et al, 2014). The Health and 
Social Care Information Centre (2014) reported that about 600 million (60 per cent) of 
the one billion drug items dispensed in the community in 2013 were for people aged 
65 years or over. As discussed in section 1.2.1., factors associated with increased 
incidence of adverse drug reactions were increasing age, especially over 70 years, 
and increasing number of medicines (Wiffen et al, 2002). Helldén et al (2009) found 
that 14% of hospital admissions of elderly patients in Sweden were primarily caused 
by ADRs and one-third were related to impaired kidney function.  
1.2.4.3 Kidney function within the context of other age-related functional 
decline 
With ageing, there is a progressive loss of the functional capabilities of most body 
organs, changes in responses to receptor stimulation and a decrease in homeostatic 
mechanisms, which have implications for drug handling. Of these changes, excretion 
is the most significant and important age-related pharmacokinetic change and is both 
predictable and measurable. Two-thirds of people aged 70-80 years having 
approximately half the kidney function of a young adult (Beers and Berkow, 2000; 
Grimley-Evans et al, 2000). 
Other pharmacokinetic changes also impact on the body’s handling of drugs. The liver 
reduces in size and blood flow declines, but overall metabolism of drugs tend to be 
only slightly impaired in the absence of liver disease. Drugs with a high first pass 
metabolism, such as morphine, will have higher blood levels where blood flow to the 
liver is reduced. However, liver function is not easily measurable; liver function tests 
indicate liver damage, but not metabolic effectiveness. Also, the clinical significance 
varies widely between individuals. Abnormal liver function tests can indicate the need 
for caution when prescribing drugs that are metabolised, but not specific levels that 
determine effect (Beers and Berkow, 2000; Grimley-Evans et al, 2000). 
Absorption of drugs is largely unchanged with ageing, but changes in body 
composition can mean water soluble drugs such as digoxin have a reduced volume of 
distribution and so higher blood levels needing reduced initial doses. Lipid-soluble 
drugs such as diazepam are concentrated in the larger volume of body fat and the 
half-life increases. There may be significant reductions in serum proteins in extreme 
old age, and in disease, that may affect highly protein bound drugs such as phenytoin. 
These effects are not easily measurable, and so the recommendations are for caution 
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and reduced dosing for older people (Beers and Berkow, 2000; Grimley-Evans et al, 
2000). 
Individuals vary widely as to whether, and to what extent, changes in receptor effect 
(pharmacodynamics) and homeostatic changes, would affect prescribing. For example 
cardiovascular changes such as a reduced orthostatic circulatory response leading to 
postural or orthostatic hypotension and falls. Drugs can add to this effect and 
exacerbate increased blood levels, for example where kidney function is reduced 
(Beers and Berkow, 2000; Grimley-Evans et al, 2000). 
The endocrine system and particular endocrine organs, including the thyroid, undergo 
functional changes during aging (Gesing et al, 2012). The prevalence of thyroid 
disorders increases with age but symptoms are more subtle and are often attributed to 
normal aging. As changes occur with increasing age, the need for regular monitoring is 
important to reduce the risk of harm from drugs. 
1.2.4.4 Increasing population of older people 
The impact for older patients, and the NHS, will be more significant in the future with 
changing population demographics. There will be 5½ million more people aged ≥65 
years by 2030 in the UK, and 19 million by 2050. People ≥80 years will almost double 
by 2030 reaching 8 million by 2050 (Cracknell, 2010). 
1.2.4.5 Research and older people 
Avorn (2010) highlights the problem that patients older than 65 years (and especially 
over 80 years) remain under-represented in clinical trials despite benefitting at least as 
much, and that costs of illnesses prevented or caused by pharmacotherapy are far 
greater than drug costs alone. 
As discussed in 1.2.3, the MDRD and CKD-EPI kidney function estimation equations 
were not designed for drug dosing decisions and the development studies did not 
evaluate performance for older people. However, eGFR is the estimate reported by 
pathology laboratories. People aged 65 years and older took 60% of all dispensed 
medications in England & Wales in 2013 (Health and Social Care Information Centre, 
2014) emphasising the importance of including older people in the development and 
assessment of these equations, and for research focussed on this age group. 
The widespread use of medications by older people, the increased risk because of a 
reduced kidney function, and the complexity and confusion arising from the 
introduction of eGFR, suggested that a pilot study should be conducted to assess 
whether research was required. 
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1.3 Are recommendations for prescribing in reduced kidney 
function applied in GP practice? 
Kidney function reduces with age which affects many drugs, but experience as a 
pharmacist in primary care suggested that this was not accounted for when prescribing 
for older people. Slower elimination of drugs could mean increased blood levels and 
risk of harm. As there had been some scepticism about whether this was really the 
case in primary care, it was suggested that a pilot study was undertaken as a proof of 
concept before applying to study for a PhD. A cross-sectional GP practice based case-
note review was therefore undertaken which aimed to investigate whether 
recommendations for prescribing in RKF were being applied (Wood et al, 2011). 
 
 Objectives 
The objectives were to assess: 
 The prevalence of patients aged 65 years and older with a documented 
eGFR<60ml/min/1.73m2 (NICE CG73, 2008) on drugs not recommended to be 
prescribed, or which need an altered dose, using the Cockcroft Gault equation 
to calculate creatinine clearance (CrCl-CG). 
 Which drugs were prescribed outside the recommended use in this population. 
 Whether using eGFR or CrCl-CG kidney function estimates would alter dosing 
decisions. 
 Whether there was any record of harm caused by use of drugs outside the 
recommendations in RKF. 
 
 Study design 
1.3.2.1 Setting 
The study was run in 5 GP practices in North Bradford. Each practice had a team of 
GPs and had list sizes ranging from 4,993 to 11,926 in the same urban area of 
Bradford. Practices A and B were my main places of work and I had done audits and 
run workshops on use of drugs in RKF. Practices C, D and E also had practice 
pharmacist input and some audit work including checking kidney function for use of 
drugs. 
1.3.2.2 Participants 
The study reviewed the clinical record of people registered at the 5 GP practices aged 
65 years or older whose latest kidney function test result recorded was reduced 
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(eGFR<60ml/min/1.73m2), as defined by the NICE chronic kidney disease guideline 
(NICE CG73, 2008). 
1.3.2.3 Sample 
All patient records at Practice A aged 65 years and over with the most recent 
documented eGFR <60ml/min/1.73m2 were reviewed. At practices B, C, D and E, a 
10% random sample of all patients aged 65 years and over with an eGFR <60 
ml/min/1.73m2 were reviewed, using a random number generator (Stattrek, 2010). 
1.3.2.4 Method 
Case-note reviews were performed between March and June 2010. For each review: 
 The eGFR was recorded from the patient record and CrCl-CG calculated. 
 All drugs on the repeat medication list were reviewed for appropriateness of 
drug use and dosing, assessed against recommendations given in the British 
National Formulary (BNF, 2010) and the Summary of Product Characteristics 
(SPC).  
 Although the study was not set up to systematically assess rates of adverse 
drug reactions (ADRs), if any were found relating to the use of medications in 
RKF, they were noted. 
 Action required was followed up with the prescriber. 
1.3.2.5 Data collection 
A data collection form was developed and completed for each review done, to 
systematically capture the required data (Appendix 1, 8).  
1.3.2.6 Analysis  
A quantitative descriptive analysis was performed. 
1.3.2.7 Governance approval 
Approval was given as a service evaluation by the Primary Care Trust (PCT) 
governance lead, and participating practices, as part of the existing prescribing 
support service. NHS ethical approval was not required as it was an in-house service 
evaluation. Patient identifiable data was kept at the practice at all times, results were 
fed back to practices, and high risk cases followed up. 
 
  
n % n % n % n % n % n % n %
A 8,993 1,285 14.3 406 4.5 406 100 29 7.1 118 29.0 88 21.7 96 23.6 123 189
B 11,926 2,019 16.9 706 5.9 71 10 5 7.0 19 26.8 13 18.3 17 23.9 21 29
C 11,446 2,164 18.9 510 4.5 51 10 3 5.9 15 29.4 14 27.5 16 31.4 24 35
D 10,883 1,673 15.4 411 3.8 41 10 2 4.8 14 34.1 14 34.1 14 34.1 22 37
E 4,993 803 16.1 246 4.9 25 10 2 8.0 7 28.0 6 24.0 8 32.0 11 18
Total 48,241 7,944 16.5 2,279 4.7 594 26 41 6.9 173 29.1 135 22.7 151 25.4 201 308
practice
total practice 
poulation
records reviewed  of 
patients aged 
≥65yrs and 
eGFR<60
people aged ≥65yrs and eGFR<60 reviewed
number aged ≥65yrs 
and eGFR<60
number aged 65yrs 
or older
number of drug 
items needing 
stopping or dose 
reducing
number of drug 
items needing 
stopping, dose 
reducing or 
review
number with 
eGFR<30
number with 
CrCl<30
number on a drug 
needing to be 
stopped or dose 
reduced
number on a drug 
needing to be 
stopped, dose 
reduced or review
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: eGFR: estimated glomerular filtration rate; CrCl: creatinine clearance  
Table 3: Summary of the case-note review results from 5 GP practice 
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 Results 
  Highlighted figures in the tables are those mentioned in the text, 
results or discussion. 
 
1.3.3.1 Prevalence of inappropriate drug use for older people with RKF 
Drugs needed to be stopped, or the dose reduced, for 22.7% (n=135) of the 594 
patients reviewed aged 65 years or older with an eGFR<60ml/min/1.73m2 (practice 
range 18.3%-34.1%), using CrCl-CG to determine the suitability of drug and dose. The 
results obtained from the five practices are summarised in Table 3. If drugs needed 
review because of a low kidney function are included then the prevalence was 25.4% 
(n=151) (range: 23.6%-34.1%). 
In practices A and B the proportion of people on drugs that needed stopping, dose 
reducing or review were 23.6% and 23.9% respectively (Table 3). For practices C, D, 
and E it was 31.4%, 34.1%, and 32.0% respectively. 
A total of 201 drugs listed as repeat medication on the 594 patient records reviewed 
needed stopping or the dose reducing, and a further 107 drugs needed review (total = 
308). 
1.3.3.2 Drugs implicated 
Seventy different types of drug were found to be used sub-optimally in this group of 
patients, listed in Table 4, and in more detail in Appendix 2 (8.2). 
The groups of drugs most frequently encountered in the audit are illustrated in Figure 4 
with lipid-lowering drugs the highest (30%), followed by angiotensin converting 
enzyme inhibitors (ACEIs) and angiotensin-II receptor blockers (ARBs) (26%), 
thiazides (17%), and osteoporosis drugs (14%). 
1.3.3.3 Categories of inappropriate drug use in RKF 
Four categories of inappropriate drug use were identified from this case-note review 
(Table 4): 
Avoid: 23% were drugs that are recommended to be avoided at levels of kidney 
function below a specified level, including alendronic acid, rosuvastatin and metformin. 
Reduce dose: 28% were drugs that are recommended to have the dose reduced at 
levels of kidney function below a specified level, including simvastatin, allopurinol and 
gabapentin. 
Ineffective: 16% were drugs that are ineffective at levels of kidney function below a 
specified level, including thiazides and nitrofurantoin. 
70,900
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Caution: 33% were drugs where the guidance is unspecific caution but are known to 
cause ADRs in RKF, including NSAIDs, ACEIs and ARBs. 
 
 
Table 4: The 70 different types of drugs judged to be used inappropriately in 
RKF with n = number found to need altering or review in 594 record reviews 
(from Appendix 2). 
 
1.3.3.4 Kidney function estimation equations 
Figure 5 shows that 29.1% of patients aged ≥65 years with a documented eGFR 
<60ml/min/1.73m2 were calculated to have a CrCl-CG of <30ml/min whilst 6.9% had 
an eGFR <30ml/min/1.73m2.  
For 22.2% (n=132) the equation used would result in a different decision being made 
about whether a drug could be safely used or whether a dose needed altering. 
drug n drug n drug n drug n
alendronic acid 24 simvastatin 52 bendroflumethiazide 24 ramipril 18
metformin 13 allopurinol 300mg 8 indapamide 5 frusemide 13
Calcichew D3 forte 10 atenolol 100mg 7 chlortalidone 5 candesartan 10
rosuvastatin 8 ranitidine 5 hydrochlorthiazide 1 valsartan 10
lercanidipine 5 digoxin 3 nitrofurantoin 1 lisinopril 9
moxonidine 2 baclofen 2 Zestoretic 1 codeine 30mg 5
strontium 2 atenolol 50mg 1 ibuprofen gel 4
anastrazole 1 bezafibrate 1 calcium no vit D 3
eplenerone 1 ciprofibrate 1 irbesartan 3
ibandronic acid 1 colchicine 1 spironolactone 3
risedronate 1 domperidone 1 lamotrogine 3
sitagliptin 1 fenofibrate 1 losartan 3
sulfasalazine 1 gabapentin 1 escitalopram 2
metoclopramide 1 hydroxyzine 1 ibuprofen 2
minocycline 1 venlafaxine 1 diclofenac gel 2
amylobarbital 1 diclofenac 2
mirtazapine 1 perindopril 2
pantoprazole 1 prochlorperazine 2
tramadol 1 telmisartan 2
bumetanide 1
buprenorphine patch 1
citalopram 1
enalapril 1
felbinac gel 1
fosinopril 1
olmesartan 1
primidone 1
propranolol 1
quinapril 1
sertraline 1
to be avoided in low 
kidney function
dose to be reduced in 
low kidney function
ineffective in low 
kidney function
use with caution in low 
kidney function
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Abbreviations: ACE: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; NSAID; non-steroidal 
anti-inflammatory. 
Figure 4: The most frequently encountered drug classes not used as 
recommended in RKF in the case-note review. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: eGFR: estimated glomerular filtration rate; CrCl-CG: creatinine clearance Cockcroft Gault 
Figure 5: The number of patients with an eGFR < 30ml/min/1.7m2 and CrCl-CG 
<30ml/min. 
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1.3.3.5 Record of harm caused 
The study was not set up to systematically assess rates of ADRs so overall rates of 
harm were not possible to asess. However, whilst reviewing the case notes, four 
examples of ADRs were recognised to be caused by drugs used in RKF and are 
described: 
Anaemia on sulfasalazine  
 A 78 year old lady had an eGFR recorded as 25 ml/min/1.73m2 six months 
previously and was taking sulfasalazine 2.5g/day. The lady had been 
investigated for anaemia and had blood transfusions but was still on the high 
dose of sulfasalazine. The CrC-CGl was calculated as 16ml/min. The SPC 
states that levels of sulfasalazine over 50mcg/ml are associated with a 
substantial risk of ADRs. The renal clearance constant is 125 ml/min 
corresponding to the glomerular filtration rate so, if the filtration rate is reduced 
to 16ml/min then the elimination of sulfasalazine would be reduced by 
approximately eight times and the plasma levels would be much higher making 
ADRs such as anaemia more likely. 
Digoxin toxicity causes hospitalisation  
 An 81 year old gentleman had been admitted to hospital in January 2010 with 
digoxin toxicity after a bout of diarrhoea. His weight was 39kg and CrCl-CG 
calculated as 23ml/min meaning a low renal reserve. 
Acute kidney injury on an angiotensin converting enzyme inhibitor (ACEI) and a 
diuretic 
 An 81 year old lady on ramipril 10mg (maximum recommended dose if 
CrCl<50ml/min is 5mg) and furosemide 20mg. The serum creatinine had been 
rising and a ‘U&Es’ kidney function check had shown an eGFR of 13 
ml/min/1.73m2 and a CrCl-CG of 11ml/min with a much increased potassium 
level, showing acute kidney injury.  
 A 76 year old man with chronic kidney disease, and CrCl-CG calculated as 
21ml/min, on lisinopril 20mg, furosemide 80mg and spironolactone 50mg was 
admitted to hospital with acute kidney injury shown by a very increased serum 
creatinine and raised potassium level. He was admitted to the renal unit and 
the ACEI and spironolactone were stopped. 
Any high risk cases found that needed action, follow-up or review were highlighted to 
the relevant prescriber. 
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 Discussion 
1.3.4.1 Principal findings 
Prevalence of inappropriate drug use in RKF 
A quarter of all people reviewed aged 65 years and older with a documented reduced 
kidney function estimate on their record were found to be taking a drug that should be 
stopped or the dose reduced. As drug levels are likely to be higher when kidney 
function is reduced there is an increased risk of harm for these patients. 
Practice A and B are both practices that I have worked with for a number of years  
where I have done audits that have included checking kidney function, for example 
statin and bisphosphonate switches. I have also run workshops at both practices on 
prescribing in RKF and use of the readily available resources. At both practices, 24% 
of patients with a documented RKF were on drugs that needed stopping, dose 
reducing or review. However, the results from the other three practices showed even 
higher proportions (31%, 34%, and 32%). My intervention at practices A and B of 
education, audit and feedback may have had an effect on prescribing in RKF, but 
there were still a quarter of people reviewed with a documented reduced eGFR who 
were on drugs or doses that were not within the recommendations.  
Drugs found to be used inappropriately in RKF 
Seventy different types of drug were used outside recommendations in RKF with 308 
instances found for the 594 people reviewed. 
Simvastatin was the drug most found to be used inappropriately (52 patients). It has 
an alternative that can be used at low kidney function (atorvastatin), so it can be 
avoided and reduce the risks of high plasma levels such as rhabdomyolysis (SPC).  
Out of 61 ACEI or ARB prescriptions identified, 8 were inappropriate and the rest were 
high dose that needed review. As they are partly or mainly excreted by the kidney, 
reduced levels of kidney function can increase blood levels and, as they can also be 
nephrotoxic, kidney function can drop further leading to acute kidney injury. 
Thiazides were the next most implicated drugs – bendroflumethiazide, chlorthalidone, 
hydrochlorthiazide and indapamide in 35 patients. Thiazides are ineffective at CrCl 
<30ml/min (BNF, 2010) and so they will not be having the desired effect for these 
patients but may be putting the patient at higher risk of side effects such as electrolyte 
disturbance. 
Twenty eight patients were on drugs for osteoporosis that were not as recommended: 
alendronic acid (24), strontium (2), ibandronic acid (1) and risedronate (1). All have 
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recommendations to be avoided at specified levels of kidney function. The 
bisphosphonates are deposited in bone and have a terminal half-life of over 10 years 
(SPC). 
Non-steroidal anti-inflammatories (NSAIDs) can affect all stages of kidney function and 
are frequently implicated in making kidney function worse (Ashley & Morlidge, 2008). 
They are highlighted in both the NICE and SIGN guidelines (NICE CG73, 2008; SIGN 
guideline 103, 2008) as being a risk factor for impairment of kidney function. In the 
case-note review 10 patients were found with NSAIDs on their repeat medication list, 
with 6 of these being as a topical formulation (systemic levels will be significantly lower 
than for oral formulations but the NSAID gels have been implicated in adverse drug 
reactions). Although the numbers found were low, there is a high risk of ADR and 
hospital admission. Also, many NSAIDs are prescribed acutely or are bought by 
patients themselves; these would not have been found in the case-note review, but 
could be significant if they have a low level of kidney function. 
This case-note review has highlighted four categories of inappropriate use in RKF:  
 Drugs that are recommended to be avoided at levels of kidney function 
below a specified level (23%). In RKF the drug will be too slowly excreted by 
the kidney, blood levels of the drug will be raised and the risk of harm 
increased. An example is alendronic acid which should be avoided at CrCl less 
than 35ml/min (SPC). 
 Drugs that are recommended to have the dose reduced at levels of kidney 
function below a specified level (28%). The dose should be reduced in RKF 
or blood levels are likely to be increased with a risk of side effects. Simvastatin 
has a recommendation to not use doses above 10mg if the CrCl is <30ml/min 
(SPC).  
 Drugs that are ineffective at levels of kidney function below a specified 
level (16%). Not only could harm be caused from ineffective treatment, but 
side effects are more likely. Nitrofurantoin is not likely to work at CrCl lower 
than 45ml/min (MHRA, 2014) but there is a significant association between 
RKF (<50 ml/min/1.73 m²) and pulmonary adverse events leading to 
hospitalisation (Geerts, 2013).  
 Drugs where the guidance is unspecific caution but are known to cause 
ADRs in reduced kidney function.  For example ACEIs or ARBs are used for 
patients with reduced kidney function but they need regular review and 
assessment of use and dose as they can be nephrotoxic.  
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Kidney function estimation 
A substantial difference was found between estimating kidney function using eGFR 
(calculated using the MDRD equation, 6.9%) and CrCl (calculated using the Cockcroft 
Gault equation, 29.1%) for the people reviewed. For 22.2% of the 65 year olds and 
over, the equation used would result in a different decision being made about whether 
a drug could be safely used or whether a dose needed altering.  
Harm caused 
Examples of harm were found from drugs when kidney function was reduced. Of the 4 
examples, 3 had resulted in admission to hospital. As this study did not systematically 
search for ADRs, the rate of harm could have been higher. Applying the 
recommendations readily available in the BNF and SPCs might have reduced the risk 
of harm. 
1.3.4.2 Strengths and limitations 
Consistent use of a standard method was used to review the use of medicines for 594 
older people with RKF, compared with BNF and SPC recommendations. There are a 
number of ways that this case-note review may have not included all relevant patients 
and drugs.  Only repeat medications were reviewed so drugs prescribed acutely such 
as NSAIDs and antibiotics would have been missed, and non-prescription medicine 
use was not assessed. Patients with a documented eGFR on their record were 
reviewed, but not those who have never had serum creatinine checked. The last 
recorded serum creatinine was used, but if it had not been checked recently, the result 
may not have still been relevant.  
The cross-sectional assessment of the current repeat medication list did not allow for 
inclusion of patients who have tried medications in the past but had to stop them 
because of ADRs. This could be important in identifying drugs particularly causing 
ADRs in the reduced kidney function of the older person. 
The GP practices included were in one small urban area of Bradford and so the results 
may not be valid in a wider population. 
1.3.4.3 What this study adds to the literature 
The findings of this study have been presented as a poster at the Royal 
Pharmaceutical Society conference 2011 and the Renal Association conference 2012, 
with an abstract publication from the former (Wood et al, 2011). Areas that need to be 
studied further include: 
 What is the evidence base for prescribing for older people with RKF, including 
which equation should be used for drug use and dosing decisions? 
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 Are the case-note review findings generalisable for a wider population? 
1.3.4.4 What this study adds to practice and policy 
This study has highlighted that practice needs to be improved when prescribing for 
older people with RKF in primary care and the findings will inform further research. A 
quarter of older people with RKF were at risk from their medications, many drugs were 
implicated, and evidence of harm found. A change in practice and policy would need to 
be comprehensive and be able to encompass the four different categories of 
inappropriate use identified in this study i.e. drugs: 
 To avoid. 
 To reduce the dose. 
 That are ineffective. 
 Where caution is needed from a high risk of ADRs.  
Local practice has been improved in the practice pharmacy team with kidney function 
assessment being added to audits for older people and greater awareness of the 
issues. However, it needs to be investigated in a wider population before assessing 
the need for a change in national policy. 
 
 Conclusion from the case-note review 
Evidence of harm, and increased risk of harm, for older patients on drugs excreted by 
the kidney has been highlighted in this case-note review. A quarter of older people 
were prescribed at least one medication that needed altering because of their kidney 
function, indicating that the BNF prescribing recommendations are not followed by 
prescribers in primary care.  
 
1.4 Prescribing behaviour and behaviour change 
The case-note review findings led to further questions on: 
 Why are recommendations for prescribing in RKF frequently not applied in 
primary care?  
 Would an analysis of the prescribing behaviour illuminate the determinants? 
 How might that behaviour be changed to reduce the risk of harm for patients? 
 
 Prescribing behaviour 
Aronson (2006), editor of ‘Meyler’s Side Effects of Drugs’ and chairman of the editorial 
board of the British Journal of Clinical Pharmacology, states that “Prescribing is 
difficult. It requires a thorough knowledge and understanding of the pathophysiology of 
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disease, the pharmacological properties of the relevant drugs, and the ways in which 
the two dovetail.” Prescribing comes towards the end of a clinical decision-making 
process of assessment and diagnosis, where it is concluded and agreed that an 
intervention of a drug prescription is required, rather than ‘wait and see’, ‘obtain more 
information’, or an alternative intervention (Hunink et al, 2001). The World Health 
Organisation (WHO) (de Vries et al, 1994) recommends a systematic stepped 
approach to prescribing: 
1. Define the patient’s problem. 
2. Specify the therapeutic objective. 
3. Verify the suitability of the drug, the most effective, safe, suitable and cheap 
option. 
4. Write a prescription. 
5. Give information, instructions, and warnings. 
6. Monitor (and stop?) the treatment. 
A reduced kidney function would need to be part of the prescribing decision process at 
Step 3 as to whether there are any recommendations for prescribing in RKF that would 
mean a drug is ‘unsuitable’, and whether it would be ‘unsafe’ unless a reduced dose, 
or alternative were used. It would also impact on Step 6 as kidney function can 
change, and so it would need monitoring to ensure the drugs and dose is still suitable. 
The level of kidney function would need to be considered at both initiation of a drug, 
and at medication review. 
 
 Behaviour change  
Behaviour change is key to improving health care and changing behaviour is more 
effective if interventions are developed on evidence-based principles of behaviour 
change (Cane et al, 2012). Designing interventions based on intuition rather than 
theory precludes the possibility of understanding the processes that underlie effective 
interventions, and of applying this knowledge to inform the design of future 
interventions (Abraham et al, 2009). Influencing behaviour change needs an in depth 
investigation of all the determinants to fully understand and explore that behaviour. 
Using a theoretical approach allows identification of factors and strategies that are 
more likely to be successful in influencing behaviour change (Nilsen, 2015). Two main 
issues have been identified as reducing the likelihood of success of implementation 
strategies (Dyson et al, 2011); 
 A failure to identify barriers and enablers to implementation of evidence based 
practice (Grimshaw et al, 2004; NICE, 2007). 
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 A lack of theoretical basis for the interventions used to support the 
implementation of evidence into practice (Grimshaw et al, 2004; Michie et al, 
2005). 
Foy et al (2011) found that theories provide a way of understanding and predicting the 
effects of interventions intended to prevent or mitigate harm caused by healthcare, or 
risks of such harm. Also, theory-driven evaluations would help generalise findings to 
other contexts and build a cumulative understanding of the nature of change. Use of 
theory may explain why some implementation strategies are more effective than 
others (Eccles et al, 2005) 
There are many theoretical models to explain behaviour change with multiple 
contending theories. An example is the Theory of Planned Behaviour (TPB) based on 
intentions and motivations (Ajzen, 1991). However, the TPB does not explore habit, 
emotion or working environment, for example, which may be important in prescribing. 
Michie et al (2005) have highlighted that such a large number of theories and 
theoretical constructs cannot be fully applied, critical theories might be missed, and 
there was a need for a method to select among them. The ’Theoretical Domains 
Framework’ (TDF) has addressed the need for an overarching determinant framework 
and was developed to identify individual factors known to influence the gap between 
evidence based practice and the routine delivery of health care. It was constructed on 
the basis of a synthesis of 128 constructs related to behaviour change found in 33 
behaviour change theories, including many social cognitive theories (Cane et al, 
2012). The constructs are sorted into 14 theoretical domains such as knowledge, 
skills, goals, and beliefs about capabilities. There were originally 12 domains (Michie 
et al, 2005) and they were validated and restructured to 14 in 2012. (Cane et al, 2012; 
Michie et al, 2014). The TDF domains have been categorised to what influences 
capability, opportunity or motivation for the behaviour, the ‘COM-B model’, shown in 
Table 5 (Michie et al, 2011, 2014). 
For any behaviour to occur there needs to be: 
 Capability - knowing what to do and how to do it. 
 Opportunity - the environment is conducive, both physically and socially. 
 Motivation - both reflective (conscious goals and intentions) and automatic 
(impulses and habits).  
Understanding the behaviour in context will highlight what needs to change. 
Interventions need to change behaviour(s) in one or more of ‘capability/ opportunity/ 
motivation’ in such a way as to put the system into a new configuration and minimise 
the risk of it reverting.  
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Table 5: COM-B categories and TDF domains (Michie et al, 2014). 
 
 
The TDF has been successfully applied to understand behaviour in a range of clinical 
areas (Francis et al, 2012). It has been used to identify key theoretical domains that 
are perceived to influence healthcare professionals (HCPs) to improve appropriate 
polypharmacy for older people in primary care (Cadogan et al, 2015), and investigation 
of prescribing errors among trainee doctors (Duncan et al, 2012). 
Duncan et al (2012) explored beliefs among trainee doctors, including that prescribing 
errors were not likely to have consequences for patients, and found that seven 
theoretical domains were relevant: social professional role and identity, environmental 
context and resources, social influences, knowledge, skills, memory, attention, and 
decision making, and behavioural regulation. Potentially important domains were 
beliefs about consequences and abilities which could be targeted for an intervention. 
The findings show the complex nature of prescribing behaviour. 
Cadogan et al (2015) found that all the theoretical domains, except ‘Emotion’, were 
considered relevant to the target behaviour of ‘prescribing of appropriate 
polypharmacy in primary care’. This also illustrates the complex nature of the 
behaviour as well as the challenge faced by the researcher when developing 
interventions for change. The authors were able to purposefully select eight key 
domains that would assist HCPs in taking action in the clinical setting; they were then 
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able to use these to select behaviour change techniques (BCTs) for inclusion in a 
future intervention for prescribing for this older population.. 
 
1.5 Summary 
This chapter has highlighted that assessment of kidney function is important when 
prescribing, as many drugs and metabolites are excreted from the body by the kidney, 
and RKF can increase the risk of harm. This is particularly important for older people 
as kidney function reduces with age. Whilst kidney function is easily measured, there 
is now more than one equation to calculate the estimated level: eGFR is reported by 
the pathology laboratories when kidney function blood tests are done and so is easily 
available, but not designed to inform drug dosing decisions; CrCl-CG has historically 
been used for drug dosing decisions, and has been used by drug companies for 
dosing studies and reported in the drug SPCs. A case-note study has found that many 
older people are prescribed drugs that are not recommended at their level of kidney 
function, and has suggested that using eGFR or CrCl-CG gives different results in 
older people. This suggested a need to explore further to find if there is supporting 
evidence in the literature for which equation should be used for prescribing for older 
people. 
The pilot study in primary care reported in this chapter has suggested that 
recommendations for prescribing in RKF are not applied, and an investigation in a 
wider population might show if this finding is generalisable, and whether an 
intervention is needed to help prescribers. 
An analysis of the complex prescribing behaviour, and an exploration of the 
determinants, could provide an in-depth understanding of the factors involved in 
recommendations for prescribing in RKF not being applied. If a change in prescriber 
behaviour is found to be needed to reduce risk of harm for patients, it is more likely to 
be effective if an intervention is developed on theory and evidence based principles of 
behaviour change. 
The questions raised informed the mixed methods research plan. 
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1.6 Research Plan 
 
 Methodology 
A pragmatic sequential mixed methods design (Robson, 2011) was proposed to 
produce a comprehensive picture of prescribing for older people with RKF in primary 
care. From the case-note review, the inquiry would be driven by the research 
questions, and derived from the integration of methods and results from the previous 
studies (Bazeley, 2009). The programme of research was planned to combine both 
quantitative and qualitative methods, and resulting data, to address the different 
research questions and enhance the validity of the findings (Cresswell, 2009; Robson, 
2011).  
 
 Research question 
Are recommendations for prescribing applied for older people with reduced kidney 
function in primary care, and if not, what are the barriers to implementation? 
 
 Aims 
The aims of this mixed methods programme of research were to: 
 Systematically determine the size and nature of the current evidence base on 
prescribing for older people with reduced kidney function, identify any gaps in 
the literature, and use this to inform the ongoing research plan. 
 Investigate whether recommendations for prescribing in reduced kidney 
function (RKF) were being applied for older people across a (former) Primary 
Care Trust (PCT) population. 
 Explore why GPs do not apply the drug licence recommendations when 
prescribing for older people with reduced kidney function. 
 Prioritise a strategy for intervention and research. 
 
 Research plan 
The sequential research plan and chapter numbers are shown in Figure 6. To provide 
an overview, the research questions, data collection and analysis procedures for this 
mixed methods project are presented in Table 6.  
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Figure 6: The sequential mixed methods research plan. 
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 chapter method research questions
theoretical/ 
conceptual basis
data sources data analysis integration 
1
Cross-sectional Case-
note Review
Are recommendations for prescribing in reduced 
kidney function being applied in 5 GP practices?
Variable relationship 
testing.
Case-note review.
Quantitative descriptive 
analysis.
• Provided the basis for the 
  subsequent studies in the project.
2
Scoping Literature 
Review
What is the size and nature of the evidence 
base on prescribing for older people with 
reduced kidney function in primary care, are 
there gaps in the literature, and what future 
primary research is needed?
Arksey & O'Malley 
scoping literature 
review.
Research 
databases.
Framework analysis in 6 
key areas.
• 6 key areas to review based on the 
  Case-note Review findings
• Update in 2015, and analysis, led to 
  re-analysis of the PCT survey data.
3
PCT-wide Cross- 
sectional Survey
Are drugs, that require kidney function 
assessment, prescribed according to 
recommendations for use in reduced kidney 
function for people aged 65 years and older 
across a PCT population?
Variable relationship 
testing.
PCT wide 
prescribing data.
Quantitative descriptive 
analysis.
• Variables tested based on those 
  found in the Case-note Review.
• Methods and variables informed by 
  similar studies from hospital and 
  other countries found in the Scoping
  Literature Review.
• Re-analysis of data to give 'cases   
  missed', after Scoping Review update.
4
Qualitative GP interview 
study
Why are prescribing recommendations not 
applied for older people with reduced kidney 
function in primary care?
Behaviour change 
theory - theoretical 
domains framework.
GP interviews. Qualitative TDF analysis.
• Participant pre-reading and topic  
  guide based on the findings from the 
  Case-note Review and PCT-wide
  survey.
5
RAND Appropriateness 
method Consensus 
Group Study
Do experts in fields relating to prescribing in 
reduced kidney function find the evidence from 
the four project studies generalisable, 
acceptable, and feasible for an intervention, and 
what are the priorities future research?
Behaviour change 
theory - TDF.
Consensus group 
questionnaire on-
line survey, group 
discussion, and 
final statement 
rating.
Quantitative descriptive 
analysis and a qualitative 
TDF analysis.
• Statements for rating based on the 
  GP interview study findings.
• Group discussion based on the 
  Case-note Review, Scoping Literature
  Review, PCT-wide Survey, and GP
  Interview studies.
• Continued use of the TDF working 
  from the GP Interview study.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: PCT: Primary Care Trust; TDF: Theoretical Domains Framework 
Table 6: Research questions, data collection and analysis procedures for this mixed methods project. 
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 ‘The use of drugs in patients with impaired renal function can give rise to problems for 
several reasons….many of these problems can be avoided by careful choice and use 
of drugs.’ 
The Renal Drug Handbook 4th Edn (Ashley & Currie (Eds), 2014) 
 
2 Chapter 2: A scoping literature review to identify the 
evidence base on prescribing for older people with reduced 
kidney function 
 
2.1 Background 
A quarter of people aged 65 years and older with reduced kidney function (RKF) were 
prescribed a drug that is recommended to be avoided, or the dose reduced, and 
evidence of harm was found in the case-note review in 5 GP practices in Bradford 
(Chapter 1). Also highlighted was that there are two different kidney function 
estimation equations, creatinine clearance calculated using the Cockcroft Gault 
equation (CrCl-CG) and eGFR calculated using the MDRD equation which gave 
different results for older people. For 22% of the older people reviewed, the prescribing 
decision would have been different depending on which equation had been used.  
This study aimed to review the literature and systematically determine the size and 
nature of the current evidence base for prescribing to older people with reduced kidney 
function, identify gaps in the literature, and inform the ongoing research plan. 
 
2.2 Research question and objectives for the literature 
review 
Research question 
What is the size and nature of the evidence base on prescribing for older people (≥65 
years) with reduced kidney function in primary care, whether there are there gaps in 
the literature, and what future primary research is needed? 
Objectives 
 To outline what is already known, and identity gaps in the existing literature, on 
the prevalence of prescribing for older people with reduced kidney function in 
UK primary care. 
 To formulate the key areas for review of the evidence base in this field. 
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 To investigate the extent, range and nature of any research in each key area, 
quantitative or qualitative as appropriate. 
 To consolidate the research plan. 
 
2.3 Methodology 
A comprehensive, and systematic, mapping of the literature for a broad topic was the 
aim of this study, so the required breadth needed to answer the research question 
suggested a ‘scoping literature review’ methodology. The Centre for Reviews and 
Dissemination at York University (2009) state that ‘a scoping review determines the 
size and nature of the evidence base for a particular topic area, which can in turn be 
used to identify gaps in the literature and make recommendations for future primary 
research’. The literature search should be as extensive as possible, but it differs from 
standard systematic reviews in that a scoping review does not attempt to synthesise 
the evidence and that it is not appropriate to use a scoping review to answer a clinical 
question. Armstrong et al (2011) from the Cochrane Public Health Group state that 
published scoping reviews are a valuable resource that can be of use to researchers, 
policy-makers and practitioners, reducing duplication of effort and guiding future 
research. A scoping review methodology was used for this study as the aim was not to 
answer a precise question, but to explore the range of literature in the area of 
prescribing for older people with reduced kidney function. 
A key methods paper for scoping reviews is the methodological framework by Arksey 
and O’Malley in 2005. Levac et al (2009) has since provided recommendations to 
clarify and enhance each stage, which may increase the consistency with which 
researchers undertake and report scoping studies. Clarifying and linking the purpose 
and research question, balancing feasibility with breadth and comprehensiveness of 
the scoping process, and identifying the implications of the study findings for policy, 
practice, or research were suggested.  
Arksey and O’Malley state that a key strength of the scoping study is that it can 
provide a rigorous and transparent method for mapping areas of research. It provides 
a ‘narrative’ or ‘descriptive’ account of available research. However, the limitations are 
that a scoping review does not formally appraise the quality of evidence and there can 
be a large quantity of data generated leading to decisions on breadth versus depth. 
Levac et al (2009) discusses the need to assess included studies for methodological 
quality, and Brien et al (2010) state that a lack of quality assessment makes the results 
of scoping studies more challenging to interpret. Grant and Booth (2009) imply that a 
lack of quality assessment limits the uptake of scoping study findings into policy and 
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practice, but Levac concluded that it remains unclear whether not including quality 
assessment impacts the uptake and relevance of scoping study findings. An 
assessment of the quality of the included studies would give an indication of where the 
current literature is of sufficient quality to answer the research question, or if there is a 
need for further, higher quality, investigation to have greater confidence in the findings. 
Levac states that it is a challenge to assess quality among the vast range of published 
and grey literature that may be included in scoping studies. By including a quality 
assessment, to be feasible there necessarily needed to be a reduction in the scope of 
the searches, so only published studies were included, and opinion and discussion 
articles were excluded. Inclusion of only published empirical literature introduces the 
risk of publication bias, by not assessing the effect of unpublished studies that are 
more likely to be negative, and by a reduction in the breadth of the investigation.  
Studies were charted as described in the Arksey & O’Malley framework. 
Appropriateness of study design and study quality were assessed. A hierarchy of 
evidence was developed for each scoping review area based on the Oxford Centre for 
Evidence-Based Medicine (OCEBM) levels of evidence (Oxford Centre for Evidence-
Based Medicine, 2011) (Table 7). The table shows the ‘Step 1’, or ‘Level 1’, types of 
studies that are likely to give the highest level of evidence for the type of question 
posed, reducing down to ‘Step 5’, or ‘Level 5’, for the study designs that would give the 
lowest degree of confidence in the results. Levels of evidence were developed for 
each scoping area based on the research question and adapted from Table 7. This 
was an iterative process with additional levels being added where required having 
reviewed the studies found. 
The studies were also critically appraised using the Critical Appraisal Skills 
Programme (CASP) checklists for appraising systematic reviews, randomised 
controlled trials (RCTs), cohort studies, case-controlled studies, and qualitative 
research, the Centre for Evidence Based Management (CEBM) checklist for surveys, 
and in addition the ‘Consolidated criteria for reporting qualitative research’ (COREQ) 
for appraisal of the qualitative studies.  The checklists aided assessment of whether 
the conclusions of each study were valid in that they were supported by the results 
presented and consistent with the methods used, and the reported detail of the 
methods were sufficient to repeat the study and obtain similar conclusion.
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Table 7: The hierarchy of evidence from the Oxford Centre for Evidence-Based Medicine (2011) 
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CASP gives the three broad issues to be considered when appraising a study report 
as: 
 Are the results valid i.e. does the study provide an unbiased estimate of what it 
claims to show? 
 What are the results? 
 Will the results help locally? 
The screening questions provided in the checklists were used to appraise each 
included study. 
 
2.4 Study design 
 Method 
The framework proposed by Arksey and O’Malley (2005), with the Levac et al (2009) 
recommendations, has been used to conduct and structure the literature review to 
provide a rigorous, robust and reproducible method. 
Once initial search plans and criteria had been drafted, advice was sought from Mark 
Clowes (University of Leeds Health Library Services) to ensure the search terms and 
strategies were comprehensive enough to find the relevant literature. One researcher 
(myself) conducted all stages of the scoping literature review. 
2.4.1.1 Stage 1: identify the key areas for review and the research 
question for each  
Arksey and O’Malley recommend maintaining a wide approach to ensure breadth of 
coverage, and that parameters can be set once the scope of the field has been 
assessed. The findings from the case-note review (Chapter 1) were interrogated using 
a mind map approach to identify the key areas for review and the research question 
for each.  
Figure 7 is the mind map showing the case review findings leading to the six key areas 
for review: 
1. To what extent are older people (≥65 years) on drugs and doses not 
recommended at their level of kidney function in primary care? 
2. How should kidney function be estimated when prescribing for older people in 
primary care? 
3. What are the risks to the older person in primary care of not following the 
recommendations for prescribing in reduced kidney function?
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Abbreviations: ADRs: adverse drug reactions; eGFR: estimated glomerular filtration rate. 
Figure 7: Mind map to identify key areas for the scoping literature review from the case-note review findings. 
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4. Why do prescribers not apply prescribing recommendations in reduced kidney 
function in primary care? 
5. What UK national guidelines and resources are available on drug use and 
dosing in the reduced kidney function of the older person? 
6. Have interventions been evaluated to help prescribers in primary care to apply 
recommendations for use of drugs in reduced kidney function? 
The development of the research questions was an iterative process and only fully 
defined through the initial literature search.  
2.4.1.2 Stage 2: identify relevant studies for each key area for review 
The aim was to be as comprehensive as possible. The literature for key areas 1,2,3,4, 
and 6 was identified by database literature searches. For key area 5, guidelines and 
resources were identified through expert advice (renal, elderly care, clinician and 
pharmacist). For each key area the review was based on stages defined by Hagell and 
Bourke Dowling (1999). 
The database searches were first run between October 2011 and March 2012. They 
were then re-run in October 2012 to update for the transfer report, and updated again 
in October 2015. 
A preliminary map of the issues in the area.  
The case-note review findings, mind mapping, and an initial unstructured search of the 
literature identified the relevant topics. 
Research reviews  
The Cochrane Library database of systematic reviews was searched to identify any 
reviews relating to prescribing for older people with reduced kidney function in the 6 
key areas. The Database of Abstracts of Reviews of Effects (DARE) was also checked 
for existing or ongoing reviews. Research reviews were searched for in Medline and 
then highlighted from each database searched. 
Database search 
The search for each key area aimed to comprehensively identify relevant studies, and 
was run on each of the following databases: Medline, Embase, PsychINFO (for the 
psychological perspective on healthcare), CINAHL (for a nursing perspective), and 
Web of Science.  
The search terms for each key area were set up using the following categories where 
appropriate. Appendix 3 (0) details the subject headings, and key word, search terms, 
and synonyms under each of the following categories: 
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 Prescribers (which includes physician as well as the misspelling 
‘phycisian’ as the library expert advised it can find more studies being a 
term that is frequently misspelled). Non-medical prescribers were 
included by the use of the term ‘prescriber’. 
 Prescribing.  
 Guidelines/recommendations (which includes ‘guidance’ and the 
misspelling ‘guideance’). 
 Primary Care.  
 Renal impairment.  
 Elderly.  
 Adverse drug reactions (ADRs). 
 Decision support tools.  
 Prescriber Behaviour.  
 Kidney function Equations/diagnostic tests.  
 Additions – English language/reviews/qualitative. 
Within each category the synonyms were searched using ‘OR’. The relevant 
categories were then used in the searches for each key review area using ‘AND’. An 
example of a Medline search strategy is given in Appendix 4 (8.3) for key review area 
4. 
Type of research for each key area 
The type of research searched for is dependent on the research question and is 
discussed under each key area section (2.4.1.2 - 0). 
Reference organisation 
EndNote X5 was used to organise and manage the references found for each key 
area and background to the research. 
2.4.1.3 Stage 3: study selection for each key area for review 
By aiming to keep the search sensitive, in order to be comprehensive, specificity can 
be reduced so that many irrelevant studies are picked up. To eliminate irrelevant 
studies inclusion and exclusion criteria were developed and listed under each key area 
section. 
The resultant list of articles found for each search were initially reviewed by title and 
abstract. The selected articles were exported to EndNote and then the abstracts 
reviewed having removed any duplicates. Full text copies were obtained for the 
studies identified to be included for review. 
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2.4.1.4 Stage 4: chart the data 
The significance of the included studies was then considered, and the quality 
assessed. A data charting form was developed based on the criteria used by Arksey 
and O’Malley (2005) to collect: 
 Author(s), year of publication, study location. 
 Intervention type and comparator (if any); duration of intervention. 
 Study populations. 
 Aims of study. 
 Methodology. 
 Outcome measures. 
 Important results. 
The form also listed the CASP screening questions to aid appraisal. All studies 
identified for review were charted. This stage allowed further scrutiny as to whether the 
study fitted the search criteria, or whether the search criteria needed amendment.  
The level of evidence for the review area question was also assessed, and the 
selected literature appraised. The OCEBM Levels of Evidence applicable to the 
research question were used to develop a hierarchy of evidence table, adapted for 
each key review area (Oxford Centre for Evidence-Based Medicine, 2011). Each study 
was then assessed for level of evidence and methodological quality using the relevant 
checklists (CASP, CEBM or COREQ), which was added to the charting process, and 
allowed ordering of the included studies. 
2.4.1.5 Stage 5: collate, summarise, and report the results 
The final literature to be included in each key search area was assessed and the 
findings scrutinised. The studies were categorised and evaluated for common themes 
and findings to collate and summarise the results of the review.  
2.4.1.6 Stage 6: consultation (optional) 
Arksey and O’Malley (2005) discuss an optional final stage of consultation so that 
practitioners and consumers can contribute to the work. They state that contributors 
can provide additional references and valuable insights about issues that the scoping 
review alone may not provide. Time limits have meant that this stage has not been 
included, but a consultation is intended before publication. 
 
 Ethics and governance 
As a literature review with no participant involvement, no ethics or governance 
approval was required. 
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2.5 Key review area 1 – evidence on whether prescribing 
recommendations are applied for older people with 
reduced kidney function in primary care. 
 
 Research question for key review area 1 
To what extent are older people (≥65 years) on drugs and doses not recommended at 
their level of kidney function in primary care? 
 
 Identification of relevant studies - search criteria 
The search categories were ‘Prescribing’ AND ‘Renal impairment’ AND ‘Elderly’ AND 
‘Primary Care’ AND English language (see Appendix 3, 0, for the subject headings 
and key words for each search category). The search term ‘review’ was added to the 
Medline search to highlight any relevant review papers.  
 
 Study selection – inclusion/exclusion criteria 
The research question is focussed on primary care, however other healthcare settings 
were included in case the primary care evidence was limited, and for comparison. No 
date range was applied to the searches so that the scope would include studies from 
prior to the introduction of the national CKD guidelines in 2005. 
Study selection from the search results were based on the following criteria: 
Inclusion 
 English language. 
 Primary empirical research and reviews. 
 Outcome relating to assessment of compliance with prescribing 
recommendations in reduced kidney function. 
Exclusion 
 Opinion or discussion articles. 
 
 Hierarchy of evidence and appraisal 
The research question asked ‘how common is the problem?’ so the OCEBM Levels of 
Evidence (2011) gives the ‘Level 1’ evidence, which would give greatest confidence in 
the findings, to be ‘local and current random sample surveys (or censuses)’. If good 
level 1 evidence is not found then studies of lower level relevance, and non-local 
evidence, would give an insight into whether further research is needed. Table 8 lists 
the hierarchy of evidence developed for key review area 1 based on the OCEBM 
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Levels of Evidence. Non-local levels have been added, and a grade ‘b’ where the 
evidence is not current or not based in primary care, which would reduce the external 
validity for current UK primary care. 
 
 
Table 8: Hierarchy of evidence table for key review area 1 ‘how common is the 
problem?’ developed from the OCEBM Levels of Evidence.  
 
The issues considered when appraising the report of a descriptive survey were 
whether ‘the results of the study were valid, what were the results, and would the 
results help locally’, as defined by critical appraisal tools such as the CASP. For this 
review, ‘locally’ would be applicability to UK primary care. To aid the quality 
assessment the CEBM ‘Critical Appraisal of a Survey’ tool was used (Centre for 
Evidence Based Management). For other study designs, the CASP ‘Study checklists’ 
informed the review. Studies were assessed and only included where the focus, 
methods, recruitment and sampling, valid and reliable objective measurements used, 
and outcomes were clearly defined, relevant and appropriate to the research question. 
 
 Collation and appraisal 
2.5.5.1 Description of studies 
Twenty-five relevant studies were identified from the database searches (Figure 8) that 
aimed to investigate the extent to which drugs and doses prescribed are not 
recommended at their level of kidney function. Table 9 lists the included studies in 
order of the level of evidence they provide. 
hierarchy of 
evidence
description
Level 1 Local and current random sample surveys (or censuses)
Level1b Local random sample surveys (or censuses) - not current/ not primary care
Level 2 Systematic review of surveys that allow matching to local circumstances
Level 2b Systematic review of surveys that allow matching to local circumstances - not current/ low quality for primary care
Level 3 Local non-random sample
Level 4 Local case series
Non-local level 1 Non-local and current random sample surveys (or censuses)
Non-local level  1b Non-local random sample surveys (or censuses) - not current/ not primary care
Non-local level 3 Non-local non-random sample
Non-local level 3b Non-local non-random sample - not current/ not primary care
Non-local level 4 Non-local case series
Non-local level 4b Non-local case series - not current/ not primary care
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Figure 8: Number of studies identified for key review area 1. 
 
CKD guidelines began to be published in the early 2000’s, in the UK it was 2005 when 
the first were introduced (Joint Specialty Committee for Renal disease of the Royal 
College of Physicians of London and the Renal Association, 2005), and most of the 
studies date from that time onwards, suggesting an increased awareness of kidney 
function in relation to prescribing. The earlier studies were all hospital based, with the 
first primary care study being published in 2005. 
The OCEBM Levels of Evidence for prevalence studies suggest that local studies are 
the most appropriate and applicable (Oxford Centre for Evidence-Based Medicine, 
2011), but only two UK based studies other than the Chapter 1 case-note review were 
found, and those were hospital based. There were no geographical limits put on the 
scoping review searches and most studies were based in countries that might be 
considered to have similar populations to the UK, although the healthcare systems 
may be different, for example the USA (x4), Australia (x2), Canada (x1), and Western 
Europe (x11) (see Table 9). Four studies were from differing populations, and were all 
hospital based, South Africa (Decloedt et al, 2010), Iran (Emami et al, 2012), South 
Korea (Sheen et al, 2008), and Palestine (Sweileh, 2007). These studies, that report a 
similar range of substantial non-compliance rates with prescribing guidelines, suggest 
it should be recognised as a multi-national problem. 
Only seven studies found were based in primary care, and none in the UK other than 
the case-note review. The prescribing systems and procedures are different to those in 
hospitals, including advanced computerised patient record systems used in UK 
primary care that could mean different findings to hospital based studies.
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principal author
hierarchy of 
evidence (based on 
OCEBM)
year country study type
prospective, cross-
sectional, or retrospective
setting
participant 
numbers
participant type outcomes
Wood Level 1 2011 UK survey cross-sectional primary care 594 ≥65yrs 25% had repeat medication that was inappropriate for their level of kidney function.
Jones Level 1b 2013 UK survey - case review retrospective hospital 100
> 70 years with eGFR <60 
ml/min/1.73m2
56% of consecutive cases were prescribed at least one medication that was 
potentially inappropriate.
Wong Level 1b 1998 UK cohort retrospective hospital 1162
discharged from geriatric ward 
with CrCl <20 ml/min
20% with CrCl 10-20ml/min had drug prescriptions on discharge that contradicted 
the BNF recommendations, and 67% of those with CrCl<10ml/min.
Long Level 2b 2004 USA systematic literature review mixed mixed 6 studies included
Renal dosing guideline non-compliance rates ranged from 19-69% across all 
settings with the largest in ambulatory care.
Breton Non-local level 1 2011 France cohort prospective primary care 8,701 ≥65yrs 13.3% overall prevalence of inappropiate drug use in RKF.
Schmidt-Mende Non-local level 1 2012 Sweden survey cross-sectional primary care 3,345 ≥65 years with hypertension 48% drugs prescribed were potentially inappropriate.
Khanal Non-local level 1 2015 Australia survey retrospective primary care 4,035 ≥65yrs
28.1% had inappropriate prescribing of the 31 drugs analysed; only 25% had a 
documented kidney function.
Emarmi Non-local level 1b 2012 Iran survey prospective primary care
193 prescriptions 
which  would need 
dose adjustment
eGFR ≤50 ml/min/1.73m2 on a 
drug that might need adjustment
23.2% of orders written for patients with varying degrees of renal impairment 
required adjustment but were performed in only 45.5% of these cases.
Yap Non-local level 1b 2005 USA survey retrospective primary care 224 <50ml/min 25% were prescribed an inappropriately high dose.
Blix Non-local level 1b 2006 Norway cohort prospective hospital 515
medical admissions with 
eGFR<60 ml/min/1.73m2
17% of drugs on admission, and 34% of drugs started in hospital, needed dose 
adjustment.
Decloedt Non-local level 1b 2010 South Africa survey prospective hospital 97 eGFR ≤50 ml/min/1.73m2 71% received one or more drugs that required dose adjustment.
Falconnier Non-local level 1b 2001 Switzerland case control prospective hospital 1648
eGFR ≤50 ml/min/1.73m2 on a 
drug
67% regimens not adjusted in RKF in the control group.
Sheen Non-local level 1b 2008 South Korea survey retrospective hospital 431,119 prescriptions Overdose rates: 1.3% mild RKF, 27.8% moderate RKF, 29% severe RKF.
Cantu Non-local level 3b 1992 USA survey prospective hospital 60 CrCl <40 ml/min 45% were receiving dosages in excess of the manufacturers' recommendations.
Drenth van 
Maanen 
Non-local level 3b 2015 Netherlands cohort retrospective hospital 1,327
eGFR 10-50 ml/min/1.73m2 
prescribed defined drugs
46% non-adherence with the Dutch dosing in RKF guideline.
Falconnier Non-local level 3b 2001 Switzerland case-control prospective hospital 70 CrCl <50 ml/min and on a drug 67% did not have doses adjusted to renal function
Gibert Non-local level 3b 2013 France survey cross-sectional hospital 412 ≥75 years
When kidney fuction calculation was present, an inappropriate dosage was 
performed for 30% of drugs requiring adjustment.
Hu Non-local level 3b 2001 USA survey-  chart review retrospective hospital 1,044
> 80 years prescribed the study 
antibiotics
Dosing errors were identified in all of the antibiotics studied; overall dosing error 
rate was 34%; factors predictive of dosage errors were advanced age and low 
body weight
Pillans Non-local level 3b 2003 Australia survey prospective hospital 192
CrCl <40 ml/min prescribed 
defined drugs
42.2% of doses were inappropriately high on admission, and 29.3% were 
continued
Salomon Non-local level 3b 2003 France survey prospective hospital 164 inpatients with a raised SrCr
34% were inappropriate, 14% being contra-indicated and 20% with inappropriate 
dosage given the patient's renal function. 
Sweileh Non-local level 3b 2007 Palestine survey cross-sectional hospital 78
CrCl <60ml/min prescribed at 
least 1 drug
74% of relevant drugs were prescribed inappropriately.
Van Dijk Non-local level 3b 2006 Netherlands survey retrospective hospital 237 eGFR <51 ml/min/1.73m2 79.3% had 1 or more drugs needing dosage adjustment, 23.9% of prescriptions.
Vanier Non-local level 3b 2011 France survey - note review retrospective hospital 170 ≥65yrs
Concordance for renal function was required for 82.9%, for at least one 
prescription.
Farag Non-local level 4 2014 Canada case series prospective primary care 1,464 prescriptions ≥66yrs with CKD 4-5 64% antibiotics prescribed where kidney function was too low.
Ingrasciotta Non-local level 4 2014 Italy case-series retrospective primary care 1,989 diagnosis of CKD 49.8% prescribed 1 or more nephrotoxic drugs; 35.6% had NSAIDs for > 3 months.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: CrCl: creatinine clearance; CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate; NSAID: non-steroidal anti-inflammatory; RKF: reduced kidney function; SrCr: 
serum creatinine. 
Table 9: Studies found for scoping review area 1, listed in order of level of evidence. 
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Also the hospital patients would be likely to be acutely ill, and the drugs studied might 
be for acute conditions making these studies less applicable to primary care. All the 
primary care studies found dated from 2011, suggesting a recent awareness about 
prescribing in RKF. 
The research question was to focus on prevalence in older people, and 9 of the 
studies had older participants only. Other studies were included as many discussed 
that older people are more likely to have reduced kidney function, and statistical 
analyses in some highlighted old age as a ‘risk factor’. For some studies without 
defined age inclusion or exclusion criteria, the study populations were reported to have 
mean ages over 65 years; for example, mean ages of 70 years (Salomon et al, 2003), 
73 years (Pillans et al, 2003), and 75 years in the Flaconnier et al (2001) study. 
2.5.5.2 Heterogeneity  
The included studies showed considerable variation in the characteristics of healthcare 
settings, patients versus prescriptions, drugs studied, and kidney function 
measurement and estimation. Where it was defined that older people would be 
studied, there were age thresholds of 65 year and older (x4 studies), ≥66 years, >70, 
≥75 and over 80 years (Table 9). All the studies clearly defined the way kidney 
function was recognised, measured and levels estimated, but many different methods 
and thresholds were used: CKD stages 3-5 or 4-5; eGFR <40, ≤50, 10-50, <60 
ml/min/1.73m2; CrCl <20, <40, <50, and <60 ml/min. The subjects for most of the 
studies were patients, but two studies (Emami et al, 2012; Sheen et al, 2008) focussed 
on the drugs prescribed. Most of the studies assessed any drugs that might need dose 
adjustment in RKF, but some studies were more defined, for example Hu et al (2001) 
looked specifically at antibiotic prescribing, whilst Drenth van Maanen et al (2015) and 
Khanal et al (2015) had a defined list of drugs. Schmidt-Mende et al (2012) only 
looked at patients with a diagnosis of hypertension.  
As a consequence of the wide variation, it is inappropriate to make direct comparisons, 
or pool data. The studies were reviewed by healthcare setting. 
2.5.5.3 Methodological quality 
Use of the OCEBM hierarchy of evidence levels reveals that only four of the studies 
would be considered as relevant to a local UK population, and three of those were 
hospital-based rather than primary care, or not recent and so may no longer reflect 
what is currently happening (Table 9). The research question was focussed on primary 
care, however other healthcare settings were included in case the primary care 
evidence was limited, and for comparison; inclusion of international studies has 
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allowed review of the evidence in many different countries and healthcare settings. 
Three studies were classified as ‘Non-local Level 1’ where CEBM survey appraisal 
suggested acceptable or good quality primary care based design and reporting. 
Khanal et al (2015) reported that 25% of their retrospective sample on a decision 
support database of 30,898 elderly patients (aged 65 years or over) had a recorded 
kidney function level. Those who had their renal function reported (n = 7,625) were 
selected for further analysis, and out of these, a total of 4,035 patients who were 
taking at least one of the 31 renally cleared drugs on their defined list were included in 
the final sample. For the other 75% of the database population it was not reported how 
many were taking the 31 drugs, and so total in the population could not be assessed.  
The studies that used CKD or eGFR, for example, to identify their study population, 
would not be able to show the degree to which they might be missing cases that 
should be assessed. Some studies analyse the participants who were excluded to 
show that they were similar to the study population, but it is still unknown what the 
kidney function levels are for that group, and whether it might change the findings of 
the study, introducing the possibility of bias. However, these studies do show that even 
with a kidney function test available, prescribing was not adjusted.  
Most of the studies found were designed as surveys and they were included for review 
as they met most or all of the criteria required of a survey by the Centre for Evidence 
Based Medicine. A well designed cross-sectional survey in a local setting is likely to 
give the best evidence for a prevalence study as it provides a locally applicable picture 
of relevant data. Lower quality evidence may introduce biases that reduce the 
confidence in the findings being applicable. If the survey is not local, does not have a 
similar population, or if it was completed so long ago that circumstances may have 
changed, then the findings are less likely to be applicable. The cohort, case control 
and case series studies were not specifically designed to assess prevalence, although 
prevalence was an outcome reported. The longitudinal studies may have attrition bias 
if not all patients are followed up to the end, and the retrospective studies may have 
missing data from selection bias and information bias where the exposure, record 
keeping or outcome assessment cannot be controlled. 
2.5.5.4 Prevalence outcomes: level 1 evidence UK primary care 
No studies, other than the pilot study case-note review (Chapter 1; Wood et al, 2011), 
were found to provide current local evidence of the extent to which older people are on 
drugs and doses not recommended at their level of kidney function in UK primary care. 
This study found 25% of people aged 65 years or older with documented RKF were on 
at least one repeat medication that was inappropriate for their level of kidney function. 
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The limitations of this study, such as the being based in one small urban area of 
Bradford meaning that the results may not be generalisable in a wider population, and 
the design leading to only those with a kidney function test on the record being 
included, suggest that a prevalence study in a wider population would provide greater 
confidence on the extent of the problem generally in UK primary care. 
2.5.5.5 Prevalence outcomes: reviews 
Only one prevalence review paper was found, Long et al (2004). It reported a robust 
method but is now over ten years old and only found six studies for inclusion. None of 
the studies were large and the studies showed considerable variation in setting, design 
and population. The studies, published between 1996 and 2002, included four of the 
hospital based studies found for the current review, Cantu et al (1992), Falconnier et al 
(2001), Hu et al (2001), and Wong (1996). The other two were a care home study from 
Canada reporting a non-compliance with prescribing recommendations rate of 34%, 
and the ambulatory care pilot study was an abstract from the USA indicating a 69% 
non-compliance. The authors suggest the paucity of evidence found suggested a need 
for more research, particularly for ambulatory care settings where the majority of 
patients with reduced kidney function receive care. 
2.5.5.6 Prevalence outcomes: primary care evidence from other 
countries 
The French primary care study by Breton et al (2011) was of high methodological 
quality, and as the population is likely to be similar to the UK, the findings could be 
considered in relation to the UK. It is a prospective cohort study so selection and 
information biases should be reduced as missing data is less likely, and the exposure, 
record keeping and outcome assessments can be controlled. However, as it is 
longitudinal, it is sensitive to drop out of participants over time (attrition bias) (Green et 
al, 2011). This was a multi-centre trial in three cities designed to focus on prescribing 
for older people with RKF in primary care and included 8,701 participants with only 8 
lost to follow-up when they assessed mortality at 6 years, so attrition bias was very 
low. Although recruitment was for all those with an available baseline eGFR, they 
compared the population with those without an eGFR to show that they were similar 
populations. There was an objective validated measurement of kidney function, a clear 
and objective procedure for assigning an eGFR threshold for all prescribed drugs, all 
subjects were classified using the same procedure, and there was detailed a reliable 
system for detecting exposure. There was no blinding, but confounding factors were 
taken into account by use of logistic regression and mortality hazard ratios, both crude 
and adjusted for many factors such as socio-demographic variables, cardiovascular 
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disease or risk, and co-morbidities. Exposure to the risk of inappropriate drug use was 
found in 13.3% of participants aged ≥65 years with RKF, 52.5% in those with eGFR 
30-59 ml/min/1.73m2, and 96% in eGFR<30ml/min/1.73m2 over 4 years. The authors 
state that they may have underestimated the extent of the problem as participation 
rate was low and those participating were at the younger end of the age group. 
Analysis also highlights that they used eGFR as their kidney function estimation 
equation based on the Froissart et al (2005) study on the predictive performance of the 
MDRD and CrCl-CG equations for estimating kidney function. However, Froissart’s 
conclusions are based on kidney disease staging and not drug dosing and they do 
state that CrCl-CG is more precise and accurate for age ≥65 years and low kidney 
function. This might also have meant that they have underestimated the problem. 
Kidney function estimation equations will be discussed further in the next key review 
area, section 2.6.  
Schmidt-Mende et al (2012) in Sweden used a cross-sectional study to assess all the 
cases on a cardiovascular database with a diagnosis of hypertension; 3,345 older 
people were dispensed 27 different antihypertensive drugs in CKD stages 3-5 with 
over half being judged inappropriate.  
Emami et al (2012) and Yap et al (2005) were also classed as ‘non-local level 1, like 
the previous two studies, but graded ‘b’ as the Emami study was in a very different 
population, and the Yap study was retrospective which could mean there was 
selection bias and information bias where the exposure or outcome assessment 
cannot be controlled, but instead there is a need to rely on others for accurate record 
keeping. Emami et al randomly selected 142 patients with an elevated SrCr; 830 drug 
orders were evaluated and 23.2% were found to need dose adjustment. Yap et al 
found 25% of patients who came to an ambulatory care clinic with CrCl <50 ml/min 
were prescribed inappropriately high doses. 
Khanal et al (2015) used a retrospective survey design to find that 28.1% of 4,035 
Australians aged ≥65 years had inappropriate dosing of 31 different drugs. As only 
25% of the original 30,898 cases reviewed had a documented kidney function, three 
quarters of the population could not be included in the survey, even though they may 
also be taking the relevant drugs. 
In Canada older people with RKF prescribed antibiotics had excess dosing in 64%, 
and nitrofurantoin had been prescribed 169 times when contra-indicated in the 1,464 
prescriptions studied in the prospective cohort study (Farag et al, 2014). This study 
was designed as a case-series to look at whether the introduction of eGFR reporting 
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had made a difference to prescribing in RKF. Case-series lack a comparator group 
and so can mean that intervening variables may not be recognised and the internal 
validity is compromised (Polgar and Thomas, 2013). In this study there was no 
difference seen before and after eGFR reporting, and here the prevalence figures are 
used. Also designed as a case-series was a retrospective assessment of patients with 
CKD in Italy which found 49.8% received at least one prescription for a nephrotoxic 
drug, and that 35.6% had taken NSAIDs for longer than 3 months (Ingrasciotta et al, 
2014). 
2.5.5.7 Prevalence outcomes: evidence from a hospital setting 
Two studies were UK based so were classified as higher level evidence as they were 
local, but the hospital setting might mean they are not as relevant to primary care. 
Wong (1998) reported a prospective cohort note review of discharges from an elderly 
care ward in Oxford over three years and found that 25% had inappropriate drug 
prescribing based on their kidney function. A much more recent study retrospectively 
analysed case records from consecutive patients aged over 70 years medically 
admitted to a Hull hospital (UK) (Jones and Bhandari, 2013). They showed 56 of 100 
consecutive records had one or more potentially inappropriate medication prescribed 
during the acute admission period, and 81 out of the 622 medications prescribed were 
‘inappropriate’ with antibiotics and anti-hypertensives accounting for the majority.  
In studies from many countries the non-compliance rates with recommendations for 
prescribing in RKF in the hospital setting ranged from 17% to 82.9% (Table 9). 
Salomon et al (2003) reviewed 886 hospital prescriptions and found 34% were 
inappropriate, 14% contra-indicated and 20% with inappropriate dosage given the 
patient's kidney function. In 2009 they went on to assess medical residents’ 
prescribing behaviour in RKF through a simulated clinical setting where 62% of 
residents wrote an inappropriate order for gentamicin, 42% for diclofenac, 52% for 
enalapril and 28% under-dosed amlodipine. Sheen et al (2007) was a retrospective 
interrogation and the largest study found. They also found drug over-dosing was 
common in hospital patients with reduced kidney function having analysed four years 
of prescriptions totalling 21,768; 28% of those with moderate to severe RKF had 
excessive doses.  Hu et al (2001) and Drenth van Maanen et al (2015) were the other 
larger studies found. Hu et al looked at antibiotic use for 1,044 patients aged over 80 
years in a retrospective chart review. Dosing errors were found for all the antibiotics 
surveyed and the overall error rate was 34%. Drenth van Maanen et al was the largest 
prospective study and so may have fewer potential sources of bias and confounding. 
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They looked at the discharge medication for 1,327 participants and found 46% did not 
follow prescribing recommendations, and 71% of those were felt to have the potential 
to cause moderate to severe harm.  
2.5.5.8 Drugs implicated 
Very many different drugs were found to be prescribed where the kidney function was 
too low in the studies found. In primary care, Breton et al (2011) reported contra-
indicated drugs were mainly antidiabetic agents and antihistamines, with 29 different 
classes of drug reported. The main classes of drugs implicated in the Level 1 primary 
care studies were: 
 ACEIs and ARBs (Breton et al, 2011; Khanal et al, 2015; Schmidt-Mende et al, 
2012). 
 Antidiabetic drugs including metformin and gliptins (Breton et al, 2011; Khanal 
et al, 2015; Emami et al, 2012). 
 Bisphosphonates (Breton et al, 2011; Khanal et al, 2015). 
 Lipid-lowering drugs (Breton et al, 2011; Khanal et al, 2015). 
Other drugs frequently mentioned were other antihypertensives, analgesics and 
digoxin.  
In the UK hospital studies, similar drugs were implicated, but antibiotics were the 
highest reported drug class, reflecting both the high acute use in hospital, and that the 
primary care study designs focussed on repeat medication (Jones and Bhandari, 
2013). 
 
 Summary 
No UK primary care studies were found that would corroborate the case-note review 
findings from Chapter 1 to show the extent to which older people are on drugs and 
doses not recommended in RKF. However, evidence from primary care in other 
countries, where the populations are likely to be similar to the UK, has shown that 
prescribing for patients with reduced kidney function does not always follow the 
recommendations. The Breton et al (2011) French primary care large prospective 
cohort study found 13.3% of older people were exposed to the risk of inappropriate 
drug use, and 52.5% where eGFR was 30-59 ml/min/1.73m2, giving a good indication 
that there was likely to be inappropriate prescribing in reduced kidney function in a 
wider primary care UK population, and that it should be investigated in the UK. Older 
people were highlighted as a particular group where prevalence of inappropriate 
prescribing in RKF is higher. 
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2.6 Key review area 2 – evidence on kidney function 
estimation for older people 
 Research question for key review area 2 
How should kidney function be estimated when prescribing for older people? 
 
 Identification of relevant studies - search criteria 
The UK national guidelines and resources now recommend use of ‘eGFR’ for kidney 
function estimation and disease staging, so first the relevant guidelines were reviewed 
for any recommendations on prescribing drugs in RKF and whether there is any 
assessment in relation to use for older people. 
The literature was then searched to identify relevant studies. The search categories 
were ‘Kidney function Equations/diagnostic tests’ AND ‘Elderly’ AND ‘Renal 
impairment’ AND ‘English language’ (see Appendix 3, 0, for the subject headings and 
key words for each search category). The search term ‘review’ was added to the 
Medline search to highlight any relevant review papers. 
 
 Study selection – inclusion/exclusion criteria 
Study selection from the search results were based on the following criteria. Although 
the research question is focussed on prescribing for older people, studies were 
included that compared kidney function estimation for drug dosing without an age 
limitation, as many older people have RKF and would be affected. 
Inclusion 
 English language. 
 Primary empirical research and reviews of primary empirical research. 
 Comparison of kidney function estimation equations for drug dosing. 
 Comparison of kidney function estimation equations for prescribing for the 
older patient. 
Exclusion 
 Opinion or discussion articles. 
 Comparison of equations for CKD, research or any other reason other than 
prescribing. 
 
 Hierarchy of evidence and appraisal 
The OCEBM Levels of Evidence (2011) question ‘is the monitoring test accurate’ fits 
best with the Key review area 2 aim to assess which kidney function estimation should 
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be used to inform prescribing decisions. The ‘Level 1’ evidence, which would give 
greatest confidence in the findings, would therefore be ‘Systematic review of cross-
sectional studies with consistently applied reference standard and blinding’. Table 10 
lists the hierarchy of evidence developed for key review area 2 based on the OCEBM 
Levels of Evidence. A grade ‘b’ has been added where the level may be reduced from 
the ideal, for example where a systematic review has not clarified or considered 
blinding. 
As this search was looking for evidence to compare equations for prescribing, studies 
looking at patient outcomes would be the best test of whether an equation for 
estimating kidney function was effective. Studies on outcomes were searched for 
initially but, as this was a scoping review, the search criteria were left open to capture 
all relevant studies to give an overview of the evidence on kidney function estimation 
equations when prescribing for older people. 
 
 
Table 10: Hierarchy of evidence table for key review area 2 ‘is the monitoring 
test accurate?’ to inform prescribing decisions, developed from the OCEBM 
Levels of Evidence. 
The issues considered when appraising the report of a cross-sectional study were 
whether the results of the study were valid, what were the results, and would the 
results help locally in UK primary care? To aid the quality assessment the ‘Critical 
Appraisal of a Survey’ tool from the Centre for Evidence Based Management was 
used. For other study designs, the CASP ‘Study checklists’ informed the review. 
Studies were assessed and only included where the focus, methods, recruitment and 
hierarchy of 
evidence
description
Level 1 Systematic review of cross-sectional studies with consistently applied reference standard and blinding
Level 1b Systematic review of cross-sectional studies with consistently applied reference standard but blinding not considered
Level 1c Systematic review but use of mathematical calculation for comparison rather than in-vivo study
Level 1d Narrative review, unclear method of study selection
Level 2 Individual cross-sectional studies with consistently applied reference standard and blinding
Level 2b Individual descriptive studies with consistently applied reference standard (clinical outcomes) to compare equations
Level 2c Individual descriptive studies with consistently applied reference standard (drug blood levels) to compare equations
Level 2d Individual descriptive studies with consistently applied reference standard (drug effect marker) to compare equations
Level 2e Individual descriptive studies with consistently applied reference standard (kidney function marker) to compare equations
Level 3 Non-consecutive studies, or studies without consistently applied reference standards
Level 4 Case-control studies, or poor or non-independent reference standard
Level 5 Mechanism-based reasoning
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sampling, valid and reliable objective measurements used, and outcomes were clearly 
defined, relevant and appropriate to the research question. 
 
 Collation and appraisal 
2.6.5.1 UK national guidelines 
Since 2005 when the first CKD guidelines were published (Joint Specialty Committee 
for Renal disease of the Royal College of Physicians of London and the Renal 
Association, 2005), and continued in the most recent NICE CKD guideline (NICE 
CG182, 2014), it is recommended that kidney function is estimated using eGFR 
calculated using the MDRD equation. The eGFR is now reported by pathology 
laboratories in the UK, making it a readily available estimate of kidney function. 
However, as discussed in Chapter 1 (1.2.3.1) the pharmaceutical companies have 
historically used creatinine clearance as calculated using the Cockcroft Gault equation 
for their dosing recommendations in the SPCs. The UK Renal Pharmacy Group in 
2006 stated that Cockcroft Gault should remain the gold standard when adjusting drug 
doses to an individual’s kidney function; eGFR should not be used to adjust drug 
doses (Devaney et al, 2006). 
The NICE guidelines do not discuss use of eGFR for prescribing, or specifically in the 
older population. The Scottish Intercollegiate Guidelines Network (SIGN) CKD 
guidelines (2008) discuss the fact that only 3 out of 14 studies cited found that CrCl-
CG was more accurate, but that these studies looked at older patients; they also state 
that the MDRD equation is not validated for older people.  
The BNF quotes the levels of kidney function for drug prescribing as ‘eGFR’ but the 
figures are those from the drug companies that have used Cockcroft Gault creatinine 
clearance. 
International and national guidelines for prescribing in RKF will be discussed further in 
section 0. 
2.6.5.2 Description of studies 
Forty-one relevant studies were found from the database searches (Figure 9) 
investigating how kidney function should be estimated when prescribing, particularly 
for older people. Table 11 lists the included studies in order of the level of evidence 
they provide.  
Until eGFR was introduced in the early 2000’s CrCl-CG was the only kidney function 
estimate used, so all the studies found were published no earlier than 2004 when the 
questions first started to be raised about whether the new equation was appropriate for 
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drug dosing. Over half the studies found were published in the last 5 years suggesting 
an increased awareness and questioning of the issues.  
 
 
Figure 9: Number of studies identified for key review area 2. 
 
The studies found were from a wide spread of countries, although most were from the 
USA (21) where eGFR was first introduced. Fifteen of the studies were from Europe, 3 
of which were UK based. There is much discussion in the literature on the different 
creatinine assay methods and the effects that might have on the equation use and 
accuracy. This might mean that it is difficult to compare studies from different 
countries, however, if there is good evidence from many different countries, it lends 
confidence in the generalisability of the findings. 
Nearly half the studies included focussed specifically on the effect for older people, 
although the age thresholds varied with ≥65/ 70/ 75/ 80 years being used.  
2.6.5.3 Heterogeneity 
Studies included showed wide variation in study design, kidney function measurement, 
estimation and analysis, which equations investigated, what drugs or reference 
markers, and different healthcare settings. There was also a lack of consistency in the 
reporting of outcome measures. As a consequence, it is inappropriate to make direct 
comparisons, or pool data, but by grouping according to outcome measures it has 
allowed independent comparison. The outcomes for the kidney function equation 
review are ordered in relation to level of evidence in comparing equations.
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principal 
author
hierarchy 
of 
evidence 
(based on 
OCEBM)
year country study type setting
participant 
number
drugs/ reference studied outcomes
Hellou Level 1b 2010 France literature review 27 studies
CG was safer and less biased than MDRD in an older population in the 1 most relevant study found 
(Lamb et al, 2005).
Spruill Level 1c 2008 USA literature review 28 studies
There are substantial mathematical differences inherent in the prediction equations that make any 
clinical comparison difficult; the decline in kidney function with age is expressed linearly with CG 
and exponentially with MDRD.
Hudson Level 1d 2011 USA literature review 10 studies
Substantial discrepancies exist in estimates of kidney function in the elderly, and that dosing 
regimens for most currently available drugs are based on pharmacokinetic studies that use 
creatinine clearance.
Nyman Level 1d 2011 USA literature review The available evidence did not support substitution of CG with MDRD for drug dosing purposes.
Corsonello Level 2b 2012 Italy retrospective survey hospital 10,442 older patients
CKD-EPI-based estimates out-performed CG, and particularly MDRD-based estimates as a 
predictor of ADRs with hydrosoluble drugs.
Howard Level 2b 2013 UK cross-sectional survey primary care 37 older people taking nitrofurantoin
Older patients with reduced kidney function were more likely to need a follow up course of an 
alternative antibiotic if MDRD was used to calculate the kidney function.
Melloni Level 2b 2008 USA retrospective survey hospital 46,942 Anticoagulant GP IIb/IIIa inhibitors
MDRD identified fewer patients for dose adjustment and increased the likelihood of dose-
associated bleeding.
Chin Level 2c 2013
New 
Zealand
retrospective 
pharmacokinetic analysis
hospital 240 gentamicin clearance
CG was associated with the highest percentage equation result within 30% of the reference 
gentamicin marker: 69%, adjusted p<0.001 compared with MDRD, and p=0.001 with CKD-EPI).
Glatard Level 2c 2015 France pharmacokinetic analysis hospital 78 vancomycin clearance
The use of an equation different from that used in the original dosing studies could significantly alter 
predictive performance.
Roberts Level 2c 2009
Australia & 
Denmark
pharmacokinetic analysis hospital 68 gentamicin clearance
MDRD overestimated kidney function as age increased (29% and up to 69%) and CG 
underestimated kidney function, though this was of a smaller magnitude (10%), consistent across 
age.
Ryzner Level 2c 2010 USA
retrospective 
pharmacokinetic analysis
hospital 55 gentamicin clearance CG was found to have a better agreement with actual drug clearance than MDRD.
Dufour Level 2d 2012 France prospective survey hospital 92 enoxaparin CG equation was able to predict the risk of higher anti-Xa levels, whilst MDRD did not
Chauvelier Level 2e 2012 France prospective cohort hospital 157 measured creatinine clearance
CG gave a better prediction for measured creatinine clearance than MDRD, the result within 30% 
of the reference were 63% for CG and 37% for MDRD.
Dowling Level 2e 2013 USA cross-sectional survey primary care 269 measured creatinine clearance
MDRD and CKD-EPI equations significantly overestimated measured creatinine clearance in 
elderly individuals which would lead to dose calculation errors for many drugs.
Pequinot Level 2e 2009 France prospective cohort hospital 121 measured creatinine clearance
CG slightly underestimates creatinine cleaerance, and MDRD strongly overestimates it. CG gave a 
better prediction of measured creatinine clearance than MDRD
Rimon Level 2e 2004 Israel prospective cohort hospital 154 measured creatinine clearance Found no equations to be accurate.
Stevens Level 2e 2009 USA pharmacokinetic analysis 5,504
iodine-125–iothalamate urinary 
clearance
Conclude that MDRD can be used for pharmacokinetic studies and drug dosage adjustments.
Denetclaw Level 4 2011 USA case report hospital 2 taking dofetilde
For an 83 year old woman, and a 92 year old man, calculations with MDRD caused significant 
increases in the QTc interval, indicating an adverse effect on the heart.
Cabello-
Muriel
Level 5 2015 Spain cross-sectional survey hospital 222 nephrotoxic drugs 145 (65%) dose would have been different (CG lower).
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Corsonello Level 5 2011 Italy survey
nursing home 
hospital
177 NH
439 hosp
general CG different to MDRD/CKD-EPI in up to a 1/3 of patients.
Daniel Level 5 2011 USA retrospective survey hospital 495 general CG most appropriate for drug dosing.
Dowling Level 5 2009 USA correspondance
Using iodine-125–iothalamate urinary clearance as a reference inherently favours MDRD as that 
was what was used to derive the equation.
Farnier Level 5 2013 USA prospective survey hospital 249 general Use of MDRD or CKD-EPI would give an overdose in 20-25% of older patients.
Gill Level 5 2007 Canada cross-sectional survey care home 180 digoxin and amantadine MDRD  20% fewer patients would have qualified for a dose reduction.
Golik Level 5 2008 USA prospective survey hospital 207 general
A significant difference in drug dosing regimens between the MDRD method and the Cockcroft Gault 
method.
Hanlon Level 5 2011 USA longitudinal survey nursing home 1,304 general
11.89% patients via CG and only 5.98% via MDRD had evidence of potentially inappropriate 
prescribing of at least 1 renally cleared medication.
Helldén Level 5 2013 Sweden retrospective survey primary care 790 dabigatrin, gabapentin,valaciclovir MDRD would result in higher doses.
Hermsen Level 5 2009 USA retrospective survey hospital 372 antimicrobials 40% would get different doses.
Huang Level 5 2014 USA cross-sectional survey hospital 356 metformin MDRD higher odds of inappropriate dose.
Hudson Level 5 2014 USA retrospective survey hospital 4,160
allopurinol, enoxaparin, 
gabapentin, piperacillin/ 
tazobactam and 
sulfamethoxazole/trimethoprim
MDRD and CKD-EPI give higher KF estimates than CG.
Laroche Level 5 2006 France retrospective suvey
hospital & 
primary care
2,765 general Clearance values higher with MDRD.
Lessard Level 5 2013 USA retrospective survey primary care general Only 59.6% of patients would have been recommended the same dose.
McCallum Level 5 2013 UK cross-sectional survey primary care 4,120 NOACs
MDRD would mean many elderly patients with AF would either incorrectly become eligible for a 
NOAC or would receive too high a dose.
Moranville Level 5 2009 Italy retrospective survey hospital 4,698 general Total dosing errors for MDRD ranged from 9.8% to 18.2%, depending on the medication (p < 0.01).
Norris Level 5 2009 Canada retrospective survey care home 538 oseltamivir MDRD would have meant no dose changes.
Nyman Level 5 2015 USA prospective cohort hospital 6,881 general
Clinically and statistically significant differences in estimated GFR were found for CKD-EPI versus 
CG.
Park Level 5 2012 USA cross-sectional FDA 36 drugs multiple Using MDRD in place of CG for dosage modification yielded higher dosing recommendations. 
Roblin Level 5 2009 France prospective cohort hospital 140 general CG was 61 mL/min vs. 78 ml/min/1.73 m
2
 for MDRD (p<0.0001).
Wargo Level 5 2006 USA survey hospital 409 antimicrobials Different doses in 21-37% of patients.
Wargo Level 5 2010 USA survey hospital 409 antimicrobials A discordance rate of 15-25%.
Wood Level 5 2011 UK cross-sectional survey primary care 594 ≥65 years
28.7% had a kidney function level of <30ml/min calculated using CrCl-CG but only 6.6% with 
MDRD.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: CrCl: creatinine clearance; CG: Cockcroft Gault; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration equation; MDRD: Modification of Diet in Renal Disease equation; NOAC: Novel oral anticoagulant. 
Table 11: Studies found for scoping review area 2, listed in order of level of evidence. 
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2.6.5.4 Methodological quality 
More than half the studies found in this search were ‘mechanism-based reasoning’ 
(Level 5, see Table 11) in that they investigated a potential risk by calculating the 
different kidney function estimation equations and commenting on the degree to which 
they differ and would alter prescribing decisions. This is useful to highlight the potential 
problem, particularly for older people, and has been assessed for many different drugs 
and healthcare settings in the 23 studies. Better quality of evidence, that would provide 
greater confidence in the need to change practice, would be well designed studies to 
show whether any difference in the equation results would affect clinical outcomes, or 
which equation gives a better indication on the effect of kidney function on blood 
levels. Thirteen studies were classified as ‘Level 2’: 
 3 studies looked at clinical outcomes which would give the greatest confidence 
in what is the best estimate to reduce the risk of harm for patients (Level 2b). 
 4 studies looked at the effect on drug levels which would be the next best 
indicator as a high drug level would be an increased risk of ADR (Level 2c). 
 6 made comparisons with measured creatinine or in-vitro markers which are 
not directly linked to risk of harm but have been shown to be an indicator 
(Levels 2d & 2e).  
The included studies used objective and validated measurements and outcomes with 
analyses such as linear regression analysis and analysis of variance to investigate 
correlation and account for confounding factors.  
No good published Level 1 systematic review evidence was found of the use of kidney 
function estimation for prescribing decisions.  
2.6.5.5 Outcomes: Level 1 evidence - reviews 
Four reviews were found that aimed to explore differences between the historically 
used CrCl-CG and the now widely reported eGFR for prescribing decisions, and/or use 
for estimating the kidney function of older people. Helou (2010) reviewed 27 studies, 
included if they used a gold standard glomerular filtration rate measure. This review 
did not assess use for prescribing, but did look at older people as a defined group. A 
systematic method was described, performance and bias measures discussed, but 
issues of blinding were not considered. The sample populations varied considerably, 
so they did not pool the data, but stratified to gather homogenous samples based on 
patient characteristics, including ‘geriatrics’. Helou reported that MDRD was more 
precise, safe and accurate than CrCl-CG in predicting the glomerular filtration rate 
except in CKD patients with normal serum creatinine, where CrCl-CG was ‘clearly 
superior’. Three studies were identified investigating the equation use in the older 
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patient, and one further study that allowed extraction of an older age sub-group. 
However, they identified weaknesses with all but one study (Lamb et al, 2005) which 
found that CrCl-CG was safer and less biased than MDRD in their study population 
(age range 69-92 years, mean 80±5). The author comments that the success of the 
Cockcroft Gault equation is not due to the original development study itself, which 
contained several weaknesses, but to its validation in several later studies compared 
to both measured CrCl values and reference GFR measurement methods.  
Spruill et al (2008) identified 28 studies in their review to make mathematical 
comparisons between the equations. They discuss that there are substantial 
mathematical differences inherent in the prediction equations that make any clinical 
comparison difficult; the decline in kidney function with age is expressed linearly with 
CrCl-CG and exponentially with MDRD. None of the articles identified found that the 
use of the MDRD equation in the older person was better than the Cockcroft Gault 
equation for estimating renal drug elimination. The authors conclude that, although 
MDRD may be useful for estimating glomerular filtration rate, CrCl-CG should still be 
used for drug adjustments.  
Two narrative reviews were found on estimating glomerular filtration rate for drug 
dosing, and considering older patients as a special population in this field. Both were 
not systematic reviews, and the method for study selection was not given. The 
Nephrology Practice and Research Network of the American College of Clinical 
Pharmacy (Nyman et al, 2011) reviewed the evidence comparing kidney function 
estimation equations. They concluded that the available evidence did not support 
substitution of CrCl-CG with MDRD for drug dosing purposes. Hudson & Nyman 
(2011) highlight that substantial discrepancies exist in estimates of kidney function in 
the elderly, and that dosing regimens for most currently available drugs are based on 
pharmacokinetic studies that use creatinine clearance estimated by Cockcroft Gault as 
the measure of kidney function.  
2.6.5.6 Outcomes: use of patient based clinical outcomes to compare 
equations 
Use of clinical outcomes to test the validity of the kidney function estimates for 
prescribing decisions, and for older people, would provide evidence of what actual 
harm might be caused. Four studies were found that investigated patient based clinical 
outcomes. Two were high quality, large trials. The other two were one case study 
report and a small single practice pilot study that give an indication of other possible 
differences in patient outcomes with use of the different equations. 
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Melloni et al (2008), surveyed patient records on a registry of those admitted for non-
ST-segment elevation acute coronary syndromes, and whether the kidney function 
estimation equation used would inform the dosing of injected anticoagulants 
(glycoprotein-IIb-IIa-inhibitors e.g. eptifibitide, or low molecular weight heparins e.g. 
enoxaparin). There was a linear relationship between glomerular filtration rate and risk 
of bleeding. The sample of 46,942 patients only needed 5.5% to be excluded for the 
final analysis because of key variables not being available (such as SrCr, age, weight). 
Objective validated measurements and outcomes were clearly defined and there was 
a detailed analysis of possible confounding factors such as race, diabetes, or prior 
myocardial infarction. Major bleeding events were more frequent in individuals who 
received doses of glycoprotein-IIb-IIa-inhibitors as assessed by the MDRD equation 
versus CrCl-CG (21.8% vs 17.8%; odds ratios MDRD 1.57 [95%CI: 1.35-1.84], CrCl-
CG 1.31 [95%CI: 1.12-1.54]). MDRD identified fewer patients for dose adjustment and 
increased the likelihood of dose-associated bleeding. From a safety perspective, the 
authors state that their results support current recommendations for use of the CrCl-
CG formula for antithrombotic dosing in an acute coronary syndrome population.  
Corsonello et al (2011) surveyed data from a large collaborative observational study 
group ‘The Italian Group of Pharmacoepidemiology in the Elderly’ which periodically 
surveys drug consumption and occurrences of ADRs. Records for 17,186 patients, 
mean age 70.2 ±14.9 years, were reviewed. In this study 39% needed to be excluded 
because variables were not available, which is a limitation of this design. The 6,744 
patients excluded were significantly older (age >80 years 40.1% vs 28.8%, p<0.001), 
more likely to be female, and have functional and cognitive impairment, which might 
impact on the results of this study. In the 10,442 hospitalised patients CKD-EPI-based 
estimates out-performed CrCl-CG, and particularly MDRD-based estimates as a 
predictor of ADRs with hydrosoluble drugs. They state that this study shows there is a 
difference, but that it does not prove use of any of the equations would lead to a 
reduction in ADRs, but that it strengthens the need for a formal trial.  
Two case studies of older patients have been reported where the USA antiarrhythmic 
agent dofetilde dose calculations with MDRD, as opposed to CrCl-CG caused 
significant increases in the QTc interval, indicating an adverse effect on the heart 
(Denetclaw and Dowling, 2011). A small pilot audit on the effectiveness of 
nitrofurantoin suggested that older patients with reduced kidney function were more 
likely to need a follow up course of an alternative antibiotic if MDRD was used to 
calculate the kidney function (Howard & Wood, 2012). The records of 37 older patients 
who had had a course of nitrofurantoin at one GP practice were reviewed. Where CrCl 
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was >60ml/min, 15 were reviewed and none needed further antibiotics or had any 
record of still being symptomatic; for the 22 with CrCl <60ml/min 18 had further 
antibiotics or were recorded as still symptomatic. Only 7 of the latter group had an 
eGFR <60 ml/min/1.73m2 so many would have been missed. 
2.6.5.7 Outcomes: Use of drug levels to compare equations 
Drug levels are used in healthcare to indicate whether effective levels have been 
reached, or risk of ADR if levels are too high. Use of drug levels is therefore a good 
indicator for comparison of kidney function estimation equations. 
Gentamicin 
Three studies have used gentamicin as a marker for comparison of the equations. 
Gentamicin is a highly water-soluble antibiotic that undergoes complete renal excretion 
via filtration so it is well suited as a marker of kidney function, and there is standard 
pharmacokinetic monitoring. Roberts et al (2009) studied the gentamicin clearance for 
68 patients in 2 hospitals. They describe objective and validated measurements and 
outcomes with linear regression analysis and analysis of variance to investigate 
correlation and account for confounding factors. They found that MDRD overestimated 
kidney function as age increased (29% and up to 69%) and CrCl-CG underestimated 
kidney function, though this was of a smaller magnitude (10%), consistent across age, 
and thus the CrCl-CG is better suited for dose calculation, especially for older people; 
age significantly influenced MDRD overestimation in their population (p = 0.037).  
Ryzner (2010) did a retrospective review of patients receiving aminoglycoside therapy 
(e.g. gentamicin). Fifty-five patients were identified on a hospital internal pharmacy 
database. CrCl-CG was found to have a better agreement with actual drug clearance 
than MDRD. The concordance correlation coefficient was 0.53 (0.18-0.88) for CrCl-CG 
and 0.41 (0.04-0.78) for MDRD, and this was agreed with the Pearson’s coefficient 
(0.76 for CrCl-CG, and 0.65 for MDRD). Subgroup analysis showed highest 
correlations for the CrCl-CG equation was for >65 year olds, females, and African 
Americans. 
Chin et al (2013) reviewed data for 240 patients on a gentamicin dosing database. 
They found that CrCl-CG was associated with the highest percentage equation result 
within 30% of the reference gentamicin marker: 69%, adjusted p<0.001 compared with 
MDRD, and p=0.001 with CKD-EPI. CKD-EPI performed better when adjusted for 
body surface area, but that is not done in practice. The authors state that their study 
adds to the evidence base for using CrCl-CG for drug dosing. 
 
82 
 
Vancomycin 
The rate of elimination of vancomycin is directly related to creatinine clearance. 
Glatard et al (2015) compared the abilities of different kidney function estimation 
equations to describe vancomycin pharmacokinetics in 78 elderly patients. Their 
analyses showed considerable variation for the different estimation equations and they 
conclude that the use of an equation different from that used in the original dosing 
studies could significantly alter predictive performance. 
2.6.5.8 Outcomes: use of a drug effect marker to compare equations 
Older people have an increased risk of low molecular weight heparin accumulation 
leading to an increased bleeding risk from raised ‘anti-Xa’ levels. In 92 consecutive 
hospitalised patients older than 65 years receiving prophylactic enoxaparin treatment, 
the CrCl-CG equation was able to predict the risk of higher anti-Xa levels, whilst 
MDRD did not (Dufour et al, 2012). A significant correlation was observed between 
anti-Xa activity and glomerular filtration rate estimated with the CrCl-CG (r=0.43; p 
=0.0002), but no significant association between anti-Xa levels and MDRD estimated 
glomerular filtration rate (p=0.33) was observed. 
2.6.5.9 Outcomes: use of kidney function markers to compare 
equations 
Comparison with measured creatinine clearance 
When comparing results using kidney function estimation equations with measured 
creatinine clearance, 3 of the 4 studies looking at the effect in older people found that 
MDRD was least effective. Pequignot et al (2009) compared the MDRD and CrCl-CG 
formulae with 24hr urine creatinine for 121 consecutive patients aged over 70 years; 
they concluded that in elderly hospitalised patients, CrCl-CG slightly underestimates 
creatinine clearance, and MDRD strongly overestimates it. CrCl-CG gave a better 
prediction of measured creatinine clearance than MDRD. Dowling et al (2013) report a 
cross-sectional analysis of data from 269 community-dwelling volunteers (mean age 
81 ±6 years) randomly selected from the Baltimore Longitudinal Study of Aging. They 
found the MDRD and CKD-EPI equations significantly overestimated measured 
creatinine clearance in elderly individuals which would lead to dose calculation errors 
for many drugs. Chauvelier et al (2012) conducted a prospective, cross-sectional, 
observational study in four hospital geriatric wards, and recruited 157 consecutive 
patients admitted to the wards who were aged >75 years and had an indwelling urinary 
catheter. They too found CrCl-CG gave a better prediction for measured creatinine 
clearance than MDRD, the result within 30% of the reference were 63% for CrCl-CG 
and 37% for MDRD. Rimon et al (2004) found no equations to be accurate in their 
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prospective, observational study of 154 consecutive patients aged ≥80 years with 
urinary catheters, admitted over a 12-month period to the acute geriatric ward, 
although their threshold was set at ± 10% from measured creatinine clearance which 
is lower than other studies. 
Comparison with chemical markers 
Stevens et al (2009) is frequently quoted as having the largest study population to 
compare drug dosing recommendations based on measured glomerular filtration rate 
and kidney function estimating equations. They used a pooled data set of 5,504 
patients from 6 studies and 4 clinical populations, and they concluded that MDRD can 
be used for pharmacokinetic studies and drug dosage adjustments. However, the 
mean population age was 47 years and so there cannot be confidence that this finding 
is applicable to an older population. Comments on this study by Hudson & Nyman 
(2011) highlight that the reference was to measured iodine-125–iothalamate 
glomerular filtration rate, which is different to how drug pharmacokinetic studies are 
done, making comparisons less valid.  Dowling et al (2009) points out that using 
iodine-125–iothalamate urinary clearance as a reference inherently favours MDRD as 
that was what was used to derive the equation. 
Froissart et al (2005) used renal clearance of the marker 51chromium edetic acid 
(51CrEDTA), which is not metabolized and is excreted solely by the kidney, to compare 
using either the CrCl-CG equation or the MDRD formula in a cohort of 2,095 adult 
Europeans. Their conclusions were based on staging kidney disease, not drug dosing, 
but they did state that MDRD was more precise and accurate except for women aged 
≥65 years with low kidney function. 
2.6.5.10 Outcomes: comparison of the effect of equation choice by 
calculation 
The difference in dosing resulting from calculations using the different equations has 
been reported on in many studies. This ‘mechanism-based reasoning’ has been 
classified as ‘Level 5’ in the OCEBM Levels of Evidence (Oxford Centre for Evidence-
Based Medicine, 2011) and the 23 studies found are listed in Table 11 as ‘Level 5’. All 
these studies suggest that there would be a significant difference in the dose of drugs, 
or use of drugs, depending on whether eGFR (calculated using MDRD) or CrCl-CG 
has been used. The largest prospective cohort study (n=6,881) found clinically and 
statistically significant differences for CKD-EPI versus CrCl-CG (Nyman et al, 2015), 
and a retrospective study (n=4,698) found total dosing errors for MDRD ranged from 
9.8% to 18.2%, depending on the medication (p < 0.01) (Moranville, 2009). In the case 
note review (Chapter 1) 28.7% had a kidney function level of <30ml/min calculated 
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using CrCl-CG but only 6.6% with MDRD. However, the study designs do not include 
any reference markers or outcomes to see if there are actually any differences on the 
effect of the drug for patients, or ADRs caused.  
2.6.5.11 The need to use estimation equations not serum creatinine 
Several studies have shown that older people can have significantly low kidney 
function despite a ‘normal’ serum creatinine level (SrCr). For example, in a prospective 
assessment of 2,781 people referred for a SrCr level in Canada, 91.4% were normal 
but for 12.6% of those aged 60-69 years CrCl was ≤50ml/min, and 47.3% of those 
aged 70 years and older (Duncan et al, 2001). Also in Canada, a look back at out-
patients found that just 15 of the 55 people with severe renal failure had been referred 
to nephrology because only SrCr had been assessed (Swedko et al, 2003). Gianelli et 
al (2007) compared SrCr to measured CrCl and 25% of those aged ≥65 years with a 
normal SrCr had a measured CrCl of <60ml/min, and Malyszko et al (2011) found that 
those aged ≥65 years had a significantly lower kidney function compared to younger 
people despite identical SrCr. 
2.6.5.12 Drugs implicated 
The range of studies found highlight that prescribing decisions for many drugs would 
be affected by which equation is used; examples include gabapentin, antibiotics, and 
anticoagulants (Hudson and Nyman, 2011; Melloni et al, 2008; McCallum et al, 2013). 
 
 Summary 
Only two good quality outcome studies were found that would give the most valid 
measure of effect for patients, and they were for specific drugs only. However, drug 
blood level studies, and chemical marker studies, using different drugs and methods, 
show that the Cockcroft Gault calculation should still be used for drug dosing decisions 
and, in particular for the older patient because the MDRD equation is likely to 
overestimate the kidney function level. The theoretical calculation studies suggest that 
a wide range of drugs would be affected by the choice of estimation equation used for 
prescribing decisions. 
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2.7 Key review area 3 – evidence on the risks of prescribing 
in reduced kidney function 
 
 Research question for key review area 3 
What are the risks to the older person in primary care of not following the 
recommendations for prescribing in reduced kidney function? 
 
 Identification of relevant studies- search criteria 
The search categories were ‘Renal impairment’ AND ’ADRs’ AND ‘Elderly’ AND 
‘Primary Care’ (see Appendix 3, 0, for the subject headings and key words for each 
search category). The search term ‘review’ was added to the Medline search to find 
any relevant review papers.  
 
 Study selection – inclusion/exclusion criteria 
Study selection from the search results were based on the following criteria. Although 
the research question is focussed on primary care, other healthcare settings were 
included for comparison. 
Inclusion 
 English language. 
 Primary empirical research and reviews of primary empirical research. 
 Intervention or outcome relating to assessment risks associated with not 
applying the prescribing recommendations in reduced kidney function. 
Exclusion 
 Opinion or discussion articles. 
 
 Hierarchy of evidence and appraisal 
The research question asked ‘what are the risks of treatment harm?’ As the potential 
risk of harm is from drugs with a known ADR profile, the enquiry is ‘how common is the 
problem’ of ADRs when kidney function is not taken into account’. The OCEBM Levels 
of Evidence (2011) would then give the ‘Level 1’ evidence to be ‘local and current 
random sample surveys (or censuses)’, where, for example, an ADR has caused a 
hospital admission. Some ADR effects may need to be studied over time, for example 
mortality, where a longitudinal study would be required. If good level 1 evidence is not 
found then studies of lower level relevance, and non-local evidence, would give an 
insight into whether further research is needed. Table 12 lists the hierarchy of 
evidence developed for key review area 3 based on the OCEBM Levels of Evidence.  
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The issues considered when appraising the report of a descriptive survey were 
whether the results of the study were valid, what were the results, and would the 
results help locally, i.e. in UK primary care. To aid the quality assessment the ‘Critical 
Appraisal of a Survey’ tool from the Centre for Evidence Based Management was 
used. For other study designs, the CASP ‘Study checklists’ informed the review. 
Studies were assessed and only included where the focus, methods, recruitment and 
sampling, valid and reliable objective measurements used, and outcomes were clearly 
defined, relevant and appropriate to the research question. 
 
Table 12: Hierarchy of evidence table for key review area 3 ‘how common is the 
problem?’ developed from the OCEBM Levels of Evidence.  
 
As this search was looking for evidence of the risks of not following the prescribing 
recommendations for RKF, a prospective investigation would give more precise 
estimates of the relative risk of the outcome based on exposure, and have fewer 
potential sources of bias and confounding than retrospective studies. However, where 
a risk might be small, the large numbers needed might require a retrospective design 
to make it feasible. The search criteria were left open to capture all relevant studies. 
 
 Collation and appraisal 
2.7.5.1 Description of studies 
Thirty-two relevant papers were found from the database searches (Figure 10) on the 
risks to patients if prescribing in reduced kidney function does not follow the 
recommendations. Table 13 lists the included studies in order of the level of evidence 
they provide.  
ADRs resulting from inappropriate prescribing in RKF seems to have been recognised 
in the literature from the 1990s, with studies found dating from that time. Most of the 
hierarchy of 
evidence
description
Level 1 Local and current random sample surveys (or censuses)
Level1b Local random sample surveys (or censuses) - not current/ not primary care
Level 2 Systematic review of surveys that allow matching to local circumstances
Level 2b Systematic review of surveys that allow matching to local circumstances - not current/ low quality for primary care
Level 3 Local non-random sample
Level 4 Local case series
Non-local level 1 Non-local and current random sample surveys (or censuses)
Non-local level  1b Non-local random sample surveys (or censuses) - not current/ not primary care
Non-local level 3 Non-local non-random sample
Non-local level 3b Non-local non-random sample - not current/ not primary care/ very different population
Non-local level 4 Non-local case series
Non-local level 4b Non-local case series - not current/ not primary care
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studies found come from the early 2000s onwards suggesting an increased awareness 
and enquiry into the risks of drugs when kidney function is reduced. 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Number of studies identified for key review area 3 
 
The OCEBM Levels of Evidence state that local evidence is best to understand how 
common a problem might be (Oxford Centre for Evidence-Based Medicine, 2011), but 
only three studies were identified from the UK, and all were drug specific (NSAIDs, 
heparin, and nitrofurantoin). There were no geographical limits put on the scoping 
review searches and most studies were based in countries that might be considered to 
have similar populations to the UK, although the healthcare systems may be different, 
for example the USA (x7), Australia (x2), and Western Europe (x13) (see Table 13). 
Seven studies were from differing populations, and were all hospital based, Taiwan 
(Chen et al, 2014), Israel (Zaidenstein et al, 2002), India (Cestalino et al, 2011; Joshua 
et al, 2007), Malaysia (Hassan et al, 2011), and 2 from Dubai (both Sharif-Askari et al, 
2014). These studies, that report a wide range of ADRs related to prescribing in RKF, 
suggest it should be recognised as a multi-national problem. 
Only six studies found were based in primary care, one in the UK. Three further 
studies looked at ADRs on admission which were most likely to have originated in 
primary care, one of which was UK based focussing on NSAIDs as a cause of 
hospitalisation (Evans et al, 1995). The prescribing systems and procedures are 
different to those in hospitals, including advanced computerised patient record 
systems used in UK primary care that might mean different findings to hospital based 
studies.  
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principal 
author
hierarchy of 
evidence (based on 
OCEBM)
year country study type setting
participant 
number
participant type outcomes
Evans Level 1b 1995 UK case control
hospital 
admission
207 admission with AKI
Recent exposure to NSAIDs and previous exposure to aspirin were 
independently associated with hospitalisation for AKI.
Marcum Level 2b 2011 USA
narrative literature 
review
anti-hypertensives
The most common ADRs associated with antihypertensive use in CKD 
include hyperkalemia, AKI, and orthostatic hypotension.
Howard Level 3 2013 UK
cross-sectional 
survey
primary care 37
older people taking 
nitrofurantoin
Older patients with reduced kidney function were more likely to need a 
follow up course of an alternative antibiotic if they had RKF and 
nitrofurantoin was prescribed.
Farooq Level 3 2004 UK case-note review hospital 10 on heparin 8% ADR rate found related to use of drugs in RKF
Breton Non-local Level 1 2011 France prospective cohort primary care 8,701 ≥65 years 
Mortality increased by 40% for older people on drugs inappropriate for 
level of kidney funciton.
Borchelt Non-local Level 1 1994 Germany
cross-sectional 
survey
primary care 336 ≥70 years 25.8% had a definite and specific ADR, related to kidney function.
Adams Non-local Level 1 2011 Australia longitudinal survey primary care 357 general population 30.8% on NSAIDs had Stage 3 or higher CKD.
Helldén Non-local Level 1 2009 Sweden
retrospective 
survey
hospital 
admission
154 ≥65 years 
14% of hospital admissions were primarily caused by ADRs and one-
third of these were related to impaired kidney function. 
Geerts Non-local Level 1 2013 Netherlands
retrospective 
cohort
primary care 21,317
had a course of 
nitrofurantoin
Risk of pulmonary adverse events leading to hospitalisation was 
significantly increased (HR 4.1, 95 % CI 1.31-13.09).
Handler Non-local Level 1 2014 USA
retrospective 
survey
nursing home 249
nursing home resident with 
AKI alert
AKI alerts for 249 patients still led to 70 cases of kidney injury and 44 
cases of failure
Chen Non-local Level 1b 2014 Taiwan case control hospital 295 ≥65 years 
Increased concentration of serum creatinine was an independent risk 
factor for an ADR caused hospital admission.
Caamano Non-local Level 1b 2005 Italy
cross-sectional 
survey
hospital 19,070
≥65 years registered for 
home care
RKF is associated with ADR at hospital admission (odds ratio [OR] = 
1.76; 95% CI: 1.41–2.55). 
O'Connor Non-local Level 1b 2012 Ireland prospective hospital 513 >65 years 26% of 513 had an ADR, and RKF increased the risk of ADR 
Leendertse Non-local Level 1b 2012 Netherlands
prospective case-
control
hospital 714
medication-related 
admission
10% of admissions were considered to be related to renal impairment.
Blix Non-local Level 1b 2006 Norway prospective survey hospital 201  eGFR<60 ml/min/1.73m2
62% had drug realted problems linked with renal risk drugs, and 26% of 
the renal risk drugs were associated with DRPs.
Cestac Non-local Level 1b 2003 France prospective survey hospital 334 on heparin 10.5% ADR rate found related to use of drugs in RKF
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Henry Non-local Level 1b 1997 Australia
retrospective 
survey
hospital 
admission
110
acute admission with raised 
SrCr
Association found between consumption of NSAIDs and the development 
of functional renal impairment.
Melloni Non-local Level 1b 2008 USA
retrospective 
survey
hospital 46942
Anticoagulant GP IIb/IIIa 
inhibitors
There was an increased risk of bleeding.
Corsonello Non-local Level 1b 2012 Italy
retrospective 
survey
hospital 10442 older patients Increased ADRs with hydrosoluble drugs.
Corsonello Non-local Level 1b 2005 Italy
retrospective 
cohort
hospital 11,687 ≥65 years 
Both concealed  and overt renal failure were associated with ADR to 
hydro-soluble drugs. 
Corsonello (2) Non-local Level 1b 2005 Italy
retrospective 
cohort
hospital 2,257 diabetic patients
Both concealed  and overt renal failure were associated with ADR to 
hydro-soluble drugs. 
Zaidenstein Non-local Level 3b 2002 Israel prospective survey hospital 496 on CVD drug Higher urea levels (RKF) associated with ADRs
Castelino Non-local Level 3b 2011 India prospective cohort hospital 308 RKF 19% had an ADR on a nephrology ward
Hassan Non-local Level 3b 2011 Malaysia prospective cohort hospital 300 CKD
44% ADRs, 22.7% suspected as the cause for admission, and 21.3% 
happened during admission
Hug Non-local Level 3b 2009 USA prospective cohort hospital 900 reduced CrCl 10% ADR rate found related to use of drugs in RKF
Schuler Non-local Level 3b 2008 Austria prospective cohort hospital 543 ≥75 years 17.8%  ADR rate found related to use of drugs in RKF
Sharif-Askari Non-local Level 3b 2014 Dubai prospective cohort hospital 512 stage 3-5 CKD 12.1%  ADR rate found related to use of drugs in RKF
Sharif-Askari Non-local Level 3b 2014 Dubai prospective cohort hospital 488
 unfractionated heparin or 
enoxaparin
Major bleeding occurred in a third of CKD patients who received 
enoxaparin or heparin
Joshua Non-local Level 3b 2007 India
retrospective 
survey
hospital 244 ADR on a nephrology ward 17%  ADR rate found related to use of drugs in RKF
Fischer Non-local Level 3b 2013 USA
retrospective 
cohort
hospital 7,413
Acute coronary syndrome 
on clopidogrel
Significantly higher risk of death and an over 2 fold increase in major 
bleeding in eGFR <60 ml/min/1.73m2
Denetclaw Non-local level 4b 2011 USA case report hospital 2 taking dofetilde
For an 83 year old woman, and a 92 year old man, calculations with 
MDRD caused significant increases in the QTc interval, indicating an 
adverse effect on the heart.
Lazarou Not classified 1998 USA
narrative literature 
review
kidney function was a factor rarely reported in the studies sampled and 
so they could not determine the effect on ADR rate
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: ADR: adverse drug reaction; AKI: acute kidney injury; CKD: chronic kidney disease; DRP: drug related problem; MDRD: Modification of Diet in Renal Disease equation; NOAC: Novel oral anticoagulant; NSAID: 
non-steroidal anti-inflammatory; RKF: reduced kidney function; SrCr: serum creatinine. 
Table 13: Studies found for scoping review area 3, listed in order of level of evidence. 
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The research question was to focus on older people, and 9 of the studies had older 
participants only. Other studies were included as many discussed that older people 
are more likely to have reduced kidney function; also, many studies reported older 
mean ages. 
2.7.5.2 Heterogeneity 
The included studies showed considerable variation in the characteristics of healthcare 
settings, patients versus drugs analysed, age thresholds, and kidney function 
measurement and estimation differences, similarly as discussed in previous sections.  
How renal risk drugs were defined and recognised also varied considerably, with 
different reference sources quoted, although many mentioned the BNF as well as their 
local reference sources. Some studies looked at ADRs from all drugs affected by RKF, 
whilst some focussed specifically on one drug or drug class, e.g. NSAIDs or 
anticoagulants. 
Definition, recognition and measurement of ADRs and their frequency were also 
widely varied. Nine studies describe using the World Health Organisation (WHO) 
definition of ADR as ‘a noxious, unintended, and undesired effect of a drug, which 
occurs at doses in humans for prophylaxis, diagnosis, or therapy’ (World Health 
Organisation, 1966). ‘Adverse drug event’ (ADE) is used in 7 studies which is ‘an injury 
resulting from administering a drug’ (Bates et al, 1993); this includes errors of 
administration, although that would not be relevant for this review. One study used 
‘drug-related-problem’ defined by the Pharmaceutical Care Network Europe (2002) as 
‘an event or circumstance involving drug therapy that actually or potentially interferes 
with desired health outcomes’, which differs by including potential adverse effect. 
Another study use ‘medication related problem’ (MRP) which is a standardised 
classification by Strand et al (1990). 
As a consequence of the wide variation, it is inappropriate to make direct comparisons 
for the whole set of included studies, or pool data. The studies were therefore grouped 
by healthcare setting to allow comparison, and then further organised into ADR type, 
for example, mortality, general ADR rate, NSAIDs, and anticoagulants. 
2.7.5.3 Methodological quality 
Use of the OCEBM hierarchy of evidence levels, and CEBM/CASP appraisal 
checklists, reveal only 4 of the studies would be classified as there were just 3 ‘local 
‘UK studies found, and 1 review (Table 13). The review had no method reported and 
was specific to ADRs associated with antihypertensives among older adults with 
chronic kidney disease. The 3 UK studies had a narrow drug focus and so, again, 
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would not provide generalisable evidence. However, the evidence from other countries 
was classified as ‘non-local’ but ‘Level 1’ in 6 studies, and ‘Level 1b’ in 11 studies, 
mostly where they were hospital based rather than primary care. A further 9 studies 
were given a level of ‘Non-local level 3’ where the study population was less likely to 
be similar to UK patients, or where it was not clear that the sampling was randomised 
or census. 
The longitudinal studies may have attrition bias if not all patients are followed up to the 
end, and the retrospective studies may have missing data from selection bias and 
information bias where the exposure, record keeping or outcome assessment cannot 
be controlled. 
2.7.5.4 Risk of harm outcomes: reviews 
No reviews were found that looked specifically at the effect of reduced kidney function 
on ADR rate.  
In Lazarou and Pomeranz’s USA review (1998) it was reported that kidney function 
was a factor rarely reported in the studies sampled and so they could not determine 
the effect on ADR rate. 
Marcum and Fried (2011) reviewed the literature to describe the potential medication 
errors and ADRs associated with antihypertensives among older adults with chronic 
kidney disease. This was a narrative review with no method provided other than ‘we 
have reviewed the literature’, consequently this was not classified as Level 1 evidence, 
but Level 3 at best. However, it is interesting that they state that few studies have been 
published describing ADEs in older adults with CKD, and that there is a paucity of 
clinical trial data in older adults with hypertension. They report the most common 
ADEs associated with antihypertensive use in this high risk population of older adults 
with CKD include hyperkalaemia, acute kidney injury, and orthostatic hypotension. 
2.7.5.5 Risk of harm outcomes: local studies based in UK primary care 
No studies were found to provide evidence of what the risks are to the older patient of 
not following the recommendations for prescribing in reduced kidney function in the UK 
primary care. 
2.7.5.6 Risk of harm outcomes: primary care based studies in other 
countries 
Mortality 
The high quality French prospective cohort study in primary care by Breton et al (2011) 
has been discussed previously regarding its prevalence data (2.5.5.6). This 
longitudinal study also aimed to assess any effect on mortality for older people taking 
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one or more drugs inappropriate in reduced kidney function. The 6-year mortality was 
assessed by active follow-up of all 8,701 participants, with only 8 for whom it remained 
unknown. Exposure of older people (≥65 years) to inappropriate drug use in RKF was 
independently related to higher all-cause mortality (hazard ratio 1.4, 95% CI 1.0–1.9) 
in participants with eGFR <60ml/min/1.73m2; all-cause mortality was significantly 
increased by 40%.  
General ADR rate 
Borchelt and Horgas (1994) report from the Berlin Aging Study where a representative 
sample of the primary care population aged 70 years and older (n=336) were screened 
for ADRs, fluid and electrolyte balance, and kidney function. They found 25.8% had a 
definite and specific ADR related to level of kidney function. Nursing home residents 
(mean age 74.2 years) in the USA were studied by Handler et al (2014) in a 
retrospective survey to determine the incidence of drug-associated acute kidney injury 
(AKI). They found that 668 AKI alerts for 249 patients still led to 70 cases of kidney 
injury and 44 cases of kidney failure. The most common medication classes included 
in the AKI alerts were diuretics, ACEIs/ARBs, and antibiotics. 
NSAIDs 
Non-steroidal anti-inflammatory drugs (NSAIDs) are a common cause of reported 
adverse drug side-effects including toxicity to the kidney. Adams et al (2011) analysed 
data from 3,206 adults attending first follow-up of the North West Adelaide Health 
Study in 2004-2006, a longitudinal representative population study. Objective and 
validated measurements were described and Pearson's Chi-square tests determined 
significant differences in proportions and multiple logistic regression was used to 
examine associations of socio-demographic characteristics with use of NSAIDs. They 
found that there was a high prevalence of NSAID use in Australia among groups at-
risk for significant drug-related adverse events: 60.8% had hypertension, 30.8% had 
Stage 3 or higher chronic kidney disease, 17.2% had a history of cardiovascular 
disease and 20.7% had a > 15% 10-year CVD risk. 
Nitrofurantoin  
Geerts et al (2013) used a large retrospective cohort study to determine whether 
treatment with the antibiotic nitrofurantoin in women with urinary tract infection (UTI) 
and renal impairment in primary care is associated with a higher risk of ineffectiveness 
and/or serious adverse events than in women without renal impairment. The 
secondary outcome in the design of this study was the occurrence of serious adverse 
events of nitrofurantoin leading to hospitalisation within 90 days. In the cohort of 
21,317 people who had taken nitrofurantoin the overall incidence density for adverse 
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events was 0.02 per 1,000 person-days, but in patients with renal impairment (<50 
ml/min/1.73 m2) the risk of pulmonary adverse events leading to hospitalisation was 
significantly increased (HR 4.1, 95 % CI 1.31-13.09). In the Howard at al (2013) pilot 
study discussed in Key review area 2 (1.6.5.6) older patients with RKF were more 
likely to need a follow up antibiotic indicating a lack of effect of nitrofurantoin and an 
increased risk from the infection. 
2.7.5.7 Risk of harm outcomes: hospital admissions 
Although these studies are based in hospital, by focussing on admissions the causes 
are most likely to have originated in primary care.  
Older people (≥65 years) registered to receive home healthcare admitted to the 
emergency department of a Swedish hospital were studied by Helldén et al (2009) to 
look at ADR rate and whether level of kidney function was a factor. This retrospective 
cohort study of 154 participants found that 14% of hospital admissions were primarily 
caused by ADRs and one-third of these were related to impaired kidney function. 
Creatinine clearance was significantly lower in the group with ADRs than those 
without. This cohort was more likely to be admitted than the comparison group who 
were not registered for homecare; they were older and more fragile. This study 
highlights the particular importance of kidney function assessment for very elderly and 
frail patients to reduce hospital admission. 
In a much larger cross-sectional database study, Caamaño et al (2005) aimed to 
identify and to measure the association between socio-demographic factors and the 
prevalence of adverse drug reaction at hospital admission in an elderly population in 
Italy. They assessed 19,070 admissions and found that 4.3% were diagnosed with an 
ADR and that the presence of RKF is associated with ADR at hospital admission (odds 
ratio [OR] = 1.76; 95% CI: 1.41–2.55). They used logistic regression to assess the 
effect of hepatic and renal diseases, number of diseases, number of drugs used, 
albumin index (indicator of nutritional condition) and cognitive function. Other factors 
associated with admission were number of drugs consumed (OR = 1.74; 95% CI: 1.47-
2.08) and, to a lesser extent, a low nutritional status (OR = 1.39; 95% CI: 1.17-1.64).  
In the Netherlands, 714 medication-related hospital admissions reported in the 
prospective multicentre study HARM (Hospital Admissions Related to Medication) 
were analysed. The patients (mean age 68 years) were divided into 3 groups based on 
the availability of creatinine levels: group A, the home-monitored group (n = 227); 
group B, the hospital-monitored group (n = 420); and group C, the unmonitored group 
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(n = 67). After adjustment for confounders, 70 admissions (10%) were considered to 
be related to renal impairment (Leendertse et al, 2012).  
One study was found based in Taiwan where the population and healthcare system is 
likely to be different to that of the UK. It also shows that RKF can be a factor in ADRs 
leading to admission. This prospective case-control study used logistic regression 
analysis to show that increased concentration of serum creatinine was an independent 
risk factor in 295 ADRs in older people that led to an emergency department visit 
(adjusted OR=1.5; 95% CI: 1.1-2.2); diuretics, analgesics, cardiovascular agents, anti-
diabetic agents and anticoagulants were the medications most commonly associated 
with an ADE (Chen et al, 2014).  
NSAIDs 
NSAIDs are frequently cited as a factor in causing hospital admission. Two case-
control studies highlight that NSAIDS are an important cause of RKF and AKI. Henry 
et al (1997) analysed the relationship between recent use of NSAIDs and the presence 
of functional renal impairment present at the time of hospitalisation with a range of 
clinical problems. In 110 consecutive hospital admissions, with 189 controls, the 
association between consumption of NSAIDs (including non-prophylactic aspirin) and 
the development of functional renal impairment, adjusted OR, was 6.6 (0.75, 57.8) in 
subjects with a previous history of renal disease.  
A UK case-control study of patients hospitalised with AKI showed that recent exposure 
to NSAIDs and previous exposure to aspirin were independently associated with 
hospitalisation for AKI, with adjusted odds ratios of 2.20 (1.49-3.25) and 2.19 (1.46-
3.30), respectively (Evans et al, 1995). There is an approximate doubling of the risk of 
hospitalisation with AKI with use of oral NSAIDs. 
2.7.5.8 Risk of harm outcomes: studies based in hospital 
ADR rate 
ADR rates relating to RKF ranged from 3% to 62% in the fourteen hospital based 
studies found. The largest is an earlier retrospective study of the hospital data from the 
‘Italian Group of Pharmacoepidemiology in the Elderly’ (GIFA) collaborative 
observational study group to that discussed in 1.6.5.6 on risk of ADRs in RKF and 
which equation would be a better predictor (Corsonello et al, 2012). Analysis of 11,687 
older people (>65 years) consecutively admitted to the participating centres revealed 
that 8% had an ADR during their hospital stay, and a third of those were from hydro-
soluble drugs (Corsonello et al, 2005). The 3 categories studied were grouped 
according to creatinine level and eGFR. After adjusting for potential confounders, both 
96 
 
concealed (OR, 1.61; 95% CI, 1.15-1.25) and overt (OR, 2.02; 95% CI, 1.54-2.65) 
renal failure were associated with ADR to hydro-soluble drugs. ‘Concealed’ renal 
failure was defined as renal insufficiency despite a normal serum creatinine, as is 
more likely for older people because of loss of muscle mass (and consequently lower 
production of creatinine). As has been highlighted for many other studies, 5,499 (32%) 
of the patients had been excluded, most of whom because a kidney function 
estimation was not available, although they were analysed to show that the excluded 
patients did not differ otherwise from the study population. The authors found similar 
results when they studied 2,257 older diabetics, where RKF is highly prevalent, from 
the same GIFA study group where 10% had an ADR during their hospital stay, and 
42% of those were to hydrosoluble drugs (Corsonello et al (2), 2005). Multivariable 
Cox regression analysis showed that both concealed (hazard ratio = 1.90; 95% 
confidence interval, 1.04-3.48; p =.036) and overt (hazard ratio = 2.23; 95% 
confidence interval, 1.40-3.55; p =.001) renal failure were significantly associated with 
ADR to hydrosoluble drugs. 
In the prospective multi-centre design used by Blix et al (2006), fewer participants 
were enrolled (827), but only 2.3% needed to be excluded because of kidney function 
data not being available, a strength of this design. ‘Drug related problems’ (DRPs) 
linked to the renal risk drugs were found for 62% of the patients with eGFR 
<60ml/min/1.73m2, and 26% of the renal risk drugs were associated with DRPs. The 
most common drug classes associated with DRPs were antibacterials, antithrombotic 
agents, angiotensin-converting enzyme (ACE) inhibitors, opioids and non-steroidal 
anti-inflammatory drugs (NSAIDs).  
O’Connor et al (2102) prospectively studied 513 acutely ill patients aged >65 years in 
a hospital in Ireland; 26% of 513 had an ADR, and RKF increased the risk of ADR 
(OR: 1.81, 95% CI: 1.12-2.92). Schuler et al (2008) studied hospital patients aged 75 
years and older and found ADEs for 17.8%, half of which had caused the admission to 
hospital; renal dysfunction was one of the risk factors found for ADE. In the 90 ADEs 
found in 900 USA community hospital patients with RKF exposed to nephrotoxic 
drugs, 51% were serious, 4.6% life-threatening and 91% were judged preventable; this 
report had a minimal description of the method used, but a comprehensive 
presentation of results (Hug, 2009).  
Five further studies were found from countries that are likely to have a very different 
population, but they have been included to compare whether ADRs from renally 
excreted drugs are a problem in other parts of the world. A retrospective study of 
inpatients with ADRs (July 2005-June 2006) in a nephrology ward in India found that of 
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1,464 case records reviewed, 267 drugs contributed to 294 ADRs. Serious ADRs 
accounted for 12% of the total ADRs, including acute renal failure (22%), 
hypo/hyperglycaemia (13%), hyper/hypokalaemia (13%), bone marrow suppression 
(5%) and hepatic injuries (4%). Three patients died out of the 244 included 
participants. Polypharmacy, serious ADRs, multiple ADRs, longer time to recover, and 
longer period of hospitalisation were found to be more frequent among the renal 
dysfunction group (p < 0.05) (Joshua et al, 2007). In another Indian renal unit study of 
308 patients, 19% had a ‘medication related event’ (Castelino et al, 2011). 
A prospective cohort study of patients on a Malaysian nephrology ward showed a high 
rate of 44% ADEs, 22.7% suspected as the cause for admission, and 21.3% 
happened during admission. The medication classes most frequently involved in ADEs 
were diuretics, antibacterials, drugs used for diabetes mellitus, antithrombotic agents, 
mineral supplements and antihypertensive drugs (Hassan et al, 2010). In Dubai, 
12.1% of 512 CKD patients experienced an ADR whilst in hospital (Sharif-Askari et al, 
2014), and in Israel Zaidenstein et al (2002) found that serious ADEs were developed 
by 4% of hospitalised patients taking cardiovascular drugs. Those at highest risk were 
older, were receiving multiple drug therapy, and had higher urea levels indicating RKF. 
Anticoagulants and antiplatelets 
Anticoagulants have been studied in relation to kidney function and risk of bleeding if 
blood levels are too high. As discussed in the previous Key review area 2 (2.6.5.6), the 
Melloni et al (2008) study showed that RKF increased the risk of major bleeding when 
the anticoagulant GP IIb/IIIa inhibitors such as eptifibitide were prescribed. Cestac et 
al (2003) and Farooq et al (2004) studied patients with RKF given low molecular 
weight heparin and found an ADR rate of 10.5% and 8% respectively. The Cestac 
study was a larger prospective survey (n=334, whilst the Farooq case-note review had 
10 participants) and showed that a decrease in creatinine clearance (by 10 ml/min) 
was associated with an increased haemorrhagic risk (RR = 1.34, 95% CI: 1.12-1.65; p 
< 0.05). Major bleeding occurred in a third of CKD patients who received enoxaparin or 
heparin during hospitalisation (HR, 4.61 CI: 2.05-10.35) in a Dubai hospital (Sharif-
Askari et al (2), 2014). The two case studies discussed in 2.6.5.6 highlighted that the 
USA anticoagulant dofetilde can cause a significant increase in the QTc interval 
indicating an adverse effect on the heart (Denetclaw and Dowling, 2011). 
Fischer (2013) retrospectively studied 7,413 acute coronary syndrome patients 
discharged on clopidogrel. There was a significantly higher risk of death for the 34.5% 
with an eGFR 30-60ml/min/1.732 (HR 1.45; 95% CI: 1.18-1.76) and the 11.6% <30 
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ml/min/1.732 (HR 2.48; 95% CI: 1.97-3.13), with an over two fold increased risk of 
major bleeding. 
 
 Summary 
Examples of frequent serious ADRs have been shown in well-designed studies from 
many different countries, although only two studies were found in UK primary care, 
one on NSAIDs causing hospital admission, and the other on the ineffectiveness of 
nitrofurantoin prescribed for older people with RKF. The reported figures may be an 
underestimate as the studies are based on recognised ADRs. Many may have been 
missed such as a falls that could have been related to high blood levels of some 
drugs. The inclusion of hospital based studies has shown that the prevalence of RKF 
related ADRs is high across the sectors, and that further research to identify how to 
implement effective interventions in hospitals as well as primary care is necessary. 
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2.8 Key review area 4 – evidence on why prescribers do not 
apply the recommendations 
 
 Research question for key review area 4 
Why do prescribers not apply prescribing recommendations in reduced kidney function 
in primary care? 
 
 Identification of relevant studies - search criteria 
The search categories were Prescribers ‘AND’ Guidelines/recommendations ‘AND’ 
Prescribing ‘AND’ Prescriber Behaviour ‘AND’ Renal impairment ‘AND’ Primary Care 
‘AND’ English language (see Appendix 3, 0, for the subject headings and key words 
for each search category). As this search was looking for evidence of why prescribing 
recommendations are not applied in RKF, the search was limited to qualitative studies. 
The search term ‘review’ was added to the Medline search to find any relevant review 
papers. 
 
 Study selection – inclusion/exclusion criteria 
Study selection from the search results were based on the following criteria.  
Inclusion 
 English language. 
 Primary empirical qualitative research and reviews of primary empirical 
qualitative research. 
 Relating to prescribing in reduced kidney function. 
 Primary care. 
Exclusion 
 Opinion or discussion articles. 
 
 Hierarchy of evidence and appraisal 
The research question asks why prescribers not apply prescribing recommendations in 
RKF in primary care and so a qualitative enquiry would be needed to give an in-depth 
understanding of human behaviour and the reasons that govern that behaviour. 
The OCEBM (Oxford Centre for Evidence-Based Medicine, 2011) states that a 
systematic review is generally better than an individual study; a meta-synthesis of 
qualitative studies would aim to combine themes and interpret the thematic findings to 
generate a new all-encompassing theory. Table 14 shows the hierarchy of evidence 
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developed for this review where the Level 1 evidence, which would give greatest 
confidence in the findings, would be a meta-synthesis of qualitative studies relevant to 
the research question. The table was updated to include ‘Related Levels’ when no 
studies were found specifically exploring why recommendations are not applied for 
prescribing in reduced kidney function. The search was therefore widened to find 
studies with a more general focus of inappropriate prescribing. 
The issues considered when appraising the report of a qualitative study were whether 
the results of the study were valid, what were the results, and would the results help 
locally, i.e. in UK primary care. To aid the quality assessment the CASP ‘Study 
checklist’ for qualitative research informed the review. The Consolidated Criteria for 
Reporting Qualitative Research (COREQ) checklist was also used to assess for 
completeness of reporting and potential for bias in studies of interviews or focus 
groups (Tong et al. 2007). 
 
 Collation and appraisal 
2.8.5.1 Description of studies 
No studies were found specifically exploring why recommendations are not applied for 
prescribing in reduced kidney function. The search was then widened to include 
qualitative studies and reviews on why inappropriate prescribing in general occurs in 
primary care. Seven studies were included for review (Figure 11). Prescribing errors 
and potentially inappropriate prescribing were the focus for the 2 meta-syntheses and 
1 further study published since. Prescribing decisions was the focus for 3 studies, and 
1 on implementation of prescribing guidelines (see Table 15). 
 
 
Table 14: Hierarchy of evidence table for key review area 4 ‘why are prescribing 
recommendations in RKF not applied’ developed from the OCEBM Levels of 
Evidence. 
 
 
hierarchy of 
evidence
description
Level 1 Meta-syntheses of qualitative studies relevant to the research question.
Level 2 Qualitative studies relevant to the research question.
Level 2b Qualitative studies relevant to the research question but reduced confidence in applicability e.g. not current.
Level 3 Other studies on prescriber behaviour relevant to the research question.
Related level 1 Meta-syntheses of qualitative studies not specific, but related, to the research question.
Related level 2 Qualitative studies not specific, but related to the research question.
Related level 2b Qualitative studies not specific, but related to the research question - reduced confidence in applicability e.g. not current.
Related level 3 Other studies on prescriber behaviour not specific, but related to the research question.
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Figure 11: Number of studies identified for key review area 4. 
 
Six of the included studies were published recently. Only the Bradley et al study was 
not current from 1992, which might mean it is not as relevant to GP behaviour today. 
Five studies were based in the UK, with the other 2 from The Republic of Ireland and 
Australia so similar populations and healthcare systems. The 2 meta-syntheses 
included studies from all healthcare settings, whilst the other 5 studies were all UK 
primary care based.  
 
2.8.5.2 Heterogeneity 
The two meta-synthesis studies included 7 studies (Cullinan et al 2014) and 21 studies 
(Anderson et al, 2014), with 4 studies common to both as they aimed to explore 
potentially inappropriate prescribing, with Cullinan focussing on prescribing for older 
people only. The Slight et al (2013) study was similar to the included studies but was 
published later. The other 4 studies differed in that they focussed on decision making 
and implementation of guidelines.  
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Abbreviations: PCT: Primary Care Trust. 
Table 15: Studies found for scoping review area 4, listed in order of level of evidence. 
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2.8.5.3 Methodological quality 
As no studies were found specifically exploring why recommendations are not applied 
for prescribing in RKF, no Level 1-3 studies could be included. The search was 
expanded to include studies exploring the wider question of why prescribing errors in 
general occur, prescribing decision-making, and why prescribing guidelines are not 
always implemented. These studies might highlight some of the determinants likely, 
but will not be able to show factors specific to prescribing in RKF, for example where 
monitoring is required and kidney function estimation equations used.  
The 2 meta-syntheses studies, rated ‘Related level 1’, reported that their included 
papers were good quality, meeting most of the CASP/ COREQ criteria. Common 
weaknesses were that none of the papers considered the relationship between 
researcher and participants so researcher bias could not be excluded. Also methods 
for data collection were not justified or data saturation discussed, and most did not 
apply triangulation. The other studies included for this review were similar in not giving 
any indication of the researcher/ participant relationship, and data saturation was not 
discussed. In 2 studies ethical consideration was not apparent, though both did not 
include patients (Rashadian et al, 2008; Bradley, 1992). Otherwise the studies met the 
CASP/ COREQ criteria. Three studies were rated ‘Related level 2’ as recent good 
quality qualitative studies. One study was ‘Related level 2b’ because it was published 
in 1992 and may need extra consideration as to whether the findings are relevant to 
prescribers today, and 1 study was rated ‘Related level 3’ as a correlational 
questionnaire study of decision-making behaviour. 
Neither of the meta-analysis studies discuss whether evidence-based theories were 
used in their included studies, although the Anderson et al (2014) discuss their results 
under overall themes of awareness, inertia, self-efficacy and feasibility. The analysis 
by Slight et al (2013) was informed by Reason’s accident causation model (Reason, 
1990), Rashidion et al (2008) used the Theory of Planned Behaviour (Ajzen, 1991), 
and Bradley (1992) used an analysis based on the critical incident technique 
(Flanagan, 1954). The Presseau et al (2014) study aimed to clarify and combine 
theoretical models, but the other 2 qualitative studies had no evidenced theoretical 
base reported. 
2.8.5.4 Outcomes - inappropriate prescribing  
Anderson et al (2014) report a meta-synthesis of 21 studies to review prescribers’ 
perspectives on factors which shape their behaviour towards continuing or stopping 
potentially inappropriate medications. They did a COREQ assessment for all included 
studies finding that 8-22 of the 32 items were reported. A limitation was that many of 
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the studies focussed on few drug classes (e.g. psychotropic drugs) and only 4 on 
polypharmacy. The method describes a thematic synthesis. Many factors related to 
prescribers in stopping, or altering a medication a patient has been on for some time, 
were found to be involved, which were highly interdependent and impacted by 
considerable clinical complexity. The themes broadly fell into awareness, inertia, self-
efficacy and feasibility. They found that where there was polypharmacy, prescribers 
could not easily identify which medications were inappropriate. 
A meta-synthesis of qualitative studies by Cullinan et al (2014) explored potentially 
inappropriate prescribing in older patients and aimed to understand why it happens 
from a prescriber's perspective. Seven papers were included which were assessed as 
high quality meeting most of the CASP criteria. They describe a clear 7 step method of 
meta-ethnography used previously in other healthcare research. Four key concepts 
were identified as being causal factors: the need to please the patient, the feeling of 
being forced to prescribe, tension between prescribing experience and prescribing 
guidelines, and prescriber fear. Restrictions to prescribing appropriately were because 
of a combination of factors, rather than any one dominant factor. 
Complex underlying causes of prescribing and monitoring errors in English general 
practices were highlighted in the recent qualitative study by Slight et al (2013). This 
was a good quality qualitative study where all CASP criteria were completed, except 
there was no discussion on the relationship between researcher and participants. They 
describe semi-structured interviews with GPs on different types of errors. There were 
also 6 focus groups with a range of practice staff to discuss safeguards in general 
practice. A thematic analysis informed by Reason’s accident causation model 
(Reason, 1990) was clearly described. Seven categories of high level error-producing 
conditions were highlighted: the prescriber, the patient, the team, the working 
environment, the task, the computer system, and the primary-secondary care 
interface. Some of the error-producing conditions included the prescriber’s therapeutic 
training, drug knowledge and experience, their perception of risk, and the working 
environment, extensive workload, time pressures, and interruptions. The authors too 
highlighted the computer-related issues of unnecessary or inappropriate alerts. 
2.8.5.1 Outcomes - prescribing decision-making 
Solomon et al (2013) report an exploration of prescribing and medicine-taking 
decisions by patients, GPs and local policy makers. All COREQ criteria were 
completed, apart from discussion on the relationship between researcher and 
participants. Semi-structured interviewed with 24 participants were analysed using a 4-
step framework analysis. They then used the findings to develop a quantitative 
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questionnaire which was completed by 305 GPs and 533 patients. The 2 phases were 
then synthesised. They found that GPs were evidence-based, with 85% claiming to 
use clinical evidence in their prescribing decisions, but most GPs also incorporated 
patient factors and experience into their decision-making interpreting guidelines in the 
context of individual patients. 
Presseau et al (2014) investigated prescribing behaviours for hypertension and 
diabetes in a UK primary care prospective correlational study of GPs and nurses. They 
concluded that both reflective and impulsive processes predict behaviour and that 
quality improvement interventions should consider both reflective and impulsive 
approaches to behaviour change. Prescribing behaviours require the use of an 
extensive knowledge base, and have strong potential adverse consequences for 
patient health if performed incorrectly, and so they expected the reflective process to 
override the impulsive process. However, they found prescribing behaviours were both 
driven directly by intention, with action planning, and in parallel by automaticity, for 
blood pressure prescribing. This has implications for designing interventions, as 
targeting the impulsive system may require a specification of patient and/or 
environmental characteristics that would cue behaviour automatically. 
Bradley (1992) qualitatively sought to understand how prescribing decisions are made 
in primary care using GP interviews and analysis based on the critical incident 
technique (Flanagan, 1954). All COREQ criteria were completed, apart from 
discussion on the relationship between researcher and participants, and also ethical 
considerations were not discussed. The findings exposed the complexity of decision-
making that precedes prescribing. Bradley highlighted discomfort of GPs with 
prescribing and the struggle to balance several disparate considerations; also that 
ignorance was a factor but that it was often other things that had more impact such as 
negotiating change in treatment. 
2.8.5.2 Outcomes - clinical guidelines 
Rashidian et al (2007) aimed to explore key themes for the implementation of 
guidelines’ prescribing recommendations using a GP interview study in UK primary 
care. Again all COREQ criteria were reported apart from the relationship between 
researcher and participants, and also ethical considerations. They reported that a 
focus on GP’s attitudes and personal beliefs may provide a better insight into 
prescribing than historical work on influencing GPs. The main conclusions were that 
GPs were critical of guidelines development, relevance and implementation and that 
future studies should quantify the relationship between the evidence base of 
recommendations and implementation. Practitioners do not have a universal view of 
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valid ‘evidence’, and GPs use credibility of source or view of influential others to 
ascertain validity of guidelines. 
 
 Summary 
No research was found specifically on why recommendations are not applied for 
prescribing for the older patient with reduced kidney function in primary care.  
Rigorous and credible meta-syntheses and qualitative studies were found on 
inappropriate prescribing in general in primary care which highlight that there is 
complexity in decision making in prescribing and monitoring, and many factors are 
involved in the underlying causes of errors. Although these studies have explored the 
factors in UK primary care, there is a need understand the determinants for prescribing 
in reduced kidney function where regular monitoring is required and application of 
kidney function estimate calculations, for example, which may be important in 
developing an intervention that is more likely to be useable and effective. 
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2.9 Key review area 5 – evidence from UK national 
guidelines and resources 
 
 Research question for key review area 5 
What UK national guidelines and resources are available on drug use and dosing in 
the reduced kidney function of the older person? 
 
 Identification of relevant guidance and resources 
The most routinely used and recognised resources and national guidelines in primary 
care were scrutinised: 
 The British National Formulary (BNF) was analysed for guidance on 
prescribing in reduced kidney function as a key resource for prescribers in the 
UK.  
 The regulatory authority drug licence and safety information were considered 
from the Medicines and Healthcare products Regulatory Agency (MHRA), the 
Summary of product characteristics (drug licence data sheets, SPCs), and the 
Food and Drug Administration (United States of America) (FDA). 
 The National Institute for Health and Care Excellence (NICE) for England, 
Wales and Northern Ireland, and the Scottish Intercollegiate Guidelines 
Network (SIGN), websites were searched for relevant guidelines.   
 The Kidney Disease Improving Global Outcomes Foundation (KDIGO) was 
searched as a global organisation developing and implementing evidence 
based clinical practice guidelines in kidney disease to improve the care and 
outcomes of kidney disease patients worldwide. 
Any further guidelines found during the literature process would be analysed, and 
expert advice was sought to ensure the key resources had been included. 
Inclusion criteria 
Included resources would be in the English language, and be the current guidance for 
the management of people with reduced kidney function used in the UK. 
 
 Collation and appraisal 
2.9.3.1 British National Formulary (BNF) 
The BNF is a respected resource, and widely used by prescribers for information 
about drugs in the UK. Prior to 2009, the guidance on use of drugs in ‘renal 
impairment’ was presented in the BNF Appendix 3, based on the information provided 
108 
 
in the published SPCs. There was no sign-posting to the guidance in the individual 
drug monographs.  
From 2009, the BNF changed to having the information on use and dosing in reduced 
kidney function in each drug monograph where appropriate, making it much more 
accessible. The general guidance on prescribing in renal impairment was moved to a 
section in the front of the book version. Also in 2009, the BNF started quoting the 
levels of kidney function in the guidance as ‘eGFR’ but the figures are still those from 
the SPCs that are creatinine clearance calculated using Cockcroft Gault. They state 
that ‘although the two measures of renal function are not interchangeable, in practice, 
for most drugs and most patients of average build and height eGFR (MDRD) can be 
used to determine dose adjustment in place of creatinine clearance’, but that ‘for 
potentially toxic drugs with a small safety margin and in some patients (e.g. at 
extremes of weight) creatinine clearance Cockcroft Gault should be used’.  
After the European guidance on use of the new oral anticoagulants (NOACs) 
recommended that creatinine clearance should be used to estimate kidney function 
(Heidbuchel et al, 2013), the BNF drug monographs for dabigatran, rivaroxaban and 
apixaban were changed from 2014 to specify use of the Cockcroft Gault equation.   
2.9.3.2 Regulatory Authorities 
For a drug licensed in the UK, the dosing and elimination pharmacokinetic details are 
set out in the SPCs including dosing in renal impairment, although it is not always 
relevant or complete (Saldago et al, 3013). Since 2010 the USA Food and Drug 
Administration (FDA) have required pharmacokinetic studies for new drugs to include 
both eGFR and CrCl-CG whilst the European Medicines Agency (EMA) still only need 
‘accurate well established methods’ to be used.  
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued Drug 
Safety Alerts relating to use of drugs in RKF, for example for dabigatran and the risk of 
serious haemorrhage (MHRA, 2012), and ineffectiveness of nitrofurantoin with 
increased risk of pulmonary adverse events and hospitalisation (MHRA, 2014). 
2.9.3.3 Chronic and acute kidney disease guidelines 
In 2003 the UK adopted the US Kidney Disease Quality Outcomes Initiative leading to 
the new chronic kidney disease (CKD) guidelines describing the degree of renal 
function and detailing clinical care in five stages (Joint Specialty Committee for Renal 
disease of the Royal College of Physicians of London and the Renal Association, 
2005). The National Service Framework (NSF) for Renal Services was introduced in 
2005 and in 2006 Quality Outcome Framework (QOF) markers have led to the 
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formation of registers of patients with CKD stages 3, 4 and 5 as calculated by the 
MDRD equation to give a glomerular filtration rate estimate normalised for a body 
surface area of 1.73m2 (eGFR). Then in 2008 the joint National Institute for Clinical 
Excellence/Royal College of Physicians (NICE CG73) guideline on CKD and the 
Scottish Intercollegiate Guidelines Network (SIGN) guideline were introduced to give 
recommendations for early identification and management of CKD in adults in primary 
and secondary care.  
The NICE/RCP guidelines and the NSF had very little on drugs except the chronic use 
of non-steroidal anti-inflammatories (NSAIDs) being a risk factor for reducing kidney 
function and also the use of angiotensin-converting enzyme inhibitors (ACEIs) and 
angiotensin-II receptor blockers (ARBs) in treatment. The NICE guidance was updated 
in 2014 (NICE CG182) but there is still no guidance on prescribing in RKF apart from 
‘review the medicines’. 
The SIGN CKD guideline (2008) states that kidney function is lower in older people but 
that ‘there is uncertainty as to whether age associated decline in glomerular filtration 
rate is pathological and should be afforded the same significance as declining function 
in other situations’. They do state that ‘alterations in drug dosing in patients with 
reduced renal function should be made on the basis of creatinine clearance as 
estimated by Cockcroft Gault.’  
‘Virtually all published recommendations for dose adjustment in patients with 
reduced renal function, including the British National Formulary (BNF), and 
manufacturers’ summaries of product characteristics are based on creatinine 
clearance estimated by the Cockcroft-Gault formula. There is no evidence that 
this estimate can be used interchangeably with the four variable MDRD 
formula. The current practice of using the Cockcroft-Gault formula for drug 
dosing should be continued until such evidence is forthcoming’ (SIGN103, 
2008, p.11). 
Acute kidney injury guidance has been recently introduced (NICE CG169, 2013). This, 
and initiatives such as the ‘Think Kidneys’ NHS campaign (NHS England, 2015), 
include reducing the risk of nephrotoxic drugs on the kidney, and also highlight the 
need to review use of drugs excreted by the kidney. 
The international foundation Kidney Disease: Improving Global Outcomes Foundation 
(KDIGO) published a paper in 2011 (Matzke et al) on drug dosing consideration in 
kidney disease. They had many recommendations for clinical practice, further 
research and regulatory authorities. They recommend that eGFR should be reported in 
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ml/min rather than ml/min/1.73m2, as it is never adjusted for body surface area (BSA) 
in practice. The report did not review prescribing for the older person with RKF as a 
separate group. 
 
 Summary 
National and international policies and guidance have advised on management of 
kidney disease but do not cover dosing of drugs that need altering in the reduced 
kidney function of the older patient. The introduction of a different kidney function 
estimation equation for eGFR (MDRD) has not been clarified in relation to use for 
prescribing decisions for older people. 
  
111 
 
2.10 Key review area 6 – evidence of intervention evaluation 
to aid prescribing in reduced kidney function 
 
 Research question for key review area 6 
Have interventions been evaluated to help prescribers in primary care to apply 
recommendations for use of drugs in reduced kidney function? 
 
 Identification of relevant studies - search criteria 
The search categories were ‘Decision support tools’ AND ‘Prescribing’ AND ‘Renal 
impairment’ AND ’Primary Care’ AND ‘English language’ (see Appendix 3, 0, for the 
subject headings and key words for each search category). The search term ‘review’ 
was added to the Medline search to find any relevant review papers.  
 
 Study selection – inclusion/exclusion criteria 
Study selection from the search results were based on the following criteria. Although 
the research question is focussed on primary care, other healthcare settings were 
included in case the primary care evidence was limited, and for comparison. 
Inclusion 
 English language. 
 Primary empirical research and reviews of primary empirical research. 
 Intervention or outcome relating to evaluation of how to improve prescribing in 
reduced kidney function. 
Exclusion 
 Opinion or discussion articles 
 
 Hierarchy of evidence and appraisal 
The research question asked ‘does this intervention help’, so the OCEBM Levels of 
Evidence (2011) gives the ‘Level 1’ evidence, which would give greatest confidence in 
the findings, to be ‘Systematic review of randomised trials, or n-of-1 trial’, and 
individual randomised controlled trials as level 2. Table 16 lists the hierarchy of 
evidence developed for key review area 6 based on the OCEBM Levels of Evidence. A 
grade ‘b’ has been added where the level may be reduced from the ideal, for example 
where a systematic review is not only of randomised trials. As this search was looking 
for evidence of intervention evaluation, an RCT method would be the gold standard to 
research effectiveness (Robson, 2011, p.99). RCTs and reviews of RCTs would be the 
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studies searched for initially but, as this was a scoping review, the search criteria were 
left open to capture all relevant studies to give an overview of interventions tried. 
The issues considered when appraising were whether the results of the study were 
valid, what were the results, and would the results help locally in UK primary care? To 
aid the quality assessment the CASP ‘Study checklists’ informed the review. Studies 
were assessed and only included where the focus, methods, recruitment and 
sampling, valid and reliable objective measurements used, and outcomes were clearly 
defined, relevant and appropriate to the research question. 
Table 16: Hierarchy of evidence table for key review area 6 ‘does this 
intervention help’’ developed from the OCEBM Levels of Evidence. 
 
 
 Collation and appraisal 
2.10.5.1 Description of studies 
Thirty-one relevant studies were found from the database searches (Figure 12) on 
evaluation of interventions to improve prescribing in reduced kidney function. Table 17 
lists the included studies in order of the level of evidence they provide, and whether 
the intervention had a positive effect or made no change.  
All the studies included date from the early 2000s, since CKD national guidelines in 
many countries were introduced. Computer systems have become more developed in 
that time, and pharmacist roles have advanced.  
hierarchy of 
evidence
description
Level 1 Systematic review of randomised trials, or n-of-1 trial
Level 1b Systematic review of prospective trial, not all randomised
Level 2 Randomised trial, or observational study with dramatic effect
Level 2b Randomised trial, or observational study with dramatic effect; not primary care
Level 3 Non-randomised controlled cohort/ follow-up study
Level 3b Non-randomised controlled cohort/ follow-up study; not primary care
Level 4 Case series, case-control studies, or historically controlled studies
Level 4b Case series, case-control studies, or historically controlled studies; not primary care
Level 4c Non-randomised, non-controlled survey where appropriate
Level 4d Non-randomised, non-controlled survey where appropriate; not primary care
Level 5 Mechanical-based reasoning
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Figure 12: Number of studies identified for key review area 6. 
Only one UK based study was found that had some relevance. Avery et al (2012) 
showed that a pharmacist-led information technology intervention (PINCER) is an 
effective method for reducing a range of medication errors in general practices with 
computerised clinical records. They did not include an outcome that assessed the 
effect on inappropriate prescribing in RKF, but they did find that kidney function testing 
when taking an ACEI or diuretic could be improved. All but three of the other studies 
were from countries where the populations are likely to be similar to that of the UK 
(Western Europe x16, USA and Canada x10, Australia x1) (see Table 17), but 
healthcare systems and information technology may be different to the UK. Taiwan, 
Iran, and Saudi Arabia, where the other 3 studies were from, are likely to have 
populations that differ more from the UK population. 
Eleven studies were based in primary care, and 19 were hospital interventions which 
may be less relevant to a primary care setting, but may give insights into what might 
be effective or ineffective, especially if there is an assessment of the reasons why. 
2.10.5.2 Heterogeneity 
The included studies aimed to assess the effectiveness of an intervention, but varied 
widely in design, focus, population, measures, and outcomes assessed. Some study 
designs were intervention compared with a control, some were pre and post 
assessments, whilst others sought to investigate how an intervention was used. The 
populations studied varied in age, 4 looked at older people; some defined certain 
drugs to study, such as antibiotics, or a diagnosis such as hypertension or diabetes.  
As in the other review areas, kidney function measures were well defined but the 
estimate equation used, and threshold levels, differed. 
The type of interventions were also diverse. Information technology solutions included 
alerts provided in various forms, and to varying degrees of specificity, and other 
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decision support tools, either linked to the patient record system, or needing separate 
operation. Interventions involving pharmacists were investigated in 6 of the studies. 
The wide variation means it is inappropriate to make direct comparisons for the whole 
set of included studies, or pool data. The studies were therefore grouped by 
healthcare setting to allow comparison, and then further organised into interventions 
used. 
2.10.5.3 Methodological quality 
No ‘Level 1’, but one ‘Level 1b’ systematic review of studies evaluating CDSS was 
found (Tawadrous et al, 2011) which addressed a clearly focused relevant question 
and looked for prospective studies with clinical or patient outcomes, although not all 
studies were RCTs that would be likely to give the least biased results. Patient-
important outcomes such as adverse drug events were considered in 7 of the 32 
included studies, which would be the best evidence to show whether there is a 
reduced risk for patients. All the studies found since this review assessed the 
intervention effect on reducing inappropriate prescribing, rather than on patient-based 
outcomes. Although the review was reported within the last 5 years, there have been 
many studies published since, and computer technology solutions have been further 
developed, so reviewing more recent literature is likely to add to the evidence.  
Four ‘Level 2’ RCTs based in primary care were found that are the study design most 
likely to give the least biased evidence for whether an intervention to improve 
implementation of the recommendations for prescribing in RKF, although there are 
limitations to each that might reduce the generalisation to UK primary care. The 
‘PINCER’ trial (Avery et al, 2012) was large multicentre, cluster randomised, controlled 
trial (RCCT) in UK primary care. It was a high quality study which found that the 
pharmacist led intervention is an effective method for reducing a range of medication 
errors in general practices, but, more specifically, they assessed whether the 
intervention could improve the testing of kidney function level for patients taking an 
ACEI or a diuretic, not whether that reduced inappropriate prescribing.  
In the Bhardwaja et al (2011) large RCT conducted in primary care in the USA, of the 
244,031 people allocated to the intervention group, 75,560 (31%) had no creatinine 
clearance measurement. Although this was similar in the control group, it was not 
possible from their design to assess how many people taking the study drugs did not 
have a kidney function level available, and whether that was significant for reducing 
risk of prescribing these drugs. Also, the 20 pharmacies involved would have had 
participants from both intervention and control groups, so contamination could be 
possible.
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Sellier Level 4b 2009 France case control hospital 603
for prescribers, re 24 drugs when 
eGFR reduced
Inappropriate prescribing did not reduce with alerts. no change
Barnes Level 4c 2014 USA prospective survey
primary care, 
care home
146 pharmcist dosing service
Dosing recommendations made for an average of 1 per 
patient and the GP accepted 65.2%.
+ve
Geerts Level 4c 2012 Netherlands prospective survey primary care 650
Aged > 70 years with diabetes or 
CVD
13.7% therapeutic recommendations for patients aged 
>70 years with diabetes or cardiovascular disease.
+ve
Gheewala Level 4c 2014 Australia survey primary care 28 care home resident with CKD
83.8% of recommendations made by the pharmacist 
were accepted by GPs.
+ve
Joosten Level 4c 2013 Netherlands prospective survey 1,369
for community pharmacists when 
eGFR<40ml/min
A medication error was detected in 15% of the alerts, 
most were significant or serious.
+ve
Boussadi Level 4d 2013 France prospective survey hospital 3,228 for pharmacists when RKF Alerts highlighted more errors than pharmacist review. +ve
Cho Level 4d 2014 USA retrospective survey hospital 584 for prescribers when RKF 78.2% alerts were over-ridden. no change
Frolich Level 4d 2011 Switzerland cross-sectional survey hospital 509 RKF CDSS identified a large number of alerts N/A
Garcia-Molina Level 4d 2013 Spain prospective survey hospital 29 CrCl < 60ml/min
Pharmacist found 21% of renal risk drugs needed dose 
adjustment
+ve
Hudali Level 4d 2015 USA survey hospital 6 antibiotics in RKF Errors reduced from 15.4% to 3.7% (p<0.001). +ve
Nielson Level 4d 2014 Denmark prospective survey hospital 232 eGFR 10-49 ml/min/1.73m
2 Inappropriate dosing continued after automatic eGFR 
reporting.
no change
Youseff Level 4d 2015 Saudi Arabia retrospective survey hospital 314 for prescribers when RKF
Alerts over-riden - 14% contra-indicated but 
administered despite alert.
no change
Geerts
Level 5 
(feasibility)
2013 Netherlands feasibility study primary care 50
40 patients,5  GPs, 5 pharmacy 
staff
Point-of-care creatinine testing feasible in a community 
pharmacy.
N/A
Helldén
Level 5 
(pilot)
2015 Sweden
pilot: qualitative questionnaire 
and focus group
primary care 8 GPs
Approved automatic presentation of CrCl status on 
opening the medication list, and ability to actively look 
up specific drug recommendations in two steps.
N/A
Shemeikka
Level 5 
(pilot)
2015 Switzerland
proof-of-concept; 
questionnaire
hospital 86  physicians Pilot of CDSS well received. N/A
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: CDSS: computer decision support system; CKD: chronic kidney disease; CrCl: creatinine clearance; CVD: cardiovascular disease; eGFR: estimated glomerular filtration rate; RKF: reduced kidney function. 
Table 17: Studies found for scoping review area 6, listed in order of level of evidence. 
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Similarly, in the Field et al (2009) RCCT, physicians would prescribe in both 
intervention and control groups, even though the healthcare units were randomly 
allocated,.  
The follow-up analysis of the Erler et al (2012) RCCT revealed that the effect was 
mostly related to ACEIs and ARBs, even though the dosing software covered 800 
drugs, which might reduce the usefulness for all drugs affected by kidney function. 
Sample size calculation was used, but only 10 patients per practice were recruited 
which might have reduced the capacity of the study to pick up a wider drug effect 
range. 
Studies that are not randomised and controlled are more likely to be subject to biases 
that might weaken confidence in the results. Where the intervention and control groups 
are not randomly allocated, confounding factors may not be the same for each group, 
and in pre and post studies there may be changes over time. 
As discussed in Chapter 1 (1.4.2) an intervention is more likely to be effective if it is 
developed on evidence-based principles of behaviour change (Cane et al, 2012). Only 
the PINCER study protocol (Avery et al, 2009) discussed using theory to develop their 
intervention; they used the principles of Human Error theory (Reason et al, 2000) to 
consider the causes of medication errors in primary care from their literature review 
and empirical research. No other included study defines evidence-based theory for the 
development of their intervention other than having found a problem. 
2.10.5.4 Intervention outcomes: UK primary care 
No studies were found that specifically aimed to provide evidence of what intervention 
evaluation to help prescribers in UK primary care to apply recommendations for use of 
drugs in reduced kidney function. 
The ‘PINCER’ large multicentre RCCT found that a pharmacist-led information 
technology intervention was an effective method for reducing a range of medication 
errors in UK general practices with computerised clinical records (Avery et al, 2012). 
They included one kidney related outcome, finding that patients aged 75 years and 
older in the intervention group were significantly less likely to be taking an ACE 
inhibitor or diuretic without having had kidney function measured in the preceding 15 
months. Having a recent kidney function test available is required to be able to 
prescribe according to the recommendations, but this study does not provide evidence 
for whether this would translate to appropriate prescribing. 
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2.10.5.5 Intervention outcome: reviews  
Tawadrous et al (2011) systematically reviewed 32 studies using clinical decision 
support systems (CDSS) for kidney-related drug prescribing. This was a well reported 
review which focussed on prospective studies reporting clinical and/or patient 
outcomes, but a limitation was the heterogeneity of the designs. The studies were 
mostly in academic hospital settings and in 17 studies decision support systems were 
computerised, whilst in 15 studies they were manual pharmacist-based systems. 
Systems prompted for drug dosing adjustments in relation to the level of decreased 
kidney function (25 studies) or in response to serum drug concentrations or a clinical 
parameter (7 studies). For computerised systems, clinician prescribing outcomes, such 
as frequency of appropriate dosing, were considered in 11 studies, with all 11 
reporting statistically significant improvements. Similarly, manual DSSs that 
incorporated clinician prescribing outcomes showed statistically significant 
improvements in 6 of 8 studies. Patient-important outcomes such as adverse drug 
events were considered in 7 studies of CDSSs, with statistically significant 
improvements in 2 studies. For manual DSSs, 6 studies measured patient-important 
outcomes and 5 reported statistically significant improvements. The authors concluded 
that the results were promising; however, only 2 of 5 studies looking at patient-
important outcomes from computerised CDSSs were beneficial which shows that 
further research is required. 
2.10.5.6 Intervention outcomes: primary care based from other countries 
Reporting of eGFR - primary care 
The universal reporting of eGFR might have been expected to improve awareness of 
kidney function and so allow prescribers to apply the results to prescribing. Dosing 
errors for antibiotics in older people with CKD stages 4 or 5 were assessed before and 
after the introduction of eGFR reporting in a primary care time-series analysis in 
Canada (Farag et al, 2014). Reporting of eGFR had no impact on the error rate (68 
per 100 antibiotic prescriptions; P = 0.9). Nitrofurantoin, which is contraindicated in 
patients with CKD, was prescribed 169 times throughout the study period. The authors 
state that they ‘attribute the dosing errors to poor awareness of dosing guidelines’ but 
they ‘did not assess physician knowledge to confirm this’. 
CDSS - primary care 
Erler et al (2012) used a multi-faceted intervention in an RCCT in primary care 
practices in Germany. Using a cluster design meant there was a reduced likelihood of 
contamination between the groups, but blinding was not possible. The intervention of a 
workshop, desk-top checklist, patient information and dosing software for over 800 
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drugs was aimed at prescribers. Forty-six practices were randomly allocated to 
intervention or control, the practices identified a list of potential participants and then 
10 patients per practice were randomly identified for the study. In 404 participants (198 
intervention and 206 control) the proportion of patients receiving one or more 
prescriptions exceeding the recommended maximum daily dose was significantly 
lower in the intervention group after 6 months: 19.2% vs 34.5% for the control group 
(OR = 0.45, 95% CI: 0.29-0.70; p<0.001). However, follow-up analysis revealed that 
the effect was mostly related to ACEIs and ARBs which might reduce the usefulness 
for all drugs affected by kidney function. The dosing software provided was well 
received, but it could not integrate with the patient record system and so the prescriber 
needed to remember to use the system for affected drugs, which might be why few 
drugs were altered. Sample size calculation was used, but only 10 patients per 
practice were recruited which might have reduced the capacity of the study to pick up 
a wider drug effect range. 
The Canadian RCT in 22 long-term care facilities aimed to assess whether CDSS with 
an alert would improve prescribing in RKF over 12 months (Field et al, 2009). The 
randomisation was done by unit, though the method was not clear, and the 
intervention and control groups were shown to be very similar. Alerts were triggered 
when a physician ordered a listed drug for a patient with a reduced creatinine 
clearance, and rates of alerts were similar for each group. It isn’t clear from the report 
whether there was blinding at any stage, and the authors do highlight that physicians 
would prescribe in both intervention and control groups. The control group continued 
to have the current creatinine clearance displayed as had been happening prior to the 
study. Significantly higher proportions of final drug orders were appropriate in the 
intervention units: relative risk 2.6 for drugs that should be avoided (95% CI: 1.4, 5.0), 
1.8 for alerts to acquire missing information (95% CI: 1.1, 3.4), and overall final drug 
orders were appropriate significantly more often in the intervention units relative risk 
1.2 (95% CI: 1.0, 1.4). However, the system did not improve the rate at which 
appropriate doses were ordered, partly because the control group showed high levels 
of appropriate dosing. 
Helldén et al (2015) in Sweden has reported a proof-of-concept study of a CDSS in 
primary care. This qualitative questionnaire and focus group study found the automatic 
presentation of the creatinine clearance status on opening the medication list, and the 
ability to actively look up specific drug recommendations in two steps was appreciated. 
The GPs wanted to continue the use of the CDSS and to recommend it to others. 
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Pharmacist based intervention - primary care 
A large randomised controlled trial (n=32,917) showed alerts to pharmacists 
significantly reduced errors from 49% to 33% (p<0.001) in ambulatory care in the USA 
(Bhardwaja et al, 2011). This study clearly set out the focus and methods, with blinded 
random allocation, similar intervention and control (usual care) groups, and a blinded 
research pharmacist to decide whether there had been a true medication error. An 
alert was triggered in the dispensing pharmacy for patients with CrCl-CG <50ml/min 
prescribed one of the 15 investigation drugs; however, of the 244,031 people allocated 
to the intervention group, 75,560 (31%) had no creatinine clearance measurement. 
Although this was similar in the control group, it was not possible from their design to 
assess how many people taking the study drugs did not have a kidney function level 
available, and whether that was significant for reducing risk of prescribing these drugs. 
The ‘usual care’ group had a high level of medication errors reported, 49%, even 
though the 20 pharmacies involved would have had participants from both intervention 
and control groups. The alert intervention, which would not allow the prescription label 
to be printed, did result in a significant reduction of errors, but at 33%, a third of people 
were still at risk from their medication. 
Joosten et al (2013) reports in their survey that a medication error was found in 15% of 
alerts generated where eGFR <40ml/min/1.73m2 for community pharmacists in The 
Netherlands, and most were significant or serious. There were 1,369 alerts which was 
5.3% of all creatinine assays done, and the median age of patients was 78 years. The 
pharmacists recommended 342 medication changes, with 66% accepted by the 
physician. This was not a controlled study, but does show the concept that allowing 
community pharmacists to have renal data can significantly reduce serious errors. The 
authors suggest that this can be done relatively straight forwardly with minimal 
expense. 
Three further studies showed that community pharmacy interventions might be useful 
to reduce the risk of harm. Geerts et al (2013) showed that it was feasible for Dutch 
community pharmacists to test kidney function and advise GPs where alterations to 
prescribing were needed. They had previously shown in a prospective survey that 
community pharmacists provided with kidney function level by the GP practice, and 
using alerts, resulted in 13.7% therapeutic recommendations for patients aged >70 
years with diabetes or cardiovascular disease, although only half were agreed by the 
GP (Geerts et al, 2012). A non-randomised historically controlled study in Spain 
showed community pharmacist intervention improved appropriate prescribing for older 
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people with RKF, although only a third of recommendations were followed through by 
GPs (Via-Sosa et al, 2013). 
A survey of a pharmacist review service to care homes in Australia identified 
inappropriate prescribing of renally cleared medications in 16% of residents with CKD; 
in this study 83.8% of recommendations made by the pharmacist were accepted by 
GPs (Geewala et al, 2014). Also in a pharmacist service to care homes in the USA, 
dosing recommendations were made for an average of 1 per patient and the GP 
accepted 65.2% (Barnes et al, 2014). 
2.10.5.7 Intervention outcomes: hospital based 
Reporting of eGFR - hospital 
Reporting of eGFR has been associated with improved physician recognition of 
chronic kidney disease in elderly hospitalised patients in California, but it did not lead 
to a change in physician prescribing in a retrospective and prospective time-series 
analysis (Quartarolo et al, 2007). There was only a transient effect of eGFR reporting 
on dosing for patients aged ≥70 years in the USA (Kalender-Rich et al, 2011), and in 
Denmark inappropriate dosing continued after automatic eGFR reporting (Nielson et 
al, 2014). 
Alerts - Hospital 
Three hospital studies found alerts to prescribers led to reductions in inappropriate 
prescribing when kidney function is reduced. Hudali et al (2015) used a survey design 
to look at the effect of an alert on prescribing antibiotics as recommended in RKF and 
found a highly significant reduction in errors from 15.4% to 3.7%. A text alert when 
CrCl-CG was less than 50 ml/min led to a significant increase in dose alteration 
(p<0.001), but not for drug discontinuation, in a case-control study (Forough et al, 
(2014). Melton et al (2015) reported a qualitative exercise and a redesign of their 
alerts; when they then tested the new alert there were 43% fewer prescribing errors 
compared with the original alerts (p = 0.001). When laboratory links were presented on 
the redesigned alert, laboratory information was accessed 3.5 times more frequently. 
Other studies revealed some problems with alerts. Both Cho et al (2014) and Youssef 
et al (2015) found that alerts were overridden. In the former retrospective survey on 
renal alerts, 78.2% were overridden. 14% of the alerts in the latter were contra-
indications but were still administered to the patient; multivariate logistic regression 
showed that the odds of receiving the contraindicated drugs increased in those with 
severe renal insufficiency (OR = 23.4, 95% CI 9.9-54.9, p < 0.001) after adjusting for 
confounding factors. The Desmedt et al (2012) prospective case control study also 
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found alerts were ignored and they did not find a significant reduction in prescribing 
errors. Sellier et al (2009), in another case-control study, found that inappropriate 
prescribing did not reduce with alerts. 
Frolich et al (2011) surveyed the effect of a CDSS and found it generated a large 
number of alerts. For the 2,729 prescriptions written for the 509 patients enrolled in the 
study there were generated 2,558 interaction alerts and 1,849 comments, with only a 
minor fraction likely to be of substantial risk to the patient. Czock et al (2015) used a 
prospective cohort study to show that a non-specific alert system would yield an 
average number of alerts per medication regimen of 2.22, but by tailoring alerts to be 
patient and drug specific, the alert burden was reduced by 90% to 0.094 per 
medication regimen. 
CDSS – hospital 
In a recent study, a CDSS to support prescribing in RKF using an integrated electronic 
health record system was piloted in a geriatric clinic, an internal medicine admission 
ward and two outpatient healthcare centres (Shemeikka et al, 2015). In total 86 
physicians completed an initial questionnaire about their expectations on the CDSS, 
there was a focus group discussion after 5 weeks, and a follow-up questionnaire was 
completed at the end. It was well received with 97% wanting to continue using it. 
Wang et al (2012) describe the development of a CDSS for antibiotic prescribing in 
RKF. The instances of inappropriate antibiotic dosage prescriptions were decreased 
by approximately 80% after the calculator was implemented (RR, 0.18 - 0.23; p < 
0.001), and the incidence rates of renal function deterioration were lowered from 
12.39% to 9.47%. The frequency of antibiotic calculator utilisation by physicians 
increased from 239 times per year in 2005 to 3,480 times per year in 2008, and the 
acceptance rate of the calculator's dosage recommendations went from 68.2% in 2005 
to 94.7% in 2008. The average acceptance rates of pharmacist recommendations by 
physicians were 97.7%. 
Pharmacist based intervention - hospital 
Falconnier et al (2001) used a case-control study to show that using immediate 
concurrent feedback by pharmacists, the dose of 81% of renally eliminated drugs in 
patients with CrCl-CG ≤50ml/min were adjusted to renal function, compared with 33% 
in the control group. In a non-randomised, pre-post intervention study, Diaz et al 
(2013) assessed a CDSS that helped pharmacists to identify patients with RKF, 
identify medication orders that may require dosage modifications based on renal 
function, and generate an alert with a recommendation of specific dosage adjustment. 
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Before the intervention, the frequency of appropriate prescribing based on kidney 
function was 65%, and after was increased to 86% (p<0.001). 
Two prospective surveys also suggest that alerts can aid pharmacists in highlighting 
errors. Boussadi et al (2013) found a clinical decision rule-based alert system for drug 
dose adjustment in patients with renal failure helped pharmacists to find errors, and 
suggest that an alert system would be complementary to the pharmacists' activity, 
contributing to drug prescription safety. A pharmacist intervention for drug dosage 
adjustment of renal risk in patients with RKF during their admission found 293 renal 
risk drugs in 29 patients, 21% of them required a dose adjustment (Garcia-Molina et 
al, 2013).  
 
 Summary 
This review found no studies evaluating interventions to help prescribers in UK primary 
care to apply recommendations for use of drugs in reduced kidney function. The 
reporting of eGFR might have raised awareness of kidney disease but studies in both 
primary care and hospital have shown that it has not improved prescribing in RKF. 
Evaluations of alerts and more sophisticated CDSSs have shown mixed results, but 
the studies that investigated pharmacist-led interventions all showed reductions in 
inappropriate prescribing. None of the studies found aiming to improve prescribing in 
RKF were based on theory or determinants of why prescribing was not appropriate, 
which might be a factor for studies not showing benefit if the intervention was not 
addressing the barriers.  
 
 
2.11  Discussion  
Six key areas were identified for this scoping literature review using the mind map 
developed from the findings of the pilot case-note review study (2.4.1.1, Figure 7). The 
mind map has been developed further in Figure 13 to summarise how knowledge, 
themes, and implications for ongoing research have been developed through the key 
findings.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: ACEI: angiotensin-converting enzyme inhibitor; ADR: adverse drug reaction; AKI: acute kidney injury; BNF: British National Formulary; CrCl: creatinine clearance; CG: Cockcroft Gault; CKD: chronic kidney 
disease; eGFR: estimated glomerular filtration rate; KDIGO: Kidney Disease Improving Global Outcomes Foundation; MDRD: Modification of Diet in Renal Disease equation; NICE: National Institute for Health and Clinical 
Excellence; NOAC: Novel oral anticoagulant; NSAID: non-steroidal anti-inflammatory; RKF: reduced kidney function; SPC: summary of product characteristics. 
Figure 13: Summary of the literature review findings in the 6 key review areas from the mind map (Figure 7) 
 Description of included studies 
The Cockcroft Gault equation to calculate creatinine clearance was introduced in 1971 
to estimate kidney function (Cockroft and Gault, 1971), but most of the studies 
identified for this review were from the early 2000s onwards. Very few studies on 
prescribing and RKF were found before 2000; in Lazarou and Pomeranz’s USA review 
(1998) it was reported that kidney function was a factor rarely reported in the studies 
sampled and so they could not determine the effect on ADR rate. CKD guidelines 
began to be published in many countries in the early 2000s. In the UK it was 2005 
when the first were introduced (Joint Specialty Committee for Renal disease of the 
Royal College of Physicians of London and the Renal Association, 2005), and most of 
the studies date from that time onwards suggesting an increased awareness of kidney 
function in relation to prescribing. The development of computer systems, and of 
pharmacist roles, over this time also seems to have been a factor in the more recent 
studies undertaken. 
Very few studies were based in UK primary care which would give the best local 
evidence for this review, particularly for the prevalence questions, and where the 
healthcare system and working environment might be important. However, studies 
from countries with similar populations were found that have given key themes and 
implications for research in the UK. 
The first primary care studies were published from the mid-2000s, with the earlier 
studies being hospital based. The hospital studies have tended to investigate drugs 
used for more acute conditions and acutely ill patients, with different healthcare 
processes, and so the results may not be as applicable to UK primary care. The 
prescribing systems and procedures are different in primary care to those in hospitals, 
including advanced computerised patient record systems used in UK primary care that 
might mean different findings to hospital based studies. However, inclusion of hospital 
based studies has shown that the prevalence of recommendation non-compliance is 
high across the sectors, and that further research to identify how to implement 
effective interventions in hospitals as well as primary care is necessary. 
The research questions focussed on older people, and studies were found that had 
older participants only, although the definition of ‘old age’ differed with thresholds from 
65 years to 85 years cited. However, other studies were included as many discussed 
that older people are more likely to have reduced kidney function, and statistical 
analyses in some across ages highlighted old age as a ‘risk factor’. Older mean ages 
were reported, even if the study design was not specifically to study older people, for 
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example, means ages of 70 years (Salomon et al, 2003), 73 years (Pillans et al, 2003), 
and 75 years in the Flaconnier et al (2001) study. 
This review has highlighted that kidney function was measured and calculated in 
different ways in the included studies, and the thresholds used varied widely in the 
studies found, making it not possible to make precise comparisons. It has also shown 
that many patients did not have a kidney function estimate on their record, even 
though they were prescribed drugs that would require adjustment if kidney function 
was low. This could also mean that these studies are reporting an underestimate of 
the problem. 
 
 Methodological quality 
A limitation of the Arksey and O’Malley scoping review method is that it does not 
formally appraise the quality of evidence (Arksey and O’Malley, 2005). It remains 
unclear whether not including quality assessment impacts the uptake and relevance of 
scoping study findings (Levac et al, 2009). The current study included an assessment 
of the quality to give an indication of where the current literature is of sufficient quality 
to answer the research question, and whether there is a need for further investigation 
to have greater confidence in the findings. By including a quality assessment, to be 
feasible, only published studies were included, and opinion and discussion articles 
were excluded, introducing a limitation, the risk of publication bias, and reducing the 
breadth of the investigation. The quality of the studies found was appraised using 
standard checklists such as CASP and COREQ, assessing for validity, the extent to 
which conclusions of each study were supported by the results presented and 
consistent with the methods used, and for reliability, whether the methods were 
reported in sufficient detail to repeat the study and obtain similar conclusions. 
The hierarchy of evidence tables developed for each key area allowed a systematic 
assessment of the appropriateness of study design for the research question and 
methodological quality. By ordering the studies by the level of evidence and quality, it 
has shown the lack of ‘Level 1’ UK primary care based studies that would give 
generalisable evidence in a UK setting. It has highlighted that no UK primary care 
based studies were found to show:  
 To what extent older people are on drugs and doses not recommended at their 
level of kidney function in primary care.  
 What the risks are to the older patient of not following the recommendations in 
UK primary care. 
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 Why prescribers do not apply the recommendations for prescribing in RKF in 
primary care. 
 What interventions are needed to help prescribers in UK primary care to apply 
recommendations for use of drugs in reduced kidney function. 
A systematic review is generally better than an individual study (Oxford Centre for 
Evidence Based Medicine, 2011), but only one systematic review was found overall, 
and that did not only include RCTs that would be the best evidence for intervention 
studies (Tawadrous et al, 2011). It is a good quality systematic review of interventions 
to improve prescribing in RKF, and more recent studies found have added to the 
findings, although only 4 of 30 of those were RCTs. Narrative reviews were found for 
the prevalence, kidney function equation, and ADR reviews, although they were found 
to have some issues that need to be considered. The Long et al (2004) review was 
over 10 years old and found very few prevalence studies, whilst many studies have 
been published since that would give a better, more up to date indication, such as the 
high quality, large, multi-centre, French primary care prospective cohort study (Breton 
et al, 2011). Four narrative reviews on the use of kidney function estimation equations 
were found; Helou (2010) did not review use of the equations for prescribing, but did 
look at the issues for older people, and Spruill et al (2008) looked at mathematical 
comparisons only. The other two reviews did look at prescribing for older people, but 
neither gave the method used for study identification, making it not possible to assess 
whether there was bias in the selection. The one narrative review found looking at the 
risks of not applying prescribing in RKF recommendations, also gave no method for 
study selection (Marcum and Fried, 2011). Two good quality meta-syntheses were 
found that gave insights into inappropriate prescribing, but none were found looking 
specifically at the determinants for prescribing in RKF. 
Much of the evidence found is ‘non-local’, reducing the level of evidence assigned. In 
the kidney function equation review, the locality is less important for the assessment of 
calculation, but would be when considering the effect of methods of assay and of 
reporting. In this review over half the studies were assigned a ‘Level 5’ as they were 
‘mechanical reasoning’ only; however, these studies are useful in highlighting the large 
range of drugs that could be affected, especially when prescribed for older people. 
As has been highlighted in previous sections, many of the studies need a kidney 
function estimate available for the analyses, and participants are excluded where it 
cannot be extracted. Retrospective studies are more likely to be affected by this as 
they are reliant on whether the data was collected at the time, whilst prospective 
studies allow collection specifically for the study if needed. For example, in the large 
128 
 
Corsonello et al retrospective study (2005), 5,499 (32%) of the patients had to be 
excluded, most of whom because a kidney function estimation was not available, 
whereas the prospective study by Blix et al (2006) only needed to exclude 2.3%. Some 
studies, like Corsonello, analysed the participants who were excluded to show that 
they were similar to the study population, but it is still unknown what the kidney 
function levels are for that group, and whether it might change the findings of the 
study, introducing potential bias. Confidence in the findings for the population are 
reduced, but it does highlight a problem of kidney function not being applied even 
though drugs affected by RKF are prescribed. This suggests a need to check whether 
kidney function is checked regularly in UK primary care for people prescribed drugs 
with recommendations for altered use in RKF. 
As discussed in Chapter 1 (1.4.2), changing behaviour is more effective if interventions 
are developed on evidence-based principles of behaviour change (Cane et al, 2012), 
and using a theoretical approach allows identification of factors and strategies that are 
more likely to be successful in influencing behaviour change (Nilsen, 2015). However, 
none of the studies found aiming to improve prescribing in RKF (review area 6) were 
based on theory or determinants of why prescribing was not appropriate, which might 
be a factor for some of the studies not showing benefit if the intervention was not 
addressing the barriers. Only the PINCER study protocol (Avery et al, 2009) discussed 
using theory to develop their intervention; they used the principles of Human Error 
theory (Reason et al, 2000) to consider the causes of medication errors in primary 
care from their literature review and empirical research. However, this high quality 
study, although showing that the pharmacist led intervention is an effective method for 
reducing a range of medication errors in general practices, did not study specifically 
whether it would reduce inappropriate prescribing in RKF. 
Whilst recognising the limitations found for some studies in the methods used and 
reported, overall, this scoping literature review has found a wide range to outline what 
is already known, and identity gaps in the existing published literature, on the issues 
relating to prescribing for older people with reduced kidney function in UK primary 
care. 
 
 Principal findings 
Figure 13 summarises how knowledge, themes, and implications for ongoing research 
have been developed through the key findings in this scoping literature review.  
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2.11.3.1 Prevalence 
No studies were found that would give prevalence data in UK primary care for 
inappropriate prescribing in RKF. Evidence from other countries, and from the hospital 
setting, shows that prescribing for patients with reduced kidney function does not 
always follow the recommendations. The high quality, large, multi-centre, French 
primary care prospective cohort study (Breton et al, 2011), and the UK hospital case-
record analysis (Jones and Bhandhari, 2013), give a good indication that there may be 
a problem in UK primary care and that it should be investigated. Across the studies, 
many drugs have been found to be prescribed inappropriately in RKF (Breton et al, 
2011; Khanal et al, 2015; Emami et al, 2012), and drugs mentioned frequently include: 
 ACEIs,  
 Antidiabetic drugs, such as metformin. 
 Bisphosphonates, such as alendronic acid. 
 Lipid-lowering drugs, such as simvastatin. 
Old age has been highlighted as a risk factor, for example, Khanal et al (2015) showed 
that the factors independently associated with patients being prescribed one or more 
potentially inappropriate renally cleared drugs included advancing age. Many good 
quality studies have highlighted the extent of inappropriate prescribing in older people 
with RKF (Breton et al, 2011; Schmidt-Mende et al, 2012; Khanal et al, 2015). 
The findings of this review suggest that an investigation is needed into the prevalence 
of inappropriate prescribing in RKF in a wider population of older people in UK primary 
care than the pilot case-note study. 
 
2.11.3.2 Kidney function assessment for prescribing decisions for older 
people 
Patient outcome and drug blood level data shows that the Cockcroft Gault calculation 
should still be used to estimate kidney function for drug dosing decisions, in particular 
for the older patient (Melloni et al, 2008; Roberts et al, 2008). Four review papers all 
conclude that the MDRD equation for eGFR should not be used for drug dosing 
decisions (Spruill et al, 2008; Hellou, 2010; Nyman et al, 2011, Hudson and Nyman, 
2011). Using eGFR to inform prescribing decisions has been shown to overestimate 
the kidney function level, and that the effect increases with age meaning that the 
greatest risk is for the oldest patients (Roberts et al, 2008). Using eGFR would mean 
that patients who should have their drug treatment altered might be missed (Melloni et 
al, 2008). It is also clear that the prescribing decisions for many drugs would be 
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affected by which equation is used; examples include gabapentin, antibiotics, and 
anticoagulants (Hudson and Nyman, 2011; Melloni et al, 2008; McCallum et al, 2013). 
The findings of this review suggest that when investigating the prevalence in UK 
primary care, there is a need to assess kidney function using both CrCl-CG and 
MDRD equations, and to see how many patients would be missed if eGFR (MDRD) is 
used, that should have their treatment altered. 
 
2.11.3.3 Risk to the patient if prescribing recommendations in RKF are 
not applied. 
Inappropriate prescribing in RKF leads to a significantly increase in all-cause mortality 
of 40% (Breton et al, 2011), and increased risk of ADRs and hospital admissions 
(Helldén et al, 2009) in older people. The prevalence studies showing that older 
people have more inappropriate prescribing would suggest that they are more likely to 
be at increased risk of harm, and many of the studies reporting ADRs and hospital 
admission either had an older population, or reported high mean ages. 
The drugs highlighted as causing harm in the studies are also similar to those 
implicated in the other review areas, for example: 
 NSAIDs were frequently cited as causes of ADRs, including toxicity to the 
kidney, and hospital admission (Adams et al, 2011; Evans et al, 1995) 
 Nitrofurantoin, both being ineffective as an antibiotic, and increased risk of 
hospitalisation from pulmonary ADRs, at low levels of kidney function (Geerts 
et al, 2013; Howard et al, 2013). 
 Anticoagulants such as NOACs and heparin where there is an increased risk of 
bleeding if doses are not adjusted in RKF (Melloni et al, 2008; Cestac et al, 
2003). 
The risk of harm found in this review emphasises the need for further research into 
how to reduce inappropriate prescribing in RKF, particularly for older people. 
 
2.11.3.4 Why do prescribers not implement prescribing 
recommendations? 
No studies were found that aimed to explore the underlying behaviours and 
determinants of why the recommendations for prescribing when kidney function is 
reduced are not applied, and the barriers and enablers to improvement. There have 
been some good quality meta-syntheses and additional qualitative studies into 
inappropriate prescribing more generally (Anderson et al, 2014; Cullinan et al, 2014; 
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Slight et al, 2013). These studies have pointed to prescriber factors such as lack of 
problem awareness, fear of consequences of change, and personal ability. Also 
extrinsic factors such as the working environment, the feasibility of altering prescribing, 
and applying guidelines versus experience. The many factors involved were found to 
be complex and interdependent, with no one factor being dominant.  
As there are important factors, such as the need for kidney function estimation 
calculation, there may be barriers and enablers to inappropriate prescribing that relate 
specifically to RKF and older people that should be explored before development of an 
intervention. 
 
2.11.3.5 Are there resources to help with prescribing in RKF? 
National and international policies and guidance have advised on management of 
kidney disease but do not cover dosing of drugs that need altering in the reduced 
kidney function of the older patient. The introduction of a different kidney function 
estimation equation for eGFR (MDRD) has not been clarified in the guidelines in 
relation to use for prescribing decisions, and for older people in particular (NICE 
CG182, 2014).  
The BNF is a widely used and respected resource for prescribing, but the statement 
that eGFR gives similar results to creatinine clearance has been shown to not be the 
case for older people in this review. The BNF gives the recommendations for drug use 
in RKF in the drug monographs as eGFR, except for the NOACs where European 
guidance has stipulated that it needs to CrCl-CG; however, the figures are taken from 
the SPCs where CrCl-CG has been used. This scoping review would suggest that the 
BNF guidance is not adequately evidence-based because of the over-estimation of 
kidney function when eGFR is used in older people. 
If the evidence can be strengthened on the impact in UK primary care, there might 
then be a case for the BNF to alter its guidance, and inform future national guidance 
on prescribing in RKF. 
2.11.3.6 Have any interventions been evaluated to help prescribers 
apply recommendations for use of drugs in RKF? 
The reporting of eGFR might have raised awareness of kidney disease but it has not 
improved prescribing in RKF. Evaluations of alerts and more sophisticated CDSSs 
have shown mixed results in a systematic review (Tawadrous et al 2011), but the 
studies that involved pharmacists in the intervention showed universally positive 
results. The Four RCTs found also showed positive effects: 
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 Dosing software improved ACEI/ARB prescribing in hypertension in older 
people (Erler et al, 2012). 
 CDSS with an alert significantly improved prescribing in RKF (Field et al, 
2009). 
 Alerts to pharmacists significantly reduced errors for prescriptions in RKF 
(Bhardwaja et al, 2011). 
 A pharmacist-led information technology intervention (PINCER) is an effective 
method for reducing a range of medication errors in general practices, including 
improvement of kidney function testing when taking an ACEI or diuretic (Avery 
et al, 2012). 
None of the studies found aiming to improve inappropriate prescribing in RKF were 
based on theory or determinants of why recommendations were not applied, which 
might be a factor if the intervention was not addressing where the barriers are. A 
behaviour change theory based intervention for UK primary care needs to be 
developed and tested to reduce inappropriate prescribing. 
 
 Strengths and limitations 
Use of a robust method for the scoping literature review made this study transparent 
and reproducible. A limitation is the reduced rigour having only one researcher with 
challenges such as uncertainty about which studies to include, variables to extract, 
and nature and extent of detail. These were sought to be reduced by searching on 
multiple databases, allowing re-evaluation of studies against the search criteria. Also, 
the systematic method was used to reduce the risk of bias and a one-sided view. Only 
studies published in English were included which may mean some relevant evidence 
may have been missed. 
 
 What this study adds to the literature 
This study has been able to provide an update to the reviews such as Long et al 
(2004). With the international KDIGO guidelines and policy on CKD and AKI, there 
appears to now be greater interest in kidney disease and an increasing body of 
literature. Finding the gaps for future research confirmed the research plan to 
investigate prescribing for older people with RKF in UK primary care.    
 
 What this study adds to practice and policy 
The review has highlighted that the guidelines and policy do not assess older people 
as a specialist group or provide guidance on use of drugs in reduced kidney function 
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and how to reduce risk of harm. A recent systematic examination of recommendations 
in twelve NICE clinical guidelines also concluded that drug-disease interactions with 
chronic kidney disease were common and that guideline developers should particularly 
consider whether chronic kidney disease is common in the target population 
(Dumbreck et al, 2015). 
The BNF current guidance may not be evidence-based because of the over-estimation 
of kidney function when eGFR is used in older people. If the evidence can be 
strengthened on the impact in UK primary care, there might then be a case for the 
BNF to alter its guidance, and inform future national guidance on prescribing in RKF. 
 
 Progression and integration of methods and findings 
The pilot study case-note review in Chapter 1 provided the key areas of literature 
review. Similar results to those found in GP practices in Bradford were found in studies 
from other countries, both for prevalence of inappropriate dosing, and discrepancies in 
the use of the different kidney function estimation equations for older people. As no 
other UK research was found in primary care, there was a need to test the findings in a 
wider population. 
The scoping literature review has confirmed the research plan, and provided examples 
of methods and analyses, to: 
 Study the extent of not applying recommendations in a larger population in UK 
primary care. 
 Investigate the extent to which kidney function is tested for older people 
prescribed drugs that are affected by RKF. 
 Explore why prescribers are not applying the recommendations in UK primary 
care, so that development of an intervention can address barriers and enablers 
and so be more likely to be effective. 
 
2.12 Conclusion 
The prescribing for the older patient with reduced kidney function does not always 
follow the recommendations and this can lead to an increased risk of ADRs and 
hospital admissions. The introduction of the nationally reported eGFR as a kidney 
function estimation did not improve prescribing in RKF, and its use overestimates the 
level of kidney function for older people meaning that they are at increased risk of 
harm. Gaps in the literature have been identified and research is needed to investigate 
prescribing for older people with RKF in UK primary care. 
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‘The use of medications in older patients is arguably the single most important health 
care intervention in the industrialized world.’ 
J. Avorn, 2010 
 
3 Chapter 3: A cross-sectional survey of prescribing data to 
investigate whether recommendations for prescribing are 
applied for older people across a PCT population 
 
3.1 Background 
A quarter of older patients with a documented reduced kidney function (RKF) were 
found to be taking drugs that were not recommended, in the small localised case-note 
review (Chapter 1). The scoping literature review (Chapter 2) found no other 
prevalence studies on prescribing for older people with RKF in UK primary care. 
Studies based in hospitals, and in other countries, suggest that recommendations in 
RKF are often not applied, with increased risk of harm and hospital admission. 
This study aimed to test the case-note review findings in a wider population in UK 
primary care by quantifying inappropriate prescribing in a representative sample of 
drugs that require kidney function assessment prescribed for people aged 65 years 
and older. 
 
3.2 Study question and objectives 
Study question 
Are drugs, that require kidney function assessment, prescribed according to 
recommendations for use in reduced kidney function for people aged 65 years and 
older across a Primary Care Trust (PCT) population? 
Objectives 
Primary objective: 
 To assess the prevalence of a representative sample of drugs that require 
kidney function assessment for patients aged 65 years and over where the 
kidney function is too low for recommended use. 
Secondary objectives:  
 To assess whether a kidney function estimate was on the patient record where 
drugs that require kidney function assessment are prescribed. 
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 Whether using eGFR (MDRD equation) or CrCl-CG (Cockcroft Gault equation) 
would alter dosing decisions. 
 Whether age is a factor in having a kidney function estimate too low for 
recommended use of drugs that require kidney function assessment. 
 
3.3 Methodology 
Drugs, age, and parameters related to kidney function needed to be investigated to 
give an indication of the extent to which drugs are prescribed outside 
recommendations for use RKF in primary care. A quantitative strategy was required to 
examine the relationships between and among the variables (Cresswell, 2009). As the 
intention was to test the findings from the case-note review in a wider population, an 
option might have been to extend that study. However,  
 Case-note reviews are a lengthy process. 
 GP practices would need to give consent to be included in a service evaluation 
beyond the usual workplace, and individual patients would need to give 
consent to allow their medical record to be accessed.  
 Repeating the method would not allow a more detailed statistical analysis. 
A cross-sectional survey design would allow a ‘snap-shot’ rapid investigation at a 
single moment in time in a larger sample. To allow the inclusion of large numbers of 
prescribing data, it was proposed to do the data collection by a structured record 
interrogation (Fink, 2002) for all people aged 65 years and older in the PCT 
population. Use of variables derived from the case-note review would allow the 
findings to be investigated further. Inclusion of all four categories (see below) of 
inappropriate drug use in RKF would explore any differences, and ensure the results 
were more likely to be generalisable, i.e.: 
 Drugs to avoid in RKF 
 Dose reduction required in RKF 
 Drugs that are ineffective in RKF 
 Drugs requiring caution as they are known to frequently cause adverse drug 
reactions (ADRs) in RKF. 
Investigation of prescribing where there had never been a kidney function test done, or 
where there was not a recent check, would address one of the limitations of the case-
note review study. Kidney function can alter over time, and as a result of disease, so a 
recent test should be available when making drug choice and dosing decisions for 
drugs affected by level of kidney function. 
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3.4 Study design 
 Setting 
The former Bradford & Airedale Primary Care Trust (PCT) area was the setting for the 
prescribing data survey run in 2011. PCTs were part of the NHS in England from 2001 
to 2013. They were large administrative bodies, responsible for commissioning 
primary, community and secondary health services from providers. Over 80% of all 
NHS funding went to PCTs (Department of Health, 2012).    
The health of the people in Bradford is mixed, and deprivation higher, compared with 
the England average. Life expectancy for both men and women is lower (men: 76.6 
years compared to 78.6 years, range 73.6 - 85.1 years; and women: 80.8 years 
compared to 82.6 years England average, range 79.1 - 89.8 years) (Public Health 
England, 2012). The 2011 Health Profile (Table 18) also shows the Bradford 
population is younger than the England & Wales average with fewer people aged 65 
years and older (13% vs 16%), and 85 years and older (1.8% vs 2.2%), for both males 
and females (Office for National Statistics, 2011). 
 
 
Table 18: Census 2011 population statistics for Bradford and England & Wales 
(Office for National Statistics, 2011). 
 
 Drug choice 
Two drugs, or drug classes, were identified from each of the four categories of 
inappropriate prescribing in RKF, i.e. for: 
 Drugs to avoid in RKF 
 Dose reduction required in RKF 
 Drugs that are ineffective in RKF 
 Drugs requiring caution as they are known to frequently cause adverse drug 
reactions (ADRs) in RKF. 
The eight choices of drugs were based on the most frequently prescribed outside the 
recommendations in the case-note review, the strength of the evidence base, the 
impact on patients, and expert advice from a renal physician, geriatrician, hospital 
renal pharmacist, and an antibiotics expert pharmacist. The experts made their 
England & 
Wales
Bradford
all 53,012,456 522,452 8,660,529 16% 69,392 13% 1,180,128 2.2% 9,604 1.8%
male 26,069,148 257,132 3,844,839 15% 29,984 12% 383,568 1.5% 3,011 1.2%
female 26,943,308 265,320 4,815,690 18% 39,408 15% 796,560 3.0% 6,593 2.5%
whole population 65yrs and older 85yrs and older
England & Wales England & WalesBradford Bradford
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judgement independently based on their experience. The evidence sources included 
the standard recommendations for use of drugs in RKF, such as the Summary of 
Product Characteristics (SPC) and British National Formulary (BNF). The basis for the 
drug choices are summarised in Table 19, and discussed in more detail below.  
 
 
Abbreviations: ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; CrCl: creatinine clearance; NSAID: 
non-steroidal anti-inflammatory; RKF: reduced kidney function. 
Table 19: Choices of drugs and drug classes to investigate in the cross-
sectional survey. 
 
3.4.2.1 Drugs to avoid in RKF 
Alendronic acid is a bisphosphonate used to reduce the risk of bone fractures. The 
SPC states that it should be ‘avoided if CrCl<35ml/min due to lack of experience’ 
which implies that there is no evidence base to support the use in low kidney function, 
although it also states that ‘somewhat greater accumulation of alendronic acid in bone 
might be expected in patients with impaired renal function.’ The terminal half-life 
recommendation 
in RKF
drug
% prescribed 
inappropriately 
in the case-
note review
recommendation in 
respected national 
resource
references highlighting 
inappropriate 
prescribing 
comments from experts
alendronic acid 4.0 avoid if CrCl<35ml/min
Khanal et al,(2015).
Breton et al (2011).
Agreed to be included.
metformin 2.2 avoid if CrCl<30ml/min
Breton et al (2011)
Khanal et al (2015)
Schmidt-Mende et al 
(2012)
Suggested by a renal physician 
and a geriatrician as they see 
admissions to hospital caused 
by metformin in RKF.
simvastatin 8.8
maximum dose 10mg 
if CrCl<30ml/min
Breton et al (2011) 
Agreed to be included as a 
widely used drug with an 
alternative available.
gabapentin and 
pregabalin
0.2
table of reduced 
doses at specified 
levels of CrCl
Breton et al (2011)
Added at the suggestion of the 
renal pharmacist because of 
frequent side effects seen in the 
renal unit.
thiazides 17.0
ineffective at 
CrCl<30ml/min
Howard et al (2003) Agreed to be included.
nitrofurantoin
0.2 
(on repeat)
ineffective at 
CrCl<45ml/min
Farag et al (2014) 
Howard and Wood 
(2013) 
Geerts et al (2013) 
Added after discussion with a 
pharmacist with expertise in 
antibiotics.
NSAIDs on 
repeat
1.7 caution in RKF
Guthrie et al (2011) 
Howard et al (2003) 
Evans et al (1995)
Ingrasciotta et al (2014) 
NSAIDs affect all stages of 
kidney function and are 
frequently a cause of hospital 
admission.
ACEIs and 
ARBs
26.0 caution in RKF
Khanal et al (2015) 
Breton et al (2011)
Schmidt-Mende et al 
(2012)
Handler et al (2014) 
Although ACEIs and ARBs are 
used in renal disease, they can 
also be nephrotoxic so the 
consultant experts suggested 
inclusion.
caution  in RKF
avoid
reduce the dose
ineffective
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exceeds 10 years so once taken up in the bone it is only eliminated extremely slowly, if 
at all.  
a) Findings from the case-note review 
Alendronic acid was the second most frequent drug found prescribed inappropriately in 
the case-note review with 24 patients, in the cohort of 594 (4%), found with a kidney 
function too low for recommended use (see Appendix 2, 8.2). 
b) The evidence base 
The evidence for restricted use in RKF has been described as ‘not robust’ by Courtney 
and Maxwell (2009). They state that initial safety issues were raised in the mid-1980s 
with reports of bisphosphonate accumulation in the kidneys of rodents. Later it was 
recognised that clinically significant renal failure can follow the rapid intravenous 
administration of bisphosphonates in humans. This information, together with the 
knowledge that approximately 50% of oral administered bisphosphonate is excreted by 
the kidney, led to the exclusion of persons with raised serum creatinine values from 
clinical trials. Cunningham (2007) found that individuals with CKD stage 2–4 (i.e. 
eGFR ≥15ml/min/1.73m2) did not show evidence of increased toxicity or adverse 
effect. In patients with stage 5 CKD it has been suggested that reducing the dosage to 
half for post-menopausal osteoporosis seems reasonable from known bisphosphonate 
pharmacokinetics (Miller, 2005). 
Alendronic acid was cited as one of the top five drugs prescribed inappropriately for 
older people in the Australian primary care prevalence study (Khanal et al, 2015); in 
16.3% of 543 patients alendronic acid would be contra-indicated because of the 
reduced level of kidney function. The large, high quality, multi-centre, prospective 
cohort, French primary care study by Breton et al (2011) reported bisphosphonates as 
a group where they found 14% were prescribed inappropriately. 
c) The impact for patients 
Europe-wide reviews of bisphosphonates have been carried out since 2008 and have 
been recently summarised by the MHRA (MHRA, 2014). These include a low but 
increased risk of atrial fibrillation for zoledronic acid, pamidronate, and possibly for 
alendronate, that alendronic acid use is associated with an increased risk of atypical 
stress fractures of the proximal femoral shaft and a warning was subsequently added 
to alendronic acid product information, and that renal toxicity is a recognised adverse 
reaction associated with intravenous bisphosphonates. 
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d) Expert advice 
The expert advisors independently agreed the inclusion of alendronic acid for this 
study. 
Metformin is an anti-diabetic drug. The NICE recommendation is to avoid use of 
metformin at eGFR <30ml/min/1.73m2 (NICE NG28, 2015). When kidney function is 
impaired, clearance of metformin is decreased and the elimination half-life prolonged, 
leading to increased levels of metformin in plasma.  
For older people there is the specific recommendation in the SPC that ‘due to the 
potential for decreased renal function in elderly subjects, the metformin dosage should 
be adjusted based on renal function. Regular assessment of renal function is 
necessary’. It also stipulates that kidney function needs testing regularly at least 2-4 
times a year in elderly subjects (estimated from serum creatinine using the Cockcroft-
Gault formula). On elimination, renal clearance of metformin is stated as >400 ml/min, 
indicating that metformin is eliminated by glomerular filtration and tubular secretion. 
When kidney function is impaired, the clearance though the kidney is decreased in 
proportion to that of creatinine and so the elimination half-life is prolonged, leading to 
increased levels of metformin in plasma. 
a) Findings from the case-note review 
Thirteen patients (2.2%) were found where kidney function was too low for 
recommended use, or the dose needed review, and so was in the top five drugs that 
were not recommended for use because of RKF or the dose needed review.  
b) The evidence base 
Metformin was frequently cited in the studies in primary care found in the scoping 
review as being prescribed to patients when contra-indicated because of RKF, 15.3% 
of metformin prescribing in France (Breton et al, 2011), 17.8% in Australia (Khanal et 
al, 2015), and 8.4% in Sweden (Schmidt-Mende, 2012). 
c) The impact for patients 
Lactic acidosis is a metabolic complication that can occur due to metformin 
accumulation and occurs primarily in diabetic patients with impaired kidney function or 
acute worsening of kidney function (SPC). It is very rare, but is serious with a high 
mortality rate in the absence of prompt treatment. 
d) Expert advice 
Metformin was independently suggested for inclusion in this study by the renal 
physician and the geriatrician as they experienced patients admitted to hospital with 
lactic acidosis from use of metformin in RKF. 
140 
 
3.4.2.2 Dose reduction required in RKF 
Simvastatin is widely used to reduce cholesterol levels, and in 2011 was the ‘statin’ of 
choice in Bradford. The SPC states that ‘in patients with severe renal insufficiency 
(creatinine clearance <30 ml/min), dosages above 10 mg/day should be carefully 
considered and, if deemed necessary, implemented cautiously’.  
a) Findings from the case-note review 
Simvastatin was the highest frequency single drug (x52, 8.8%) found to be prescribed 
outside the recommendations in the case-note review (see table Appendix 2, 8.2). 
b) The evidence base 
In a Personal Communication by S Wood to Merck Sharp & Dohme (12/10/11), the 
drug company stated that the dose reduction recommendation is based on a 
comparator statin, lovastatin, where the ‘area under the plasma concentration-time 
curve’ (AUC) for total and active HMG-CoA reductase inhibitory activity was 2 to 3 
times higher in patients with RKF (mean CrCl 24ml/min, range 12-39ml/min) than in 
controls (Quérin et al, 1991).  
An MHRA Drug Safety Update on dose limitations for simvastatin with interacting 
drugs found that concurrent use of drugs such as amlodipine with simvastatin causes 
a significant increase in blood levels of simvastatin which is associated with an 
increased risk of myopathy and/or rhabdomyolysis (MHRA, 2012). Studies have found 
that after 10 days of amlodipine (10 mg), the AUC of simvastatin and simvastatin acid 
following a single dose of simvastatin 80 mg increased by 1.58- and 1.77- fold 
respectively, compared with that following a single dose of simvastatin 80 mg without 
prior amlodipine administration (Merck, Sharp & Dohme, 1991). The fact that the 
MHRA needed to issue a Drug Safety Alert, and implement the changes in the dose 
requirements for simvastatin based on a nearly doubling of the AUC with an interacting 
drug, would lend weight to the fact that increases in AUC of 2-3 times in RKF should 
be taken seriously and could be increasing risk of harm for patients. 
The French primary care study found that 3.8% of all statins needed dose adjustment 
(Breton et al, 2011). 
c) The impact for patients 
Increased blood levels of simvastatin are associated with an increased risk of 
myopathy and/or rhabdomyolysis (SPC). As the dose of simvastatin can be reduced 
when kidney function is low, and there is the option to switch to an alternative statin, 
atorvastatin, which does not need dose changes in RKF, any impact for patients can 
be avoided. 
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d) Expert advice 
The expert advisors independently agreed the inclusion of simvastatin for this study. 
Gabapentin and pregabalin SPCs state that they are eliminated solely though the 
kidney and that in older patients, and in patients with impaired kidney function, the 
plasma clearance is reduced. The elimination-rate constant, plasma clearance, and 
renal clearance are directly proportional to creatinine clearance.  
The recommendations for use of gabapentin in RKF in the SPC show doses need 
altering at different levels of kidney function (Table 20). The SPC for pregabalin 
specifically details that the dose reduction in patients with compromised renal function 
must be individualised according to creatinine clearance (CrCl), as indicated in  
Table 21, that should be determined using the Cockcroft & Gault formula; the formula 
is provided in the SPC to be very clear about how the estimate should be calculated.  
 
 
 
 
 
 
 
 
 
Table 20: Dose recommendations in RKF for gabapentin (SPC)     
 
Table 21: Dose recommendations in RKF for pregabalin (SPC) 
 
The SPC for pregabalin states that clearance tends to decrease with increasing age 
and that this is consistent with decreases in creatinine clearance associated with 
Kidney function (CrCl) Total daily dose (mg)
80ml/min or higher 900-3600
50-79 ml/min 600-1800
30-49 ml/min 300-900
15- 29 ml/min 150-600 (150mg as 300mg alt days)
<15 ml/min 150-300
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increasing age. Reduction of pregabalin dose may be required in patients who have 
age related compromised kidney function. 
a) Findings from the case-note review 
Only one patient in the case-note review had been found to be on gabapentin at a 
dose too high for their kidney function, and no patients on pregabalin, so they were not 
initially highlighted as drugs for investigation in the survey. 
b) The evidence base 
Breton et al (2011) reported that in 5.6% of antiepileptics in the French primary care 
study required dose adjustment because of RKF had not been done, which included 
gabapentin and pregabalin. 
c) The impact for patients 
Somnolence, dizziness, ataxia, and fatigue are described in the SPC as very common 
(≥ 1 in 10), and many ‘common’ ADRs are listed, including psychiatric, nervous 
system, skin and gastrointestinal reactions (≥ 1/100). Although used for epilepsy, they 
have increasingly been prescribed for neuropathic pain. 
NHS England (2014) analysed electronic prescribing data for primary care for 
prescribing of gabapentin and pregabalin, and in 2013 the total use in England of both 
was 8.2 million prescriptions; this represents a 46% rise in prescribing of gabapentin 
and 53% rise in pregabalin prescribing since 2011. The increase in use of these drugs 
in primary suggests an increase in risk for patients if kidney function is not assessed 
and doses altered accordingly.  
d) Expert advice 
Gabapentin and pregabalin were suggested for inclusion on the advice of the renal 
pharmacist because ADRs are frequent and often related to dose and kidney function 
level.  
3.4.2.3 Ineffective in RKF 
Thiazides are usually prescribed for hypertension, but they require an adequate level 
of kidney function to work and they are ineffective at CrCl <30ml/min (BNF70, 2015). 
In the SPC for indapamide, for example, it states that in severe renal failure (CrCl <30 
ml/min), treatment is contraindicated and that thiazides are fully effective only when 
kidney function is normal or only minimally impaired. 
a) Findings from the case-note review 
Thiazides were the third most implicated class of drugs in the case-note review with 
17% found to be prescribed when kidney function was <30ml/min (see table Appendix 
2, 8.2). 
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b) The evidence base 
Howard et al (2003) investigated reasons for preventable drug related admissions to a 
medical admissions unit in the UK. Thiazides were one of the drug classes most 
frequently associated with preventable drug related admissions due to monitoring 
problems. They cite failure to monitor kidney function, fluid balance and electrolytes as 
a factor in ADRs such as over diuresis causing dehydration and renal failure. 
c) The impact for patients 
The risk for patients is from both under-treatment as well as increased risk of side 
effects such as electrolyte disturbance.  
d) Expert advice 
The expert advisors independently agreed the inclusion of thiazides for this study. 
Nitrofurantoin is used to treat urinary tract infection (UTI) and is most often 
prescribed as a short course. The SPC and BNF (2010) at the time of the survey 
stated that nitrofurantoin is ineffective if CrCl is less than 60ml/min as there would not 
be an adequate concentration in the urine to be active against infection. The Renal 
Drug Handbook 2nd Edition (Ashley & Currie, 2007) also stated that nitrofurantoin was 
contra-indicated at CrCl <60ml/min.  
a) Findings from the case-note review 
The case-note review only reviewed long term medication and so did not assess the 
usual acute use of nitrofurantoin in RKF. However, one patient was found who was 
taking regular prophylactic nitrofurantoin but kidney function was lower than 
recommended. 
b) The evidence base 
The recommendation for prescribing in RKF had originally been based on inadequate 
urinary concentration at <60ml/min found in a small study of eleven subjects with 
normal kidney function and six with renal insufficiency (Felts et al, 1971). In 2014 the 
MHRA published a Drug Safety Update to change the recommendations to be 
contraindicated at eGFR <45 ml/min/1.73m2, to consider checking kidney function 
when choosing to treat with nitrofurantoin, especially in the elderly, and to closely 
monitor for signs of pulmonary, hepatic, neurological, haematological, and 
gastrointestinal side effects during treatment. The revision in recommendations was 
based on two studies. Oplinger and Andrews (2013) suggested the limited data 
available would support use of nitrofurantoin in CrCl of 40ml/min or higher. Geerts et al 
(2013) found that nitrofurantoin treatment was not associated with a higher risk of 
ineffectiveness in women with a moderately reduced kidney function (30-50 
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ml/min/1.73 m²). The analysis of the survey data was altered to reflect the change in 
recommendation. 
Farag et al (2014) investigated antibiotic use in RKF for older people in Canada; they 
noted that nitrofurantoin had been prescribed when contra-indicated 169 times in the 
1,464 antibiotics prescriptions studied. 
The addition of a drug that is mostly acute use as a short course addresses one of the 
limitations in the case-note review where only repeat medications were assessed. 
c) The impact for patients 
ADRs are more likely in RKF and an infection may not be treated. A small pilot audit 
on the effectiveness of nitrofurantoin suggested that older patients with reduced kidney 
function were more likely to need a follow up course of an alternative antibiotic if the 
kidney function was low (Howard & Wood, 2012). Geerts et al (2013) found a 
significant association between renal impairment (<50 ml/min/1.73 m²) and pulmonary 
adverse events leading to hospitalisation.  
d) Expert advice 
The antibiotics expert pharmacist suggested inclusion as use was increasing with the 
national aim to reduce methicillin-resistant staphylococcus aureus (MRSA) and 
clostridium difficile infection after antibiotic use (NICE KTT9, 2016). However, the 
recommendations were that nitrofurantoin was ineffective at CrCl <60ml/min which 
would exclude many older people, and there was interest in investigating the numbers 
of patients that would be affected.  
3.4.2.4 Caution because known to frequently cause ADRs in RKF 
Non-steroidal anti-inflammatories (NSAIDs) reduce pain and inflammation, but their 
effect on prostaglandin synthesis leads to many side effects including the inhibition of 
renal prostaglandin synthesis and affect all aspects of the function of the kidney 
(Ashley and Morlidge, 2008; Ashley and Currie, 2014). If the NSAID is also eliminated 
via the kidney, such as naproxen (95%), then the adverse effect can be compounded 
as the blood levels are increased. The BNF states in each drug monograph for 
NSAIDs:  
‘Avoid if possible or use with caution in patients with renal impairment; the 
lowest effective dose should be used for the shortest possible duration, and 
renal function should be monitored. Sodium and water retention may occur and 
renal function may deteriorate, possibly leading to renal failure’ (BNF70, 2015, 
pp.917-937).  
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NSAIDs are specifically mentioned in the NICE CKD and AKI guidance (NICE CG182, 
2014; CG169, 2013) including chronic use of NSAIDs as a risk factor for progression 
of CKD and the requirement for monitoring kidney function at least annually in people 
prescribed drugs known to be nephrotoxic, such as NSAIDs. 
The BNF guidance to avoid in severe renal impairment (defined in previous BNFs as 
<30ml/min, BNF55, 2008) informed the decision to set this level as the marker. 
a) Findings from the case-note review 
Four patients (1.7%) in the case-note review had an NSAID on their repeat medication 
list when their kidney function was <30ml/min. A further 6 had a topical NSAID gel.  
b) The evidence base 
NSAIDs are frequently cited in the research literature as being prescribed 
inappropriately causing ADRs and hospital admission. Wiffen et al (2002) reported that 
NSAIDs were responsible for between 60% and 70% of all ADRs leading to hospital 
admission, or causing ADRs within a hospital episode. NSAIDs were the most 
commonly prescribed contra-indicated nephrotoxic drugs prescribed to CKD patients 
in an Italian primary care study, 56.3% had at least one prescription for an NSAID, a 
third were treated for over 90 days, and 16.5% for greater than 6 months (Ingrasciotta 
et al, 2014). Guthrie et al (2011) found that 8.2% of patients aged 65 years and over 
with a glomerular filtration rate <60 ml/min received a ‘high risk prescription’ of an 
NSAID.  
c) The impact for patients 
NSAIDs were a drug class most frequently associated with preventable drug related 
admission in the UK due to prescribing problems including not monitoring kidney 
function in the Howard et al study (2003), and  Evans et al (1995) showed that there 
was an approximate doubling of the risk of hospitalisation with acute renal failure with 
use of oral NSAIDs. 
d) Expert advice 
The expert advisors independently agreed the inclusion of NSAIDs for this study. 
Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin-II receptor 
blockers (ARBs) affect the renin-angiotensin hormone system which controls blood 
pressure and the volume of fluids in the body. Drugs that have an inhibitory action on 
the renin-angiotensin hormone system (including ACEIs and ARBs) are used to treat 
high blood pressure and congestive heart failure. The BNF (BNF70, 2015) details that, 
although ACEI and ARBs are prescribed in kidney disease, they can be nephrotoxic 
and higher than normal plasma levels can cause further renal impairment and set up a 
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cycle leading to acute kidney injury. It states that kidney function and electrolytes 
should be checked before starting ACEIs or ARBs, or increasing the dose, and 
monitored during treatment.  
a) Findings from the case-note review 
ACEI/ARBs were inappropriately dosed, or needing review, in 26% of patients in the 
case-note review. They were also involved in two cases of acute kidney injury noted 
whilst doing the review, one causing hospitalisation. 
b) The evidence base 
Prevalence studies found in the literature review reported ACEI and ARBs frequently 
inappropriately prescribed. Perindopril was the top drug prescribed outside 
recommendations in the Australian retrospective survey study at 44.1%, and 
olmesartan was also one of the top five drugs contra-indicated in older people with 
RKF (Khanal et al, 2015). Breton et al (2011) found 2.9% of their older study 
population were taking drugs affecting the renin-angiotensin system that were contra-
indicated or needed the dose adjusting. Schmidt-Mende et al (2012) showed that 
enalapril and candesartan were particularly notable for inappropriate prescribing. 
Handler et al (2014) found that the most common drugs causing AKI alerts to be 
triggered were ACEI/ ARBs. 
c) The impact for patients 
Some ACEIs are mostly excreted via the kidney, such as lisinopril and enalapril. The 
latter has an ‘AUC’ eight times normal at CrCl of <30ml/min (SPC), and so a patient 
with a kidney function level of <30ml/min given a ‘usual maintenance’ dose of 20mg a 
day would be getting the equivalent of 160mg and be at very high risk of serious 
adverse effects, including nephrotoxicity, and thus making kidney function even worse.  
Renal impairment, hyperkalaemia, and hypotension are amongst many side effects 
that are more common in patients with RKF (SPC). As cited in the studies found in the 
literature review, and in the case-note review, inappropriate prescribing in RKF causes 
ADRs and increased risk of hospitalisation. 
d) Expert advice 
The renal physician and geriatrician suggested that ACEI/ARBs should be included in 
the survey as patients are frequently hospitalised as a result of prescribing in RKF 
causing AKI. 
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 Variables 
‘Patient drug event’ definition 
A ‘patient drug event’ is when a patient has had at least one prescription for the study 
drug. For the 7 drugs that were prescribed for regular use, a ‘patient drug event’ was 
defined as the drug being on the repeat medication list at the time of the survey. For 1 
drug (nitrofurantoin), as a drug most usually prescribed acutely as a short course, 
‘patient drug event’ was defined as the drug was prescribed at least once in the 
previous 12 months. 
Variables 
The variables for data collection were: 
 Age – actual age at time of search. 
 Gender. 
 Weight (kg) and date last recorded. 
 Serum creatinine (SrCr) (micromol/l) and date last recorded. 
 eGFR (ml/min/1.73m2) and date last recorded. 
 No eGFR on the record. 
The date ‘last recorded’ would be what the prescriber would have available when 
making the decision whether to prescribe or reauthorise after review. It would also 
allow assessment for those who have a ‘recent’ estimate on the record, defined as 
within the last 15 months as used by the primary care general practice Quality 
Outcomes Framework (QOF) (Health & Social Care Information Centre, 2015).  
For each drug surveyed, every ‘patient drug event’ had eGFR and CrCl-CG (using 
both actual weight and ideal body weight) kidney function estimates recorded, as 
detailed below. A reminder of the kidney function estimate definitions and 
abbreviations is provided in Table 1 (Page 22) with the abbreviations table to give an 
easy reference for this chapter.  
 eGFR:  recorded from the patient record. Even though the literature review 
found evidence that CrCl-CG should be used in prescribing decisions for older 
people, eGFR is reported by pathology and so widely available. Inclusion 
allows assessment of the proportion of patients that might be missed if eGFR 
was used instead of CrCl-CG. 
 CrCl-CG AW: creatinine clearance calculated using actual weight, SrCr and 
age variables. The BNF stipulates using ideal body weight (IBW) in the 
Cockcroft Gault equation as a measure of muscle mass (BNF70, 2015). 
However, at least one of the primary care patient record systems (SystmOne) 
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used actual weight in the renal calculator for CrCl-CG at the time of the survey 
(the SystmOne renal calculator has now been revised to use IBW). Inclusion 
allows assessment of the proportion of patients that might be missed if actual 
weight was used instead of IBW. 
 CrCl-CG IBW: creatinine clearance calculated using ideal body weight (or 
actual if lower), SrCr and age variables. An average ideal body weight of 60kg 
for females and 70kg for males was used as ideal body weight or lean body 
weight was not available to search. This is a reasonable assumption to make 
as the highest weights are reduced to a level more likely to approximate the 
lean body weight and give an indication of muscle mass (rather than body fat). 
CrCl-CG IBW is included as the kidney function calculation recommended by 
the BNF for ‘toxic drugs with small safety margins’ (BNF70, 2015). 
Kidney function varies widely between individuals but does generally decline with 
age, whether that is related to disease or senescence (Glassock and Winearis, 
2009). It would be anticipated that the problem of inadequate kidney function for 
prescribing of renally excreted drugs would be greater for older people. Age was 
included to see the effect of increased age on whether each drug would be 
appropriately prescribed. Age bands were used to enable comparison of the 
‘younger old’ with the ‘oldest old’. The Office for National Statistics (2011) starts 
the old age band at 65 years, and the ‘older old’ band at 85 years. To give three 
older age bands for comparison, the data was analysed in the following age 
categories: 
 65 – 74 years. 
 75 – 84 years. 
 85 years and older. 
By including a search for those with ‘no eGFR’ on the record ensured it was 
possible to calculate the total number of people taking each drug, and therefore the 
number of those who did not have any of the variables required to estimate their 
kidney function. 
 
 Sample inclusion criteria 
The samples to be investigated were all ‘patient drug events’ for each of the included 
drugs prescribed for people aged 65 years and older in the PCT population. 
Eight separate sample populations of ‘patient drug events’ for the following drugs were 
planned to be extracted for analysis: 
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 Alendronic acid on repeat prescription.  
 Metformin on repeat prescription.  
 Simvastatin on repeat prescription.  
 Gabapentin and pregabalin on repeat prescription.  
 Nitrofurantoin prescribed within the previous 12 months.  
 A thiazide on repeat prescription. 
 An NSAID on repeat prescription.  
 An ACEI, or ARB on repeat prescription. 
 
 Method 
3.4.5.1 Data extraction 
Having defined the variables and drugs to investigate, the criteria that needed to be 
collected by the searches were discussed with a PCT data analyst to ensure they 
could be extracted from the prescribing data. All GP practices across the Bradford & 
Airedale PCT used the SystmOne patient record system and so the prescribing data 
searches only needed to be run on SystmOne. The PCT data analyst ran the required 
searches for each drug at the end of October 2011 resulting in an anonymised data 
set for each drug. 
The anonymised data extracted was presented as an Excel workbook and forwarded 
to the research team for analysis. The first two data sheets were: 
 Total population – age and gender patient count. 
 Total number of patients aged ≥65 years with eGFR <60ml/min/1.73m2. 
Then three excel data sheets for each of the eight drugs or drug classes for people 
aged ≥65 years: 
 Age, gender, weight and SrCr for calculation of CrCl (both using actual body 
weight (CrCl AW) and estimated ideal body weight or actual if lower (CrCl 
IBW)). 
 eGFR. 
 No eGFR in the last 15 months. 
An assessment of missing data and outliers was then conducted: 
 The searches used meant that only drug prescriptions where a kidney function 
test, or variables to calculate kidney function level, were extracted. An analysis 
was undertaken to find the number of ‘patient drug events’ for each drug that 
occurred when there was no kidney function estimate on the record. This would 
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indicate the number that were missing from the analyses, and how reliable the 
findings would be for the whole population. 
 The data sheets were checked for any missing variable data. As the extraction 
was done using searches for the variables, missing variable data was unlikely. 
However, a missing data analysis was performed to confirm this (3.4.5.2). 
 Outliers were examined in the data, and assessed whether they should be 
included in the final analysis. Kidney function can be good, even in old age, or 
it can be extremely low because of disease. A kidney function variable would 
only be excluded if it was assessed to be most likely to have been a recording 
error. For example, weight data that was found to be lower than possible for an 
adult was assessed, and the patient drug event removed before analysis. 
3.4.5.2 Missing data analysis 
In order to ensure that any missing variables were identified, the effect on the final 
analyses, and to flag up any potential for bias, a missing data analyses was 
performed. As it was intended that the statistical program SPSS would be used for the 
inferential analysis, it would be important to do a missing data analysis as  the 
program may automatically remove cases with missing variables without deleting from 
the data set; this may be significant, especially if a dataset has a high percentage of 
values missing. Also statistical procedures such as regression analysis will not work as 
well, or at all, on a data set with missing values. As the aim is to make inferences 
about the entire target population, it is necessary to clarify that the cases included for 
inferential analysis are representative (Rubin et al, 2002). 
By doing a missing data analysis, the extent and pattern can be clarified and an 
assessment can be made as to whether to omit everyone without complete data and 
do a complete case (or available case) analysis. When only a very few observations 
are missing there will be little effect, but when many are missing, omitting all patients 
without full data might result in a large proportion of the data being discarded, and the 
results may be biased unless the data are missing completely at random (Altman & 
Bland, 2007). 
3.4.5.3 Descriptive analysis 
The anonymised data was assessed by a descriptive analysis. Statistician advice was 
sought because of the non-linearity of the data, the possible linkages where different 
study drugs might be prescribed to the same patients, and to ensure the statistical 
analysis would give clarity to the large set of data.  
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As the data extraction was done for ‘patient drug events’ where all parameters were 
available, a ‘complete case analysis’ was undertaken. Data could only be analysed for 
drug events where a kidney function estimate was on the patient record. It is 
recognised that biases may occur as data was not missing completely randomly; the 
data is unknown for drug events where the patient had no kidney function estimate on 
their record. 
A descriptive analysis using Excel was completed for each drug to organise and 
‘illuminate the data’ and answer the objectives (Bowers, 2008) to give: 
 Population statistics:  
- Total population in Bradford & Airedale PCT 
- Number aged ≥65 years, and in the age bands 65-74, 75-84, and ≥85 
years. 
- Number aged ≥65 years, and in the age bands 65-74, 75-84, and ≥85 years 
for male and female. 
 The numbers of people aged ≥65 years taking each of the study drugs in the 
Bradford & Airedale PCT population, and in the age bands 65-74, 75-84, and 
≥85 years. 
 The number of older people with a documented RKF in the population, defined 
as eGFR <60 ml/min/1.73m2 for CKD (NICE CG182, 2014), in those aged ≥65 
years, and in the age bands 65-74, 75-84, and ≥85 years. This would give an 
indication of the level of recorded CKD in the Bradford & Airedale PCT 
population and allow comparison with other areas. It is noted that not all people 
with CKD will have had an eGFR check. The missing data analysis (3.4.5.2) 
will be able to give an assessment of the number of people prescribed the drug 
but without an available kidney function level on their record. 
Separately for each of the eight selected, representative, drugs: 
 The number of ‘patient drug events’ where a recent kidney function was 
available but was too low for the recommended use. 
 The number of ‘patient drug events’ that would be missed if eGFR or actual 
weight was used to calculate creatinine clearance (CrCl-CG AW) were used 
instead of ideal body weight (CrCl-CG IBW),  
 A line plot charting the range of kidney function at each age level. 
 An assessment of correlation between age and level of kidney function (see 
3.4.5.4 for further details). 
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 A logistic regression analysis to explore the effect of older age on likelihood of 
having a kidney function too low for appropriate prescribing of the drug (see  
3.4.5.5 for further details). 
Kidney function estimates done within the previous 15 months were used for the final 
three analyses, rather than any test on the record, as this would be more accurate and 
ideally a recent test should be available to make drug use and dose decisions. 
Any results from the data analyses that were unexpected, were checked against 
figures found in one large GP practice for corroboration. 
3.4.5.4 Correlation analysis 
Use of the Pearson’s correlation analysis assumes that: 
 The two variables are continuous. 
 There is a linear relationship between the two variables. 
 There are no significant outliers. 
 The variables are approximately normally distributed. 
The data extraction is for people aged 65 years and older and so there are a much 
larger number of the population in the lower older age categories than at the oldest 
ages and the data is likely to be skewed. There are also outliers in the kidney function 
data in this older population where a few have very high level of function, and a few 
have a very low function because of disease. 
Spearman's rank correlation coefficient is appropriate when one or both variables are 
skewed or ordinal and is robust when extreme values are present (Bowers, 2008). The 
age variable in these analyses were skewed when tested using IBM SPSS 22.  
A Spearman correlation was run for each drug on IBM SPSS 22 to determine the 
relationship between an individual's age and level of kidney function. Both variables 
are continuous, and the data was assessed to ensure there was a linear relationship 
between the variables. 
Definitions for the results reported: 
r = correlation coefficient (range -1 to +1) 
n = number included for analysis 
p = level of statistical significance 
3.4.5.5 Inferential analysis 
A logistic regression analysis was performed using IBM SPSS 21 to investigate 
whether the independent variable, age, predicts higher odds of having a kidney 
function estimate too low for recommended use of the investigation drug (the 
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dependent variable). The independent variable was investigated in three age bands: 
65-74 years, 75-84 years and aged 85 years and older. The dependent variable is 
kidney function level in relation to the recommendations for use of the investigation 
drugs. The 75-84 years, and aged 85 years and older, age groups were compared to 
the 65-74 age group. 
It was decided to use the kidney function estimates done within the previous 15 
months, rather than any test on the record, however long ago it was done, as ideally a 
recent test should be available to make drug use and dose decisions. Fifteen months 
is a time period used by the primary care general practice Quality Outcomes 
Framework as cut off for what would be considered a time period when there should 
have been monitoring for clinical review (Health & Social Care Information Centre, 
2015). 
The 95% confidence interval (CI) were assessed to estimate the precision of the odds 
ratios. A large CI indicates a low level of precision of the odds ratio, whereas a small 
CI indicates a higher precision. If the CI overlaps the null value (=1 for this analysis), 
there cannot be confidence that the outcome will occur given the particular exposure.  
This analysis does not address the possibility of confounding, where a non-casual 
association is observed between a given exposure and outcome is as a result of the 
influence of a third variable. The findings need to be interpreted with this in mind. 
Stratification and multiple regression techniques are two methods used to address 
confounding, and produce ‘adjusted’ odds ratios, but were not within the scope of this 
analysis. 
 
 Ethics and governance 
Approval was granted from the PCT governance lead on 21/10/11 as a service 
evaluation (Letter of access: Appendix 5, 8.4). It was confirmed with the National 
Research Ethics Service on 4/11/11 that, as part of an audit, NHS ethics approval was 
not required (Appendix 6, 8.5). All data had been anonymised before being released 
for analysis and there was no GP practice or patient identification possible. 
 
 
3.5 Results  
   Highlighted figures in the tables are those mentioned in the text, 
results or discussion. 
 
70,900
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 Population statistics. 
70,900 people in Bradford & Airedale PCT were aged 65 years and older, 12.9% of the 
549,533 total population, and 1.8% were ≥85 years (Table 22).  
 
Table 22: Bradford & Airedale PCT study population statistics. 
 
 The numbers of people aged ≥65 years taking the study drugs. 
At least 40% of the 70,900 study population were on one or more drugs affected by 
level of kidney function in this population with 39.9% of all ≥65 year olds prescribed an 
ACEI or ARB. Table 23 shows that the proportions of the population taking the study 
drugs ranged from the 39.9% taking an ACEI or ARB, to 2% on gabapentin or 
pregabalin, and are shown in Figure 14. The high number found taking ACEI/ARBs 
was checked with the number in one GP practice which had a similar percent and so 
corroborated the result as the level that wold be expected. 
For those aged ≥85 years the range was from 1.9% on NSAIDs to 35.9% on 
ACEI/ARBs.  
 
Abbreviations: ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; NSAID: non-steroidal anti-
inflammatory; RKF: reduced kidney function. 
Table 23: Numbers prescribed each of the cross-sectional survey drugs. 
 
number % of those
aged 65-
74yrs
number % of those
aged 75-
84yrs
number
% of those
aged ≥85yrs 
alendronic acid 4,230 6.0 1,471 4.0 1,827 7.4 932 9.6
metformin 6,436 9.1 3,594 9.9 2,365 9.6 480 4.9
simvastatin > 10mg 21,733 30.7 11,200 30.7 8,249 33.4 2,284 23.5
gabapentin or pregabalin 1,448 2.0 725 2.0 526 2.1 197 2.0
nitrofurantoin (acute) 3,489 4.9 1,356 3.7 1,322 5.3 811 8.3
a thiazide 12,098 17.1 5,993 16.4 4,662 18.9 1,443 14.8
NSAID on rpt 3,363 4.7 2,194 6.0 987 4.0 182 1.9
ACE/ARB 28,254 39.9 13,739 37.7 11,023 44.6 3,490 35.9
number
aged ≥65yrs
% of  those
aged ≥65yrs
aged 65-74yrs aged 75-84yrs aged ≥85yrs
number
% of total 
population
male
% of total 
population
female
% of total 
population
total PCT population 549,533
total aged ≥65yrs 70,900 12.9 30,953 5.6 39,947 7.3
total aged 65-74yrs 36,466 6.6 17,471 3.2 18,995 3.5
total aged 75-84yrs 24,711 4.5 10,431 1.9 14,280 2.6
total aged ≥ 85yrs 9,723 1.8 3,051 0.6 6,672 1.2
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number
% of those
aged 65-
74yrs
number
% of those
aged 75-
84yrs
number
% of those
aged 
≥85yrs 
total 18,397 25.9 5,502 15.1 8,078 32.7 4,817 49.5
male 6,811 22.0 2,262 12.9 3,132 30.0 1,417 46.4
female 11,586 29.0 3,240 17.1 4,946 34.6 3,400 51.0
aged 65-74yrs aged 75-84yrs aged ≥85yrs
number with eGFR 
≤60ml/min/1.73m
2
number
aged 
≥65yrs
% of  those
aged 
≥65yrs
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; NSAID: non-steroidal anti-
inflammatory; RKF: reduced kidney function. 
Figure 14: The percentage of people aged ≥65 years prescribed each of the 
study drugs (from Table 23).       
   
 
 The level of documented RKF in the population. 
Using the NICE CKD level of eGFR <60ml/min/1.73m2, 25.9% of those aged ≥65 
years, and 49.5% aged ≥85 years, had a documented reduced kidney function on their 
record (Table 24). More females than males had a lower kidney function in all three 
age bands, 17.1% vs 12.9% for the 65-74 years, 34.6% vs 30% for the 75-84 years, 
and for ≥85 years 51% of females and 46.4% of males had a reduced eGFR. 
 
 
 
 
 
 
Table 24: Number of people aged ≥65 years with an eGFR <60ml/min/1.73m2. 
 
 
 Missing data and outliers analysis 
3.5.4.1 Missing data for age and gender 
Virtually no ages or genders were missing from the data set. This is as expected as 
the GP patient record systems have age and gender as required fields. 
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3.5.4.2 Missing data for kidney function estimate calculation  
Only 0.2% (metformin) to 9.7% (NSAIDs) of the patient drug events for each drug 
studied did not have an eGFR available on the patient record, and 0% (metformin) to 
5.7% (NSAIDs) did not have the parameters to calculate CrCl-CG, i.e. age, gender, 
weight, and serum creatinine (Table 25). 
Metformin at 2.8% to 17.5% (NSAIDs), did not have a recent eGFR in the previous 15 
months and 2.4% to 21.9% did not have a recent SrCr on the record (weight was not 
included for a ‘recent’ value as ideal body weight was the BNF suggested variable; 
however, two thirds of cases did have a recent weight value on their record) (Table 
25). 
Figure 15 charts the percentage of patient drug events for the study drugs with no 
eGFR, or no eGFR in the previous 15 months. 
The figures were similar for the ≥85 year olds but slightly higher at 1.5% - 19.8% for a 
recent eGFR and 2.5% - 20.9% for SrCr (Table 25). 
The missing data analysis for patients who had a kidney function estimate in the 
previous fifteen months, has shown that approximately 10% of the data would not be 
used for the final analysis (9,911 out of 96,900). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: ACE: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; eGFR: estimated glomerular filtration 
rate; NSAID: non-steroidal anti-inflammatory. 
Figure 15: The percentage of ‘patient drug events’ for people aged ≥65 years 
with no eGFR on the record, or no eGFR in the last 15 months (from Table 25). 
drug
yes yes yes yes yes yes
alendronic acid
4,016 214 5.3 4,056 174 4.3 3,469 580 14.3 3,400 656 16.2 766 166 17.8 748 184 19.7
metformin 6,415 16 0.2 6,433 0 0.0 6,233 182 2.8 6,278 155 2.4 473 7 1.5 468 12 2.5
simvastatin >10mg
21,404 329 1.5 21,420 313 1.5 19,483 1,921 9.0 19,433 1,987 9.3 2,063 226 9.9 2,047 237 10.4
gabapentin or pregabalin 1,397 51 3.7 1,387 61 4.4 1,233 164 11.8 1,387 176 12.7 166 31 15.7 162 36 18.3
nitrofurantoin
3,383 106 3.1 3,385 104 3.1 3,013 370 10.9 2,979 406 12.0 754 57 7.0 737 74 9.1
thiazides 11,936 162 1.4 11,907 191 1.6 10,876 1,060 8.9 10,807 1,100 9.2 1,267 176 12.2 1,246 197 13.7
NSAIDs
3,054 309 9.7 3,181 182 5.7 2,498 556 17.5 2,483 698 21.9 145 36 19.8 144 38 20.9
ACE/ARB 28,063 191 0.7 27,875 379 1.4 26,222 1,841 6.6 26,117 1,758 6.3 3,215 275 7.9 3,168 322 9.2
"no"
aged ≥65yrs
eGFR (ever)
aged ≥65yrs
weight & SrCr
(ever)
aged ≥65yrs
eGFR
(in last 15 mths)
aged ≥65yrs
SrCr (in last 15 mths)
and weight ever
aged ≥85yrs
eGFR
(in last 15 mths)
aged ≥85yrs
SrCr (in last 15 mths)
and weight ever
"no" "no" "no" "no" "no"
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: ACE: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; eGFR: estimated glomerular filtration rate; NSAID: non-steroidal anti-inflammatory; RKF: reduced 
kidney function; SrCr: serum creatinine. 
Table 25: Kidney function variables available on the patient record for each of the study drugs ever, and in the previous 15 months, 
for age ≥65 years and ≥85 year 
total
KF < 
recmd'd
% CI (±) total
KF < 
recmd'd
% CI (±) total
KF < 
recmd'd
% CI (±) total
KF < 
recmd'd
% CI (±)
alendronic acid 3,400 804 23.6 0.04 1,120 49 4.4 0.01 1,532 342 22.3 0.02 748 413 55.2 0.07
metformin 6,276 267 4.3 0.03 3,491 30 0.9 0.0005 2,319 124 5.3 0.004 466 113 24.2 0.08
simvastatin > 10mg 19,434 1,465 7.5 0.01 9,894 167 1.7 0.0003 7,494 643 8.6 0.002 2,046 655 32.0 0.02
gabapentin or pregabalin 1,209 132 10.9 0.1 598 43 7.2 0.02 450 56 12.4 0.05 161 33 20.5 0.2
nitrofurantoin 3,185 1,262 39.6 0.04 1,206 141 11.7 0.02 1,242 535 43.1 0.04 737 586 79.5 0.04
thiazide 10,805 797 7.4 0.02 5,371 62 1.2 0.0004 4,189 303 7.2 0.003 1,245 432 34.7 0.04
NSAID 2,483 86 3.5 0.08 1,577 8 0.5 0.001 762 36 4.7 0.01 144 42 29.2 0.3
ACE/ARB 26,109 2,521 9.7 0.01 12,663 288 2.3 0.0004 10,280 1,062 10.3 0.002 3,166 1,171 37.0 0.01
drug
aged 65yrs and older aged 65-74yrs aged 75-84yrs aged 85yrs and older
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: ACE: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; CI: confidence intervals; KF<recmdd: kidney function less than recommended; NSAID: non-steroidal anti-inflammatory. 
Table 26: Number of drugs prescribed for people aged ≥65 years with a kidney function estimate (CrCl-CG IBW) in the previous 15 
months too low for recommended use. 
3.5.4.3 Outliers 
No eGFR or SrCr values were considered to be errors as both the lower and higher 
values were possible when kidney function is very low or is normal. Only five weight 
values across all the 79,644 values extracted for the eight drugs were assessed as 
likely to be a recording error as they were too low to be an adult weight. The five 
‘patient drug events’ were removed from the analysis, but such a low level in the whole 
study population would not bias the study findings. 
 
 Analysis of the eight sample drugs 
The data for each drug was collected separately without data linkage. The statistical 
analysis could therefore only be conducted for each drug individually. Tables 26 and 
27 are used to list the data that will then be used in the individual drug sections. 
Table 26 shows the number of drugs prescribed in the study population (people aged 
≥65 years) with a kidney function estimate (CrCl-CG IBW) in the previous 15 months 
too low for recommended use. Table 27 gives the results comparing the effect of using 
the recommended equation for prescribing decisions (i.e. CrCl-CG IBW) with using 
actual weight in the equation (CrCl-CG AW) or using the nationally reported eGFR. 
The data is presented as the number of patients prescribed the drug but who have a 
kidney function too low and would be missed if CrCl-CG IBW was not used.  
The data is presented hierarchically for each drug to show: 
 The total number of patients with a kidney function check (shown by an eGFR 
on the record) in the previous 15 months. 
 Below is the number of patients found with a kidney function too low using 
CrCl-CG IBW.  
 Below that is the number found if actual weight is used instead of ideal body 
weight (CrCl-CG AW). Next on that row is the CrCl-CG IBW minus the number 
found using actual weight which gives the number of patients that would be 
missed that should have their drug prescription altered.  
 Finally is the number found if eGFR is used. Next on that row is CrCl-CG IBW 
minus the number found using eGFR which gives the number of patients that 
would be missed that should have their drug prescription altered. 
For example, for the 3,436 people aged 65 years and older prescribed alendronic acid: 
 3,436 people taking alendronic acid had a kidney function check (shown by an 
eGFR on the record) in the previous 15 months. 804 of those were found to 
have a CrCl-CG IBW below 35ml/min. 
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Abbreviations: ACE: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; CrCl-CG IBW: 
creatinine clearance Cockcroft Gault using ideal body weight; CrCl-CG AW: creatinine clearance Cockcroft Gault using 
actual body weight; eGFR: estimated glomerular filtration rate; NSAID: non-steroidal anti-inflammatory. 
Table 27: Number of ‘patient drug events’ where the kidney function was too 
low, but would be missed if CrCl-CG AW or eGFR are used instead of CrCl-CG 
IBW. 
 Using actual weight in the CrCl-CG calculation would mean that 614 patients 
would be considered to have too low a kidney function, and 190 patients would 
have been missed. That is 23.6% of those found using CrCl-CG IBW, and 5.5% 
of all those taking alendronic acid and with a recent kidney function test. 
 Using eGFR would only have found 108 patients with a low kidney function, 
and 696 of the patients that should have their alendronic acid stopped would be 
missed; that is 86.6% of those who should have been identified, and 20.3% of 
all people aged over 65 years prescribed alendronic acid with a recent kidney 
function test. 
number pts 
missed
% of CrCl-
CG IBW
% of total 
with eGFR
number pts 
missed
% of CrCl-
CG IBW
% of total 
with eGFR
eGFR in the last 15 months 3,436 766
CrCl-CG IBW < recommended 804 413
CrCl-CG AW < recommended 614 190 23.6 5.5 343 70 16.9 9.1
eGFR < recommended 108 696 86.6 20.3 53 360 87.2 47.0
eGFR in the last 15 months 6,233 473
CrCl-CG IBW < recommended 267 113
CrCl-CG AW < recommended 135 132 49.4 2.1 72 41 36.3 6.7
eGFR < recommended 20 247 92.5 4.0 5 108 95.6 22.8
eGFR in the last 15 months 19,477 2,063
CrCl-CG IBW < recommended 1,465 655
CrCl-CG AW < recommended 1,019 446 30.4 2.3 517 138 21.1 6.7
eGFR < recommended 344 1,121 76.5 5.8 90 565 86.3 27.4
eGFR in the last 15 months 1,233 165
CrCl-CG IBW < recommended 132 33
CrCl-CG AW < recommended 79 53 40.2 4.3 31 2 6.1 1.2
eGFR < recommended 41 91 68.9 7.4 11 22 66.7 13.3
eGFR in the last 15 months 3,226 754
CrCl-CG IBW < recommended 1,262 586
CrCl-CG AW < recommended 955 307 24.3 9.5 525 61 10.4 8.1
eGFR < recommended 354 908 71.9 28.1 147 439 74.9 58.2
eGFR in the last 15 months 10,876 1,267
CrCl-CG IBW < recommended 797 432
CrCl-CG AW < recommended 547 250 31.4 2.3 338 94 21.8 7.4
eGFR < recommended 129 668 83.8 6.1 40 392 90.7 30.9
eGFR in the last 15 months 2,498 145
CrCl-CG IBW < recommended 86 42
CrCl-CG AW < recommended 53 33 38.4 1.3 29 13 31.0 9.0
eGFR < recommended 4 82 95.3 3.3 2 40 95.2 27.6
eGFR in the last 15 months 26,223 3,215
CrCl-CG IBW < recommended 2,521 1,171
CrCl-CG AW < recommended 1,687 834 33.1 3.2 896 275 23.5 8.6
eGFR < recommended 579 1,942 77.0 7.4 160 1,011 86.3 31.4
aged  85yrs and older
drug
alendronic acid
metformin
total total
numbers missed using the other 
equations rather than CrCl-CG IBW
numbers missed using the other 
equations rather than CrCl-CG IBW
aged 65 years and older
NSAID
ACEI/ARB
nitrofurantoin (acute)
thiazide
simvastatin >10mg
gabapentin or 
pregabalin
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Alendronic acid – recommended to be avoided at <35ml/min. 
 Number of patient drug events where a recent kidney function was 
available but was too low for the recommended use. 
In 3,400 patients aged 65 years and older, 23.6% (CI ±0.04) were prescribed 
alendronic acid despite a recent kidney function <35 ml/min on the patient record.  
This was 4.4% (CI ±0.01) of the 1,120 65-74 year olds that had CrCl-CG IBW <35 
ml/min, 22.3% (CI ±0.02) of the 1,532 75-84 year olds, and 55.2% (CI ±0.07) of the 
748 ≥85 year olds (Table 26). 
Number where alendronic acid should be stopped, but would be missed if eGFR 
were used instead of CrCl-CG using ideal body weight. (Table 27) 
For ≥65 year olds, 696 (86.6%) of the cases found with a kidney function too low using 
CrCl-CG IBW would have been missed if eGFR had been used. That is 20.3% of all 
the alendronic acid repeat prescriptions studied which had a lower than recommended 
kidney function but would not be identified if eGFR was used. 
For ≥85 year olds, 360 (87.2%) of the cases found with a kidney function too low using 
CrCl-CG IBW would have been missed if eGFR had been used. That is 47.0% of all 
the repeat prescriptions studied which had a lower than recommended kidney function 
but would not be identified if eGFR was used. 
Number where alendronic acid should be stopped, but would be missed if actual 
weight rather than ideal body weight were used in CrCl-CG. (Table 27) 
For ≥65 year olds, 190 (23.6%) of the cases found with a kidney function too low using 
CrCl-CG IBW would have been missed if actual weight had been used. That is 5.5% of 
all the repeat prescriptions studied which had a lower than recommended kidney 
function but would not be identified if CrCl-CG AW was used. 
For ≥85 year olds, 70 (16.9%) of the cases found with a kidney function too low using 
CrCl-CG IBW would have been missed if actual weight had been used. That is 9% of 
all the repeat prescriptions studied which had a lower than recommended kidney 
function but would not be identified if CrCl-CG AW was used. 
 Line plot charting the range of kidney function at each age level. 
The range of kidney function estimated using CrCl-CG IBW from SrCr, reported within 
the previous 15 months, for the 3,400 alendronic acid patient drug events are plotted 
in Figure 16 at each age level from 65 years. The level of 35 ml/min is marked, and 
any points under the line show use of the drug where the kidney function would be 
considered too low for recommended use. 
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Figure 16: Line plot charting the range of kidney function (CrCl-CG IBW within 
the previous 15 months) for alendronic acid prescribed for people at each age 
level 65 years and older. 
A Spearman correlation analysis was run to determine the relationship between an 
individual's age and their level of kidney function. The data showed no violation of 
linearity. There was a moderate negative correlation between age and level of kidney 
function, which was statistically significant (r = -0.579, n = 3400, p < 0.0005); kidney 
function tends to reduce with age in people prescribed alendronic acid. 
 Logistic regression analysis 
Using any of the three equations, compared to age band 65-74yrs, those aged 75-
84yrs have higher odds of having a kidney function too low for the alendronic acid 
prescribed, and those aged 85yrs and over have even higher odds of having a kidney 
function lower than recommended (Table 28). Using CrCl-CG IBW, patients aged 74-
84 years have 6.3 times greater odds of having a kidney function too low to be 
prescribed alendronic acid, and 26.9 times greater odds for those aged ≥85 years. 
   
Abbreviations: CrCl-CG IBW: creatinine clearance Cockcroft Gault using ideal body weight; CrCl-CG AW: creatinine clearance Cockcroft 
Gault using actual body weight; eGFR: estimated glomerular filtration rate. 
Table 28: Odds ratios for the effect of older age on having a kidney function too 
low to be prescribed alendronic acid. 
 
65-74yrs
eGFR 1 1.958 (1.076-3.561) 5.486 (3.069-9.807)
CrCl-CG AW 1 5.107 (3.591-7.264) 24.115 (16.925-34.358)
CrCl-CG IBW 1 6.282 (4.605-8.569) 26.946 (19.556-37.129)
odds ratio
75-84yrs 85 years and older
odds ratio
alendronic acid 
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Metformin – recommended to be avoided at <30ml/min. 
 Number of patient drug events where a recent kidney function was 
available but was too low for the recommended use. 
In 6,276 patients aged 65 years and older, 4.3% (CI ±0.03) were prescribed metformin 
despite a recent kidney function <30 ml/min on the patient record, when it is contra-
indicated.  This was 0.9% (CI ±0.0005) found in the 3,491 65-74 year olds, 5.3% (CI 
±0.004) in the 2,319 74-85 year olds, and 24.2% (CI ±0.08) of the 466 ≥85 year olds 
that had a CrCl-CG IBW <30ml/min (Table 26). 
Number where metformin should be stopped, but would be missed if eGFR were 
used instead of CrCl-CG using ideal body weight.  (Table 27) 
For ≥65 year olds, 247 (92.5%) of the cases found with a kidney function too low using 
CrCl-CG IBW would have been missed if eGFR had been used. That is 4.0% of all the 
repeat prescriptions studied which had a lower than recommended kidney function but 
would not be identified if eGFR was used. 
For ≥85 year olds, 108 (95.6%) of the cases found with a kidney function too low using 
CrCl-CG IBW would have been missed if eGFR had been used. That is 22.8% of all 
the repeat prescriptions studied which had a lower than recommended kidney function 
but would not be identified if eGFR was used. 
Number where metformin should be stopped, but would be missed if actual 
weight rather than ideal body weight were used in CrCl-CG. (Table 27) 
For ≥65 year olds, 132 (49.4%) of the cases found with a kidney function too low using 
CrCl-CG IBW would have been missed if actual weight had been used. That is 2.1% of 
all the repeat prescriptions studied which had a lower than recommended kidney 
function but would not be identified if CrCl-CG AW was used. 
For ≥85 year olds, 41 (36.3%) of the cases found with a kidney function too low using 
CrCl-CG IBW would have been missed if actual weight had been used. That is 8.7% of 
all the repeat prescriptions studied which had a lower than recommended kidney 
function but would not be picked up if CrCl-CG AW was used. 
 Line plot charting the range of kidney function at each age level. 
The range of kidney function estimated using CrCl-CG IBW from SrCr, reported within 
the previous 15 months, for the 6,276 metformin patient drug events are plotted in 
Figure 17 at each age level from 65 years. The level of 30 ml/min is marked, and any 
points under the line show use of the drug where the kidney function would be 
considered too low for recommended use. Also marked is the 45 ml/min level, below 
which caution and reduced dose is recommended. 
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Figure 17: Line plot charting the range of kidney function (CrCl-CG IBW within 
the previous 15 months) for metformin prescribed for people at each age level 
65 years and older. 
A Spearman correlation analysis was run to determine the relationship between an 
individual's age and their level of kidney function. The data showed no violation of 
linearity. There was a moderate negative correlation between age and level of kidney 
function, which was statistically significant (r = -0.516, n = 6,276, p < 0.0005); kidney 
function tends to reduce with age in people prescribed metformin. 
 Logistic regression analysis 
Using CrCl-CG IBW or AW, compared to age band 65-74yrs, those aged 75-84yrs have 
higher odds of having a kidney function too low for the metformin they were prescribed, 
and for all 3 equations those aged 85yrs and over have higher odds of having a kidney 
function lower than recommended (Table 29). Using CrCl-CG IBW patients aged 74-84 
years have 6.5 times greater odds of having a kidney function too low to be prescribed 
metformin, and 36.9 times greater odds for those aged ≥85 years. 
 
Abbreviations: CrCl-CG IBW: creatinine clearance Cockcroft Gault using ideal body weight; CrCl-CG AW: creatinine 
clearance Cockcroft Gault using actual body weight; eGFR: estimated glomerular filtration rate. 
Table 29: Odds ratios for the effect of older age on having a kidney function too 
low to be prescribed metformin. 
 
65-74yrs
eGFR 1 2.257 (0.802-6.348) 6.145 (1.868-6.348)
CrCl-CG AW 1 5.896 (3.195-10.877) 48.643 (26.704-88.609)
CrCl-CG IBW 1 6.517 (4.358-9.746) 36.93 (24.334-58.048)
odds ratio
75-84yrs 85 years and older
odds ratio
metformin
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Simvastatin >10mg – recommended dose reduction at <30 ml/min. 
 Number of patient drug events where a recent kidney function was 
available but was too low for the recommended use. 
In 19,434 patients aged 65 years and older, simvastatin was prescribed at doses 
greater than 10mg on repeat prescription for 1,465 (7.5%) (CI ±0.01) despite a recent 
kidney function <30 ml/min on the patient record. This was 167 (1.7%) (CI ±0.0003) of 
the 9,894 65-74 year olds that had CrCl-CG IBW <30 ml/min, 643 (8.6%) (CI ±0.002) 
of the 7,494 75-84 year olds, and 655 (32%) (CI ±0.02) of the 2,046 ≥85 year olds 
prescribed simvastatin at doses greater than 10mg (Table 26). 
Number where simvastatin should be stopped, but would be missed if eGFR 
were used instead of CrCl-CG using ideal body weight. (Table 27) 
For ≥65 year olds, 1,121 (76.5%) of the cases found with a kidney function too low 
using CrCl-CG IBW would have been missed if eGFR had been used. That is 5.8% of 
all the repeat prescriptions studied which had a lower than recommended kidney 
function but would not be identified if eGFR was used. 
For ≥85 year olds, 565 (86.3%) of the cases found with a kidney function too low using 
CrCl-CG IBW would have been missed if eGFR had been used. That is 27.4% of all 
the repeat prescriptions studied which had a lower than recommended kidney function 
but would not be picked up if eGFR was used. 
Number where metformin should be stopped, but would be missed if actual 
weight rather than ideal body weight were used in CrCl-CG. (Table 27) 
For ≥65 year olds, 446 (30.4%) of the cases found with a kidney function too low using 
CrCl-CG IBW would have been missed if actual weight had been used. That is 2.3% of 
all the repeat prescriptions studied which had a lower than recommended kidney 
function but would not be picked up if CrCl-CG AW was used. 
For ≥85 year olds, 138 (21.1%) of the cases found with a kidney function too low using 
CrCl-CG IBW would have been missed if actual weight had been used. That is 6.7% of 
all the repeat prescriptions studied which had a lower than recommended kidney 
function but would not be picked up if CrCl-CG AW was used. 
 Line plot charting the range of kidney function at each age level. 
The range of kidney function estimated using CrCl-CG IBW from SrCr, reported within 
the previous 15 months, for the 19,434 simvastatin >10mg patient drug events are 
plotted in Figure 18 at each age level from 65 years. The level of 30 ml/min is marked, 
and any points under the line show use of the drug where the kidney function would be 
considered too low for recommended use. 
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Figure 18: Line plot charting the range of kidney function (CrCl-CG IBW within 
the previous 15 months) for simvastatin prescribed for people at each age level 
65 years and older. 
A Spearman correlation analysis was run to determine the relationship between an 
individual's age and their level of kidney function. The data showed no violation of 
linearity. There was a moderate negative correlation between age and level of kidney 
function, which was statistically significant (r = -0.577, n = 19,434, p < 0.0005); kidney 
function tends to reduce with age in people prescribed simvastatin doses >10mg. 
 Logistic regression analysis 
Using any of the three equations, compared to age band 65-74yrs, those aged 75-
84yrs have higher odds of having a kidney function too low for the simvastatin they 
were prescribed, and those aged 85yrs and over have even higher odds of having a 
kidney function lower than recommended (Table 30). Using CrCl-CG IBW patients 
aged 74-84 years have 5.5 times greater odds of having a kidney function too low to 
be prescribed simvastatin, and 27.4 times greater odds for those aged ≥85 years.  
 
Abbreviations: CrCl-CG IBW: creatinine clearance Cockcroft Gault using ideal body weight; CrCl-CG AW: creatinine 
clearance Cockcroft Gault using actual body weight; eGFR: estimated glomerular filtration rate. 
Table 30: Odds ratios for the effect of older age on having a kidney function too 
low to be prescribed higher dose simvastatin 
65-74yrs
eGFR 1 2.445 (1.887-3.167) 4.983 (3.706-6.701)
CrCl-CG AW 1 5.028 (4.055-6.234) 30.635 (24.727-37.95)
CrCl-CG IBW 1 5.467 (4.598-6.499) 27.427 (22.933-32.802)
75-84yrs 85 years and older
odds ratio odds ratio
simvastatin >10mg
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Gabapentin and pregabalin – recommendations for dose reductions at 
specified levels of kidney function give in the SPCs. 
 Number of patient drug events where a recent kidney function was 
available but was too low for the recommended use. 
In 1,209 patients aged 65 years and older, gabapentin or pregabalin were prescribed 
at doses greater than recommended on repeat prescription for 132 (10.9%) (CI ±0.1) 
despite a recent kidney function on the patient record being too low for the formulation 
dose (Table 15). This was 43 (7.2%) (CI ±0.02) of the 598 65-74 year olds, 56 (12.4%) 
(CI ±0.05) of the 450 75-84 year olds, and 33 (20.5%) (CI ±0.2) of the 161 ≥85 year 
olds where CrCl-CG IBW was lower than recommended (Table 26).  
Number where the dose should be reduced, but would be missed if eGFR were 
used instead of CrCl-CG using ideal body weight.  (Table 27) 
For ≥65 year olds, 91 (68.9%) of the cases found with a kidney function too low using 
CrCl-CG IBW would have been missed if eGFR had been used. That is 7.4% of all the 
repeat prescriptions studied which had a lower than recommended kidney function but 
would not be identified if eGFR was used. 
For ≥85 year olds, 22 (66.7%) of the cases found with a kidney function too low using 
CrCl-CG IBW would have been missed if eGFR had been used. That is 13.3% of all 
the repeat prescriptions studied which had a lower than recommended kidney function 
but would not be identified if eGFR was used. 
Number where the dose of should be reduced, but would be missed if actual 
weight rather than ideal body weight were used in CrCl-CG. (Table 27) 
For ≥65 year olds, 53 (40.2%) of the cases found with a kidney function too low using 
CrCl-CG IBW would have been missed if actual weight had been used. That is 4.3% of 
all the repeat prescriptions studied which had a lower than recommended kidney 
function but would not be identified if CrCl-CG AW was used. 
For ≥85 year olds, 2 (6.1%) of the cases found with a kidney function too low using 
CrCl-CG IBW would have been missed if actual weight had been used. That is 1.2% of 
all the repeat prescriptions studied which had a lower than recommended kidney 
function but would not be identified if CrCl-CG AW was used. 
 Line plot charting the range of kidney function at each age level. 
The range of kidney function estimated using CrCl-CG IBW from SrCr, reported within 
the previous 15 months, for the 1,209 gabapentin and pregabalin patient drug events 
are plotted in Figure 19 at each age level from 65 years. The levels of 30 ml/min and 
60 ml/min are marked. 
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Figure 19: Line plot charting the range of kidney function (CrCl-CG IBW within 
the previous 15 months) for gabapentin and pregabalin prescribed for people at 
each age level 65 years and older. 
 
A Spearman correlation analysis was run to determine the relationship between an 
individual's age and their level of kidney function. The data showed no violation of 
linearity. There was a moderate negative correlation between age and level of kidney 
function, which was statistically significant (r = -0.565, n = 1,209 p < 0.0005); kidney 
function tends to reduce with age in people prescribed gabapentin and pregabalin. 
 Logistic regression analysis 
Using any of the three equations, compared to age band 65-74yrs, those aged 75-84yrs 
have higher odds of having a kidney function too low for the gabapentin or pregabalin they 
were prescribed, and those aged 85yrs and over have even higher odds of having a kidney 
function lower than recommended (Table 31). Using CrCl-CG IBW patients aged 74-84 
years have 1.8 times greater odds of having a kidney function too low to be prescribed 
gabapentin or pregabalin, and 3.3 times greater odds for those aged 85 years and older.  
Abbreviations: CrCl-CG IBW: creatinine clearance Cockcroft Gault using ideal body weight; CrCl-CG AW: creatinine clearance Cockcroft 
Gault using actual body weight; eGFR: estimated glomerular filtration rate. 
Table 31: Odds ratios for the effect of older age on having a kidney function too 
low to be prescribed too high a dose of gabapentin or pregabalin. 
 
65-74yrs
eGFR 1 2.729 (1.265-5.888) 4.279 (1.784-10.258)
CrCl-CG AW 1 2.972 (1.545-5.717) 9.958 (5.251-18.884)
CrCl-CG IBW 1 1.834 (1.208-2.786) 3.328 (2.033-5.446)
75-84yrs 85 years and older
odds ratio odds ratio
Gabapentin/pregabalin
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Nitrofurantoin – ineffective below 45 ml/min 
 Number of patient drug events where a recent kidney function was 
available but was too low for the recommended use. 
In 3,185 patients aged 65 years and older prescribed nitrofurantoin in the previous 12 
months, 1,262 (39.6%) (CI ±0.04) were prescribed despite a recent kidney function 
<45 ml/min on the patient record. This was 141 (11.7%) (CI ±0.02) of the 1,206 aged 
65-74 years, 535 (43.1%) (CI ±0.04) of the 1,252 75-84 year olds, and 586 (79.5%) (CI 
± 0.04) of the 85 years and older patients with a recent CrCl-CG IBW <45 ml/min 
(Table 26). 
Number where nitrofurantoin would be ineffective, but would be missed if eGFR 
were used instead of CrCl-CG using ideal body weight.  (Table 27) 
For ≥65 year olds, 908 (71.9%) of the cases found with a kidney function too low using 
CrCl-CG IBW would have been missed if eGFR had been used. That is 28.1% of all 
the repeat prescriptions studied which had a lower than recommended kidney function 
but would not be identified if eGFR was used. 
For ≥85 year olds, 439 (74.9%) of the cases found with a kidney function too low using 
CrCl-CG IBW would have been missed if eGFR had been used. That is 58.2% of all 
the repeat prescriptions studied which had a lower than recommended kidney function 
but would not be identified if eGFR was used. 
Number where nitrofurantoin would be ineffective, but would be missed if actual 
weight rather than ideal body weight were used in CrCl-CG. (Table 27) 
For ≥65 year olds, 307 (24.3%) of the cases found with a kidney function too low using 
CrCl-CG IBW would have been missed if actual weight had been used. That is 9.5% of 
all the repeat prescriptions studied which had a lower than recommended kidney 
function but would not be identified if CrCl-CG AW was used. 
For ≥85 year olds, 61 (10.4%) of the cases found with a kidney function too low using 
CrCl-CG IBW would have been missed if actual weight had been used. That is 8.1% of 
all the repeat prescriptions studied which had a lower than recommended kidney 
function but would not be identified if CrCl-CG AW was used. 
 Line plot charting the range of kidney function at each age level. 
The range of kidney function estimated using CrCl-CG IBW from SrCr, reported within 
the previous 15 months, for the 3,185 nitrofurantoin patient drug events are plotted in  
Figure 20 at each age level from 65 years. The level of 45 ml/min is marked, and any 
points under the line show use of the drug where the kidney function would be 
considered too low to be effective.  
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Figure 20: Line plot charting the range of kidney function (CrCl-CG IBW within 
the previous 15 months) for nitrofurantoin prescribed for people at each age 
level 65 years and older. 
 
A Spearman correlation analysis was run to determine the relationship between an 
individual's age and their level of kidney function. The data showed no violation of 
linearity. There was a moderate negative correlation between age and level of kidney 
function, which was statistically significant (r = -0.608, n = 3,185 p < 0.0005); kidney 
function tends to reduce with age in people prescribed nitrofurantoin. 
 Logistic regression analysis 
Using any of the three equations, compared to age band 65-74yrs, those aged 75-84yrs 
have higher odds of having a kidney function too low for the nitrofurantoin they were 
prescribed, and those aged 85yrs and over have even higher odds of having a kidney 
function lower than recommended (Table 32). Using CrCl-CG IBW patients aged 74-84 
years have 5.6 times greater odds of having a kidney function too low to be prescribed 
nitrofurantoin, and 29.2 times greater odds for those aged 85 years and older.  
 
Abbreviations: CrCl-CG IBW: creatinine clearance Cockcroft Gault using ideal body weight; CrCl-CG AW: creatinine clearance Cockcroft 
Gault using actual body weight; eGFR: estimated glomerular filtration rate. 
Table 32: Odds ratios for the effect of older age on having a kidney function too 
low to for nitrofurantoin to be effective. 
65-74yrs
eGFR 1 3.03 (4.198-4.177) 5.243 (3.781-7.27)
CrCl-CG AW 1 6.786 (5.161-8.923) 41.334 (30.865-55.356)
CrCl-CG IBW 1 5.644 (4.581-6.952) 29.23 (22.748-37.559)
75-84yrs 85 years and older
odds ratio odds ratio
nitrofurantoin
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Thiazides – ineffective below 30 ml/min 
 Number of patient drug events where a recent kidney function was 
available but was too low for the recommended use. 
In 10,805 patients aged 65 years and older prescribed thiazides on repeat 
prescription, 797 (7.4%) (CI ±0.02) were prescribed despite a recent kidney function 
<30 ml/min on the patient record. This was 62 (1.2%) (CI ±0.0004) of the 5,371 65-74 
year olds, 303 (7.2%) (CI ±0.003) of the 4,189 75-84 year olds, and 432 (34.7%) (CI 
±0.04) of the ≥85 year olds with a CrCl-CG IBW <30 ml/min (Table 26). 
Number where a thiazide would be ineffective, but would be missed if eGFR 
were used instead of CrCl-CG using ideal body weight.  (Table 27) 
For ≥65 year olds, 668 (83.8%) of the cases found with a kidney function too low using 
CrCl-CG IBW would have been missed if eGFR had been used. That is 6.1% of all the 
repeat prescriptions studied which had a lower than recommended kidney function but 
would not be identified if eGFR was used. 
For ≥85 year olds, 392 (90.7%) of the cases found with a kidney function too low using 
CrCl-CG IBW would have been missed if eGFR had been used. That is 30.9% of all 
the repeat prescriptions studied which had a lower than recommended kidney function 
but would not be identified if eGFR was used. 
Number where a thiazide would be ineffective, but would be missed if actual 
weight rather than ideal body weight were used in CrCl-CG. (Table 27) 
For ≥65 year olds, 250 (31.4%) of the cases found with a kidney function too low using 
CrCl-CG IBW would have been missed if actual weight had been used. That is 2.3% of 
all the repeat prescriptions studied which had a lower than recommended kidney 
function but would not be identified if CrCl-CG AW was used. 
For ≥85 year olds, 94 (21.8%) of the cases found with a kidney function too low using 
CrCl-CG IBW would have been missed if actual weight had been used. That is 7.4% of 
all the repeat prescriptions studied which had a lower than recommended kidney 
function but would not be identified if CrCl-CG AW was used. 
 Line plot charting the range of kidney function at each age level. 
The range of kidney function estimated using CrCl-CG IBW from SrCr, reported within 
the previous 15 months, for the 10,805 thiazide patient drug events are plotted in  
Figure 21 at each age level from 65 years. The level of 30 ml/min is marked, and any 
points under the line show use of the drug where the kidney function would be 
considered too low to be effective. 
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Figure 21: Line plot charting the range of kidney function (CrCl-CG IBW within 
the previous 15 months) for thiazides prescribed for people at each age level 65 
years and older. 
 
A Spearman correlation analysis was run to determine the relationship between an 
individual's age and their level of kidney function. The data showed no violation of 
linearity. There was a moderate negative correlation between age and level of kidney 
function, which was statistically significant (r = -0.573, n = 10,805 p < 0.0005); kidney 
function tends to reduce with age in people prescribed a thiazide. 
 Logistic regression analysis 
Using any of the three equations, compared to age band 65-74yrs, those aged 75-84yrs 
have higher odds of having a kidney function too low for the thiazide they were prescribed, 
and those aged 85yrs and over have even higher odds of having a kidney function lower 
than recommended (Table 33). Using CrCl-CG IBW patients aged 74-84 years have 6.7 
times greater odds of having a kidney function too low to be prescribed a thiazide, and 
45.5 times greater odds for those aged 85 years and older.  
 
Abbreviations: CrCl-CG IBW: creatinine clearance Cockcroft Gault using ideal body weight; CrCl-CG AW: creatinine clearance Cockcroft 
Gault using actual body weight; eGFR: estimated glomerular filtration rate. 
Table 33: Odds ratios for the effect of older age on having a kidney function too 
low for a thiazide to be effective. 
65-74yrs
eGFR 1 2.185 (1.418-3.365) 5.293 (3.324-8.427)
CrCl-CG AW 1 5.603 (3.960-7.927) 49.666 (35.521-69.444)
CrCl-CG IBW 1 6.677 (5.065-8.802) 45.5 (34.518-59.976)
75-84yrs 85 years and older
odds ratio odds ratio
thiazides
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NSAIDs – caution in RKF as frequently cause ADRs 
 Number of patient drug events where a recent kidney function was 
available but was too low for the recommended use. 
In 2,483 patients aged 65 years and older prescribed NSAIDS on repeat prescription, 
86 (3.5%) (CI ±0.08) were prescribed despite a recent kidney function <30 ml/min on 
the patient record. This was 8 (0.5%) (CI ±0.001) of 1,577 65-74 year olds, 36 (4.7%) 
(CI ±0.01) of the 762 75-84 years, and 42 (29.2%) (CI ±0.3) of the 144 patients aged 
85 years and older with a CrCl-CG IBW <30 ml/min (Table 26).  
Number where an NSAID should be stopped, but would be missed if eGFR were 
used instead of CrCl-CG using ideal body weight. (Table 27) 
For ≥65 year olds, 82 (95.3%) of the cases found with a kidney function too low using 
CrCl-CG IBW would have been missed if eGFR had been used. That is 3.3% of all the 
repeat prescriptions studied which had a lower than recommended kidney function but 
would not be identified if eGFR was used. 
For ≥85 year olds, 40 (95.2%) of the cases found with a kidney function too low using 
CrCl-CG IBW would have been missed if eGFR had been used. That is 27.6% of all 
the repeat prescriptions studied which had a lower than recommended kidney function 
but would not be identified if eGFR was used. 
Number where an NSAID should be stopped, but would be missed if actual 
weight rather than ideal body weight were used in CrCl-CG. (Table 27) 
For ≥65 year olds, 33 (38.4%) of the cases found with a kidney function too low using 
CrCl-CG IBW would have been missed if actual weight had been used. That is 1.3% of 
all the repeat prescriptions studied which had a lower than recommended kidney 
function but would not be picked up if CrCl-CG AW was used. 
For ≥85 year olds, 13 (31.0%) of the cases found with a kidney function too low using 
CrCl-CG IBW would have been missed if actual weight had been used. That is 9.0% of 
all the repeat prescriptions studied which had a lower than recommended kidney 
function but would not be identified if CrCl-CG AW was used. 
 Line plot charting the range of kidney function at each age level. 
The range of kidney function estimated using CrCl-CG IBW from SrCr, reported within 
the previous 15 months, for the 2,483 NSAID patient drug events are plotted in Figure 
22 at each age level from 65 years. The level of 30 ml/min is marked, as the level used 
in the analysis. The 60 ml/min level is also shown on the graph as use of NSAIDs in 
any degree of reduced kidney function needs caution and assessment. 
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Figure 22: Line plot charting the range of kidney function (CrCl-CG IBW within 
the previous 15 months) for NSAIDs prescribed for people at each age level 65 
years and older. 
A Spearman correlation analysis was run to determine the relationship between an 
individual's age and their level of kidney function. The data showed no violation of 
linearity. There was a moderate negative correlation between age and level of kidney 
function, which was statistically significant (r = -0.497, n = 2,483 p < 0.0005); kidney 
function tends to reduce with age in people prescribed an NSAID. 
 Logistic regression analysis 
Using any of the three equations, compared to age band 65-74yrs, those aged 75-
84yrs have higher odds of having a kidney function too low for the NSAID they were 
prescribed, and those aged 85yrs and over have even higher odds of having a kidney 
function lower than recommended (Table 34). Using CrCl-CG IBW patients aged 74-84 
years have 9.7 times greater odds of having a kidney function too low to be prescribed 
an NSAID, and 80.8 times greater odds for those aged 85 years and older.  
Abbreviations: CrCl-CG IBW: creatinine clearance Cockcroft Gault using ideal body weight; CrCl-CG AW: creatinine 
clearance Cockcroft Gault using actual body weight; eGFR: estimated glomerular filtration rate. 
Table 34: Odds ratios for the effect of older age on having a kidney function too 
low to be prescribed and NSAID. 
65-74yrs
eGFR 1 4.201 (1.048-16.843) 3.676 (0.380-35.566)
CrCl-CG AW 1 3.498 (1.524-8.031) 43.934 (20.313-95.026)
CrCl-CG IBW 1 9.725 (4.498-21.028) 80.757 (36.94-176.549)
75-84yrs 85 years and older
odds ratio odds ratio
NSAIDs
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ACEIs and ARBs – although used in CKD, they can have an adverse effect on 
the kidneys and need caution in low levels of kidney function. 
 Number of patient drug events where a recent kidney function was 
available but was too low for the recommended use. 
In 26,109 patients aged 65 years and older prescribed ACEIs or ARBs on repeat 
prescription, 2,521 (9.7%) (CI ±0.01) were prescribed where there was a recent kidney 
function <30 ml/min on the patient record. This was 288 (2.3%) (CI ±0.0004) of 12,663 
65-74 year olds, 1,062 (10.3%) (CI ±0.002) of 10,280 75-84 year olds, and 1,171 
(37%) (CI ±0.01) of 3,166 patients aged 85 years and older with a recent CrCl-CG IBW 
<30 ml/min (Table 26).  
Number where an ACEI/ARB should be stopped or dose reduced, but would be 
missed if eGFR were used instead of CrCl-CG using ideal body weight. (Table 27) 
For ≥65 year olds, 1,942 (77.0%) of the cases found with a kidney function too low 
using CrCl-CG IBW would have been missed if eGFR had been used. That is 7.4% of 
all the repeat prescriptions studied which had a lower than recommended kidney 
function but would not be identified if eGFR was used. 
For ≥85 year olds, 1,011 (86.3%) of the cases found with a kidney function too low 
using CrCl-CG IBW would have been missed if eGFR had been used. That is 31.4% of 
all the repeat prescriptions studied which had a lower than recommended kidney 
function but would not be identified if eGFR was used. 
Number where an ACEI/ARB should be stopped or dose reduced, but would be 
missed if actual weight were used in CrCl-CG. (Table 27) 
For ≥65 year olds, 834 (33.1%) of the cases found with a kidney function too low using 
CrCl-CG IBW would have been missed if actual weight had been used. That is 3.2% of 
all the repeat prescriptions studied which had a lower than recommended kidney 
function but would not be identified if CrCl-CG AW was used. 
For ≥85 year olds, 275 (23.5%) of the cases found with a kidney function too low using 
CrCl-CG IBW would have been missed if actual weight had been used. That is 8.6% of 
all the repeat prescriptions studied which had a lower than recommended kidney 
function but would not be identified if CrCl-CG AW was used. 
 Line plot charting the range of kidney function at each age level. 
The range of kidney function estimated using CrCl-CG IBW from SrCr, reported within 
the previous 15 months, for the 26,109 patient ACEI and ARB drug events are plotted 
in Figure 23 at each age level from 65 years. The level of 30 ml/min is marked, and 
any points under the line show where caution and reassessment may be required. 
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Figure 23: Line plot charting the range of kidney function (CrCl-CG IBW within 
the previous 15 months) for ACEI/ARBs at each age level 65 years and older. 
A Spearman correlation analysis was run to determine the relationship between an 
individual's age and their level of kidney function. The data showed no violation of 
linearity. There was a moderate negative correlation between age and level of kidney 
function, which was statistically significant (r = -0.585, n = 26,109 p < 0.0005); kidney 
function tends to reduce with age in people prescribed an ACEI or ARB. 
 Logistic regression analysis 
Using any of the three equations, compared to age band 65-74yrs, those aged 75-84yrs 
have higher odds of having a kidney function too low for the ACE or ARB they were 
prescribed, and those aged 85yrs and over have even higher odds of having a kidney 
function lower than recommended (Table 35). Using CrCl-CG IBW patients aged 74-84 
years have 5.0 times greater odds of having a kidney function too low to be prescribed an 
ACEI or ARB, and 25.2 times greater odds for those aged 85 years and older. 
 
Abbreviations: CrCl-CG IBW: creatinine clearance Cockcroft Gault using ideal body weight; CrCl-CG AW: creatinine 
clearance Cockcroft Gault using actual body weight; eGFR: estimated glomerular filtration rate. 
Table 35: Odds ratios for the effect of older age on having a kidney function too 
low to be prescribed an ACEI or ARB, or for the dose. 
 
65-74yrs
eGFR 1 1.811 (1.488-2.205) 3.842 (3.086-4.784)
CrCl-CG AW 1 4.725 (3.979-5.610) 29.007 (24.273-34.38)
CrCl-CG IBW 1 4.95 (4.334-5.654) 25.221 (21.985-28.933)
75-84yrs 85 years and older
odds ratio odds ratio
ACE/ARBs

Abbreviations: ACE: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; CrCl-CG IBW: creatinine clearance Cockcroft Gault using ideal body weight; CrCl-CG AW: creatinine clearance 
Cockcroft Gault using actual body weight; eGFR: estimated glomerular filtration rate; NSAID: non-steroidal anti-inflammatory. 
Table 36: Number of patient drug events where kidney function was found to be below recommended, using eGFR, CrCl-CG 
AW or CrCl-CG IBW. 
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 Patients found with a kidney function too low using eGFR and CrCl-
CG IBW 
 
Figure 24 presents the percentage of ‘patient drug events’ found where kidney function 
was assessed to be too low using eGFR (top) and the percentage of ‘patient drug 
events’ found where kidney function was assessed to be too low using CrCl-CG IBW 
(bottom). The figures are taken from the full table of results (Table 36). 
 
 
 
 
 
 
 
 
 
 
 
 
% on each drug identified with RKF using eGFR 
 
 
 
 
 
 
 
 
 
 
  
  
  % on each drug identified with RKF using CrCl-CG IBW 
 
Figure 24: A comparison between the percentage of patient drug events where 
kidney function was too low by eGFR (top) and CrCl-CG IBW (bottom) in the 3 
age bands (from Table 36).  
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3.6 Discussion  
 
 Data quality 
The study population numbers (Table 22) were comparable to the Office of National 
Statistics 2011 figures for Bradford (Table 18) suggesting this was a representative 
population in the former Bradford & Airedale PCT area. The Bradford population has a 
lower proportion of older people than the national average which could mean that any 
findings in this study relating to people aged 65 years and older might be an 
underestimate for the wider UK population. 
As a large PCT, Bradford & Airedale had a broad range of prescribers, from medical 
students to GP trainers, and GP practices ranging from single-handed GPs to large 
group teaching practices, making it likely that they are representative of GPs 
nationally. 
 
 Missing data analysis 
A missing data analysis was completed to ensure that any missing variables were 
identified, the effect on the final analyses assessed, and to flag up any potential for 
bias. Virtually no ages or genders were not available, which is as expected as the GP 
patient record systems have age and gender as required fields. 
The data taken from the prescribing database was only from patients who had kidney 
function test figures on their record which means that those variables would be likely to 
be complete. Numbers of patients who do not have an eGFR on their record were also 
searched on the database, and the number of patients without the variables needed to 
calculate creatinine clearance were calculated from the data. However, very few 
patients prescribed the study drugs did not have any kidney function on the record.  
As only a small number of data need to be excluded, or was not available, there is a 
greater confidence in the findings being representative of the whole Bradford PCT 
older population. 
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 Principal findings 
 
3.6.3.1 Prevalence of inappropriate prescribing in RKF  
This is the first prevalence study of inappropriate prescribing of drugs affected by 
reduced kidney function for older people in UK primary care. For all the sampled 
drugs, and for all age bands, prescribing was found where the kidney function (as 
measured by CrCl-CG IBW) was too low for recommended use, and particularly for 
those aged 85 years and older.  
The degree of inappropriate drug use and dosing varied from 13.3% to 79% in the 
prevalence studies found in the scoping literature review (Section 2.5), showing a high 
degree of inappropriate prescribing, and of the recommendations for use in RKF not 
being followed in the 14 different countries from which the studies were reported 
(Table 9). Khanal et al (2015) in Australia also used CrCl-CG as the kidney function 
estimate and found 28.1 % of patients aged 65 years and older had evidence of 
inappropriate prescribing of at least one of the 31 renally cleared drugs examined in 
their study,. The Breton et al study in French primary care (2011) used MDRD and so 
was likely to find a smaller proportion; even so, they found 13.3% exposure to the risk 
of inappropriate prescribing for people aged 65 years and older. They also looked at 
prevalence for lower kidney function finding 52.5% were on inappropriate drugs or 
doses in those with an eGFR of 30–59, and 96% in those <30ml/min/1.73m2. A 
retrospective case record analysis from patients aged over 70 years in a Hull hospital 
showed a similar level of inappropriate prescribing of renally excreted drugs to this 
study. They found of 81 out of the 622 medications prescribed (13%) were 
‘inappropriate’ (Jones and Bhandari, 2013). 
The current study found that kidney function levels varied widely at all ages studied, 
showing that kidney function does need to be checked, and drug use assessed, when 
prescribing these drugs for older people. It has also been shown that kidney function 
tends to reduce with increasing age for all the eight drugs, and will need assessment 
of kidney function in relation to the drug choice and dose.  
 
3.6.3.2 Many older people are taking drugs affected by kidney function 
The numbers of older people found taking the study drugs were large, with 39.9% of 
all people aged ≥65 years prescribed an ACEI or ARB, meaning that the impact of 
prescribing drugs that have recommendations in RKF, for older people is high if kidney 
function is low. The only comparison found reported in the literature is the French 
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primary care study (Breton et al, 2011) which found 17.1% were on ACEI/ARBs, 
15.5% on a statin, 2.4% metformin, 2.8% bisphosphonates, 8.7% NSAIDs. A larger 
number of the Bradford & Airedale whole PCT population of 70,900 people aged 65 
years and older in 2011 were on the sampled drugs, except for NSAIDs (and it could 
not be deciphered the numbers for nitrofurantoin or gabapentin/pregabalin). 
Non-steroidal anti-inflammatory drugs (NSAIDs) were on the repeat medication list for 
3,363 people (4.7%); this may be an underestimate of the total use of NSAIDs in this 
population as there had been initiatives to reduce regular use and many more are 
prescribed as an ‘acute’, when needed basis. Also, ‘low dose aspirin’ was not included 
in the searches for NSAIDS; they are classified in a different section on the prescribing 
database and in the BNF, but although ‘low dose’, aspirin is an NSAID and can cause 
all the adverse effects of the higher dose drugs. The numbers would have been very 
much higher for NSAIDs if low dose aspirin had been included as it is used widely to 
reduce risk for cardiovascular disease patients. 
Use of all the sampled drugs is similar in the over 85 year olds. Use of alendronic acid 
is higher which reflects increased incidence, and risk, of osteoporosis at increased 
age, and nitrofurantoin use is also higher which may be due to more urinary tract 
infections in older females. Use is only slightly lower for the cardiovascular drugs 
ACEI/ARBs, simvastatin and thiazides.  
Petty et al (2014) have reported that the mean total number of medicines per patient 
on repeat prescriptions is over 5 for the 60-69 year olds, and up to 7.1 for the over 80s 
so there is the probability that many people will be taking more than one drug 
eliminated via the kidneys, increasing the complexity of the impact. 
 
3.6.3.3 Age is a factor in having a kidney function estimate too low for 
recommended use of the study drugs. 
The Spearman’s correlation analyses showed a moderate negative correlation for age 
and kidney function level for all the sampled drugs. There was a trend to decreased 
kidney function level with increased age. This finding fits with the evidence that shows 
there is a progressive loss of kidney function with aging (Beers and Berkow, 2000; 
Grimley-Evans et al, 2000; Glassock and Winearis, 2009). All the prevalence data for 
inappropriate prescribing of each of the 8 drugs for people aged 85 years and older 
were higher than the younger age groups.  
The logistic regression analysis showed that, compared to patients aged 65-74yrs, those 
aged 75-84yrs have higher odds of having a kidney function too low for the drug they are 
taking, and those aged 85yrs and over have even higher odds.  Age has been shown to 
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predict higher odds of having a kidney function estimate too low for recommended use 
of the investigation drug. However, this analysis does not address the possibility of 
confounding, where a non-casual association is observed between a given exposure 
and outcome is as a result of the influence of a third variable (Szumilas, 2010). The 
findings need to be interpreted with this in mind, where there may be a factor not 
considered affecting the results. Stratification and multiple regression techniques are 
two methods used to address confounding, and produce ‘adjusted’ odds ratios, but 
were not within the scope of this analysis. However, there is broad evidence that 
kidney function reduces with age and therefore it is likely that, if prescribers are not 
assessing kidney function in relation to drugs, then this will have a greater impact for 
older people. 
The eGFR has been shown to overestimate kidney function for older people and so is 
less likely to show differences. However, even using eGFR, a higher odds of having a 
kidney function too low for the drug being taken was shown for both older age groups 
and all drugs except for metformin in the 75-84 years age band and the NSAIDs ≥85 
years age band (the low numbers in this group might have been a factor). 
Khanal et al (2014), in Australia, did a multivariate logistic regression on their data and 
the factors independently associated with patients being prescribed one or more 
potentially inappropriate renally cleared drugs were advancing age, the total number of 
renally cleared drugs prescribed, presence of diabetes, presence of heart failure and 
living in aged care facilities. 
 
3.6.3.4 Kidney function is tested for most older people 
A kidney function estimate was found to be available on the patient record for most of 
the patients taking the study drugs, and only 2.8%-17.5% did not have a test within the 
previous 15 months, meaning that kidney function could have been assessed to 
determine appropriateness of prescribing. This contrasts with many studies found in 
the scoping review where a kidney function record was not available, for example 
Corsonello et al (2, 2005) where 32% had to be excluded because there was no 
documented information on their kidney function. 
The UK Quality Outcomes Framework (QOF) targets may have helped as kidney 
function testing has been incentivised in, for example, diabetes, so with 40% being on 
an ACEI/ARB they are all likely to have kidney function testing (Quality Outcomes 
Framework, 2015). However, despite the large proportion of the patients having a 
recent kidney function estimate on their record, many were found to be prescribed 
drugs outside the recommendations for RKF. 
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In the Bradford & Airedale PCT population, a quarter of people aged 65 years and 
older had a documented eGFR <60ml/min/1.73m2 so should have been assessed for 
CKD, as well as effect on any drugs they were taking. The Breton et al (2011) study 
also reports this finding, they had 13.3% with eGFR <60ml/min/1.73m2, but did 
comment that their prevalence was lower than other reports, which may have been to 
do with the fact that their participants were mostly at the younger end of the age group. 
 
3.6.3.5 Choice of kidney function estimation equation made a substantial 
difference to whether change of drug or dose was needed. 
Using eGFR as an estimation of level of kidney function would highlight a much lower 
number of alterations required for drug or dose choice than would using CrCl-CG IBW. 
Altering or stopping drugs where needed would be missed if eGFR was used rather 
than CrCl-CG IBW in a large proportion of the ‘patient drug events’ assessed. The 
scoping literature review found 9 of the studies reported results as differences in use 
of the different equations, which ranged from 9.8% dosing errors if MDRD was used in 
an Italian hospital study (Moranville and Jennings, 2009), to 65% in a hospital study of 
nephrotoxic drugs (Cabello-Muriel et al, 2015). A primary care study in the USA found 
40% of patients should have been recommended different doses (Lessard and Zaiken, 
2013), and in the case-note review figures, 22% of the patients reviewed would have 
had different recommendations based on the equation chosen. 
The results corroborate the findings from the case-note review (Chapter 1) that using 
eGFR as an estimation of level of kidney function would suggest a much lower number 
of patients needing alteration of their drug or dose than would using CrCl-CG. In the 
French primary care study (Breton et al, 2011), 13.7% had an eGFR <60ml/min/1.732 
and 36.9% as calculated using the Cockcroft Gault equation, also highlighting the 
difference in use of the equations in an older population.  
The current survey also showed that using actual weight in the Cockcroft Gault 
equation would mean need for alteration, or avoidance of drugs, would be missed, 
though to a smaller degree than using eGFR.  
As discussed in the scoping review (2.6), studies found using blood levels and 
measured creatinine clearance to assess the equations, showed that whilst CrCl-CG 
underestimates by about 10% across all older ages, eGFR (calculated using the 
MDRD equation) overestimates as age increases by 29 - 69% (Roberts et al, 2009; 
Pequignot et al, 2009; Dowling et al, 2011) meaning that the safer estimate to use 
would be CrCl-CG. An ideal body weight, or actual if lower, should be used in the 
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CrCl-CG calculation to give an indication of muscle mass (BNF, 2014; Roberts et al, 
2009). 
 
3.6.3.6 Impact of not altering prescribing in RKF for the sampled drugs 
 Drugs that should be avoided in RKF.  
Alendronic acid is recommended to be avoided at levels less than 35ml/min, but a 
quarter of people aged 65-74 years, and over half those aged 85 years and older, had 
a kidney function lower than the recommended. Levels of alendronic acid in the bones 
are likely to be higher for these groups. Use of bisphosphonates has been increasing 
following guidelines for their use for primary and secondary prevention of osteoporotic 
fragility fractures (NICE TG160/161, 2008) which is more likely in older women. Khanal 
et al (2015) found alendronic acid to be one of the top 5 drugs prescribed 
inappropriately with 89/543 (16.3%) contra-indicated in their Australian primary care 
population aged ≥65 years, which can be compared to the 23.6% found in this study.  
For metformin there were patients found with a CrCl-CG IBW <30ml/min who would 
be at increased risk of lactic acidosis. Metformin had the lowest figures of the 8 study 
drugs and this might be because of QOF and diabetes guidelines with diabetic 
nephropathy as a complication that is routinely looked for. Even so, a quarter of the 
patient drug events for diabetics aged ≥85 years had a kidney function <30 ml/min. 
The NICE guidelines (NICE NG28, 2015) state the recommendation of use in RKF as 
eGFR and it may need assessment as to whether it should be CrCl-CG IBW for older 
people. Below 45 ml/min level the recommendation is caution and reduce the dose; 
patient drug events were found where kidney function was under this level at all ages 
65-99 years, and for the very old the majority were found to be prescribed for diabetics 
with a kidney function <45ml/min. Pillans et al (2003) looked at drugs on admission to 
an Australian hospital for patients with a CrCl-CG ≤40ml/min; in a total of 248 
prescriptions, 44.8% were found to have an inappropriately high dose; of those, 77.3% 
of metformin had doses too high for their level of kidney function. 
Khanal et al (2015) again found a similar level of inappropriate prescribing of 
metformin in Australian primary care with 3.5% (compared to 4.3% in this study) 
contra-indicated. Breton et al (2011) and Schmidt-Mende et al (2012) used eGFR to 
assess kidney function and level of CKD and so are not directly comparable, however 
Schmidt-Mende found a higher percentage at 8.4% inappropriate in Sweden, and 
Breton even higher at 15.3% contra-indicated in France. 
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 Drugs where there should be a reduced dose in RKF. 
Although use of simvastatin has reduced with changes in recommended formulations 
and the reduction in cost of alternatives since the survey was run, it is still widely used. 
Higher blood levels of simvastatin mean that risk of side effects including 
rhabdomyolysis are more common, and there are alternative statins that are not 
affected by kidney function, such as atorvastatin. Inappropriate prescribing was found 
in a third of those aged 85 years and older. Statins were also assessed in the French 
primary care study by Breton et al (2011) who found that some were inappropriately 
prescribed, with 3.8% of all statins needed dose adjustment.  
Fewer patients were taking gabapentin and pregabalin than the other study drugs, 
but they are at high risk from these drugs that frequently cause adverse effects (SPC). 
Also, use has been increasing in recent years for treatment of neuropathic pain and so 
numbers could be higher now. In 2013, 8.2 million prescriptions were dispensed in 
England for both drugs representing a 46% rise in prescribing of gabapentin and 53% 
rise in pregabalin prescribing since 2011 (NHS England, 2014) when this cross-
sectional survey was run. 
Analysis for these drugs had to be done from the dose formulation only, as dosing 
schedules were not possible to extract, and the recommendations are complex. This 
might mean that the figures are an underestimate of the number of inappropriately 
dosed drugs. 
 
 Drugs that are ineffective in RKF. 
Nitrofurantoin showed the highest figures across the age groups with the kidney 
function level below which it is ineffective, and ADRs are higher, is 45 ml/min. 
Inappropriate prescribing was found in over a third of those aged 65 years and older, 
and nearly 80% of the  ≥85 year olds. For these patients the drug may not work 
increasing risk from infection, and raised blood levels increase the risk of pulmonary, 
hepatic, neurological, haematological, and gastrointestinal side effects during 
treatment (Geerts et al, 2013). A pilot investigation at one of the GP practices into use 
of nitrofurantoin in older patients with RKF showed that in the 22 patients with a CrCl-
CG IBW <60ml/min (average CrCl 38.7ml/min), eighteen (81.8%) had further 
antibiotics or were recorded as still symptomatic (Howard & Wood, 2013). There has 
been a national strategy to use nitrofurantoin for UTI to reduce the use of 
cephalosporins, and because of increased resistance to trimethoprim (NICE KTT9, 
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2016). As UTIs are more common in older women, prescribers need help to ensure 
nitrofurantoin will be effective, and when to use an alternative. 
A limitation of the case-note review was that it did not include non-repeat medications 
and this study of nitrofurantoin has shown that short course drugs can be affected. 
Farag et al (2014) found excess dosing of antibiotics in 64% of older people in 
Canada; they noted that nitrofurantoin had been prescribed when contra-indicated 169 
times in the 1,464 antibiotics prescriptions studied. Many of the hospital based studies 
cited antibiotics as being prescribed inappropriately in RKF, for example the UK study 
by Jones and Bhandhari (2013) who found that antibiotics were the highest reported 
class. Antibiotics are widely used in primary care and need to be assessed in relation 
to level of kidney function. 
Thiazides also do not work at low levels of kidney function, below 30 ml/min. As well 
as unnecessarily taking a drug that is not likely to be effective as a treatment, the 
patient is more at risk of adverse events such as electrolyte imbalance (SPC). This 
study found many older people were prescribed thiazides when they are likely to be 
ineffective, particularly those aged 85 years and older. Howard et al (2003) 
investigated reasons for preventable drug related admissions to a medical admissions 
unit in the UK and thiazides were one of the drug classes most frequently associated 
with preventable drug related admissions due to monitoring problems. They cite failure 
to monitor kidney function, fluid balance and electrolytes as a factor in ADRs such as 
over diuresis causing dehydration and renal failure.  
 
 Drugs where there needs to be caution in RKF because of ADRs. 
Both NSAIDs and ACEI/ARBs can cause toxicity to the kidney (SPC). This study 
looked at prescribing for patients on these drugs at CrCl-CG IBW <30ml/min, a low 
rate of kidney function leaving little reserve to cope with acute illness or nephrotoxicity.  
For NSAIDs, there were relatively few patients found where prescribing was 
inappropriate in the younger age group, but over a quarter of those aged 85 years and 
older had a kidney function of CrCl-CG IBW <30ml/min, with a high risk to the kidney, 
and other adverse effects related to higher blood levels. The graph for kidney function 
in NSAID prescribing (Figure 22) also marks the 60 ml/min level and shows that the 
majority of prescribing for those aged 75 years and older had a kidney function less 
than 60 ml/min and would be at greater risk from their NSAID.  
As discussed in the reasons for choosing to study NSAIDs (3.4.2.1), many studies 
have shown inappropriate use in RKF leading to ADRs, and the NICE CKD and AKI 
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guidelines mention NSAIDs specifically as they can worsen kidney function (NICE 
CG182, 2014; CG169, 2013). Guthrie et al (2011) found that 8.2% of patients aged 65 
years and over with a glomerular filtration rate <60 ml/min received a ‘high risk 
prescription’ of an NSAID in their UK primary care study. The ‘STOPP/START’ 
screening tool of older people’s potentially inappropriate prescriptions has several 
recommendations relating to NSAIDs, including to stop NSAIDs for patients ‘with 
chronic renal failure - estimated GFR 20-50ml/min. (risk of deterioration in renal 
function)’ (Gallagher et al, 2008). 
ACEI/ARBs were found to be prescribed for very many older people. Pillans et al 
(2003) looked at drugs on admission to an Australian hospital for patients with a CrCl 
≤40ml/min, which would have been started in primary care. In a total of 248 
prescriptions, 44.8% were found to have an inappropriately high dose; of those, 32.8% 
of ACEIs had doses too high for their level of kidney function. Khanal et al (2015) cited 
perindopril as the top drug prescribed inappropriately in high doses at 44.1%, which is 
high; the current study found a similar level for ACEI/ARBs in general for those aged 
85 years and older (37%). Handler et al (2014) found their AKI alerts were mostly 
triggered by ACE/ARBs. 
There is doubt about the benefits of ACEI/ARBs in very low kidney function and 
‘STOP-ACEi’ is a currently running national multi-centre randomised controlled trial to 
test the hypothesis that stopping treatment with an ACEI or ARB, or a combination of 
both, compared with continuing on these treatments, improves or stabilises kidney 
function in patients with eGFR <30mls/minute (MDRD) (Bhandari et al, 2015). 
Although older people with RKF do not necessarily have kidney disease (Glassock 
and Winearis, 2009), the figures from this survey suggest further research is 
necessary to ensure appropriate use of ACEI/ARBs for older people. 
 
3.6.3.7 No difference discerned between drug categories 
The results tables have the study drugs listed in order of the 4 categories, but in none 
of the results was there any suggestion that there was a difference based on category. 
The differences seemed more likely to do with factors such as where monitoring is 
focussed and incentivised by QOF, and other initiatives such as diabetes (e.g. 
metformin), extent of use (ACEI/ARB high, gabapentin/pregabalin low), and where the 
recommendation level is at a higher level (e.g. nitrofurantoin at ≤45ml/min).  
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 Strengths and limitations 
Some of the limitations of the case-note review have been addressed by studying a 
larger population across a PCT. The study design allowed identification of prescribing 
with no kidney function estimation, and including the antibiotic (nitrofurantoin) meant 
that a drug used as a short course was included for analysis. However, this study was 
not able to include use of non-prescription medicines that might be significant, for 
example NSAIDs bought from pharmacies or retail outlets. Hopf et al (2008) found that 
a substantial proportion ADR-related admissions were associated with non-
prescription medicines, highlighting the need for greater awareness amongst patients, 
prescribers and other health care professionals regarding possible serious adverse 
effects. 
A ‘complete case analysis’ was undertaken for this study, recognising that biases may 
occur because it did not include prescribing of the drugs where the kidney function had 
not been tested and was not known. This effect was reduced by the fact that only a 
small proportion did not have a kidney function on the record. 
The data for each drug was collected individually, but it is likely that some patients 
would be prescribed more than one of the drugs. This has meant that inferences 
cannot be made on the group of drugs as a whole. 
Not being able to follow up any high risk cases was a limitation in the study design. No 
GP practice or patient level data was known so comparative analysis could not be 
carried out.  
 
 
 What this study adds to the literature 
The prescribing for older people with reduced kidney function in primary care in a PCT 
has been quantitatively mapped. No other studies in this area have been found in the 
UK. The findings have added to the body of literature from hospitals and other 
countries that prescribing is not altered as recommended in RKF, and that use of 
eGFR or CrCl AW would mean that many older people would not have the drugs and 
dosing altered when evidence suggests it is required. 
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 What this study adds to practice and policy 
The findings will inform further research into how practice can change to reduce the 
risk of harm for older patients with RKF. In particular for the ≥85 year olds where, not 
only is the need greatest, but the population numbers are rapidly increasing so the 
implications from the study findings will be greater. 
Issues have been raised by this survey that are important for guidelines and policy. It 
is known that kidney function reduces with age, and this survey showed that a quarter 
of ≥65s, and half of ≥85s, had an eGFR <60ml/min/1.73m2 which needs highlighting in 
practice. This, and the high number of older people found to be taking renally excreted 
drugs, means there needs to be changes in practice to reduce the risk of harm. 
 
 
 Progression and integration of methods and findings 
The PCT-wide survey built on the findings of the case-note review by testing in a wider 
population and addressing the need to assess extent of drug use and of kidney 
function testing in this population. The choice of drugs to study also came from the 
case-note review and use of the four categories of drugs ensured a broad picture. 
When the scoping literature was updated in October 2015, many more recent studies 
reporting on the difference between eGFR and CrCl were found. Analysis revealed 
that half the studies found investigating the theoretical difference between the kidney 
function equations (2.6.5.10), reported using a measure of ‘how many cases would 
have been missed’. The prescribing data from this cross-sectional survey was then re-
analysed to include a ‘cases missed’ analysis which gives a clear measure of the 
impact for patients, as well as a comparison to the other studies in the literature. 
The finding that a large majority of the drugs were prescribed where there was a 
recent kidney function test available, raised the question of why kidney function does 
not seem to be used when prescribing renally excreted drugs in primary care. This 
needed to be explored further with prescribers. 
 
3.7 Conclusion 
Prescribing recommendations in RKF were not followed for a large population of older 
people in a Primary Care Trust.  For all the study drugs, and for all age bands, there 
was prescribing of the drugs found where the kidney function was too low for 
recommended use. The numbers of older people found taking the study drugs were 
large, meaning that many patients could be at risk of harm. The Bradford population 
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has a lower proportion of older people than the national average which could mean 
that the findings might be an underestimate for the wider population.  
From the literature review findings, the case-note review, and cross-sectional survey, 
there is a need for a qualitative enquiry to understand the determinants for why 
prescribers do not apply the recommendations for prescribing in RKF in primary care. 
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“Decision making is … something which concerns all of us, both as maker of the 
choice, and as sufferers of the consequences.”  
D. Lindley 1971 
 
 
4 Chapter 4: A qualitative GP interview study to explore why 
prescribers do not apply prescribing recommendations for 
older people with reduced kidney function. 
 
4.1 Background 
Risk of harm and hospital admission are increased for older people when drug licence 
recommendations for prescribing in reduced kidney function (RKF) are not applied, as  
revealed in the scoping literature review (Chapter 2). Kidney function reduces with age 
but it is not always accounted for by prescribers in primary care, as found in the case-
note review (Chapter 1) and the PCT-wide survey of prescribing data (Chapter 3). 
No research evidence was found in the scoping literature review (Chapter 2) on why 
prescribers do not apply the recommendations for prescribing of medicines where 
kidney function is reduced. Where prescribing errors in general have been explored, 
the causes and associated factors have been found to be numerous (Slight et al, 
2013) with a complexity that would mean solutions addressing only one factor (such as 
lack of knowledge) would be likely to have only limited benefit (Tully et al, 2009).  
As introduced in Chapter 1 (1.4), where behaviour needs to be changed, it is more 
successful if an intervention is developed on evidence-based principles of behaviour 
change (Cane et al, 2012). Using a theoretical approach allows identification of factors 
and strategies that are more likely to be effective (Nilsen, 2015). The scoping review 
found a lack of theoretical underpinning in the studies aiming to improve prescribing in 
RKF (Chapter 2, 2.6), which might be a factor for the lack of benefit found in many of 
the trials if the intervention was not addressing the barriers, and provides no 
understanding of the determinants where a positive outcome was shown.  
To inform an intervention that is likely to be successful in improving recommendation 
application and reduce risk for patients, there needs to be a systematic exploration to 
understand prescribing for older patients with RKF by general practitioners (GPs) in 
the care pathway (the ‘behaviour’).  
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This study aimed to explore why GPs do not apply the drug licence recommendations 
when prescribing for older people with RKF. 
 
4.2 Research question and objectives 
Research question 
Why are prescribing recommendations not applied for older people with reduced 
kidney function in primary care? 
Objectives 
 To systematically identify the potential barriers and enablers to prescribing 
appropriately in reduced kidney function using the Theoretical Domains 
Framework (Michie et al, 2005; Cane et al, 2012) to understand whether 
prescribers have the capability, opportunity, and motivation in the care pathway 
(Michie et al, 2011). 
 To identify what needs to change in the factors affecting the care pathway to 
improve implementation of the prescribing guidance. 
 
4.3 Methodology 
 The behaviour 
The World Health Organisation describes a systematic stepped approach to 
prescribing (de Vries et al, 1994): 
1. Define the patient’s problem. 
2. Specify the therapeutic objective. 
3. Verify the suitability of the drug, the most effective, safe, suitable and cheap 
option. 
4. Write a prescription. 
5. Give information, instructions, and warnings. 
6. Monitor (and stop?) the treatment. 
A reduced kidney function would need to be part of the prescribing decision process at 
Step 3 as to whether there are any recommendations for prescribing in RKF that would 
mean a drug is ‘unsuitable’, and whether it would be ‘unsafe’ unless a reduced dose, 
or alternative were used. It would also impact on Step 6 as kidney function can 
change, and so it would need monitoring to ensure the drug and dose is still suitable. 
The level of kidney function would need to be considered at initiation of a drug, 
medication review, and whenever circumstances change, such as acute admission, 
infection or starting another nephrotoxic drug. 
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Three of the four aims of good prescribing described by Barber (1995) similarly state 
that the prescriber should maximise effectiveness, minimise risks, and minimise costs, 
both on first prescribing a drug and on subsequently monitoring it. The fourth 
additional aim stated is to respect the patient's choices (Barber, 1995). The recent 
guidelines on medicines optimisation reiterate the aim to ensure that the ‘right patients 
get the right choice of medicine at the right time’ (Royal Pharmaceutical Society, 
2013). 
Multiple other influences such as guidelines for prescribing in specific clinical 
conditions, for example NICE, drug formularies leading drug choices, and national 
strategies such as use of antibiotics, add in to make the factors determining this 
behaviour highly complex. 
As introduced in Chapter 1 (1.4) ‘COM-B’ (Figure 25) is a model which recognises that 
behaviour is part of an interacting system involving capability, opportunity and 
motivation (Michie et al, 2011). Interventions need to change one or more components 
in such a way as to put the system into a new configuration and minimise the risk of it 
reverting. Understanding the behaviour in context will highlight what needs to change 
(Michie et al, 2014).  
 
 
Figure 25: The COM-B model - a framework for understanding behaviour (Michie 
et al, 2011). 
 
Use of the COM-B model highlights questions about the behaviour of prescribing when 
kidney function is reduced. 
Capability  
 Do prescribers know that some drugs need assessment of level of kidney 
function to advise their use or level of dose? 
 Do prescribers know how to apply the recommendations? 
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 Do prescribers know about the different estimation equations and how to use 
them appropriately? 
 If they know about the recommendations, do they remember to apply them? 
 Do prescribers have the skills needed to assess kidney function in relation to 
prescribing? 
Opportunity 
 Is the environment conducive, both physical and social? 
 Are there resources available to help prescribers apply the recommendations? 
 Does the patient record system help, or hinder, appropriate prescribing? 
Motivation 
 Are there intentions, and/ or conscious goals to prescribe appropriately in 
RKF? 
 What habits or impulses are involved in the process? 
 Are factors regarding the professional role relevant? 
 What are the beliefs of prescribers about the consequences of prescribing 
appropriately, or not, in RKF? 
 
 The Theoretical Domains Framework (TDF) 
Michie et al (2014, p93) describe how a more detailed understanding of the behaviour 
can be gained by using the TDF to expand on the COM-B components, and Table 5 in 
Chapter 1 shows how the TDF domains link to COM-B and which provided the 
framework for the exploration in this study. 
Chapter 1 (1.4) introduced that changing behaviour is more effective if interventions 
are developed on evidence-based principles of behaviour change (Cane et al, 2012). 
Two main issues have been identified as reducing the likelihood of success of 
implementation strategies (Dyson et al, 2011); 
 A failure to identify barriers and enablers to implementation of evidence based 
practice (Grimshaw et al, 2004; NICE, 2007). 
 A lack of theoretical basis for the interventions used to support the 
implementation of evidence into practice (Grimshaw et al, 2004; Michie et al, 
2005). 
There are many theoretical models to explain behaviour change with multiple 
contending theories, and Michie et al (2005) have highlighted that such a large number 
of theories and theoretical constructs cannot be fully applied, and there was a need for 
a method to select among them. The TDF has addressed the need for an overarching 
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determinant framework and was developed to identify individual factors known to 
influence the gap between evidence based practice and the routine delivery of health 
care. The TDF is an integrative framework synthesising key theoretical constructs 
used in relevant theories. The scoping literature review (Chapter 2, 2.6) found a lack of 
theory underpinning the intervention studies suggesting the need for a comprehensive 
framework to consider all relevant theories. 
Originally, the  synthesis of 128 constructs related to behaviour change, found in 33 
behaviour change theories, were developed into 12 domains, such as knowledge, 
skills, goals, and beliefs about capabilities (Michie et al, 2005). The constructs were 
then validated and restructured to 14 domains in 2012. (Cane et al, 2012; Michie et al, 
2014). The 14 TDF domains have been linked to the COM-B components by Michie et 
al (2014, p92) (Table 5, Chapter 1).  
In the scoping literature review, no evidence was found on the determinants for 
prescribing in RKF, but the TDF has been used to identify key theoretical domains that 
are perceived to influence healthcare professionals and their prescribing. Cadogan et 
al, (2015) found that all the theoretical domains, except ‘Emotion’, were considered 
relevant to the target behaviour of ‘prescribing of appropriate polypharmacy in primary 
care’, which illustrates the complex nature of the behaviour as well as the challenge 
faced by the researcher when developing interventions for change. Duncan et al 
(2012) explored beliefs among trainee doctors, including that prescribing errors were 
not likely to have consequences for patients, and found that seven theoretical domains 
were relevant: social professional role and identity, environmental context and 
resources, social influences, knowledge, skills, memory, attention, and decision 
making, and behavioural regulation. Potentially important domains were beliefs about 
consequences and abilities which could be targeted for an intervention.  
 
 Study design methodology 
Face-to-face semi-structured interviews were chosen to allow each participant to talk 
in depth about particular issues and focus on individual experiences, follow up of 
interesting responses, and investigation of underlying motives. Non-verbal cues may 
add to understanding the verbal response, and franker responses may be possible if 
participants are not with their peers (Robson, 2011). The TDF has been used in 
interview studies for topic guides and analysis, for example, Francis et al (2009), who 
used methods based on theoretical construct domains to understand clinicians’ blood 
transfusion behaviour, and Dyson et al (2011) who used the theoretical approach to 
explore hand hygiene behaviour. 
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An ethnographic approach would have allowed actual behaviour to be observed but 
not access to attitudinal data, which would be important for an exploration of the 
decision making process. Also, the cross-sectional prescribing data survey suggested 
that assessment of kidney function when prescribing did not happen and so a method 
is required that can explore more than what can be observed. Themes were not yet 
known to create an appropriate questionnaire and it would have been unlikely to 
provide the depth needed or the opportunity to investigate responses further. A focus 
group may have been the method of choice to seek a broad range of ideas (Green and 
Thorogood, 2009), but would not give an in-depth exploration of individual experience, 
and individuals are less likely to disclose errors or bad practice. 
 
4.4 Method 
 Research team 
4.4.1.1 Personal characteristics 
The one researcher, and interviewer, for this study was myself as a female pharmacist 
(BPharm PG Dip MPharm) and PhD student, overseen by the supervisory team.  
Training gained to inform the setting up of the study, data collection and analysis: 
- University of Leeds School of Healthcare Research Methods Module. 
- Leeds Institute for Health Sciences Health Research: module 2: capturing data 
for research, and module 3: handling data for research.  
- Health Services Research & Pharmacy Practice Conference seminar by 
Professors S. Michie and M. Johnstone (Aberdeen, 2014). 
- UK Society for Behavioural Medicine day workshop by Dr L. Atkins 
(Nottingham, 2014) 
Experience: this was the first structured research interview study conducted, informed 
by over 20 years of professional interviewing experience as a practitioner. The 
conducting of the interviews was mentored by Professor R. Foy, and the analysis by 
Dr C. Easthall, both experienced in qualitative research and behaviour change theory. 
4.4.1.2 Relationship with participants 
The letter of invite established that the research would be conducted by a pharmacist 
who was also reading for a PhD (Appendix 8, 8.6). It was made clear at the start of 
each interview that it was being conducted by a pharmacist with a particular interest in 
prescribing in RKF. It was expected that some of the participants may know the 
interviewer professionally, and/or may have heard her talk on the subject. This was 
therefore asked, and noted as part of the demographic data collected to inform the 
analysis. 
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 Study design 
4.4.2.1 Theoretical framework 
The theoretical domains framework, as an integrative framework synthesising key 
theoretical constructs used in relevant behaviour change theories, informed the 
development of the interview topic guide and analyses framework. 
4.4.2.2 Participant selection 
Sampling 
General Practitioners were purposively sampled to give a range of length of time as a 
prescriber and whether they were a GP trainer. At least 2 participants would be 
recruited from each of the categories <8 years prescribing experience, 8-18 years, and 
>18 years, and at least two for each of GP trainer and non-trainer. The original plan 
had been to use categories for length of time as a prescriber as <5, 5-15, >15years, 
but meeting the first registrar participant made it clear that by the time doctors start GP 
training they will have had more than 5 years prescribing. Changing the categories 
would give a more realistic spread of prescribing experience in primary care. 
Method of approach 
Invitation packs were delivered to GP practice ‘pigeon holes’ by the local practice 
pharmacist team as a known and trusted route of access. 
Potential participants received a research study pack containing a letter of invitation 
(Appendix 7, 8.6), consent form (Appendix 8, 8.7) and information sheet (Appendix 9, 
8.8). One follow-up email was sent where no reply had been received.  
A certificate of attendance was provided for all interviewees as a recognition of their 
participation in research (Appendix 10, 8.9). 
Sample size 
The number of GPs recruited for interview was dependent on when data saturation 
was reached, defined as no new themes or concepts elicited. Following the 
recommendations for interview studies that use a theory-based content analysis by 
Francis, Johnstone et al (2012), the criteria for data saturation for this study were: 
 Initial analysis sample: at least 10 interviews would be conducted (with 
diversity sampling to ensure the sample covers the inclusion criteria for 
prescribing experience and trainer status). 
 Stopping criterion: when 3 further interviews had been conducted with no new 
themes emerging in each of the TDF domains, this would be defined as the 
point of data saturation. 
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Non-participation 
Non-participation rates, and the reasons, were collected. 
Pre-interview reading 
Participants were sent a short document by email to read prior to the interview 
(Appendix 11, 8.10). This pre-reading gave a short summary of the findings of the 
project so far and examples of drugs that should be avoided, dose reduced or are 
ineffective, to allow them to think about some of the issues before the discussion. The 
extent of older people on drugs that were not appropriate for their level of kidney 
function in the PCT-wide cross-sectional study (Chapter 3) suggested that many 
prescribers may not have thought about the issues. The pre-reading would allow them 
to consider the results in relation to their own practice and experience to inform the 
discussion. 
4.4.2.3 Setting 
This study was based in Bradford Districts Clinical Commissioning Group (CCG), 
encompassing 47 practices. CCGs superseded the former PCTs to organise the 
delivery of NHS services in England. Bradford Districts CCG was the larger part of the 
former Bradford & Airedale PCT where the cross-sectional PCT-wide prescribing data 
survey was run (Chapter 3), and so the interviews would be with GPs prescribing in 
the same setting. This would mean that the quantitative findings could be explored 
with the prescribers involved, but does mean that views from a wider context would not 
be captured. 
4.4.2.4 Data collection 
Semi-structured, individual, face-to-face interviews were conducted. A topic guide 
(Appendix 12, 8.11), with theory-based prompts based on the TDF, was used to 
explore attitudes, beliefs, enablers and barriers. It also aided exploration of prescribing 
different drugs for older patients with RKF, and what needs to change in the factors 
affecting the care pathway to improve implementation of the prescribing guidance. 
Open questions were used to elicit personal experience and explore responses further 
(Green et al, 2011). All the interviews were conducted by myself, introduced as a 
pharmacist but acting as a researcher for this study. Only one interview was 
conducted for each participant. 
The topic guide was developed with input from the supervisory team. It had been 
planned to pilot test the topic guide, but it had to be cancelled before the first interview 
date. The first interview was therefore used as a pilot, and if any major changes were 
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needed then it would have resulted in the transcript not being used for the final 
analysis. 
Interviews were audio-recorded with permission; field notes were made after each 
interview. Any information that could lead to a participant being identified was removed 
at the transcription stage and an identification code applied. Transcription was done by 
an administrator and checked by myself for accuracy. The data was managed using N-
Vivo QSR v10. 
 
 Analysis 
4.4.3.1 Demographic analysis 
A standard form was constructed to collect demographic data for each participant on 
length of time as a prescriber and whether they were a GP trainer. Also noted were 
gender, any special interests and whether the participant knew me and/or had heard 
me speak on prescribing for older people with RKF. Whether a participant had heard 
me discuss prescribing in RKF was noted so that any difference in themes could be 
analysed. 
4.4.3.2 Data saturation analysis 
The data saturation analysis was conducted in four steps (Francis, Johnstone et al, 
2012): 
1. Data tables were constructed for themes in each theoretical domain elicited 
for each individual. 
2. Summary tables were constructed for each domain (knowledge, skills etc.) 
with themes mentioned by each participant interviewed. 
3. Data from the summary tables were used to construct cumulative frequency 
graphs, displaying sequentially numbers of new themes elicited in each 
domain. 
4. The cumulative frequency graphs were inspected to investigate when the 
stopping criterion had been met (set at 3) for each domain and overall. 
4.4.3.3 Content analysis 
A theory-based, five stage content analysis was conducted (Pope et al, 2000). A 
second researcher (CE) was involved to explore inter-rater reliability by coding the first 
2 participant transcripts, and providing discussion where needed. CE is a pharmacist 
experienced in behaviour change theory, and with both content (prescribing) and 
methodological (qualitative research) expertise. A third person (EW) helped with 
identification of emerging themes and charting the data; as a social scientist and non-
pharmacist she brought a new perspective to help elucidate meanings. 
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Stage 1. Familiarisation 
Interview recordings were listened to and transcripts read and re-read to become 
familiar with the data, and get an initial impression of the key ideas and recurrent 
themes.   
Stage 2. Identifying a thematic framework 
The coding index was applied systematically to all the data by annotating the 
transcripts. I coded all the transcripts and then met again with CE to discuss any 
issues that were unclear and verify the findings. An example is the first page of the P1 
charting, shown in Table 37. 
Stage 3: Indexing 
The key issues, concepts and themes by which the data would be examined and 
referenced, were identified from the a-priori Theoretical Domains Framework (TDF), 
and the views or experiences from the data. For the first participant (P1), both 
researchers (myself and CE) coded independently to the TDF. The two researchers 
then met to review the coding and agree on any discrepancies by discussion. 
P2 was coded independently by both researchers, who then met again to review; this 
time there were fewer discrepancies to discuss. A coding index was developed. 
Stage 4. Charting 
The codes and quotes were manually grouped into emerging themes (Figure 26) with 
the help of EW. This was an iterative and reflective process and allowed exploration of 
intra-rater reliability by re-visiting and refining the coding. 
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Table 37: Charting to TDF domains for P1- first page. 
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Figure 26: Charting the codes and quotes and then mapping and interpretation 
to define ‘key themes’. 
 
 
Figure 27: 
Re-
mapping 
and 
analysis 
needed to 
the 
updated 
domains 
on the 
TDF.    
 
Stage 5. Mapping and interpretation 
When categorising for what needed to change in capability, opportunity and motivation 
(Michie et al, 2014), the ‘Behaviour Change Wheel’ used the updated TDF version that 
had 14 domains, with some changes to the existing categories. The re-mapping of the 
- Motivation and goals          intentions ) both in reflective motivation 
                                 goals  ) so don’t need to re-analyse 
 
- Behavioural regulation – focuses on self-regulatory processes 
 
- Beliefs about capabilities            belief about capabilities   )  both reflective motivation 
                                          optimism           ) so don’t need to re-analyse 
 
- Beliefs about consequences            Beliefs about consequences – reflective motivations 
         ‘pure beliefs’ 
                Reinforcement – automatic motivation 
                   ‘associative learning’  
 
- Nature of the behaviours removed – need to re-analyse 
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coding needed is shown in Figure 27; recoding was required for the ‘nature of the 
behaviours’ and to split ‘beliefs about consequences’ onto new domains. 
The emergent themes were mapped and interpreted under each TDF domain, 
categorised under capability, opportunity and motivation to structure the findings on 
what needs to change (Figure 26). The themes were charted in Excel and analysed for 
numbers and differences with participant type. A summary of the themes was 
developed for each of capability, opportunity and motivation. 
The range and numbers of themes was explored using Excel to give an indication of 
the frequency of discussion by participants in terms of: 
- The number of participants mentioning a theme in each domain. 
- The number of different themes identified in each domain. 
- The total number of different themes mentioned by all the participants in each 
domain. 
4.4.3.4 Identification of key themes 
This study had a qualitative design, and the interviewees were recruited to give a 
sample with a wide range of expertise and experience, rather than to be a 
representative sample. The aim was to identify the range of potentially influential 
determinants, decipher the content and nature, and enable future analysis of hierarchy 
to determine prioritisation for intervention. The identification of ‘key themes’ therefore 
aimed to be a synthesis of the range of themes elucidated, noting where themes were 
frequently mentioned, prominence of themes both from number and intensity, and also 
where there might be high importance for an intervention, even of only mentioned by 
one interviewee. 
The themes and quotes in each domain were read and re-read and the common, and 
important, research themes were identified as ‘key’ in what needs to change to 
improve prescribing for older people with RKF. The ‘key themes’ of associated 
determinants across domains and COM-B categories were developed from:  
 The TDF domains with the highest number of different themes elucidated. 
 The themes most discussed by participants. 
 Themes that might not have been frequently brought up by participants, but 
that would be likely to be important, influential and have high impact. 
 The summaries of what needed to change for greater capability, more 
opportunity and stronger motivation. 
 Common strands across the COM-B components. 
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Having drafted the ‘key themes’, they were reviewed back with the original set of 
themes and quotes under each domain to confirm that the most important findings had 
been included. 
 
 Ethics and governance 
University ethics (SHREC/RP/346 on 27/6/13, Appendix 13, 8.12), NHS governance 
assurance (on 5/11/13, Appendix 14, 8.13), and letter of access (Appendix 15, 8.14) 
were granted. NHS ethics approval was not needed as participants were healthcare 
professionals. 
 
4.5 Results  
 Recruitment 
Fifteen GPs were interviewed. Recruitment packs had been delivered to 72 GP pigeon 
holes in 26 GP surgeries. Overall there were 21 positive responses (29.2%) which 
resulted in 15 interviews; 2 had to decline because of lack of time and 4 were not 
pursued as data saturation had been reached (Figure 28). Fifty-one did not respond to 
the invitation. 
 
Figure 28: Responses resulting from the participant recruitment 
 
 Demographic analysis 
The GPs had 7-32 years prescribing experience. Nine were GP trainers. In the first 10 
participants (initial analysis sample) there was only 1 who had less than 8 years 
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prescribing experience so at least one more needed to be recruited to represent 
adequate diversity defined by the inclusion criteria. Table 38 gives a summary of the 
participant characteristics. Twenty-three wide-ranging specialities were represented in 
the sample including neurology, diabetes, mental health, drugs safety and education.  
Interviews took place between January and April 2014, and were conducted at GP 
practices, except one at a community hospital. Nobody else was present in the 
interviews except the interviewer and participant. Interviews all lasted 35-45 minutes. 
The audio-recording failed when interviewing P3 so no transcript was available for 
content analysis. Notes were written as soon as the recording failure was realised 
(later the same day). 
 
 Data saturation analysis 
Data saturation was reached after 12 interviews. No new themes were elicited from 
the final three interviewees, who were one from each ‘length of experience’ category. 
Excel tables were used to collate and assess the themes elicited in each domain, and 
presented in the following sections (Tables 40 - 45). 
Figure 29 shows the cumulative themes elicited per TDF domain sequentially as the 
interviews were completed and analysed. After 10 recorded interviews the initial 
analysis sample yielded 113 themes in total. Data saturation had not been reached for 
6 of the domains; this, as well as needing at least one more participant with <8 years 
prescribing experience, meant that further participants were recruited. 
 
Abbreviations: GPwSI: GP with Special Interest; RKF: reduced kidney function. 
Table 38: GP interviewee characteristics. 
female male <8yrs 8-18yrs >18yrs yes no
did not 
know me
knew me 
but not 
heard me 
on drugs 
and  RKF
knew me 
and heard 
me on 
drugs and 
RKF
P1 Ear/nose/throat GPwSI, men’s health, 
respiratory, prescribing lead
P2 registrar
P3 elderly care
P4
addiction and substance misuse GPwSI; 
respiratory; patient safety
P5 education
P6 neurology GPwSI
P7 general med; paediatrics; elderly
P8 diabetes GPwSI
P9 Musculoskeletal; mental health
P10 gastroenterology; diabetes
P11 diabetes; undergraduate education
P12 women's health
P13 women's health; epilepsy
P14 GP appraiser; mental health
P15 registrar; women's health
gender time as a prescriber GP trainer particular interestsparticipant knew the researcher?
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Figure 29: Themes elicited per domain summary data for saturation analysis. 
 
The 15th participant was a registrar with <8 years’ experience and so the analysis was 
then re-run. At that point there were a total of 127 themes elicited, and no new themes 
from P13, 14 or 15. It was concluded that data saturation had been reached for 
themes on experience in prescribing for older people with RKF. 
 
 Theory-based content analysis 
The data was analysed to explore the barriers and enablers when prescribing for older 
people with reduced kidney function to find out if greater capability, more opportunity 
or stronger motivation is required (Michie et al, 2014). 
4.5.4.1 Analysis of themes 
Excel tables were used to collate and assess the themes elicited in each domain, and 
are presented in the following sections. The tables were used to visualise when data 
saturation had been reached, and to analyse differences with participant type. The 
tables have also allowed an exploration of the themes in terms of frequency of 
discussion by interviewees, which has been summarised in Table 39, ordered by total 
number of themes discussed by the participants.  
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Abbreviations: eGFR: estimated glomerular filtration rate; RKF: reduced kidney function. 
Table 39: Summary of frequency of themes discussed by interviewees, ordered 
by the total number of themes mentioned by the participants. 
Themes were found across all the TDF domains, with at least 9 of the interviewees 
discussing issues in every domain. Themes on ‘knowledge’, ‘environment and 
resources’, and ‘beliefs about consequences’ were mentioned by all 14 interviewees 
recorded. The domains with the greatest number of themes from the interviewees 
were:  
 Environment and resources 
 Knowledge 
 Memory, attention and decision process 
 Beliefs about consequences 
 Motivation and goals 
4.5.4.2 What needs to change for greater capability? 
Figure 30 shows the barriers and enablers found on what needs to change for greater 
capability. 
Psychological capability  
Table 40 shows the three tables developed to chart the themes in the domains for 
psychological capability:  
Knowledge   
Memory, attention and decision process 
Behavioural regulation. 
number 
participants 
mentioning 
a theme in 
the domain
number of 
themes 
found
total 
number of 
themes 
mentioned 
by 
participants
theme most mentioned
environment and resources 14 20 69 there are competing priorities and time constraints
knowledge 14 16 56 there is a lack of knowledge about specific drugs
memory, attention and decision 12 13 52 it is difficult to remember to do, and which drugs
beliefs about consequences 14 9 34 RKF can cause toxicity from the drug, and to the kidney
motivation and goals 13 10 27 a motivation is to not do harm
nature of the behaviour 9 18 25 eGFR is used to assess kidney function
skills 13 7 22 the skill is difficult to do
behavioural regulation 12 11 20 want computer decision support
beliefs about capability 13 5 16 there is a lack of confidence in capability
emotion 11 7 15 stressed/worried/bothered if not doing it correctly
social/prof role 9 6 11 peer discussion is useful
social influences 9 5 10 pharmacist influence is valued
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Figure 30: Perceptions of barriers and enablers for what needs to change for greater capability. 
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Abbreviations: CrCl CG: creatinine clearance Cockcroft Gault; M/F: male/ female; RKF: reduced kidney function; Y/N: yes/ no. 
Table 40: Psychological capability: charting themes in 3 TDF domains  
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The knowledge domain had themes from all interviewees, and the second most total 
number of themes discussed. The 'memory, attention and decision process’ domain 
was the third most discussed. 
 Knowledge 
There was little awareness of the need to alter prescribing for the majority of 
participants when prescribing renally excreted drugs if kidney function was reduced. 
“It’s probably one of those areas where there is a bit of a blind side.” (P4) 
“I can’t think there are clinicians who are wilfully doing that [prescribing 
wrongly], erm, but it is more that they just don’t know.” (P1)    
Two participants thought that their awareness had increased recently with increased 
use of nitrofurantoin and the MHRA Drug Safety alert on use in RKF. 
“I am more aware of it than I used to be.” (P10) 
“Nitrofurantoin wasn’t coming up on my radar at all until about a year ago.” (P9) 
Lack of knowledge was widely expressed, with 11 of the 15 participants mentioning it 
without prompting, having read the pre-interview information. 
“I suspect for some clinicians, and I include myself in that, there may be a 
knowledge gap.” (P1) 
Inadequate knowledge about prescribing specific drugs in RKF was conveyed, even 
those that are regularly prescribed or where the GP had a clinical expertise: 
 “I wasn’t really aware of gabapentin and pregabalin erm, or simvastatin actually.” 
(P11) 
 “I wasn’t aware. This is terrible because I use a lot of gabapentin and pregabalin, 
obviously, in neurology.” (P6) 
Very little knowledge was expressed about the Cockcroft Gault kidney function 
estimation equation. 
“I would have no idea, cos everything that I do currently is with eGFR.” (P2) 
It was mentioned that medical students have little knowledge about drugs in general. 
“It’s amazing, no, they [medical students] don’t know anything about drugs.” 
(P6) 
“The knowledge of medical students is very, very minimal, you know. They 
don’t know the different drug names, groups of diuretics, you know. You ask 
them about what group is such and such and they just don’t know.” (P14) 
Prescribing when kidney function is reduced has not been taught. The two registrars 
were still in training and had not had teaching on this area. 
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“..but is it something we are specifically taught? No.” (P2) 
 “As a GP trainee there certainly hasn’t been a teaching session on the kidney 
– reduced kidney function.” (P15) 
Two participants highlighted a difference between the recommendation for drug use in 
RKF versus clinical guidelines; one on the use of nitrofurantoin, and the other anti-
hypertensives.  
“Although we are supposed to avoid so many other antibiotics now, it kind of 
sometimes – nitrofurantoin could be really useful.” (P2) 
“How many of our elderly patients with their high blood pressure would do 
better because they would stop falling down, or would do worse because 
actually we’d never get the blood pressure under control because the 
maximum dose we’d be using would be lower.” (P2) 
The participant’s view was that these examples were goal conflicts. However, in both 
cases, it was a lack of knowledge and understanding of the implications of RKF on 
drug blood levels that led them to their views. Nitrofurantoin would not be useful when 
trying to avoid other antibiotics in RKF because it would be likely to be ineffective. The 
reason the recommended maximum dose of the anti-hypertensive is reduced is 
because RKF would lead to increased blood levels so the dose needs reducing to 
achieve the same blood levels as someone with normal kidney function.  
 Memory, attention and decision process 
It is difficult to remember all the many drugs that are affected by kidney function, and 
that different recommendations apply to different drugs.  
“It’s remembering which medications you need to be careful with, those are the 
pitfalls.” (P12) 
“It’s just remembering lots and lots and lots of anomalies isn’t it. Different facts 
about drugs…but you can’t apply to any other drug, it’s often just applicable to 
drug you have in mind.” (P14) 
For drugs that are more regularly prescribed it might be easier to remember to check 
kidney function. 
“I can remember that [nitrofurantoin] and that’s easy, but with other stuff, you 
know like NSAIDs, or the one that I didn’t – pause – was it metformin is the one 
I don’t think about very often, cos I don’t regularly prescribe it.” (P2) 
“I suppose I just carry nuggets of bits of information around the place - the 
things that you're using more day to day.” (P11) 
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Triggers to reviewing the kidney function in relation to prescribing expressed were 
 Past experience of an adverse drug reaction. 
“Patients who were really ill as a result of drugs they had been given and I think 
I am more wary.” (P8) 
 Old age. 
“I’d probably have to think about age. Age would probably be a trigger.” (P7) 
 Acute reduction in kidney function. 
“…and occasionally you’ll see renal changes cos of meds and oh quick change 
them back and hope things pick up.” (P4) 
“If the eGFR was getting worse then I would think of an alternative.” (P10) 
 Warnings and prompts. 
“GPs are very good at being led by instruction. You know if it says use this, we 
will do it!” (P6) 
 ‘Flags’ already in the head. 
“The ones in my head that I know are good or bad I will be looking at it – It’s 
the ones that flag up, yes.” (P11) 
Kidney function was more likely to be thought of when first prescribing a drug. 
“I think that’s easier to apply [when newly prescribing], have that sort of red 
flags you know thought processes, let’s be careful.” (P11) 
“When you’re starting a new medication you start to pay a bit more attention to 
them.” (P9) 
However, kidney function is not thought about at medication review and attention is 
likely to be on other things that might not be related to the drugs. 
“Renal function isn’t one of the things that we benchmark against when we 
review medications.” (P12) 
“I think it’s so QOF orientated now, you know we are focused on perhaps the 
wrong stuff in medication reviews.” (P7) 
There are no warnings and prompts when doing a medication review. 
“With the medication review you’ve just got a list of the drugs in front of you – 
So you’ve got to have I guess that knowledge either. Well it’s got to be in your 
head or to trigger.” (P11) 
Warnings and prompts for drug use in RKF are generalised and not patient specific so 
tend not to be looked at.   
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“It’s so generalised it becomes more easy to maybe not look at it as you 
should.” (P7) 
 Behavioural regulation 
A kidney function test result is needed before the medication review is done, which 
doesn’t tend to happen currently. 
“We do the medication review and then we look and say oh yes and you’ll need 
a blood test cos you’re on these pills and then they go off and have a blood test 
and you never then actually look at the medications again in the context of the 
result.” (P12) 
“You look at the result and you think oh well that’s a stable, slightly low eGFR 
and nothing to worry about , but you don’t really go back and do it the other 
way and maybe we ought to be trying to do bloods before med reviews.” (P12) 
Improved computer decision support was seen as something that could help. 
“I need a button to just say to check on to highlight all drugs that are a problem or 
whichever GFR or if it could do that to their repeat list for you.” (P15) 
“SystmOne, SystmOne. Please flash up do not use eGFR, you must use creatinine 
clearance for this.” (P6) 
It was expressed that there was a habit of prescribing the dose of a drug that they just 
always use without thinking that it might need altering. 
“Nitrofurantoin – again just 100bd – I use a lot in the elderly so I have to hold 
my hands up.” (P4) 
Examples mentioned that have changed participant practice were reading up and 
learning about a specific drug, pharmacist teaching, and computer alerts. 
 
Physical capability  
Table 41 was developed to chart the themes in the one domain for physical capability: 
Skills. The skills domain had themes from 13 of the interviewees, but was one of the 
more minor domains in terms of number of times themes were discussed. 
 Skills 
Kidney function is often checked, but the result is not then assessed in relation to 
prescribing and review of medications. 
“We often check the bloods when we do a medication review that haven’t done 
- I don’t often drill, ever is probably the right word, drill down to the eGFR to 
see whether any of the medications that they’re on tally with the GFR.” (P9) 
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“We are very good at knowing when to re-check the U&Es, but are we actually 
correlating that with what people are on?” (P7) 
Most of the GPs did not know what to do or how to calculate CrCl, but those that knew 
how to use the SystmOne renal calculator didn’t think it was difficult. 
“I wouldn’t know how to calculate it.” (P7) 
“You can go into the clinical tools thing, can’t you, to create it or calculate it– I 
don’t think that bit’s difficult.“ (P12) 
The process within prescribing was expressed as complex, multi-stage and difficult. 
“I think it is difficult; I think it just a lot of steps isn’t it?” (P5) 
“When prescribing decisions start to get complicated and difficult and it’s after 
about 4 or 5 drugs then you’re really into uncharted territory sometimes with 
unpredictable outcomes.” (P14) 
 
 
 
Abbreviations: M/F: male/ female; Y/N: yes/ no. 
Table 41: Physical capability: charting themes in 1 TDF domain 
 
4.5.4.3 What needs to change for more opportunity? 
Figure 31 shows the barriers and enablers for what needs to change for greater 
opportunity. 
 
216 
 
 
Opportunity
Physical opportunity Social opportunity
a good role model  i s  a  faci l i tator
pharmacis t influence
Environmental context & resources Social influences
many steps  to prescribing
not discussed amongst col leagues
takes  time
lack of time
competing priori ties
aging population
reporting of eGFR when need CrCl
En
ab
le
rs
B
ar
ri
e
rs
i f don't have a  kidney function estimate then 
cannot apply the recommendations
behaviour i s  rushed; squeezed at the end of 
a  consultation
no computer decis ion support on a  home 
vis i t
Resources  as  faci l i tators : 
BNF
PSS materia ls
pharmacis t advice
on-l ine information
phone app
bel ief that i f other GPs  aren't doing i t in 
practice then that i s  how they wi l l  be judged 
and so would continue as  are doing
Physical opportunity  
Table 42 shows the table developed to chart the themes in the domain for physical 
opportunity: environmental context and resources.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: BNF: British National Formulary; CrCl: creatinine clearance; eGFR: estimated glomerular filtration rate; PSS: Prescribing 
Support Services (pharmacy team). 
Figure 31: Perceptions of barriers and enablers for what needs to change for 
more opportunity. 
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Abbreviations: CKD: chronic kidney disease; CrCl: creatinine clearance; eGFR: estimated glomerular filtration rate; M/F: male/ female; Y/N: yes/ no; PSS: Prescribing Support Services (pharmacy team). 
Abbreviations: BNF: British National Formulary; CKD: chronic kidney disease; CrCl: creatinine clearance; eGFR: estimated glomerular filtration rate; M/F: male/ female; Y/N: yes/ no; PSS: Prescribing Support Services 
(pharmacy team). 
Table 42: Physical opportunity: charting themes in 1TDF domain 
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The environmental context and resources domain had the greatest number of different 
themes identified, which were the most discussed, and by all participants. 
 Environmental context and resources 
Time constraints and prescribing being squeezed at the end of a consultation were 
frequently expressed as making it difficult to think about kidney function when 
prescribing. 
“To then go out and see exactly what their eGFR is and then the exact 
recommendations for that drug and all of that’s very time consuming.” (P5) 
“Prescriptions are done at the end and consultations often run over and the GP 
might be rushed and perhaps don’t do it as well as they should do.” (P1) 
Competing priorities and information overload were also mentioned by many 
participants. 
“I think we’re just awash with information really and it’s sometimes hard to 
know how to prioritise some time.” (P14) 
“The reality is that the world we live in in general practice is there are lots of 
boxes to tick – have you checked the blood pressure, have you done the BMI, 
code this, code that, do that.,” (P1) 
Reporting eGFR with the pathology lab reports means it is easily accessible and so is 
more likely to be used than CrCl. 
“eGFR being on the bottom of the bloods is fab, cos it means everyone that’s 
had a U&E has got their eGFR so you’d check that…That becomes a problem, 
doesn’t it, because everything is based on eGFR. All your QOF data is based 
on eGFR.” (P4) 
Resources are used, with the British National Formulary (BNF, 2015), on-line 
information, medicines management team documents, pharmacists and a phone-app 
being mentioned. The BNF was a key resource but the front section on ‘prescribing in 
renal impairment’ was not known about, and the advice on the different kidney function 
equations was unclear. 
“I was just looking at what the BNF said about the rivaroxaban...cos I wanted to 
know whether it talks about creatinine clearance, no it doesn’t , it talks about 
eGFR - following the BNF would give her too much rivaroxaban.” (P4) [note, 
the BNF has since been altered to state that CrCl should be used] 
Home visits were raised as an issue, and having the information available. 
“I suppose you have to be at a PC, cos it’s difficult to be done on a home visit.” 
(P11) 
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Abbreviations: M/F: male/ female; Y/N: yes/ no. 
Table 43: Social opportunity: charting themes in 1 TDF domain 
Social opportunity  
Table 43 shows the table developed to chart the themes in the domain for social 
opportunity: social influences. 
The social influences domain had the fewest different themes elucidated, and lowest 
degree of mentions by participants. 
 Social influences 
Kidney function and prescribing was not an area discussed amongst GPs, but it was 
suggested that perhaps there should be more discussion and sharing of knowledge. 
“We don’t really talk, I can’t say that ever I sit round and talk to the others about 
this. When you’re making prescribing decisions you usually make them on your 
own.” (P13) 
“When you share good practice with other people you pick up tips from them… 
I think there should be more sharing of knowledge… it’s very useful to share 
information this way.” (P14) 
Variability in the prescribing of colleagues was mentioned. 
“I am sometimes a little surprised at the prescribing of colleagues to elderly 
patients, for instance using high dose of things like non-steroidals, er, maybe 
starting ACE inhibitors at higher doses than I would.” (P8) 
“I think it’s an area of huge variability between practitioners – I have noticed.” 
(P15) 
Pharmacists were highlighted as having an influence on prescribing. 
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Motivation
seen as important and relevant
prescribing is a responsibility of GPs
GPs should be good at prescribing motivation is to not do harm
a GP role is to prescribe safely bad experience/ crisis make cautious
prescribing is a responsibility
incentives to apply
confidence expressed in diabetes triggers
Professional role & identity Belief in capabilities Motivation & goals Belief in consequences Reinforcement Emotion
mistakes will happen because it is 
complex
fear of overload
knowledge makes the job harder bombardment with screen messages
warnings are not specific
less capability at medication review
En
ab
le
rs
B
ar
ri
e
rs
conflicting goals (e.g. nitrofurantoin vs 
push to use)
motivation is to prescribe as best as 
possible
omission bias - harm from an act of 
commission feels worse that that of 
omission
belief that inappropriate prescribing in 
reduced kidney function can cause 
harm for patients
Automatic motivationReflective motivation
not feeling reponsibility for the 
continued prescribing of a drug at 
medication review (because somone 
else started it)
reponsibility for longer term 
monitoring rests with other healthcare 
professionals
responsibility at medication review as 
kidney function might have changed 
since the last review
a complex behaviour so cannot rely on 
human function or there are bound to 
be mistakes
lack of motivation if the patient is 'OK' 
(BP, QOF etc all normal - no trigger to 
check)
not motivated to change behaviour if 
not convinced of importance
stress/ concern/ worry about not 
prescribing correctly and causing a 
patient harm
warnings are not flagged at medication 
review
relating to kidney disease when not 
about CKD but about drug use and 
dosing
warnings when needed in the 
prescribing process (currently at 
initiation)
computer decision support to prompt 
and reinforce behaviour
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: BP: blood pressure; QOF: Quality Outcomes Framework. 
Figure 32: Perceptions of barriers and enablers for what needs to change for stronger motivation. 
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Abbreviations: BNF: British National Formulary; KF: kidney function; M/F: male/ female; RKF: reduced kidney function; Y/N: yes/ no. 
Table 44: Automatic motivation: charting themes in 2 TDF domains 
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4.5.4.4 What needs to change for stronger motivation? 
Figure 32 shows the barriers and enablers found on what needs to change for stronger 
motivation. 
Automatic motivation  
Table 44 shows the two tables developed to chart the themes in the domains for 
automatic motivation:  
Nature of the behaviour (presented here, but when the themes were remapped 
to the updated 14 domain TDF model, some of the themes were 
‘reinforcement’, and others were moved to ‘behavioural regulation’) 
Emotion 
Both these domains had lower numbers of themes found, and were mentioned less 
than other domains. 
 Reinforcement 
Computer warnings and prompts about reduced kidney function are useful and used. 
“It does come up when you prescribe doesn’t it so it does say be careful in 
renal impairment and you know the little alert comes up.” (P13) 
“It does what it’s supposed to do [computer warning] and it makes you stop and 
check.” (P12) 
However, warnings and prompts do not come up at medication review. 
“Once they are on the repeats it doesn’t then, doesn’t then flag it up again.” 
(P4) 
The warnings and prompts are not patient specific. 
“Not specific, doesn’t tell what to do, pop up boxes and templates often not 
useful or helpful, too frequent.” (P3) 
 “I don’t use that [screen that pops up] as, as it’s a warning, but it doesn’t tell 
me what to do.” (P14) 
Some expressed that they only notice warnings with ‘3 stars’ i.e. a major warning. 
“Often there is so much information in there, but unless it’s got three stars next 
to it you don’t actually pay that much attention to it for every prescription, which 
is bad, but you don’t!” (P13) 
 Emotion 
The emotions expressed were particularly about the stress and worry around 
prescribing and causing harm when getting it wrong.  
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“We are still diagnosing and prescribing as our primary function, you know if we 
are not getting that function right that bothers me really.” (P9) 
“It becomes stressful when you’re informed about something and so my 
prescribing could be doing patients harm, but I don’t have enough knowledge 
to change my prescribing.” (P2) 
Errors which occur as a result of an action by the prescriber were seen as particularly 
difficult to deal with emotionally. 
“Errors of commission are almost impossible to cope with because you have 
done something to that patient that’s harmed them. That’s the problem with 
renal function.” (P8) 
One participant was shocked that they hadn’t known about drugs they used regularly 
being affected by kidney function. 
“I was really shocked that I didn’t know about gabapentin, as I think I am fairly 
on the ball.” (P6) 
Fear was expressed about renal medicine. 
“I think the students are still terrified about renal medicine. I think it’s quite a 
difficult area of medicine.” (P11) 
“It’s just a minefield I think.” (P12) 
Reflective motivation  
Table 45 shows the four tables developed to chart the themes in the domains for 
reflective motivation:  
Professional role and identity  
Motivation (intentions) and goals 
Beliefs in capabilities and optimism  
Beliefs about consequences 
 
The 'beliefs about consequences’ domain had themes from all interviewees, and 
‘beliefs in capabilities and optimism’ from all but one. 'Beliefs about consequences’ 
and 'motivation (intentions) and goals’ both had high numbers of themes discussed 
across the participants. 
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Abbreviations: HCP: healthcare professional; M/F: male/ female; RKF: reduced kidney function; Y/N: yes/ no. 
Table 45: Reflective motivation: charting themes in 4 TDF domains 
Social/ professional role and identity 
Prescribing in general was expressed as a responsibility and that it is a GP role to be 
‘good’ at it.  
 “I still find it a responsibility when you’re prescribing something.” (P7) 
“I do think it’s important for GPs to be top of the ladder in prescribing because 
it’s mainly our primary function.” (P9) 
It is a GP role to think about toxicity and safety and that they should look it up if 
needed. 
“Toxicity is important, it is probably one of the biggest things a GP will think of I 
would think.” (P6). 
 “I don’t think that is unreasonable to do and to check and to expect a clinician 
to look that up.” (P1) 
However, less responsibility was felt when doing a medication review and that longer-
term monitoring might be something that was done by another healthcare professional. 
“When you are continuing something that somebody else has started, this is 
wrong probably, but you feel less a responsible decision to continue 
something. That’s wrong I admit.” (P7) 
“If we are talking about longer term monitoring, I suppose that falls into the 
area of what people like yourself and [Y] do isn’t it.” (P1) 
Motivation (intentions) and goals 
To apply the recommendations for prescribing in RKF was seen as important and 
relevant. 
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“It feels important, it feels important, and it feels like something that the more I 
get reminded of it the more important.” (P9) 
“Oh, it’s very relevant.” (P4) 
Not doing harm to patients is a prime motivation.   
“We want people to tolerate medications that we are giving them, we want to 
reduce side effects, we want to improve compliance, we don’t want to basically 
cause anyone any harm, so yes it’s very important.” (P7) 
“I suppose everybody follows the rule first do no harm.” (P8) 
Previous bad experiences add caution in prescribing. 
“When you’ve had a few bad experiences over the years you’re extra cautious 
aren’t you?” (P8) 
However, it was also brought up that if a patient appears stable then they are less 
likely to check parameters such as kidney function. 
“I am checking they’re still ok, blood pressure still ok, QOF data is alright, must 
be fine and they feel they are ok so it must be fine let’s move them on.” (P4) 
Understanding leads to remembering and ability to apply. 
“I need to understand why because of that I need to understand why I can’t 
prescribe it. I need to know that, partly to help me remember and also that knowing 
it would affect how I prescribe it.” (P15) 
Reduced kidney function as an area is neglected, ignored or something that is given 
little attention or care. 
“It’s a 'Cinderella' area isn’t it I suppose.” (P12) 
 Beliefs in capabilities and optimism 
The majority of comments made were that the GPs were not confident in their 
capabilities; the one exception was for those with an expertise in diabetes. 
“We tend to do them [medication reviews] very badly and sort of rush through 
them, so I have to say I don’t really do it properly. I should do!” (P14) 
 “I am not prescribing as safely as I could be in regards to these areas.” (P9) 
There was a lack of confidence in prescribing without computer support. 
“It is so complex as is medicine, increasingly complex to that to rely on human, 
to rely on human functions to pick up everything, there is bound to be 
mistakes.” (P1) 
It was felt there was more capability at drug initiation than at medication review. 
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“I’m probably quite good about thinking about kidney function when I’m starting 
new medications, but probably not very good when I’m reviewing them.” (P7) 
 Beliefs about consequences 
There was an understanding that drug use in RKF can cause harm to patients from 
toxicity to the kidneys, increased risk of adverse drug reactions, hospitalisation, and 
drugs being ineffective. 
“The reasons why these drugs have indications that their dose should be 
adjusted, or avoided, at a certain renal function is because it’s harmful and of 
course what we are doing is not doing harm isn’t it.” (P1) 
“I did have a patient that did have a low eGFR and prescribed her nitrofurantoin 
and then she ended up in hospital as a result of it really. So that was a learning 
point for me.” (P5) 
Consequences on the prescribing process were expressed that increased knowledge 
makes the reviews harder as there is more to assess. Also that there needs to be 
good communication in the prescribing decision to make actions clear in the record. 
“Knowledge! Cos if you don’t know something then you’re not going to pick it 
up are you. So medication reviews would be really easy if you didn’t know 
anything.” (P13) 
“If I’m seeing a patient again or someone else is seeing them to be able to look 
back and work out why they have been given this random drug dose, because 
if another doctor calculates the creatinine clearance, you know, otherwise 
where is the transparency?” (P2) 
4.5.4.5 Differences with participant type 
Themes were generally spread over all respondent types and there were very few 
patterns found when analysing the data by participant type. 
An exception was that the four participants with over 18 years’ prescribing experience 
did not express a lack of knowledge, or any themes to do with social and professional 
role. However, it was this group that said medication reviews are done badly, and that 
they were shocked at what they don’t know. 
The participants with less than 8 years’ experience added no themes in the ‘memory, 
attention and decision-making’ domain. 
Only GP trainers mentioned that is an important GP role to think about toxicity and 
safety. 
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For those that knew me and had experienced a workshop and audits on prescribing in 
reduced kidney function said that it is easier to remember if they do it more often and 
were more likely to have skills and knowledge, but some still said it was difficult to do.  
4.5.4.6 The key themes identified on what needs to change 
The ‘key themes’ resulted from a synthesis of the range of themes elucidated, noting 
where themes were frequently mentioned, but also where there might be high 
importance for an intervention, even if only mentioned by one interviewee. 
As previously highlighted, themes were found across all the TDF domains, with at 
least 9 of the interviewees discussing issues in every domain. Themes on ‘knowledge’, 
‘environment and resources’, and ‘beliefs about consequences’ were mentioned by all 
14 interviewees recorded implying that these are important to all the wide range of 
GPs included. The domains with the greatest number of themes from the interviewees 
were environment and resources, knowledge, memory, attention and decision 
process, beliefs about consequences, and motivation and goals. One participant 
raised that they felt less responsibility when doing a medication review for a drug 
started by someone else, and another suggested that longer-term monitoring might be 
something that was done by another healthcare professional. These themes were 
mentioned only once but were considered important when developing the key themes.  
The resulting six key themes are listed below with exemplar quotes: 
Key theme 1: in primary care there is a lack of awareness, knowledge, and 
understanding about prescribing in the reduced kidney function of older people. 
  “I suspect for some clinicians, and I include myself in that, there may be a 
knowledge gap.” (P1) 
   “I wasn’t aware. This is terrible because I use a lot of gabapentin and 
pregabalin, obviously, in neurology.” (P6) 
Key theme 2: kidney function testing is required and needs assessment when 
prescribing. 
  “We often check the bloods…but I don’t often drill, ever is probably the right 
word, drill down to the eGFR to see whether any of the medications that they’re 
on tally with the GFR.” (P9) 
“We are very good at knowing when to re-check the U&Es, but are we actually 
correlating that with what people are on?” (P7) 
 
229 
 
 
Key theme 3: the application of kidney function level to prescribing decisions is 
needed at both drug initiation and at medication review. 
  “Renal function isn’t one of the things that we benchmark against when we 
review medications.” (P12) 
“When you are continuing something that somebody else has started, this is 
wrong probably, but you feel less a responsible decision to continue 
something.  That’s wrong I admit.” (P7) 
Key theme 4: there is difficulty in remembering to apply the recommendations 
for use, and dosing, of drugs in reduced kidney function. 
  “It’s remembering which medications you need to be careful with, those are the 
pitfalls.” (P12) 
  “I think it’s so QOF orientated now, you know we are focused on perhaps the 
wrong stuff in medication reviews.” (P7) 
Key theme 5: there is a need to embed kidney function assessment within the 
prescribing process. 
“It [prescribing] is so complex, as is medicine, increasingly complex, so that to 
rely on human functions to pick up everything, there are bound to be mistakes.” 
(P1) 
“I need a button to just…check on to highlight all drugs that are a problem.” 
(P15) 
Key theme 6: there is limited use and confusion with the resources available to 
support the use, and dosing, of drugs in reduced kidney function. 
“I was just looking at what the BNF said about the rivaroxaban...cos I wanted to 
know whether it talks about creatinine clearance, no it doesn’t , it talks about 
eGFR - following the BNF would give her too much rivaroxaban.” (P4) [Note: 
the BNF has now altered the recommendations for NOACs to be CrCl, but not 
for any other drugs] 
“I should read that [looking at the BNF section on prescribing in renal 
impairment].” (P2) 
 
4.6 Discussion  
 Principal findings 
GPs need awareness, education and support to apply the prescribing 
recommendations in reduced kidney function (RKF). There is a need to raise 
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awareness and provide education on prescribing in RKF for all prescribers and 
specialities, and assessing kidney function needs to be made easier in the prescribing 
process. Patient and drug specific warnings and prompts are needed at medication 
review as well as initiation. 
Summary of what needs to change for greater capability 
There was a lack of awareness and knowledge for all levels of experience so 
increasing awareness and education is needed for all prescribers, and in clinical 
specialities, on prescribing renally excreted drugs.  
Although GPs checked kidney function it was not always thought of when prescribing, 
and particularly not at medication review. A kidney function test should be done before 
medication review so that it can be assessed whether drug choice and dosing is still 
appropriate. 
Most GPs did not know of the creatinine clearance calculation or how to do it. The skill 
is easy when it is known what to do, but the process is difficult as it is complex, multi-
step, and not part of the prescribing process.  
Summary of what needs to change for more opportunity 
Competing priorities, workload and time constraints make it difficult to assess kidney 
function when prescribing so it needs to be made easier in the care pathway and given 
greater priority to reduce risk of harm.  
Kidney function estimation using creatinine clearance estimated using the Cockcroft & 
Gault equation needs to be made easier in the prescribing process.  
Resources are used, mainly the BNF, but others were mentioned that could be helpful 
if known about more widely, such as on-line information and phone apps. However, 
the BNF information needs clarifying as the front section on ‘prescribing in renal 
impairment’ was not known about and the advice on eGFR versus CrCl is confusing. 
Guidelines could be improved to include advice on use of the relevant drugs when 
kidney function is low. 
Summary of what needs to change to strengthen motivation 
GPs see prescribing safely as an important role and there was an understanding that 
harm can be caused by drugs when kidney function is low, but they were not confident 
in their abilities to apply the recommendations for prescribing in RKF. 
Not having warnings and prompts at medication review was a particular barrier, and 
there was less of a sense of responsibility expressed for prescribing at this point in the 
care pathway. Patient and drug specific warnings and prompts at both drug initiation 
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and at medication review would be useful as a reminder when kidney function needs 
to be taken into consideration. 
4.6.1.1 Prescribing behaviour in primary care 
Bradley, in 1992, qualitatively sought to understand how prescribing decisions are 
made in primary care and exposed the complexity of decision-making that precedes 
prescribing. He highlighted discomfort with prescribing and the struggle to balance 
several disparate considerations; also that ignorance was a factor but that it is often 
other things that have more impact such as negotiating change in treatment. This 
echoes findings in the current study and if prescribers have been unaware of kidney 
function when prescribing, it will add another level of complexity.  
Since the 1990s most focus has still been in hospitals with less attention to major 
sources of harm in primary care, such as prescribing (Guthrie et al, 2011). The only 
paper found purporting to ‘assess GP prescribing behaviour for elderly patients with 
renal failure’ was a short report from France (Jonville-Béra et al, 2008); they used a 
questionnaire study to find that GPs do not sufficiently consider renal function of 
elderly patients and showed a lack of knowledge, but they did not explore why.  
The finding that there was less responsibility felt for prescribing at medication review 
was similar to a recent study by Slight et al (2013) where there was acknowledgement 
by some GPs that they became ‘slightly blasé’ about the treatment of patients they had 
known for a long time. They suggested that there may be benefits to using practice 
pharmacists to review repeat medications (Avery et al, 2012).  
Understanding the factors related to prescribers in stopping or altering a medication 
they have been on for some time had been explored in a recent systematic review 
(Anderson et al, 2014). Again, many factors were found to be involved which were 
highly interdependent and impacted by considerable clinical complexity. In 
polypharmacy, prescribers could not easily identify which medications were 
inappropriate; they state that the finding of prescribers being unaware is not surprising 
as they do not intentionally prescribe inappropriately. This was mentioned in the GP 
interview study. The prescribers rationalised continuation with the belief that the drugs 
work and have few adverse effects; they identified different thresholds for initiation 
versus continuation of a drug which suggested lack of prescriber insight. 
The Anderson et al study (2014) also discussed ‘inertia’ as in failure to ‘deprescribe’ 
when appropriate. Inertia has been linked to ‘omission bias’ where harm from an act of 
commission is felt to be worse than that from an act of omission (Ritov and Baron, 
1992; Spranca et al, 1991). This was raised as an issue by one of the participants in 
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the GP interview study that the perceived potential harm caused if a drug was stopped 
or a dose reduced because of a low kidney function would be deemed more the fault 
of the prescriber than would harm from not changing the drug or dose. 
4.6.1.2 Reducing prescribing errors 
Studies in hospital (Dornan et al, 2009; Dean et al, 2002; Tully et al, 2009; Lawton et 
al, 2012) have reported similar prescribing ‘error-producing conditions’ such as lack of 
training or experience and systems related factors.  
The recent qualitative study into the causes of prescribing errors in English general 
practices (Slight et al, 2013) has highlighted the complex underlying causes within 
seven categories of high level error-producing conditions: the prescriber, the patient, 
the team, the working environment, the task, the computer system, and the primary-
secondary care interface. Some of the error-producing conditions they found were 
similar to those found for prescribing for older people with RKF and the results of this 
GP interview study, such as the prescriber’s therapeutic training, drug knowledge and 
experience, their perception of risk, and the working environment, extensive workload, 
time pressures, and interruptions. The authors too highlighted the computer-related 
issues of unnecessary or inappropriate alerts. The current GP interview study has 
added to these findings by highlighting the problem of having no warnings or prompts 
at medication review, and the need for them to be patient and drug specific, which 
would improve medicines safety for other parameters, not just kidney function.  
4.6.1.3 The effect of eGFR reporting on prescribing  
Quartarolo et al (2007) found that although reporting of eGFR was associated with 
improved physician recognition of chronic kidney disease in elderly hospitalised 
patients in California, it did not lead to a change in physician prescribing. Van 
Pottelbergh et al (2014) also reported that automatic reporting of eGFR did not alter 
inappropriate prescribing for older people with RKF in Belgium. GPs in this study 
checked kidney function and had an eGFR available but did not apply it to their 
prescribing. Ingrasciotta et al (2014) retrospectively looked at use of nephrotoxic drugs 
before and after diagnosis of CKD and found no change in prescribing. 
 
 The key domains and themes 
The sample for this qualitative study was recruited to give a wide range of GP 
expertise and experience, rather than to be representative of all GPs. The aim for the 
identification of the key themes was therefore not a quantitative analysis of the themes 
most raised by the interviewees, but an identification of the range of potentially 
influential determinants.  
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The analysis of themes, and the identification of domains where many themes have 
been elucidated, adds an insight into what has been discussed by many of the 
interviewees, and what might be important across the experience and expertise 
represented. However, a theme that might be only mentioned by one participant can 
be an important insight. For example, where one participant revealed that they felt less 
responsibility for the prescribing at a medication review where the drug had been 
started by somebody else. When this finding has been presented where GPs are in 
attendance, including the consensus panel meeting (Chapter 5), this has been 
recognised in the behaviour of other GPs. Identification of this is likely to be important 
if an intervention is to be effective. 
As previously highlighted, themes were found across all the TDF domains, with at 
least 9 of the interviewees discussing issues in every domain, which suggests that 
development of an intervention will need to address a range of determinants. Themes 
on ‘knowledge’, ‘environment and resources’, and ‘beliefs about consequences’ were 
mentioned by all 14 interviewees recorded implying that these are important to all the 
wide range of GPs included. The domains with the greatest number of themes from 
the interviewees were: 
 Environment and resources 
 Knowledge 
 Memory, attention and decision process 
 Beliefs about consequences 
 Motivation and goals 
These domains are linked to all three COM-B categories suggesting a need for greater 
capability, more opportunity, and strengthened motivation. Identifying these domains is 
useful to direct an intervention to where the most barriers or enablers are, and be 
reflected in the key themes identified.   
The synthesis of themes across the COM-B components has resulted in six key 
themes that give the range of important requirements for change to help prescribers 
apply recommendations in RKF. It also enabled the future research analysis to 
determine the prioritisation for intervention (Chapter 5). 
 
 Behaviour change wheel (BCW) 
The BCW has been developed as a method for characterising and designing 
behaviour change interventions, synthesising frameworks of behaviour change found 
in the research literature (Michie et al, 2011). 
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Figure 33: The Behaviour Change Wheel with intervention functions and policy 
categories (Michie et al, 2011). 
 
Figure 33 shows the wheel with the COM-B model at the core. The BCW also 
identifies different intervention options that can be applied to changing each of the 
components, and policies that can be adopted to deliver those intervention functions 
(Michie et al, 2014). Intervention options in the BCW are described in general terms, 
such as education, enablement, and environmental restructuring. The policy 
categories include guidelines and environmental/ social planning.   
In this study the TDF has been used to give a more detailed understanding of the 
behaviour within the COM-B components (Michie et al, 2014, pp 91-93). Linking to 
COM-B categories will then allow use of the Behaviour Change Wheel for intervention 
development, identification of relevant behaviour change techniques, intervention 
functions and policy categories (Michie et al, 2014). 
This study has identified key themes that could inform an intervention to encompass 
greater capability, more opportunity, and strengthen motivation for GP prescribers. 
However, there is not yet inclusion of the views, opinions and experience of experts, 
stakeholders and policymakers that could confirm the study findings, and indicate the 
feasibility and acceptability of the different intervention functions and policy categories. 
This was addressed in the next study in this programme of research (Chapter 5). 
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 Engagement in the research 
Nearly 30% of GPs invited agreed to take part in the qualitative interviews which 
implied that those who participated were interested and that prescribing safety is a 
concern to them. However, it did mean that 70% of possible participants did not 
respond meaning the findings were only from a minority of self-selected GPs. Using 
the local practice pharmacist team worked well to gain access and deliver recruitment 
packs. Providing a ‘certificate of attendance’ (Appendix 10, 8.9) was well received as 
GPs need evidence of taking part in research for their continuing professional 
development (CPD).  
Guest et al (2006) concluded that about 12 is a sufficient sample for interview studies 
analysed for emergent themes. In this study no new themes were elicited after 12 
participants so fits with the Guest findings; however, it would not have been clear 
whether, or where, saturation had been reached, and in this study further recruitment 
was required for the inclusion criteria. 
 
 Strengths and limitations 
The use of the Theoretical Domains Framework allowed an exploration of the 
behaviour to give a comprehensive picture of what needs to change. As a non-
psychologist with no prior knowledge of behaviour theories, it was extremely helpful to 
have a framework to systematically explore behaviour in healthcare. An example of 
the benefit of using a systematic process to understand the issues underlying the 
behaviour was the important finding that warnings and prompts are not flagged at 
medication review which had not been recognised as a factor prior to the study. If, for 
example, the Theory of Planned Behaviour had been used (Ajzen, 1991), the 
important factors of the habit of always prescribing a dose, the emotion expressed 
about prescribing, and the many working environment issues might not have been 
brought out. 
Working in primary care helped with gaining access for the study and being able to 
have participant recruitment packs delivered to GP practice pigeon holes may have 
helped with recruitment. Prior knowledge of the GP CPD requirements led to the 
inclusion of a certificate of attendance (Appendix 10, 8.9) being offered which was well 
received and taken up by all participants. 
The effect of myself on the research may reduce the replicability of this study which 
started from a problem recognised in practice, and so there was professional as well 
as a researcher involvement in the process, setting, context, and culture (Altheide and 
Johnson, 1994). Only one researcher conducted the GP interviews and so a 
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researcher effect is likely to have been consistent across all the interviews. Chew-
Graham et al (2002) found that if the researcher was a recognised healthcare 
professional there were richer and more intuitive responses, and the interviewees 
were more likely to confide. Certainly rich data was collected. The disclosure of 
participants that they felt less of a responsibility for the prescribing decision at 
medication review was an example of the GPs feeling able to confide in something 
they expressed as being wrong. This also raised the issue of disclosure of negligent 
practice. Discussion with supervisors led to agreement that this was not an individual 
disclosure but a theme that would need addressing in an intervention.  
It was made clear to participants that the research was being done by a pharmacist 
working in Bradford primary care. Hoddinott and Pill (1997; 1999) found that her 
interviewing skills were better if she declared that she was a GP and so concluded that 
she would always make her professional background clear to respondents. Richards 
and Emslie (2000) stated that the 'clinical' interviewer should also take care to explain 
their current role as a researcher. 
Chew-Graham et al (2002) also state that there is a risk of shared conceptual 
blindness and there may have been an assumed shared language and understanding. 
Doing reflective notes immediately after each interview, and analysis of the dialogue 
on the transcripts, were used to reflect on myself as the researcher. Analysis of the 
themes by respondents who knew me previously and those who did not, only showed 
a difference in skills and knowledge suggesting that the degree to which I was known 
made little difference to the responses not linked to learning. 
The GPs recruited had a wide range of experience and interests and all spoke openly 
and candidly about their experiences. Data saturation analysis suggested a broad 
range of the factors influencing prescribing in RKF were recognised. 
However, this was a small sample of GPs from the Bradford area thereby limiting 
external validity. The GPs agreeing to take part were likely to be those more interested 
in prescribing and more open to scrutiny and so may not be a representative cross-
section. Only GPs were included in the sample as the majority of prescribers in 
primary care; however, there are also non-medical nurse and pharmacist prescribers 
and they would need to be included in any further research. These data represent the 
accounts of GPs and might not necessarily accord with their behaviour (Robson, 
2011). 
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 What this study adds to the literature 
This study has explored GP behaviour when prescribing for older people with RKF. 
The scoping literature review (Chapter 2) did not find any other research to answer the 
question of why prescribing recommendations are not applied and so this study has 
added to the evidence base. The findings have contributed to evidence on prescribing 
behaviour in primary care, reducing prescribing errors, the lack of effect of eGFR 
reporting on prescribing, and use of the TDF. 
The scoping review also found a lack of theoretical underpinning in the studies aiming 
to improve prescribing in RKF (Chapter 2, 2.6). This study has sought to explore the 
determinants that will inform future intervention research. 
4.6.6.1 Use of the theoretical domains framework (TDF) 
This study adds to the evidence base for the use of the TDF to identify factors 
influencing the gap between evidence based practice and the routine delivery of health 
care. Data was found for all domains, including important factors of habit, emotion and 
the working environment that might not have been elucidated if, for example, the 
Theory of Planned Behaviour (Ajzen, 1991) had been used. The TDF provided a 
useful, and successful, framework for both the topic guide in the interviews, and the 
content analysis, to ensure a wide exploration of the barriers and enablers.   
Francis et al, in 2012, documented the impact of the TDF on implementation research. 
They reported that 23 empirical studies had been published, with 17 investigating the 
behaviour of health professionals. Ten of the 21 studies described exploratory 
interview studies designed to identify barriers and enablers. The authors state that the 
studies provide evidence that the TDF has considerable breadth and cross-disciplinary 
impact in research about health related behaviour, and that it appears to have 
succeeded in making psychological theory useful to researchers from a variety of 
backgrounds internationally. The current study will add to the growing body of 
evidence, having used the TDF to explore GP behaviour when prescribing for older 
people with RKF.  
4.6.6.2 Future research. 
The study findings will help to inform the content and design of an intervention to 
improve prescribing in reduced kidney function in primary care. The next stage of this 
programme of research (Chapter 5) was planned to confirm and combine the findings 
with experts, stakeholders and policymakers in related fields, get an indication of 
feasibility and acceptability, and prioritise the key themes for an intervention and future 
research. 
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Rich data has been collected from the GP interviewees. Analysis was completed for 
the current project, but the data could be reanalysed in greater depth to gain more 
understanding of prescriber behaviour generally in primary care. 
 
 What this study adds to practice and policy 
Complex underlying factors for inappropriate prescribing for older people with reduced 
kidney function in primary care were found in this study. Highlighting the issues to both 
clinicians and policymakers is the first stage in minimising inappropriate prescribing in 
routine clinical practice. It was planned that the final stage of this programme of 
research would involve experts, stakeholders and policymakers in related fields 
(Chapter 5).  Further research is needed to ensure an intervention will be more likely 
to be successful in changing practice.  
The BNF was a key resource but the chapter on ‘prescribing in renal impairment’ was 
not known about and the advice on kidney function equation choice is confusing and 
so working with the Formulary Committee could help prescribers apply the 
recommendations. 
 ‘Goal conflict’ was expressed where the prescribing recommendations might be seen 
to go against clinical guidelines. This suggests that the guidelines should make explicit 
the need to apply parameters such as kidney function to the decision making, for 
example antibiotic guidelines encourage use of nitrofurantoin for urinary tract infection, 
but if kidney function is too low it may be ineffective and adverse effects are more 
likely, and an alternative should be used. It has been recommended in a recent paper 
from the Guthrie team that guideline developers should particularly consider whether 
chronic kidney disease is common in the target population (Dumbrek et al, 2015).  
 
 Progression and integration of methods and findings 
The lack of awareness and knowledge about prescribing in RKF expressed by the GP 
participants would account for the findings in the case-note review (Chapter 1) where 
25% of older people with RKF were on a drug that should be avoided or the dose was 
too high for their level of kidney function. Also for the results found in the PCT-wide 
cross-sectional survey (Chapter 3) where 3.5%-39.6% of people aged over 65 years, 
and 24.2%-79.5% of those aged 85 years and older, had a kidney function too low for 
the drug or dose they were taking. 
Many of the GPs did not recognise the drugs investigated as being affected by kidney 
function except for metformin and nitrofurantoin. However, in the PCT-wide survey, 
nitrofurantoin had the highest figures for being used when kidney function was too low. 
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This may be that being aware has not changed behaviour, or that clinicians have only 
recently been made aware and the figures might now be improved. Most of the drugs 
studied were repeat medications where there should be regular review, but the 
findings in the quantitative studies showed that kidney function was not accounted for 
and that it was worse in the older age groups, implying that review did not happen.  
Kidney function is regularly tested, which was shown in the PCT-wide survey with 
82.5-97.2% (depending on the drug) having a recent check, but the GP interviews 
found that although they tested kidney function, they did not then apply that to 
prescribing and review. 
 
4.7 Conclusion 
To reduce the risk of harm for older people on drugs excreted by the kidney, GPs need 
awareness, education, and support to apply the prescribing recommendations in 
reduced kidney function. 
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‘Old age is not the source of our problems; it is where we will find the answers’ 
Dr William Thomas, 2004 
 
 
5 Chapter 5: A consensus group method to identify key 
themes for development of an intervention strategy and 
future research into prescribing for older people with 
reduced kidney function. 
 
5.1 Background 
Older patients are at greater risk of harm when recommendations for prescribing in 
reduced kidney function (RKF) are not applied (scoping literature review, Chapter 2). A 
cross-sectional case-note review (Chapter 1) and PCT-wide prescribing data survey 
(Chapter 3) in UK primary care found that a quarter of people aged 65 years and older 
with RKF were on a drug or dose that would not be recommended at their level of 
kidney function, and the likelihood of having a kidney function too low increases with 
age. Key areas for change have been highlighted in a GP interview qualitative 
investigation (Chapter 4).  
A formal facilitated group consensus process would allow experts and stakeholders to 
rate and prioritise the barriers and enablers to applying recommendations on 
prescribing in RKF, generated from the qualitative GP interview study.  
This study aimed to explore the generalisability of findings, generate a strategy for an 
intervention, and prioritise a strategy for evaluation research. 
 
5.2 Research question and objectives 
Research question 
Do experts in fields relating to prescribing in reduced kidney function find the evidence 
from the four programme studies (case-note review, scoping literature review, 
prescribing data survey, GP interview study) generalisable, what should the strategy 
be for an intervention, and what are the priorities for future research? 
Objectives 
 To systematically combine the evidence from the four project studies with 
expert opinion. 
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 To explore the opinions of experts in the field on agreement, importance and 
feasibility for the key themes on what needs to change to improve prescribing 
for older people with RKF.  
 To gain consensus on priorities for intervention and future research. 
 
5.3 Methodology 
 Consensus method 
The ‘RAND Appropriateness Method’ was used to systematically combine the 
research evidence, synthesise and clarify expert opinion, generate a consensus, and 
capture the multidisciplinary perspective (Fitch et al, 2001; Shekelle, 2009; Campbell 
et al, 2001; Jones and Hunter, 1995; Murphy et al, 1998). The core components of the 
RAND process have been summarised by Brook et al (1986), Shekelle et al (1996; 
1998) and Fitch et al (2001). The key stages of the method are: 
 Selection of condition(s) to be assessed.  
 Systematic review of the evidence base. 
 Generation of indicators/criteria to be rated. 
 Selection of expert panellists. 
 First round individual rating. 
 Panel meeting. 
 Second round individual rating. 
 Final analyses and development of recommended indicators/criteria. 
This ‘nominal group’ method was chosen as it has been shown to be more effective 
than an ‘interacting group’ (Robson, 2011) which involves an initial group discussion 
on the topic or issue followed by a group assessment. In the nominal group method, 
respondents make their initial estimates individually, which means there is no effect 
from other participants such as social pressure and negative group influences, for 
example dominating members. There is then a panel discussion which results in a 
group view agreed, followed by a final individual rating.  
The ‘Nominal Group Technique’ (NGT) (Delbecq et al, 1975) is another method cited 
but is used primarily to generate ideas which can subsequently be rated using, for 
example, the RAND or Delphi methods.  
The ‘Delphi’ method has been used in prescribing research, for example Cantrill et al 
(1998) and Campbell et al (2000). It is a technique where individuals make 
independent estimates or give views about the issue in question. These are 
aggregated by a central group who provide feedback on the group results to the 
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individuals. The individuals subsequently confirm or revise their estimates until either a 
group consensus is reached or an acceptable range of views is achieved. The 
advantage of the Delphi method is that it does not require individuals to be brought 
together so the time and cost of participants travelling to meetings is saved, and 
anonymity of participants preserved. However, the process is time consuming to 
coordinate and manage and it can be difficult to maintain active participation by 
participants the whole way through, and so drop outs are more likely than at one off 
meetings. Also, the decision-making process is less transparent than face to face 
meetings, and can be more easily influenced by the coordinator (Linstone and Murray, 
2003).   
In a review on consensus methods in prescribing research, the main benefit found for 
the RAND method is that it combines expert opinion with evidence in a more 
quantifiable way than the other approaches, having aspects of both Delphi and NGT 
(Campbell et al, 2001). For the current study there were key themes that needed to be 
prioritised so a method that would include statement ratings was required. Also, 
evidence to be presented for consideration from the project studies was, as yet, 
unpublished and so the opportunity to present data to the panel group was useful.  
 
 Theoretical Domains Framework (TDF) and COM-B model 
The GP interview study used the TDF to highlight key themes for change in capability, 
opportunity, and motivation (the ‘COM-B’ model). Each domain of the TDF relates to a 
COM-B component (see Table 5, Chapter 1), providing a framework for a more 
detailed understanding of the behaviour within the COM-B components (Michie et al, 
2014, pp 91-93). In the GP interview analysis (Chapter 4), linking to COM-B 
components helped to strengthen the understanding of the TDF domains for the non-
psychologist researcher, and frame the findings to highlight what needed to change. 
The TDF has been used previously in expert panel studies in healthcare, for example 
Porcheret et al (2014) and Khan et al (2014). The TDF provided the framework for the 
method and analysis of this consensus panel study, and linking to COM-B components 
highlighted what needed to change to improve prescribing in reduced kidney function 
(RKF).  
 
 Panel composition  
The validity, credibility, reliability, and acceptability of the findings of a consensus 
method will depend, in part, upon the group composition. Campbell et al (2001) states 
that the panel must reflect the ‘constituency of stakeholders’ it is intended to represent. 
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There should be individuals with relevant knowledge, perspective or experience, or 
individuals who are highly regarded in the chosen field due to their academic expertise 
or experience. 
Murphy et al (1998) states that in general, having more group members will increase 
the reliability of group judgement. However, where the group members interact, large 
groups may cause coordination problems within the group. Although it is theoretically 
likely that group size will affect decision-making, the effects are subtle and difficult to 
detect. They state that below about six participants, reliability will decline quite rapidly, 
while above about 12, improvements in reliability will be subject to diminishing returns. 
 
5.4 Study design 
 Setting 
The first round statement rating was done individually on-line at a time convenient to 
the panellist. The group exercise and second round rating took place at the University 
of Leeds. 
 Participants 
To ensure credibility, the research team met to provide a robust process for 
identification of stakeholders and experts in relevant fields as possible participants. 
The aim was to include representatives with expertise in as wide a range as possible 
in the intervention functions and policy categories identified on the Behaviour Change 
Wheel (Michie et al, 2011), as discussed in Chapter 4 (4.6.3). Having expertise in 
these categories would make it more likely that the panel would have the knowledge 
and experience to consider a strategy for intervention covering the components of the 
behaviour. 
It was agreed to attempt to recruit participants from the following fields: 
 Renal specialist. 
 Elderly care specialist. 
 GP expert. 
 Pharmacist expert. 
 Patient record system (e.g. SystmOne, EMIS), decision support systems 
representative. 
 Resource, guideline, policy representative e.g. BNF. 
 Medicines safety expert. 
 Psychologist. 
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 Sample inclusion criteria and recruitment 
Participants were purposively recruited from the listed categories. They were identified 
as possible participants by the supervision team, from publically accessible websites, 
or by word of mouth from other experts in the field. Potential participants were 
contacted by email with a letter of invitation (Appendix 16, 8.15), consent form 
(Appendix 17, 8.16), and participant information sheet attached (Appendix 18, 8.17). 
Where no reply was received, one further email was sent. 
A certificate of attendance was provided for all panellists as a recognition of their 
participation in research (Appendix 19, 8.18). 
 
 Method 
The key themes derived from the GP interview study on what was needed to change 
were reviewed using a four stage process. 
Stage 1: development of statements for review. 
Stage 2: first round statement rating by the expert panel. 
Stage 3: expert panel group discussion on the statements. 
Stage 4: second round statement rating. 
After the stage 1 development of statements for review section, the study design, 
results, and summary are presented for each of the stages 2-4 in turn. 
 
 Ethics and governance 
University ethics and NHS/other organisation research governance assurance were 
granted. NHS ethics approval was not needed as participants were healthcare 
professionals. 
SHREC/RP/512 on 16/3/15 (Appendix 20, 8.19) 
Leeds West CCG on 27/5/15 (Appendix 21, 8.20) 
Bradford Districts CCG on 27/5/15 (Appendix 21, 8.20) 
Leeds Teaching Hospitals on 22/5/15 (Appendix 21, 8.20) 
Agreement from NICE (email, Appendix 21, 8.20) 
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Abbreviations: BNF: British National Formulary; CrCl: creatinine clearance; eGFR: estimated glomerular filtration rate. 
Table 46: The key themes and 22 statements for rating by the consensus panel. 
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5.5 Stage 1: Development of statements for review 
The GP interview study (Chapter 4) used a content analysis, and the emergent themes 
were mapped onto the domains of the Theoretical Domains Framework for further 
analysis. A process of reading and re-reading the themes and quotes in each domain, 
and analysis of the range, led to the development of six ‘key themes’ to identify the 
range of potentially influential determinants, and what needs to change to reduce 
inappropriate prescribing in RKF. 
For the current study, the themes derived from the GP interviews were further 
analysed within the six key themes to produce statements that could be rated by the 
expert panel. The final twenty-two statements used for the consensus panel process 
are listed in Table 46, such as: 
2.  There is a need to increase awareness of appropriate use, and dosing, of 
drugs in reduced kidney function. 
9.  Currently warnings and prompts on the patient record system are only flagged 
when initiating a drug; there need to be warnings and prompts on 
recommendations highlighted when doing a medication review. 
 
5.6 Stage 2: First round statement rating  
 Study design for stage 2 
5.6.1.1 Method 
An on-line rating process was conducted. The survey was built, data collected, 
collated, and analysed using the Bristol On-line Survey (BOS, 2015). Panellists 
individually rated each of the 22 statements for agreement, importance and feasibility 
on a 5 point Likert scale (where 1 was low and 5 was high) according to their 
experience, opinion and perception of current practice. The participants were also 
asked to choose the three statements that they considered to be their top priorities for 
implementing change. For each statement there was an opportunity to add a 
comment. 
Panellists were emailed the link to their personal on-line survey. Any panellists who 
had not completed the survey a week before the group discussion were sent a 
reminder email. 
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5.6.1.2 Data collection 
A ‘Bristol On-line Survey’ was built to allow individual rating in the participant’s own 
time. This was piloted with 2 supervisors before making available to the consented 
participants.  
5.6.1.3 Analysis 
The pre-defined criteria (5.4.3) were used to check that the panel convened was 
comprised of the required range of expertise. 
Quantitative analysis  
An ordinal scale was used (1 through to 5) to rank agreement, importance, and 
feasibility. A ‘5’ is always a more positive rank than a ‘4’, and a ‘4’ more positive than a 
‘3’, but the levels are not specified at each point and so there cannot be an assertion 
that the difference between a ‘5’ and a ‘4’ is necessarily the same as between a ‘4’ and 
a ‘3’. This suggests avoidance of measures such as means and standard deviations 
that treat the intervals as though they are equal. Instead, for each rating, the median 
was used to measure the central tendency, and a measure of agreement and 
disagreement to indicate the dispersion of the ratings. ‘Disagreement’ is defined as 
33% or more scores from the sample in both the top (4-5) and bottom (1-2) groups 
(Fitch et al, 2001). 
The results from the Bristol On-line Survey were transferred to Excel to facilitate a 
quantitative analysis to give a count, median rank and agreement/disagreement for all 
responses. Consensus was defined as the median score being: 
 1-2 without disagreement – agreement that the statement is ‘invalid’ 
 3 without disagreement – agreement that the statement is ‘equivocal’ 
 4-5 without disagreement – agreement that the statement is ‘valid’ 
Qualitative analysis 
Participants were able to add comments on the on-line survey and these were 
thematically analysed to find any new themes that needed to be added to what needs 
to change, using the TDF and linking to COM-B categories. 
 
 Results 
5.6.2.1 Demographic analysis  
Ten participants were recruited to complete the on-line statement rating out of 
eighteen invited. There was no reply from 3, and 5 expressed a wish to take part and 
support for the project but did not have the time or availability.  
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Representatives from all the fields identified by the research team were recruited for 
the consensus panel except for having a psychologist. It was agreed by the 
supervision team that this was less important as the TDF was being used to inform the 
process.  
The final panel included national and regional clinical leads and experience in 
education, research, computerised decision support, policy, formulary and standard 
setting (Table 47). 
 
 
 
Table 47: Consensus panel participants, who completed each stage, and 
reasons for non-completion. 
 
5.6.2.2 Quantitative analysis  
The results from the Bristol On-line Survey were transferred to Excel to facilitate a 
quantitative analysis giving count, median rank and agreement/ disagreement 
categorisation for all responses (Table 48). 
There were universally positive ‘valid’ ratings on agreement and importance for all 22 
statements presented to the participants with no ‘disagreement’ categorisation. 
Thirteen statements for feasibility had positive median ranks, and nine ranked 
equivocal, with one categorised as ‘disagreement’.  None of the 22 statements had a 
negative ‘invalid’ median ranking. 
Statement 13 was ranked high in all three categories. The consensus was that there 
was agreement that ‘help is needed to remember which drugs are implicated’, that it is 
important, and that it is feasible to implement. 
 
 
 
completed on-line 
survey
attended group 
discussion
completed final 
rating
C1 Renal physician/ AKI national lead C1 C1
C2 Geriatrician C2
C3 Health informatics analyst C3 C3 C3
C4 Senior university lecturer/ pharmacist C4 C4 C4
C5 Renal pharmacist/ DPharm student C5 C5 C5
C6 Senior hospital pharmacist C6
C7 Medicines safety expert pharmacist C7 C7 C7
C8 NICE pharmacist/ BNF formulary committee member C8 C8 C8
C9 GP/academic clinical fellow C9 C9 C9
C10 Renal physician/ Regional lead C10
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Negative Equivocal Positive
Median 
rank
1 - 2 3 4 - 5
agreement 2 0 8 4 N
importance 2 3 5 3.5 N
feasibility 1 5 4 3.5 N
agreement 0 1 9 4.5 N
importance 0 1 9 4 N
feasibility 2 3 5 3.5 N
agreement 0 0 10 4 N
importance 1 1 8 4 N
feasibility 4 2 4 3 Y
agreement 0 0 10 5 N
importance 0 1 9 5 N
feasibility 0 3 7 4 N
agreement 0 4 6 4 N
importance 2 3 5 3.5 N
feasibility 1 4 5 3.5 N
agreement 0 1 9 5 N
importance 0 2 7 4 N
feasibility 0 3 5 4 N
agreement 1 3 5 4 N
importance 1 2 6 4 N
feasibility 3 3 3 3 N
agreement 1 2 6 4 N
importance 0 2 7 4 N
feasibility 2 3 4 3 N
agreement 0 0 10 5 N
importance 0 2 8 4 N
feasibility 2 2 6 4 N
agreement 0 2 8 4 N
importance 1 2 6 4 N
feasibility 2 3 4 3 N
agreement 0 0 10 5 N
importance 1 2 7 4 N
feasibility 2 3 4 3 N
agreement 0 1 9 5 N
importance 0 2 8 4 N
feasibility 2 3 5 3.5 N
agreement 0 0 10 5 N
importance 0 0 10 4.5 N
feasibility 0 4 6 4 N
agreement 0 3 7 4 N
importance 0 3 7 4 N
feasibility 1 4 5 3.5 N
agreement 0 0 10 5 N
importance 0 3 7 5 N
feasibility 2 4 4 3 N
agreement 1 2 5 4 N
importance 1 3 4 3.5 N
feasibility 0 3 5 4 N
agreement 0 1 9 4 N
importance 0 4 5 4 N
feasibility 3 3 4 3 N
agreement 0 1 9 4.5 N
importance 0 4 6 4 N
feasibility 3 3 4 3 N
agreement 0 2 8 4.5 N
importance 1 2 7 4 N
feasibility 3 3 4 3 N
agreement 1 3 6 5 N
importance 2 3 4 3.5 N
feasibility 2 2 5 3.5 N
agreement 1 0 9 4.5 N
importance 1 2 6 4 N
feasibility 1 2 6 4 N
agreement 2 2 6 4 N
importance 2 2 5 4 N
feasibility 1 2 5 4 N
Number of 
participants 
choosing as a 
top 3 priority
1. In primary care 
there is a lack of 
awareness, 
knowledge, and 
understanding about 
prescribing in the 
reduced kidney 
function of older 
people.
1. need to increase understanding 3
2. need to increase awareness 6
3. need to increase knowledge
Key themes Statements for rating
Ranking 
factors
Rank value
Disagree
ment
4
4. should be taught to prescribers and 
potential prescribers
3
5. tailored teaching required for specialist 
practitioners
1
2
8. calculation of creatinine clearance needs to 
be easier in the prescribing process
1
3. The application of 
kidney function level 
to prescribing 
decisions is needed 
both at drug initiation 
and at medication 
review.
9. there need to be warnings and prompts 
when doing a medication review
3
10. a recent kidney function test should be 
available when doing a medication
2
11. the responsibility taken for prescribing 
needs to be as acute at medication review as 
it is at initiation
2. Kidney function 
testing is required 
when prescribing for 
older people.
6. kidney function needs to be checked and 
the result applied for prescribing
1
7. creatinine clearance (Cockcroft Gault) 
should be used as the kidney function 
estimate when prescribing
1
12. computer decision support would be 
useful on home visits
1
4. There is difficulty 
in remembering to 
apply the 
recommendations 
for use, and dosing, 
of drugs in reduced 
kidney function.
13. help is needed to remember which drugs 
are affected
2
14. prompts are needed as attention is on 
other things in a consultation
1
15. warnings and prompts need to be linked to 
level of kidney function, and be patient and 
drug specific
1
16. warnings and prompts need to highlight 
reduced kidney function before prescribing 
decisions need to be made
1
17. the habit of prescribing 'the usual dose 
that is always prescribed' needs to be broken
1
1
20. assessing kidney function for older people 
should be considered a required part of the 
prescribing process to reduce the risk of 
harm
0
6. There is limited 
use and confusion 
with the resources 
available to support 
the use, and dosing, 
of drugs in reduced 
kidney function.
21. prescribers need to be made aware of 
resources available to help with prescribing in 
reduced kidney
0
22. British National Fpormulary 
recommendations need clarification
1
5. There is a need to 
embed kidney 
function assessment 
within the prescribing 
process.
18. computer decision support is needed 
because prescribing is a complex, multi-step 
process
1
19. to reduce the risk of mistakes being 
made, computer decision support is needed
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 48: On-line survey statement ratings as mean rank and standard deviation 
for agreement, importance, feasibility, and top three priority. 
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Three more statements were ranked high in two categories. Agreement and 
importance were ranked high for: 
 That prescribing in RKF should be taught to prescribers and potential 
prescribers (statement 4).  
 Warnings and prompts need to be linked to level of kidney function, and be 
patient and drug specific (statement 15). 
Agreement and feasibility were ranked high for: 
 Warnings and prompts are needed at medication review (statement 9).  
Agreement with the statements 
On a Likert Scale of 1 – 5 where ‘5’ is the highest rank of agreement, eight statements 
had a median rank of ‘5’ with no disagreement: 
 That prescribing in RKF should be taught to prescribers and potential 
prescribers (statement 4).  
 Kidney function needs to be checked and the result applied for prescribing 
(statement 6). 
 Warnings and prompts are needed at medication review (statement 9).  
 The responsibility taken for prescribing needs to be as acute at medication 
review as at initiation (statement 11).  
 Computer decision support would be useful on home visits (statement 12). 
 Help is needed to remember which drugs are implicated (statement 13).  
 Warnings and prompts need to be linked to level of kidney function, and be 
patient and drug specific (statement 15). 
 Assessing kidney function for older people should be considered a required 
part of the prescribing process to reduce the risk of harm (statement 20). 
Statements agreed to be important 
The highest ratings for the degree to which the statement was thought to be important 
in implementation of change were: 
 That prescribing in RKF should be taught to prescribers and potential 
prescribers (statement 4) – median rank 5. 
 Warnings and prompts need to be linked to level of kidney function, and be 
patient and drug specific (statement 15) – median rank 5. 
 Help is needed to remember which drugs are implicated (statement 13) – 
median rank 4.5. 
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Feasibility of the statements 
Feasibility was generally rated lower with the highest median rank given being ‘4’. The 
statements found to be most feasible with a median rank of ‘4’ were: 
 That prescribing in RKF should be taught to prescribers and potential 
prescribers (statement 4). 
 Kidney function should be checked and applied to prescribing (statement 6).  
 Warnings and prompts are needed at medication review (statement 9). 
 Help is needed to remember which drugs are implicated (statement 13). 
 Warnings and prompts need to highlight RKF before prescribing decisions are 
made (statement 16). 
 Prescribers need to be made aware of resources available to help with 
prescribing in RKF (statement 21). 
 BNF recommendations need clarification (statement 22). 
Nine statements were ranked equivocally with a median rank of ‘3’. One of these, the 
feasibility of increasing knowledge (statement 3), had the only ‘disagreement’ rating 
with 4 ranking it negatively and 4 positively. These statements would be explored 
further in the group discussion. 
Priority of the statements 
The participants were also asked to choose the three statements that they considered 
to be their top priorities for implementing change. Only two respondents gave 3 
choices (C1 and C9). Three respondents gave 2 choices, two 4 choices, and one gave 
none whilst one gave 11. Two respondents commented on the survey that they had 
run out of ‘top three’ choices: 
“I started to tick the top priority boxes and then came to the conclusion that all of 
these elements are important in achieving safer prescribing in the elderly and other 
patient groups.” (C10: renal physician with a regional role)  
“Cannot fit in top 3.’” (C1: renal physician with a national role) 
This meant that the ‘top 3’ were skewed towards the first group of statements (the 
‘knowledge’ theme), however it did give an indication of the main priorities which could 
be discussed at the panel meeting. The top three priorities ranked were: 
 To increase awareness – 6 respondents. 
 To increase knowledge – 4 respondents. 
 To have warnings and prompts at the medication review – 3 respondents. 
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 Should be taught to prescribers and potential prescribers – 3 respondents. 
 To increase understanding – 3 respondents. 
When analysed under setting, role or speciality, 3 of the 4 doctors put increasing 
understanding as a top 3 priority and all ranked this highly compared to the 
pharmacists. The doctors also all strongly agreed that the calculation of creatinine 
clearance should be easier in the prescribing process; again the pharmacists tended 
to rank this lower. 
The primary care practitioners gave strongly agree ratings and top 3 priority for the 
need for having warnings and prompts at a medication review. They also gave high 
ratings for the need for the warnings and prompts to be patient and drug specific and 
to be highlighted before the prescribing decision needs to be made, the latter was not 
something other respondents ranked as high. 
Secondary care practitioners (Renal and Care for the Elderly) agreed strongly that 
assessing kidney function for older people should be considered a required part of the 
prescribing process to reduce the risk of harm, whilst primary care ranked it equivocal 
or disagreed and gave a very low feasibility. 
Renal practitioners ranked highly that prescribers should be made aware of resources 
available and that the BNF recommendations need clarification. The medicines safety 
pharmacist also ranked highly that the BNF needs clarification and gave it a top 3 
priority. 
5.6.2.3 Qualitative analysis 
Comments added to the on-line survey were thematically analysed to identify new 
themes.  
Most comments were either reiterating their ranking or questioning the premise, or 
their understanding, of the statement. These would be picked up at the panel 
discussion meeting, however, there were a few to note: 
Capability 
On the need to increase understanding, C10 suggested that it was important that 
awareness was increased of ‘Sick Day rules’ where medicines are stopped whilst 
acutely ill to reduce the risk of ‘acute on chronic’ kidney injury (Griffith et al, 2015). C10 
also suggested that: 
“Hospital blood test reports are not seen in primary care, hence recent 
episodes of acute renal deterioration may be missed”. (C10, renal physician 
with a regional role) 
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When discussing the requirement for education, the need to keep up to date with 
changes in recommendations was highlighted. 
“recommendations change and there needs to be a formal process of ensuring 
these are incorporated into practice….keeping up to date after this is probably 
more important.” (C4, senior university lecturer and pharmacist) 
Opportunity 
On the statement regarding having warnings and prompts at medication review, some 
panel members not working in primary care were unaware that warnings were not 
available when doing a medication review.  
“I wasn’t aware that such prompts didn't come up on review. Is this true of all 
systems?” (C4, senior university lecturer and pharmacist) 
Pharmacists were highlighted as health professionals that could help to improve 
prescribing in RKF. 
“... pharmacists based in primary care with the skill set to help prescribers”. 
(C5, renal pharmacist) 
Questioning the need for change 
One respondent, C4, made a few comments that implied they thought there was not a 
problem in primary care, but which were not in line with the other panellists. This was 
explored in the group discussion. 
  “Prescribers know where to look if changes in kidney function occur.”  
“Naively perhaps but I think this is already part of practice in the majority of 
cases.”  
“In my experience doses change as function changes if necessary.”  
 
 Summary 
Panel consensus on agreement, importance and feasibility on what needs to 
change. 
The individual ratings were universally positive on agreement and importance for all 22 
statements presented to the panellists, and all but nine statements for feasibility, which 
were equivocal. This provides a confirmation by the experts and stakeholders for the 
project findings. 
The themes added to the analysis from the on-line survey were: 
 That non-primary care participants were surprised that warnings and prompts 
did not come up at medication review.  
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 That recommendations change and so there is a need to keep up to date. 
 That the role of pharmacists could be increased. 
 
Priorities for intervention strategy and future research. 
The top three priorities ranked were: 
1. To increase awareness – 6 respondents. 
2. To increase knowledge – 4 respondents. 
3. To have warnings and prompts at the medication review – 3 respondents. 
3. Should be taught to prescribers and potential prescribers – 3 respondents. 
3. To increase understanding - 3 respondents. 
 
5.7 Stage 3: Group discussion 
 Study design for stage 3 
5.7.1.1 Method 
The expert panel met at Leeds University for a facilitated structured two hour meeting 
on the themes and statements they had initially rated in Stage 2. The session was led 
and facilitated by myself.  A second researcher (supervisor, LG), experienced in 
behaviour change theory, attended the group discussion to take notes and verify 
findings. 
The meeting started with a 15 minute presentation by SW to give the panellists an 
overview of the four studies that have led to the development of the key themes and 
statements on what needs to change to improve prescribing for older people with RKF. 
The Power Point slides for the presentation can be found in Appendix 22 (8.21). 
The key themes were then presented in turn, with example quotes from the GP 
interviews. For approximately 1.5 hours, the meeting was structured to facilitate wide 
discussion on all six key themes, exploration of issues raised, and any new themes 
raised. Also, issues raised from the on-line survey were discussed. 
The discussion was brought to a close 15 minutes before the scheduled end of the 
meeting to allow time for the final statement rating (Stage 4). 
5.7.1.2 Data collection 
The group discussion was digitally recorded, with consent, and anonymously 
transcribed for analysis. 
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5.7.1.3 Analysis  
Demographic analysis 
The range of expertise of the panel able to attend the discussion meeting was 
analysed compared to the agreed pre-defined criteria (5.4.3). 
Content analysis 
A theory-based, five stage content analysis was conducted on the anonymised 
transcript from the group discussion meeting (Pope et al, 2000).  
Stage 1. Familiarisation 
The meeting recording was listened to, and the anonymised transcript was read and 
re-read to become familiar with the data, and to get an initial impression of the key 
ideas and recurrent themes.   
Stage 2. Identifying a thematic framework 
Data was then coded to theoretical domains using the TDF and the emerging themes 
were mapped to those from the GP interview study, identifying where themes were 
agreed, disagreed or new themes added. A coding index was developed. 
Stage 3: Indexing 
The second researcher (LG) used the coding index to code the transcript 
independently to explore inter-rater reliability. 
Stage 4. Charting 
The codes and quotes were manually grouped into emerging themes. This was an 
iterative and reflective process and allowed exploration of intra-rater reliability by re-
visiting and refining the coding. 
Stage 5. Mapping and interpretation 
The emergent themes were mapped and interpreted under each TDF domain, and 
categorised under capability, opportunity and motivation to structure the findings and 
to find any differences with participant type. A final analysis was performed to map the 
findings to the key themes from the GP interview study (Chapter 4) and any new 
themes added on what needs to change to improve prescribing for older people with 
RKF (Table 49). 
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Table 49: An example section of the group discussion content analysis mapped onto the TDF domains and linked to COM-B 
categories, with codes. 
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 Results 
5.7.2.1 Demographic analysis 
Seven of the original 10 panellists were able to attend the group discussion (Table 47). 
One of the panellists unable to attend was a second renal physician, and another was 
a hospital based pharmacist, so there was still the expertise at the discussion meeting. 
The geriatrician could not attend so there was no elderly care expert for the 
discussion, but the secondary care clinician expertise was represented. 
5.7.2.2 Qualitative analysis 
Table 49 shows one section as an example from the content analysis where emerging 
themes were mapped onto the TDF domains, whether they were themes that 
reiterated those found in the GP interview study, or whether they were new themes 
identified. The TDF domains were mapped to the COM-B categories using the Michie 
et al (2014) linking as previously shown in Table 5.  
Themes from the group discussion reinforced those found from the GP interview study 
(Chapter 4), as well as introducing new themes to be considered on what needs to 
change to improve prescribing for older people with RKF. The importance and the 
potential to cause harm was reiterated by the panel: 
“We all think that it’s hugely important! We just don’t want to talk about it 
because we don’t really know what we’re doing!'”  (C9: GP and academic 
clinical fellow)   
“The pen is mightier than the scalpel in terms of the damage that you can do to 
a patient by writing the wrong drug and the wrong dose for a patient...there’s 
principles there that if these organs are affected then the drugs you’re 
prescribing you may not be giving the right dose.” (C1: renal physician with a 
national role) 
“I think we may underestimate how much harm we may be actually doing to 
patients by having them on the wrong drugs and wrong dosages or the wrong 
drugs at the wrong time.”  (C1: renal physician with a national role) 
To explore agreement and consensus for the key themes, example quotes from the 
meeting are presented: 
Key theme 1: in primary care there is a lack of awareness, knowledge, and 
understanding about prescribing in the reduced kidney function of older people. 
It was agreed that there is a need to increase awareness of this issue in prescribing 
and that there is a knowledge gap. 
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“I’m not generally a big fan of saying it’s about knowledge, but, given the 
figures, you know, actually you can’t do it without that knowledge.”  (C7: 
medicines safety expert pharmacist) 
“I do also think that there’s a knowledge gap here as well, because again I 
think well why is Cockroft and Gault suddenly a big thing now, so it’s kind of 
tackling that as well as tackling how can we get this information out quickly.”  
(C8: pharmacist with a role in formulary guidance and standard setting) 
There was agreement that education and training on prescribing and 
recommendations in RKF is required at all levels. 
“Certainly in terms of general practice training there’s quite a comprehensive 
curriculum that doesn’t really talk about prescribing at all.” (C9: GP and 
academic clinical fellow) 
“It’s about education, and I think doctors can learn these drugs, not necessarily 
the nuances of every single drug, but they can learn over time…I think it’s 
important that every specialty pays attention to the drugs, say the cardiologists, 
they use these medications with patients with severe heart failure, they go on 
to a cocktail of ACEI, furosemide, spironolactone and they get their acute 
kidney injury.” (C1: renal physician with a national role) 
Key theme 2: kidney function testing is required when prescribing for older 
people. 
The panel confirmed that when prescribing drugs excreted by the kidney for older 
people, kidney function needs to be checked and the result applied for use, and 
dosing, of drugs.  
“We can watch the kidney function because we know it can decrease…and we 
can we can think about the drugs we’ve already prescribed because it’s 
dynamic.” (C1: renal physician with a national role) 
After discussion, they all agreed that creatinine clearance calculated using the 
Cockcroft Gault equation should be used for prescribing decisions for older people, 
and that it should be easier in the prescribing process.  
“I’m absolutely convinced that what we should be using is the Cockcroft and 
Gault.” (C7: medicines safety expert pharmacist) 
“I personally feel that Cockcroft and Gault is the standard of what we should be 
using.” (C5: renal pharmacist) 
C9, GP and academic clinical fellow, highlighted that the ‘renal calculator’ needs 
amending on the patient record system. 
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“Well it needs making right, it needs making right! And anything that is 
developed will be freely made available to EMIS or any of the other systems.” 
(C3: health informatics analyst) 
Key theme 3: the application of kidney function level to prescribing decisions is 
needed both at drug initiation and at medication review. 
The problem of warnings and prompts not being available when doing a medication 
review was re-iterated. 
“Those pop-ups only appear when you initiate a drug and once you’ve gone 
past that and decided it’s on the repeat template you never see that again.'” 
(C9: GP and academic clinical fellow) 
“When you first write a prescription out for say X and it flashes up…a thing with 
lots of stars on it telling you you’re going to kill someone… And then when you 
see Mrs Blogs for a repeat prescription, nothing then flags up? You’ve got a list 
and you kind of look through it and go yeah that’s all okay, push a button, and 
it’s done for another twelve months. So, and nothing else pops up.”  (C9: GP 
and academic clinical fellow) 
Also the need for a recent kidney function test to be available when doing a medication 
review as it may have changed since initiation or the previous review. 
“Often people write the drug chart, and they forget that it’s dynamic and the 
patient’s kidney function can change secondary to something else such as 
pneumonia, for example.” (C1: renal physician with a national role) 
“I think if it’s been 12 months just leave it alone, but, actually, they’ve had a 
creatinine measure in that time, things might have changed, or there might 
have been other things added.” (C9: GP and academic clinical fellow) 
C3, health informatics analyst, confirmed that it is now possible to have mobile 
computer decision support and the panel agreed that would be beneficial for patient 
safety. 
“I have some very scary home visits, because I have to start scratching my 
head…thinking for myself rather than the computer.” (C9: GP and academic 
clinical fellow)   
Key theme 4: there is difficulty in remembering to apply the recommendations 
for use, and dosing, of drugs in reduced kidney function. 
It was agreed that help is needed to remember which drugs are affected by reduced 
kidney function and what to do for each. Patient and drug specific warnings and 
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prompts would help direct attention in the consultation and be more useful than those 
currently presented. 
“So the vast majority of general practice is done just on implicit knowledge, you 
know, things don’t get looked up, the vast majority of our GPs haven’t done the 
checking out what they know, and what they don’t know, in order to treat the 
patient.” (C7: medicines safety expert pharmacist) 
“You could make it personal to that patient…in SystmOne they can, I presume 
in EMIS...you could pick up that patient...a low kidney function test, pick up the 
age, pick up a frailty, it could do that and set off a template or whatever.” (C3 
health informatics analyst) 
QOF and other guidance, and policy, have become the priority in the consultation. 
“There is a hierarchy of focus in general practice and it starts with QOF, and 
NICE guidance, and if there isn’t a piece of NICE guidance about, say, 
prescribing, then it’s the 6th thing on the list.” (C9: GP and academic clinical 
fellow) 
“Do you think that approach of almost that visceral response to I need to think 
about that drug, do you think that’s watered down or feels secondary to there’s 
a NICE guideline to what you do if someone’s had an MI.” (C9: GP and 
academic clinical fellow) “Yeah I do.” (C1: renal physician with a national role) 
Key theme 5: there is a need to embed kidney function assessment within the 
prescribing process. 
Discussion around computer decision support centred on the complexity of 
prescribing. The medicines safety pharmacist (C7) discussed how prompts can also 
be beneficial in increasing knowledge, and that audit should also be part of the 
process to find those where kidney function has not been assessed.    
“Having it embedded means that you get an opportunity to consider it that you 
wouldn’t have necessarily had previously… It’s ringing the alarm bells” (C7) 
“We know that knowledge based interventions work the majority of the time. 
That’s the way general practice works, you know, they apply what they know, 
implicit knowledge, every day. But it doesn’t work all the time, so then you have 
to put something else in. And the next step is the prompts at the point where 
the decision making is made because that will then have an impact on future 
decisions, increasing knowledge.” (C7) 
It was highlighted by the panel that they thought ensuring kidney function levels are 
applied to prescribing is a patient safety issue at least as important as allergies.  
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“I think when we’ve identified that it’s awareness, then I think elevating the 
function to the point of allergy, going actually this is just as important. In fact, 
you’re more likely to hospitalise someone because of their renal function.” (C7: 
medicines safety expert pharmacist) 
“I think it’s about making it something around patient safety and making us 
more aware of the importance of it and that it is as important as doing a 
coronary cath on somebody... it’s the interventional stuff that gets people 
excited but prescribing of drugs it’s like oh god do I have to do that drug chart; 
but no, no, no, this is such an important foundation for this patient's care.” (C1: 
renal physician with a national role)    
Key theme 6: there is limited use and confusion with the resources available to 
support the use, and dosing, of drugs in reduced kidney function. 
It was agreed that guidelines need to include advice on use of drugs in RKF, and that 
resource such as the BNF could be improved to help prescribers apply the 
recommendations. 
“Have you spoken to the BNF about that? … it would be worth passing that 
on…I would write to them because it will be considered.” (C8: pharmacist with 
a role in formulary guidance and standard setting) 
Pharmacists were highlighted as a helpful resource. 
“And if there are pharmacists based in practices, and focussed on the 
medicine, then they could do the medicine review, and, by doing that, that will 
also increase the GPs awareness to focus on problem drugs.” (C5: renal 
pharmacist) 
“I think pharmacists would be in an ideal position to look at the detail.” (C8: 
pharmacist with a role in formulary guidance and standard setting) 
Additional themes elucidated 
New themes came from the consensus panel discussion that were mapped onto the 
TDF domains. The themes in the TDF domains were categorised to the ‘COM-B’ 
model (Michie et al, 2014; Table 5) to frame the themes into what needed to change 
and allow future analysis and intervention development using the Behaviour Change 
Wheel. 
Capability 
Teaching use of the patient record systems is useful so that prescribers are aware of 
how the technology can help. 
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“Those modules [on use of SystmOne] in the undergraduate course – they’ve 
been phenomenally well received out in the community… simply because we 
now have students who are IT record literate.” (C9: GP and academic clinical 
fellow) 
Cyclical audit can focus on the problem as well as ‘mop-up’ cases that have been 
missed. 
“If you’re looking at it as managing risk in a practice then cyclic audit... it really 
focuses the mind on the problem that you’re trying to solve, reducing the 
medicines burden for patients with renal disease.” (C7: medicines safety expert 
pharmacist) 
Ideal weight (or lower if actual) should be used in the CrCl-CG calculation. 
“I think it’s got to change - it uses actual weight not ideal weight.” (C5: renal 
pharmacist)  
“The calculator uses actual weight not ideal weight.” (C9: GP and academic 
clinical fellow) 
Opportunity 
There is a large impact of the findings because of the scale of prescribing, most of 
which is in primary care. 
“Most prescribing is in primary care, a vast amount of prescribing.” (C4: senior 
university lecturer and pharmacist) 
Pharmacists could take on roles such as medication review and audit.  
“There is a need to increase knowledge and understanding in primary care, 
and it’s about increasing awareness as well, so...if there are pharmacists 
based in practices, and focussed on the medicines, then they could do the 
medicine review, and, by doing that, that will also increase the GPs awareness 
to focus on problem drugs.” (C5: renal pharmacist) 
“There’s lots of issues around medication and polypharmacy isn’t there at 
medication reviews, I think pharmacists would be in an ideal position to look at 
the detail.” (C8: pharmacist with a role in formulary guidance and standard 
setting) 
If community pharmacists had access to blood results it would be another check, and 
would also allow them to review the medication use. 
“…community pharmacists being able to access blood results as well as being 
like another layer in the check when giving out prescriptions.”  (C5: renal 
pharmacist). 
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Motivation 
Renal medicine hasn't been seen as part of the GP role. It used to be managed in 
secondary care but now has moved out to primary care. 
“I think the place where chronic kidney disease is managed has changed over 
the years as well, more and more of CKD 3 and 4 is moved out to the 
community whereas it used to be a specialty managed condition.” (C9: GP and 
academic clinical fellow) 
A trigger or prompt on the medication list screen at eye level is most likely to be useful 
(like allergies but higher up on the screen). 
“Your eyes are in the middle of the screen and you’re thinking about which 
drug should I choose - I’d like that to be right under where you type in the drug 
name…where I type the drug name, right underneath it is, or even just above it, 
is your allergy status, here’s your renal function status” (C7: medicines safety 
expert pharmacist) 
National guidance, quality standards etc. act as a lever, they are transformative, 
providing a priority focus and leading to the teaching curriculum and e.g. QOF. 
“I don’t know what a NICE guidance would look like around drug prescribing 
but … it then affects the curriculums [teaching – NICE]...It’s a lever...It’s 
transforming acute kidney...It just focuses the mind, I couldn’t get people to 
take it seriously until we had the NICE guidance and suddenly it became an 
issue.” (C1: renal physician with a national role)   
“The lovely thing about NICE guidelines is it forms a focus.” (C4: senior 
university lecturer and pharmacist)    
A published guideline is not enough to cause action, an intervention is needed to enact 
the guidance. 
“I don’t see a direct relationship between what NICE publish and what GPs do. 
It’s the intervention that other people put in, in order to enact the NICE 
guidance in primary care.” (C7: medicines safety expert pharmacist) 
Patients are unaware of RKF. 
“I mean it is more of a hidden disease, in the consultation we talk about 
diabetes and heart attacks and knee pain, and it might be in the clinicians mind 
that they have to think about renal function but not the patients.” (C9: GP and 
academic clinical fellow)   
“I would think it’s a very low proportion of patients who know that they have 
reduced kidney function.”  (C5: renal pharmacist) 
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Statements on feasibility not positively ranked in Stage 1 
The feasibility statements ranked as equivocal on the on-line survey were explored by 
the discussion group. There was agreement across the panel, after discussion, that 
CrCl-CG should be used for prescribing decisions and that it should, and could, be 
made easier for prescribers in an intervention. Teaching of current and new 
prescribers was agreed as important to increase knowledge. Use of patient and drug 
specific prompts and warnings could help to break habit. 
 
 Summary 
The panel discussion confirmed the agreement, importance and feasibility of the key 
themes on what needs to change. Even the statements where feasibility had not been 
positively ranked in the on-line survey were felt to be important and that there would 
be ways of making them possible, despite being difficult to design and implement. 
New themes to be added to the overall analysis were: 
Capability 
 Teaching use of the computer patient record system is useful. 
 Cyclical audit can focus on the problem, and mop up those not presenting 
opportunistically. 
 Ideal weight (or lower if actual) should be used in the CrCl-CG calculation. 
Opportunity 
 Prescribers and patients need to be aware that pharmacists can have an 
increased role in medication review. 
Motivation 
 Renal medicine has not been seen as a GP role. 
 National guidance, quality standards etc. act as a lever and focus priority. 
 A trigger/prompt on the medication list screen at eye level would be useful. 
 Patients are unaware of kidney function. 
 
5.8 Stage 4: Second round statement rating 
 Study design for stage 4 
5.8.1.1 Method 
The panellists repeated the rating of the statements at the end of the discussion 
meeting. They individually indicated their top 3 priorities for an intervention and 
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research strategy. The 6 key themes were placed up on a board with the relevant 
statements listed below. Panellists indicated their first, second and third choice 
priorities for intervention and future research. They could choose whether their choices 
were to be anonymous. 
5.8.1.2 Data collection 
The final statement rating was done by using ‘post-it notes’ (Figure 34). Each panellist 
was asked to indicate next to the appropriate statement their first priority with a pink 
‘post-it note’, their second priority with a yellow ‘post-it note’, and their third priority with 
an orange.  
5.8.1.3 Analysis  
Demographic analysis 
The pre-defined criteria were used to check that the panellists who completed the 
stage 3 rating were comprised of the required range of expertise (5.4.2). 
Quantitative analysis 
A visual analysis of the colours and spread of the post-it notes was followed by a 
repeat analysis of the top 3 priority choices for intervention and future research. 
Qualitative analysis 
Comments were added to some of the ‘post-it notes’ and these were read and 
analysed in case they added anything further to the final analysis. 
 
 Results 
5.8.2.1 Demographic analysis 
Six panellists completed the final statement rating as the renal physician had to leave 
the meeting early (Table 47). There was still clinician, secondary care, and renal 
expertise representation for the final statement rating, as well as the primary care, 
medicines safety, health informatics, and standard setting/formulary experts. 
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Abbreviations: BNF: British National Formulary; NICE: National Institute for Health and Clinical Excellence. 
Table 50: top 3 priority ratings pre and post group discussion. 
1. need to increse understanding P P P 3
2. need to increase awareness P P P P P P 6 1 1 2 1 4
3. need to increase knowledge P P P P 4 1 1
4. should be taught to prescribers and potential 
prescribers
P P P 3
1
b
1
5. tailored teaching required for specialist 
practitioners
P 1
6. kidney function needs to be checked and the 
result applied for prescribing
P 1 2 1
7. Cockcroft Gault should be used as the kidney 
function estimate when prescribing
P P 2 2 3 2
8. calculation of creatinine clearance needs to be 
easier in the prescribing process.
P 1 1 1
9. there need to be warnings and prompts when 
doing a medication review.
P P P 3 4 1
10. a recent kidney function test should be 
available when doing a medication review
P P 2 1 3 2
11. The responsibility taken for prescribing needs 
to be as acute at medication review as at initiation
P 1
12. Computer decision support would be useful on 
home visits
P 1
13. help is needed to remember which drugs are 
affected
P P 2 3 1
14. prompts are needed as attention is on other 
things in a consultation
P 1
1
a
1 2
15. warnings and prompts need to be patient and 
drug specific
P 1 1 1
16. warnings and prompts need to highlight RKF 
before prescribing decisions need to be made
P 1
17. the habit of prescribing 'the usual dose that is 
always prescribed' needs to be broken
P 1
18. computer decision support is needed because 
prescribing is a complex, multi-step process
P 1 2 1
19. to reduce the risk of mistakes being made, 
computer decision support is needed
P 1
20. assessing kidney function a required part of the 
prescribing process to reduce the risk of harm
0 1 3 2
21. prescribers need to be made aware of 
resources available 
0
22. BNF recommendations need clarification P 1
23. use pharmacists 3 2 2
24. NICE/ general prescribing guidelines - what 
needs to be thought about, in what groups etc
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Figure 34: Consensus panel top three priority rating by post-it note. 
 
5.8.2.2 Quantitative analysis 
A clear top priority was given for the need to increase awareness with three 1st choice 
rankings and one 2nd. The second priority shown was for ‘warnings and prompts 
needed’ with two 1st choices. Two statements had one 1st and one 3rd choice and so 
were the next placed priority choice: that a recent kidney function test should be 
available at medication review, and assessing kidney function for older people should 
be considered a required part of the prescribing process to reduce risk of harm (Table 
50). 
The panellist choices were spread across five of the six themes, as shown in the 
picture of the key theme listings taken from the board (Figure 34).  There was one 
main cluster on the first sheet which was ‘need to increase awareness’. Although no 
top priority choices were places on key theme 6 at the end, there had been discussion 
on resources prior to the final rating, and it had been agreed that the BNF needed 
clarification to help prescribers implement recommendations on prescribing in RKF. 
Despite the discussion and explanations on what was requested, one participant said 
they couldn’t chose and needed four choices and another also said they couldn’t 
choose and decided they were going to give a ‘number 1’ in each of 5 key themes.  
When analysed for role, setting and speciality, no pattern was detected. 
5.8.2.3 Qualitative analysis 
The notes added to the ‘post-it-note’ choices were: 
Capability 
 ‘Educational intervention to embed top ten culprits.’ 
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Opportunity 
 ‘Links to SPC/renal database and links to secondary care.’ 
 ‘Medication review by pharmacists and cyclical audit.’ 
 ‘Computer display of kidney function like allergies.’ 
 ‘Prompts though systems not proscriptive – need to be thought about.’ 
 ‘Prompts should be patient orientated.’ 
 
 Summary 
Top priority for an intervention and future research was given for the need to increase 
awareness. The second priority was for ‘warnings and prompts needed as attention is 
on other things in a consultation’. Two statements were the third placed priority choice: 
that a recent kidney function test should be available at medication review, and 
assessing kidney function for older people should be considered a required part of the 
prescribing process to reduce risk of harm. 
The need for intervention was considered as important because of the risk of harm to 
older people. Prompts should be drug and patient specific, computer display more 
usefully placed, and education and resources improved. Pharmacists could be 
involved more in medication review and cyclical audit. 
 
5.9 Discussion  
 Principal findings 
An expert panel, with a wide breadth of experience and expertise in a range of BCW 
intervention functions and policy categories, gave support for the project findings. The 
top priorities for intervention and research were identified as: 
 There is a need to increase awareness. 
 Patient and drug specific warnings and prompts are needed. 
 Kidney function assessment for older people should be a required part of the 
prescribing process to reduce risk of harm. 
 A recent kidney function test should be available at medication review. 
The universally positive ratings on agreement and importance for all 22 statements, 
and the majority for feasibility, on the individually rated on-line survey provides a 
confirmation by the experts and stakeholders for the results from the GP interview 
study (Chapter 4). This was reinforced in the group discussion. The panel recognised 
the findings that many older patients are prescribed drugs when their kidney function 
269 
 
 
was too low for it to be appropriate, and which supported the current broader evidence 
found in the scoping literature review (2.5); for example, the primary care studies in 
France (Breton et al, 2011) and Australia (Khanal et al, 2015), and the UK hospital 
based study (Jones and Bhandhari, 2013). 
The Panel group discussion also endorsed that the importance of the statements was 
because of the consequent risk of harm caused by inappropriate prescribing in RKF, 
as found in the scoping literature review (2.7); for example increased mortality (Breton 
et al, 2011), hospital admissions (Helldén et al, 2009), and increased risk of ADRs 
(Corsonello, 2012). It was suggested in the panel discussion that patients were more 
likely to be hospitalised from ADRs from not applying the recommendations in RKF 
than for allergies, and that it should be given the same importance. The renal 
consultant with a national role suggested the findings should be framed as a safety 
issue. 
The scoping literature review (2.6) found evidence that the Cockcroft Gault equation 
should be used to estimate CrCl kidney function when making prescribing decisions 
for the older patient (Melloni et al, 2008; Roberts et al, 2008; Spruill et al, 2008; Hellou, 
2010). At the group discussion there was unanimous agreement with this finding, and 
doctors strongly agreed that ‘the calculation of CrCl should be easier in the prescribing 
process’.  
A top 3 priority was given by the panel that warnings and prompts are needed at 
medication review. This was a key theme identified from the GP interview study that 
hadn’t been identified previously as a problem, and had not been found in the scoping 
literature review. Implementing this would have a spill-over effect for all other warnings 
and prompts if they can be highlighted at medication review, for example liver function 
status. The scoping review of intervention evaluation to aid prescribing in RKF (2.10) 
did find evidence for use of alerts and more sophisticated CDSSs, but there were 
mixed results in a systematic review (Tawadrous et al 2011). Only 2 of 5 studies 
looking at patient-important outcomes from computerised CDSSs were beneficial. 
However, none of the studies found aiming to improve inappropriate prescribing in 
RKF were based on theory or determinants of why recommendations were not 
applied, which might be a factor if the intervention was not addressing where the 
barriers are. This study has aimed to explore the determinants using behaviour 
change theory so that an intervention can be developed to address what needs to 
change in practice. 
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In the scoping review (Chapter 2, 2.10), however, studies that involved pharmacists in 
the intervention showed universally positive results, for example, alerts to pharmacists 
significantly reduced errors for prescriptions in RKF in a large primary care RCT in the 
USA (Bhardwaja et al, 2011). Pharmacists were highlighted by the consensus panel 
as a resource for doing medication review, providing education and training, and for 
audit. Cyclical audit was a panel suggestion that can focus on the problem, and mop 
up patients not presenting opportunistically. The consensus panel also suggested that 
both prescribers and patients need to be aware that pharmacists can have an 
increased role in medication review. It was also suggested that if community 
pharmacists had access to blood results it would be another check, and would also 
allow them to review the medication use. In the Netherlands Geerts et al (2013) 
showed it was feasible for community pharmacists to test kidney function and advise 
GPs where needed, having previously shown a benefit for patients if they had access 
to kidney function results (Geerts et al, 2012). 
The ‘PINCER’ study (Avery et al, 2012) showed that pharmacists can be effective in 
reducing a range of medication errors. A Cochrane review (Nkansah et al, 2010) found 
forty-three studies which evaluated non-traditional roles of pharmacists. In general, the 
data included in this review supported the roles of pharmacists in patient counselling, 
therapeutic management, and providing health professional education with the goal of 
improving patient process of care and clinical outcomes. Non-traditional roles of 
outpatient pharmacists improves health care outcomes. The data showed that 
educational outreach visits may impact physician prescribing patterns. This Cochrane 
review is currently being updated (Watson et al, 2015). 
No studies were found in the scoping review (0) that explored the determinants for why 
prescribers do not apply the prescribing recommendations in RKF. There were primary 
care qualitative studies that found complex interactive factors for inappropriate 
prescribing in general, such as Slight et al (2013) and Anderson et al (2015), but the 
GP interview study (Chapter 4) was able to explore the determinants specific to 
prescribing in RKF, and the consensus panel has gone a step further in getting expert 
guidance to prioritise the complex findings. 
 
 Comparison of responses by panellists 
The doctors on the panel ranked ‘increasing understanding’ as a top 3 priority 
compared to the pharmacists, who ranked it lower. The doctors also all strongly 
agreed that the calculation of creatinine clearance should be easier in the prescribing 
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process, whilst the pharmacists again ranked this lower. The findings suggest that 
pharmacists may overestimate GP understanding. 
The primary care practitioners gave ‘strongly agree’ ratings and top 3 priority for the 
need for having warnings and prompts at a medication review and high ratings for the 
need for the warnings and prompts to be patient and drug specific and to be 
highlighted before the prescribing decision needs to be made. This had not been 
recognised as a problem by the other panellists, reiterating the incredulity expressed 
that this does not already happen. 
Secondary care practitioners (Renal and Care for the Elderly) agreed strongly that 
assessing kidney function for older people should be considered a required part of the 
prescribing process to reduce the risk of harm, whilst primary care ranked it equivocal 
or disagreed and gave a very low feasibility. After the group discussion it was a top 3 
priority for intervention; the health informatics expert had explained how the patient 
record system could be improved to use the data already available. 
Renal practitioners ranked highly that prescribers should be made aware of resources 
available and that the BNF recommendations need clarification. The medicines safety 
expert also ranked highly that the BNF needs clarification and gave it a top 3 priority. 
This became a group agreement at the discussion meeting. 
 
 Engagement in the research 
Fifteen out of the eighteen experts invited to participate responded positively with 
support for the project and a willingness to take part. This response shows a concern 
for prescribing safety and reducing risk of harm. The final panel included national and 
regional clinical leads and experience in education, research, computerised decision 
support, policy, formulary and standard setting. 
The numbers involved at each stage of the study fit with the Health & Technology 
Assessment (Murphy et al, 1998) and re-iterated by Campbell et al (2001) in that the 
numbers did not exceed 12, and did not drop below 6 for the final rating stage. At each 
stage there was a range of expertise lending weight to the findings of the panel; even 
though the number panellists had reduced to six for stage 3, they included 
representatives from clinical practice, policy, safety, and health informatics. 
 
 Strengths and limitations 
The range of expertise on the panel, and the methodological rigour used for the 
process, gives credibility to the findings. Panellists stated that it was useful to have the 
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initial statement rating phase as it got them thinking about the subject and allowed 
them to start formulating questions for the discussion. One participant remarked that: 
“The fact that we have covered all of these different areas is really important. 
The fact that we haven’t just gone down a ‘prompts will solve this problem’ 
route.” (C8: pharmacist with a role in formulary guidance and standard setting) 
This also recognises how the use of the Theoretical Domains Framework to structure 
the analysis enabled a wide exploration of the behaviour in the GP interview study. 
Linking the analysis to COM-B provided a model to strengthen the understanding of 
the TDF domains for non-psychologist healthcare professionals, structure the 
discussion around the key themes, and frame the findings to highlight what needed to 
change to improve prescribing in RKF. 
However, the consensus method may have just provided a snap-shot of current 
opinion (Campbell et al, 2001). Sometimes there can be low levels of agreement, but 
this was not the case in this study. Some aspects of the process may have been 
difficult. The participants were given only a short few sentences on the results from the 
studies in this research for the initial rating so responses were mainly based on their 
experience in this field. Choosing the top 3 statements as priorities for implementing 
change proved difficult for some participants, even after the group discussion. The 
instructions may have been unclear, the structure may have made it difficult, or maybe 
it was not easy to choose. However, even though it was not as specific as it would 
have been if all participants had chosen just three, it did give a clear indication of 
where initial plans for intervention and research should be directed. 
There was no patient or public involvement in this study. Members of the panel 
brought up in the discussion that patients do not have awareness of kidney function. 
This needs to be explored further and patients will be included in ongoing research. 
 
 What this study adds to the literature 
An expert consensus panel has considered the findings from the four studies in this 
project. The scoping literature review (Chapter 2) did not find any quantitative or 
qualitative UK primary care based studies on prescribing for older people with reduced 
kidney function (RKF). The expert panel has clarified and aggregated opinion to reach 
a consensus on priorities for intervention and future research. 
5.9.5.1 Consensus methods in prescribing research 
The RAND Appropriateness Method has been used in healthcare research to develop 
quality indicators and review criteria, for example, Avery et al (2011) and Spencer et al 
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(2014) used it to develop prescribing-safety indicators to assess the safety of 
prescribing by GPs for the purposes of revalidation. Campbell et al (1999) developed 
review criteria for assessing the quality of management of stable angina, adult asthma 
and non-insulin dependent diabetes mellitus in general practice, and To et al (2010) 
used it to define indicators of primary care for asthma. Campbell et al (2001) state that 
they believe consensus methods have an important and useful role to play in 
prescribing research for enhancing decision-making and aggregation into refined 
agreed opinion. This study has added to the evidence for the method by using it 
effectively to gain consensus to prioritise a strategy for intervention and research. 
5.9.5.2 Use of the Theoretical Domains Framework (TDF) and COM-B 
New themes found from the consensus panel discussion were mapped onto the TDF 
domains. These were linked to the ‘COM-B’ model to frame the themes into what 
needed to change and inform future analysis and intervention development using the 
Behaviour Change Wheel guide developed by Michie et al (2014). Cadogan et al 
(2015), for example, have identified key TDF theoretical domains and then ‘Behaviour 
Change Techniques’ (BCTs) directly. They explored how to improve polypharmacy for 
older people in primary care. The authors analysed data from semi-structured 
interviews using TDF domains, identified key theoretical domains, and then identified 
and selected BCTs by mapping to the TDF. The authors report that all the TDF 
domains were found to be relevant except ‘emotion’, which illustrated the complex 
nature of the behaviour, and the challenge faced in identifying key domains to target 
for intervention development. They discuss that, despite the intended nature of the 
TDF to simplify psychological theory and make it more accessible to researchers, 
there are challenges in operationalising the TDF, particularly around the 12 and 14 
domain versions, and in selecting BCTs where they found limitations and lack of 
consensus.  
Linking the analysis to COM-B provided a model to strengthen the understanding of 
the TDF domains for non-psychologist researcher, structure the discussion around the 
key themes, and frame the findings to highlight what needed to change to improve 
prescribing in RKF. It is planned that the guidance provided in ‘The Behaviour Change 
Wheel. A Guide to Designing Interventions’ (Michie et al, 2014) will inform the ongoing 
research project to develop an effective intervention to improve prescribing in RKF.  
This study adds to the literature by successfully using the TDF/ COM-B to analyse 
behaviour in a clinical setting using a consensus group method. The TDF has been 
used previously in expert panel studies, for example Porcheret et al (2014) where a 
consensus exercise was undertaken with healthcare professionals to develop a model 
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for osteoarthritis consultations. Khan et al (2014) proposes using the TDF and a 
modified Delphi approach in a multi-stage process to develop an online decision 
support tool. 
5.9.5.3 Future research. 
The top 3 priorities for intervention and research were identified as increasing 
awareness, patient and drug specific warnings and prompts needed, and kidney 
function assessment for older people should be a required part of the prescribing 
process. 
Increasing knowledge was a top ranked statement in the first round rating, but not in 
the second. However, it was clearly important from the group discussion, as was the 
importance of teaching prescribers, both new and clinical specialists.  
There is now a strategy for post-doctoral development of an intervention and future 
research. Focus will be on application for funding for a feasibility study, followed by 
research on an intervention to improve prescribing in reduced kidney function, 
particularly for older people.  
Rich data has been collected from the consensus panel. Analysis was completed for 
the current project, but the data could be reanalysed in greater depth to gain more 
understanding of general prescriber behaviour in primary care and how to improve 
patient safety. 
 
 What this study adds to practice and policy 
The scoping review of guidelines and resources (0) highlighted that national and 
international policies and guidance have advised on management of kidney disease 
but do not cover dosing of drugs that need altering in the reduced kidney function of 
the older patient. Also that the introduction of a different kidney function estimation 
equation for eGFR (MDRD) has not been clarified in relation to use for prescribing 
decisions for older people. 
The consensus panel had expertise in NICE guidance, policy development, and the 
BNF. They suggested working with the BNF Formulary Committee to clarify the 
guidance on ‘prescribing in renal impairment’ and the advice on kidney function 
equation choice. 
The panel also suggested that NICE guidance should be clearer on use of medications 
where parameters such as kidney function are not normal. A recent study has 
recommended that guideline developers should particularly consider whether chronic 
kidney disease is common in the target population (Dumbrek et al, 2015). There was 
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discussion that a NICE guideline on prescribing for older people would be useful, not 
only to give the latest evidence, but also to provide a lever and a focus for change and 
the education curriculum. 
Pharmacists were highlighted by the consensus panel as a resource for doing 
medication review, and providing education and training. 
Post-doctoral work will include liaison with health informatics to ensure the kidney 
function calculators are correct on national patient record systems. 
Priorities for change have been identified to inform development of an intervention that 
has the potential to be useable, feasible and effective in changing prescriber 
behaviour. Highlighting the issues to both clinicians and policymakers is the first stage 
in minimising inappropriate prescribing in routine clinical practice. 
 
 Progression and integration of methods and findings 
The consensus panel concurred with the findings of lack of awareness and knowledge 
about prescribing in reduced kidney function (RKF) expressed by the GP participants 
in Chapter 4. This would account for the findings in the case-note review (Chapter 1) 
where 25% of older people with RKF were on a drug that should be avoided or the 
dose was too high for their level of kidney function. Also for the results found in the 
PCT-wide cross-sectional survey (Chapter 3) where 19% of people aged over 65 
years on the investigation drugs had a kidney function too low, and 39% of those aged 
85 years and older. 
The GP interview study highlighted that warnings and prompts are not currently 
available at medication review which is likely to be a factor in the findings in the 
quantitative studies (Chapters 3 and 4). This had strongly agree ratings from the 
primary care expert panellists, and was given a top 3 priority for intervention and future 
research by the consensus panel in the final rating.  
 
5.10 Conclusion 
An expert panel gave support for the findings from this project, there is generalisability 
and acceptability, and change is needed to reduce the risk of harm for older people. 
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“We all think that it’s hugely important! We just don’t want to talk about it because we 
don’t really know what we’re doing!'” 
Participant C9, GP and academic clinical fellow (2015)  
“I think we may underestimate how much harm we may be actually doing to patients 
by having them on the wrong drugs and wrong dosages or the wrong drugs at the 
wrong time.” 
Participant C1, renal physician with a national role (2015) 
 
 
6 Chapter 6: Discussion and conclusion 
This PhD programme developed from observations in practice that recommendations 
for drug use when kidney function is reduced did not seem to be applied for 
prescribing in primary care. The research studies conducted have systematically 
investigated the extent of the problem, and explored the underlying determining 
factors. 
Sections 6.1.1-6.1.4 present the findings from each stage of the research, and how 
they fulfil the research aims.  
Sections 6.2-6.4 discuss how the intervention priorities identified need to be assessed 
in relation to the current evidence found in the literature review. Also, how the 
intervention priorities need to be considered as to how they might be developed into 
an intervention that encompasses, and works with, contextual drivers of behaviour 
relating to prescribing for older people, as well as with current national policies in the 
NHS. Finally there is a discussion on the next steps that will need to be taken towards 
intervention development, assessing intervention functions, relevant policy categories, 
behaviour change techniques (BCTs) and mode of delivery. 
 
6.1 Principal findings for the research aims 
 Prevalence of inappropriate prescribing in RKF 
Inappropriate prescribing for older people with reduced kidney function was found to 
be widespread. The initial case-note review found that a quarter of the older people 
were prescribed at least one drug that needed altering or review because of the 
reduced level of their kidney function indicating that recommendations are not applied 
for many people. A wide range of drugs were found to be prescribed inappropriately, 
whether because they should be avoided in RKF, the dose should be reduced, they 
277 
 
 
are ineffective in low kidney function, or non-specific caution because they are known 
to cause adverse drug reactions RKF.  
No studies were found in the scoping literature review that would give prevalence data 
in UK primary care for inappropriate prescribing in RKF. However, evidence from other 
countries, and from the hospital setting, showed many other examples of prescribing 
where kidney function was too low for the drug, and that this can lead to significantly 
increased all-cause mortality (Breton et al, 2011), adverse drug reactions (ADRs) 
(Corsonello et al, 2005), and increased risk of hospital admissions (Helldén et al, 
2009) in older people. 
The lack of UK primary care prevalence data found led to the cross-sectional PCT-
wide survey informed by the case-note review findings. The results corroborated the 
high prevalence in a wide population as recommendations for use in RKF were not 
followed for the 8 representative drugs prescribed. For all the older age bands studied, 
there was prescribing of the drugs found where the kidney function was too low for 
recommended use, particularly for those aged 85 years and older.  
The numbers of older people found taking the study drugs were large, and the fact that 
the Bradford population has a lower proportion of older people than the national 
average could mean that the findings might be an underestimate for the wider 
population. Kidney function tended to reduce with increasing age in the PCT-wide 
survey, and increased age meant a higher odds of having a kidney function lower than 
recommended for the drug prescribed. 
UK experts in relevant fields concurred with the prevalence findings in the consensus 
study. They confirmed that the studies described in this thesis have systematically 
investigated the size and nature of the evidence base, the UK primary care 
prevalence, and found frequent inappropriate prescribing for older people with reduced 
kidney function. 
 
 Choice of kidney function estimation equation  
When comparing the kidney function estimations using the two equations, eGFR and 
Cockcroft Gault, substantial differences were found when applied to prescribing 
decisions for the older people reviewed in the case-note review, and subsequently in 
the PCT-wide cross-sectional survey. Using eGFR as an estimation of level of kidney 
function was found to identify a much lower number of alterations required for drug or 
dose choice than would using Cockcroft Gault. Altering or stopping drugs where 
needed would be missed if eGFR was used rather than Cockcroft Gault in a large 
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proportion of the patient drug events assessed. This was similar to the many studies 
found in the evidence from hospital and other countries in the scoping review. 
Scoping review studies that looked at patient outcome and drug blood level data 
agreed that the Cockcroft Gault calculation should still be used to estimate kidney 
function for drug dosing decisions, in particular for the older patient (Melloni et al, 
2008; Roberts et al, 2008); eGFR substantially over-estimates the effect of RKF on 
drug blood levels and so risk of harm is increased. 
There was unanimous agreement by the consensus group expert panel for the need to 
use creatinine clearance calculated using Cockcroft Gault  for prescribing decisions, 
and the clinicians strongly agreed that the calculation of creatinine clearance should 
be easier in the prescribing process. 
 
 Determinants for why GPs do not apply the drug licence 
recommendations when prescribing for older people with RKF 
No studies were found in the scoping review that aimed to explore the underlying 
behaviours and determinants of why the recommendations for prescribing when 
kidney function is reduced are not applied. The qualitative interview study with GPs 
revealed that there is little awareness of the issues around prescribing and RKF, 
substantiating the quantitative study findings. Many of the GPs did not recognise the 
drugs investigated as being affected by kidney function, even by those with a specialist 
interest in the relevant clinical area. Kidney function was reported as being regularly 
tested, which was evident in the PCT-wide survey, but the GP interviews found that 
although they tested kidney function, they did not then apply that to prescribing and 
review.  
Increasing awareness and education is needed for all prescribers, and in clinical 
specialities, on prescribing renally excreted drugs. Patient and drug specific warnings 
and prompts at both drug initiation and at medication review would be useful as a 
reminder when kidney function needs to be taken into consideration. GPs see 
prescribing safely as an important role, and there was an understanding that harm can 
be caused by drugs when kidney function is low, but they were not confident in their 
abilities to apply the recommendations for prescribing in RKF. Resources are used, 
but the BNF information needs clarifying as the front section on ‘prescribing in renal 
impairment’ was not known about and the advice on eGFR versus creatinine 
clearance is confusing. Evidence found suggests that the BNF guidance is not 
adequately evidence-based, because of the over-estimation of kidney function when 
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eGFR is used in older people; also that guidelines could be improved to include advice 
on use of the relevant drugs when kidney function is low. 
The consensus expert panel concurred with the findings of lack of awareness and 
knowledge about prescribing in RKF expressed by GPs. They also strongly agreed 
that warnings and prompts should be available at medication review, and was given a 
high priority for intervention and future research.  
 
 Priorities for intervention and research 
The top four priorities for intervention and future research were agreed in a consensus 
process by experts in relevant fields as: 
 Increasing awareness of the need to assess kidney function for prescribing. 
 Patient and drug specific warnings/prompts are needed at medication review 
as well as initiation. 
 Kidney function assessment for older people should be a required part of the 
prescribing process.  
 A recent kidney function check needs to be available at medication review. 
Pharmacists were highlighted by the consensus panel as a resource for doing 
medication review, providing education and training, and for audit. This was also a 
finding in the scoping review where studies evaluating interventions to improve 
prescribing in RKF that involved pharmacists showed positive results. 
 
 
6.2 The intervention priorities with respect to known 
intervention studies on improving prescribing in 
reduced kidney function 
For 30 studies identified in the scoping literature review for evidence of intervention 
evaluation to aid prescribing in reduced kidney function (Section 0), there was no 
indication of a theory base to inform their intervention development. Not understanding 
the determinants related to prescribing in RKF might be a factor for studies showing no 
benefit. Even studies showing a positive outcome from the intervention tested, can be 
shown to have flaws that indicate the intervention is not likely to be addressing all the 
factors that have been highlighted from the GP interview and consensus panel studies. 
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The results might have been improved and been sustainable, if more barriers, or more 
relevant barriers, had been identified and addressed. 
In the following sections the intervention priorities agreed by the consensus group 
panel are discussed in relation to the intervention studies identified in the scoping 
review.  
 
 Need to increase awareness of the necessity to assess use and 
dosing of drugs in reduced kidney function 
Studies found showed that just having a kidney function level reported when 
monitoring urea and electrolytes, and having the kidney function level on the patient 
record, does not translate to appropriate prescribing in RKF (Primary care: Farag et al, 
2014. Hospital: Quartorolo et al, 2007; Kalendar-Rich et al, 2011; Nielson et al, 2004). 
Without any other input, this does not provide any increased awareness of the need to 
apply a reduced kidney function level to prescribing. 
Field et al (2009) in Canada already had creatinine clearance displayed when 
prescribing but there was still inappropriate prescribing. Their intervention was an alert 
triggered when a listed drug was ordered and CrCl-CG was <50 ml/min. Although 
significantly higher proportions of final drug orders were appropriate in the intervention 
units, the system did not improve the rate at which appropriate doses were ordered. 
This implies that not all the determinants for appropriate prescribing are being 
addressed for the prescribers, and might show a need for more education and training.  
Ehrler et al (2009) describe an intervention of a workshop, desk-top checklist, patient 
information and dosing software for over 800 drugs aimed at prescribers. However, 
follow-up analysis revealed that the positive effect found was mostly related to ACEIs 
and ARBs which suggests a reduced usefulness for other drugs affected by kidney 
function. The dosing software provided was well received, but it could not integrate 
with the patient record system and so the prescriber needed to remember to use the 
system for affected drugs, which might be why few drugs were altered. Awareness 
only seems to have been raised for one group of medicines with this intervention. 
Forough et al (2014) used a text alert system when CrCl was <50 ml/min and showed 
a benefit where doses needed alteration, but no benefit for drugs that needed 
stopping, again suggesting that not all the barriers of awareness and understanding 
had been addressed. 
Many of the interventions described involved pharmacists recognising the need for 
drugs to be altered or reviewed and then flagging that up to the prescriber. The 
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interventions are reported as having a positive outcome, but the studies report that not 
all recommendations are accepted or followed through. For community pharmacist 
interventions to GPs, there was a 66% acceptance rate in the Joosten et al (2013) 
study, 50% reported by Geerts et al (2013), and only 33% accepted in the Via Sosa et 
al (2014) study. This was similar for pharmacists making recommendations for care 
home patients on drugs needing review because of RKF (Gheewala et al, 2014; 
Barnes et al, 2014). Awareness does not seem to have been increased for prescribers 
in these interventions, and an education element may have meant an increased 
understanding of the need for altering prescribing and acceptance of the pharmacist 
recommendation. 
The GP interview study revealed a wide lack of awareness of the need to assess 
kidney function for many drugs, and the consensus group study showed that the 
doctors on the panel ranked ‘increasing understanding’ as a top 3 priority compared to 
the pharmacists, who ranked it lower. The doctors also all strongly agreed that the 
calculation of creatinine clearance should be easier in the prescribing process, whilst 
the pharmacists again ranked this lower. This suggests that pharmacists may 
overestimate GP understanding, and so may underestimate the need to include 
education and training in the intervention. 
 
 Patient and drug specific warnings/prompts are needed at 
medication review as well as initiation 
Many studies showed that alerts were overridden and not acted upon (Cho et al, 2014; 
Youseff et al, 2015; Desmedt et al, 2012; Sellier et al, 2009). These alerts clearly did 
not address the needs of the prescriber, whether there was a need for education and 
training, the alerts were popping up at the wrong times, or maybe they were not patient 
and drug specific.  
Frolich et al (2011) surveyed the effect of a computerised decision support system and 
found it generated a large number of alerts, with only a minor fraction likely to be of 
substantial risk to the patient. Czock et al (2015) showed that a non-specific alert 
system would yield an average number of alerts per medication regimen of 2.22, but 
by tailoring alerts to be patient and drug specific, the alert burden was reduced by 
90%. Melton et al (2015) seemed to have previously tried using alerts but they had not 
been successful, and so they conducted a qualitative exercise to redesign their alerts. 
They found using the new alert there were 43% fewer prescribing errors compared 
with the original alerts. When laboratory links were presented on the redesigned alert, 
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laboratory information was accessed 3.5 times more frequently. Using a qualitative 
enquiry to explore the determinants significantly improved the usability of the alert. 
No studies found explored interventions that addressed the need for assessing kidney 
function at medication review in the primary care system. The current research project 
has shown the importance of the need for warnings and prompts at medication review 
as kidney function can change, and is likely to reduce as a patients gets older, so a 
drug may have been appropriate when it was initiated, but it may not continue to be 
over time. 
 
 Kidney function assessment for older people should be a required 
part of the prescribing process 
Most of the intervention studies found in the scoping literature review did not attempt 
to make changes to the prescribing process, or encourage the prescriber to think 
about kidney function as a routine. Many were alerts triggered by a drug being 
prescribed when kidney function was low, so the prescriber hadn’t thought of it before 
choosing the drug or dose (for example, Forough et al, 2014). Other studies were also 
reacting to an ‘error’ made by the prescriber, such as the pharmacist intervention 
studies (for example, Geerts et al, 2012). These interventions rely on inappropriate 
prescribing being flagged up by a pharmacist or technology and then being accepted 
by the prescriber. The intervention has not addressed the causes of the original error, 
except maybe that there can be an educational element to the alert, or the pharmacist 
response. 
By aiming to explore how to make kidney function assessment part of the prescribing 
process, this intervention priority is wanting to help prescribers to apply the 
recommendations where needed when prescribing, and not make an error that needs 
to be corrected. 
 
 A recent kidney function check needs to be available at 
medication review 
As already mentioned, no studies were found that explored interventions addressing 
the need for assessing kidney function at medication review in the primary care 
system. Many drugs are taken by patients for a long time and changes in kidney 
function level need to be considered.  
Using a systematic theory based method to explore the determinants has highlighted 
this important factor that has not been previously recognised or addressed. 
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 Implication for the current research 
The lack of theoretical underpinning in the intervention studies found in the scoping 
literature review might be a factor where there was little or no benefit found, and 
means that any positive effect is difficult to replicate and make sustainable. The 
current research has been able to target priorities for intervention to identified barriers, 
and so is more likely to lead to an intervention that addresses what needs to change to 
help prescribers apply the recommendations in RKF.  
 
 
6.3 The research findings and intervention priorities with 
respect to current contexts when prescribing for older 
people in primary care 
In all the stages of this research, it has been highlighted that older people are at 
increased risk of harm if prescribing recommendations are not applied, as they are 
more likely to have reduced kidney function, and also more likely to be taking multiple 
medications. The intervention priorities need to be considered as to how they might be 
developed into an intervention that encompasses, and works with, contextual drivers 
of behaviour relating to prescribing for older people, as well as with current national 
policies in the NHS. 
 
 Contextual drivers of behaviour relating to prescribing for older 
people 
6.3.1.1 Medication review 
There is a progressive loss of the functional capabilities of most body organs with 
increasing age, changes in responses to receptor stimulation, and a decrease in 
homeostatic mechanisms, which have implications for drug handling. Of these 
changes though, excretion is the most significant and important age-related 
pharmacokinetic change and is both predictable and measurable (Beers and Berkow, 
2000; Grimley-Evans et al, 2000). Regular monitoring and review of medications 
therefore becomes more important with increased age. Two of the four intervention 
priorities focus on medication review, to have a recent kidney function check available 
at the review, and that the prompts and warnings available when initiating a drug 
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should be easily available at medication review. This was a key theme identified from 
the GP interview study that hadn’t been identified previously as a problem, and had 
not been found in the scoping literature review. If an intervention can be developed to 
provide warnings when reviewing medications, it would have the added benefit of 
providing warnings for other recommendations such as liver function. If the 
recommendation for patient and drug specific warnings and prompts for kidney 
function level were possible, it could also be achieved for other tests which would 
make them more relevant and helpful for the prescriber.   
Currently, GPs have limited time in a short consultation for medication review, and 
only very rarely are tools used to structure that review, such as a custom built 
template, or the ‘NO TEARS’ tool for medication review (Lewis, 2004). If a review tool 
could be developed to incorporate patient and drug specific warnings and prompts 
available, it could potentially help prescribers to highlight where to focus their time. 
Pharmacists have been highlighted by the GP interviewees and the consensus group 
expert panel as healthcare professionals who could be part of the solution by doing 
medication reviews, and audit to highlight where review is needed. They were also 
highlighted as an educational resource. The PINCER study (Avery et al, 2012) showed 
that pharmacist-led feedback, educational outreach, and dedicated support is an 
effective method for reducing a range of medication errors in general practices with 
computerised clinical records, and other studies have shown the benefit of pharmacist 
medication review, for example Zermansky et al (2001) and Blenkinsop et al (2012). 
 
6.3.1.2 Frailty 
There are current initiatives to identify ‘frailty’ in patients which has been defined by 
the British Geriatrics Society (2014) as a distinctive health state related to the ageing 
process in which multiple body systems gradually lose their in-built reserves. They 
state that around 10% of people aged over 65 years have frailty, rising to between a 
quarter and a half of those aged over 85 years, and older people living with frailty are 
at risk of adverse outcomes such as dramatic changes in their physical and mental 
wellbeing after an apparently minor event which challenges their health, such as an 
infection or new medication.  
The findings from this research project have shown that older people are more likely to 
have a lower kidney function, and so a lower reserve to react normally to assaults 
such as dehydration or nephrotoxicity by drugs. 
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Rockwood et al (2005) have described a model of frailty which assumes an 
accumulation of deficits which can occur with ageing and which combine to increase 
the ‘frailty index’ which in turn will increase the risk of an adverse outcome. They 
include multiple medications as a factor and that many drugs are particularly 
associated with adverse outcomes in frailty such as: 
- Antimuscarinics in cognitive impairment. 
- Long acting benzodiazepines.  
- Some sulphonylureas.  
- Other sedatives and hypnotics increase falls risk. 
- Opiate based analgesics increase risk of confusion or delirium. 
- NSAID can cause severe symptomatic renal impairment in frailty. 
It should be noted that all the above drug groups mentioned by the authors have 
recommendations for reduced use when kidney function is low. 
An ‘Electronic Frailty Index’ has recently been developed in the UK which aims to help 
identify and predict adverse outcomes for older patients in primary care (Clegg et al, 
2016). This index is made up of 36 deficits which include one for CKD and one for 
polypharmacy. The findings from the current project would suggest that not all older 
people with a kidney function low enough to affect their prescribed medications would 
be picked up by a ‘CKD’ marker as that uses eGFR. There has also been much 
discussion around older people not necessarily having CKD when kidney function is 
reduced as there is a natural decline with age. The Frailty Index could potentially be 
improved by using CrCl-CG linked to drugs. The intervention priorities would aim to 
improve having a recent kidney function test available and to have that as CrCl-CG in 
the patient record to be available for prescribing decisions. 
 
6.3.1.3 Multimorbidity and polypharmacy 
Having more than one long-term health condition adds complexity to the management 
and care of patients, and the prevalence of long‑term conditions is strongly linked to 
ageing (NICE NG22, 2015). There is a new NICE guideline just published, optimising 
care for people with 2 or more long-term health conditions (multimorbidity) by focusing 
on individual needs, preferences for treatments, and health priorities (NICE NG56, 
2016). There is a section on medicines which discusses medication review and use of 
tools such as the ‘STOPP/START’ criteria which aim to screen older persons' 
prescriptions for potentially inappropriate drugs called STOPP (Screening Tool of 
Older Persons' Prescriptions) and criteria for potentially appropriate, indicated drugs 
called START (Screening Tool to Alert doctors to Right, i.e. appropriate, indicated 
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Treatment) (Gallagher et al, 2008). The STOPP criteria do include stopping NSAIDs 
where eGFR is 20-50ml/min, but no other criteria related to drug use and RKF, and the 
new NICE guideline does not include guidance on monitoring. This project has 
highlighted the importance of monitoring, and an intervention priority is to have a 
recent kidney function available for prescribing decisions. 
Sinnott et al (2015) have stated that, despite the prevalence of multimorbidity, few 
interventions have been developed to improve medication management in this field. 
They discuss that multimorbidity affects over 60 % of patients in primary care, and that 
its association with polypharmacy makes the development of interventions to optimise 
medication management in patients with multimorbidity a priority. 
Older people are more likely to be taking regular medications, with around 75% of 
those aged 60 years and older, and over 90% in the over 70s taking at least one 
prescribed medicine (Petty et al, 2014). The mean number of medicines per patient on 
repeat prescriptions is over 5 for the 60-69 year olds, and up to 7.1 for the over 80s 
(Petty et al, 2014). Multimorbidity means that older people are more likely to be taking 
multiple different kinds of drugs, and many drugs used for varying medical conditions 
are excreted by the kidney. The case-note review found 70 different drugs were 
prescribed when kidney function was reduced in the sample of older people from five 
GP practices, and the latest edition of the Renal Drug Handbook has over 800 drug 
monographs (Ashley and Dunleavy, 2014). The intervention priorities are that kidney 
function should be assessed and applied to all prescribing where appropriate, so an 
intervention will need to be able to help prescribers in the complexity of polypharmacy 
and multimorbidity.  
Some groups of drugs have been highlighted for national scrutiny. For example GPs 
have been urged to review the use of anticholinergic medications in their elderly 
patients, particularly those with dementia, after researchers found their use was 
associated with declines in both physical and cognitive function in a systematic review 
(Fox et al, 2014). Declines in functioning were related to the number of anticholinergic 
drugs and length of time taken. What the authors did not consider in their report was 
that many anticholinergic medications are affected by kidney function and that many 
older people will have increased blood levels because of RKF, which could be a 
relevant factor. 
The Kings Fund report on polypharmacy, the concurrent use of multiple medications 
by one individual, states that it is driven by the growth of an ageing population and the 
rising prevalence of multi-morbidity (Duerden et al, 2013). They define ‘appropriate 
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polypharmacy’ as extending life expectancy and improving quality of life, but 
medicines use has to be optimised and prescribed according to best evidence. In 
‘problematic polypharmacy’ there can be an increased risk of drug interactions and 
adverse drug reactions, together with impaired adherence to medication and quality of 
life for patients. The intervention priorities would aim to promote ‘appropriate 
polypharmacy’ by aiming to ensure recommended drugs and doses are used in RKF. 
They will also help to stop drugs where they should not be used because kidney 
function is too low, reducing ‘problematic polypharmacy’. 
 
6.3.1.4 Deprescribing 
As described in the Kings Fund report on polypharmacy (Duerden et al, 2013), where 
it is ‘problematic’, drugs should be optimised and stopped where appropriate. The 
process of reducing or discontinuing medications, with the goal of minimising 
inappropriate use and preventing adverse patient outcomes, is increasingly referred to 
as ‘deprescribing’ (Alldred, 2014). ‘Deprescribing’ is the process of withdrawal of an 
inappropriate medication, supervised by a health care professional with the goal of 
managing polypharmacy and improving outcomes’ (Reeve et al, 2015). Although the 
term may be new, appropriate cessation or reduction of medication is a long accepted 
component of competent prescribing.  
In the meta-synthesis by Anderson et al (2014) found in the scoping review, the 
authors showed that many factors were involved related to prescribers in stopping, or 
altering a medication a patient has been on for some time, which were highly 
interdependent and impacted by considerable clinical complexity. The themes broadly 
fell into awareness, inertia, self-efficacy and feasibility. They found that where there 
was polypharmacy, prescribers could not easily identify which medications were 
inappropriate. ‘STOPP/START’ mentioned in the previous section is an example of a 
recent tool developed to help prescribers identify drugs that should be stopped 
(Gallagher et al, 2008). If the intervention priorities identified can be developed into a 
useable intervention, it will help prescribers identify where kidney function is low and 
which drugs should be avoided, giving them the tools to encourage appropriate 
deprescribing. 
 
6.3.1.5 Care homes medicines management 
The ‘CHUMS’ study aimed to establish the prevalence, types and underlying causes of 
medication errors in care homes, estimate the ensuing harm and developing solutions 
to reduce the prevalence of error (Barber et al, 2009). They concluded that there is an 
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unacceptable prevalence of medication errors in care homes, affecting some of the 
most vulnerable members of society, and ‘action is required from all concerned’. All 
the issues discussed previously around age related changes in drug handling, 
multimorbidity, polypharmacy, and deprescribing apply for people living in care homes.  
Most reviews of patients in care homes are done by the practitioner visiting the home. 
An issue raised by the GP interviewees, and the expert panel, was that they do not 
have the electronic patient record when reviewing. The intervention priorities that aim 
to ensure a kidney function level is available when reviewing medicines, and to be a 
part of the prescribing process, would necessitate access to the patient record on 
home visits. Technologies are available to give mobile access to records that would 
need to be more widely available. 
Studies found in the scoping literature review highlighted problems with medicines and 
RKF in care homes, and how pharmacists can improve prescribing by providing 
medication review with access to kidney function levels (Geewala et al, 2014; Barnes 
et al, 2014). 
 
 Contextual drivers of behaviour relating to current national 
policies in the NHS. 
6.3.2.1 Reducing admissions 
Reducing emergency admissions to hospital, both as a measure of care quality and to 
contain spiralling healthcare expenditure, is a notional priority. Emergency admissions 
in the United Kingdom rose by 47% from 1998 to 2013, from 3.6 million to 5.3 million, 
with only a 10% increase in population over this period. These admissions are 
expensive; in 2012 they cost the NHS £12.5bn. Wallace et al (2016) state that 
targeting specific conditions might reduce emergency admissions, and variation in 
medical practice should be considered. Many studies were found in the scoping 
literature review showing that not assessing kidney function in relation to prescribing 
can cause adverse effect and hospital admissions, for example Helldén et al (2009).  
The intervention priorities would help prescribers identify where drugs should be 
altered, or doses reduced, to reduce the risk of harm and hospital admission. 
 
6.3.2.2 Quality Outcomes Framework 
The Quality Outcomes Framework (QOF) is the annual reward and incentive 
programme detailing GP practice achievement results. It rewards practices for the 
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provision of quality care and helps standardise improvement in the delivery of primary 
medical services, awarding practices achievement points for: 
 Managing some of the most common chronic diseases, e.g. asthma, diabetes. 
 Managing major public health concerns, e.g. smoking, obesity. 
 Implementing preventative measures, e.g. regular blood pressure checks. 
The 2006 QOF markers included formation of registers of patients with CKD stages 3, 
4 and 5 as calculated by the MDRD equation. Although, since then there were further 
measures added including regular monitoring, the QOF marker is now back to just the 
formation of a register of CKD patients. Regular monitoring is no longer incentivised 
this way, and there has never been signposting to prescribing, or effect of RKF on 
prescribing. 
At the time of the PCT-wide survey, there were QOF markers for medication review, 
but not currently: 
‘Medicines 11 A medication review is recorded in the notes in the preceding 15 months 
for all patients being prescribed 4 or more repeat medicines Standard 80%.’ 
‘Medicines 12 A medication review is recorded in the notes in the preceding 15 months 
for all patients being prescribed repeat medicines Standard 80%.’ 
Currently there is no incentivisation through QOF for either medication review or for 
regular monitoring in CKD. The PCT-wide survey showed that it is feasible to collect 
the data required from the patient record system for kidney function level by CrCl-CG, 
and so it would be possible to set markers for safer prescribing that are encompassed 
in the intervention priorities. However, CrCl-CG is not often calculated currently, and is 
rarely read coded, which would make routine data collection more difficult. If the 
intervention priorities are developed into a usable intervention that means CrCl-CG is 
used routinely then it might be considered whether this method of incentivisation would 
help to reduce harm to patients from their medicines. 
 
6.3.2.3 NICE guidelines 
A recent systematic examination of recommendations in twelve NICE clinical 
guidelines concluded that drug-disease interactions with chronic kidney disease were 
common and that guideline developers should particularly consider whether chronic 
kidney disease is prevalent in the target population (Dumbreck et al, 2015). For 
example they state that prevalence of comorbidity with chronic kidney disease was 
about 14% in patients with type 2 diabetes, and 23% in patients with heart failure, so 
the implication might be that guideline developers should consider chronic kidney 
disease with heart failure, and possibly consider it with type 2 diabetes. 
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It has been previously discussed that the NICE CKD guidelines do not consider 
prescribing in RKF, other than for treatment, except to ‘do a medication review’. This is 
also the case in other NICE guidance such as ‘Managing medicines in care homes’ 
guidelines (NICE SC1, 2014), long‑term conditions guidance (NICE NG22, 2015), and 
multimorbidity guidance (NICE NG56, 2016). 
The expert consensus panel stated that national guidance and quality standards act as 
a lever, and that they are transformative, providing a priority focus and leading to the 
teaching curriculum and national strategy such as use of QOF. They suggested that 
NICE guidance should be clearer on use of medications where parameters such as 
kidney function are not normal. There was also discussion by the panel on the 
intervention priorities, concluding that a NICE guideline on prescribing for older people 
would be useful, not only to give the latest evidence, but also to provide a lever and a 
focus for change and the education curriculum.  
 
 
6.4 Intervention priorities – the next steps towards 
intervention development 
The Behaviour Change Wheel (BCW) describes three broad stages: understanding 
the behaviour, identifying intervention options, and identifying content and 
implementation options. (Michie et al, 2014). These are subdivided into a further eight 
steps, the first four of which have been achieved in the research project so far: 
BCW step 1: define the problem in behavioural terms. 
BCW step 2: select the target behaviour. 
BCW step 3: specify the target behaviour. 
BCW step 4: identify what needs to change to achieve the desired behaviour. 
The final four BCW steps were out with the time and scope of the PhD programme to 
undertake the additional studies. However, the intervention priorities defined by the 
consensus panel will direct the future ongoing stages of intervention development: 
BCW step 5: identify intervention functions to achieve the desired behaviour. 
BCW step 6: identify policy categories. 
BCW step 7: identify behavioural change techniques. 
BCW step 8: identify mode of delivery. 
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A systematic review of frameworks of behaviour change interventions identified 19 
frameworks which comprised nine intervention functions and seven policy categories 
(Michie et al, 2011). The resulting Behaviour Change Wheel integrated framework 
links these intervention functions and policy categories to the COM-B model (Figure 
33). 
Potential intervention functions and policy categories identified by the Behaviour 
Change Wheel need to be considered for the intervention priorities agreed by the 
consensus panel, and these will then inform the selection of potential behaviour 
change techniques. 
 
 Intervention functions 
The links between COM-B, TDF and intervention functions have been identified in a 
consensus exercise (Michie et al, 2014, pp113-115) and this has been used to indicate 
possible intervention functions to consider for the intervention priorities agreed by the 
consensus panel. Figure 35 show the priority TDF domains, and the potential 
intervention functions that might be considered for each intervention priority. The TDF 
domains are the five identified in the GP interview study linked to the four intervention 
priorities. Three further domains have been included: 
 Beliefs about consequences, as patient safety was expressed to be an 
important motivation for prescribers. 
 Professional/ social role and identity, as prescribing was described by GPs 
as a key role and they wanted to do it correctly. Also the finding that there was 
less responsibility for the prescribing felt when doing a medication review which 
should be an important consideration when developing an intervention. 
 Social influences, as pharmacists were specifically identified as a group who 
should be considered. 
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Figure 35: Potential intervention functions identified from the Behaviour Change 
Wheel (Michie et al, 2014) 
 
 
All seven of the intervention functions are listed in Figure 35 for the relevant domains, 
but restriction and coercion would not be applicable. The other five intervention 
functions can be considered for a potential intervention: 
 Education: increasing knowledge or understanding. Education will need to an 
important part of an intervention, as lack of knowledge about prescribing in 
RKF has emerged as a major theme. Suggestions from the GPs and expert 
panel have included education at all levels, in medical training, GP training, 
continued professional development, and specialist clinical areas. 
Technological solutions such as warnings or prompts can include educational 
elements, and educational outreach visits could be included. Strategies such 
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as ‘audit and feedback’ (Ivers et al, 2012) can be educational, as well as 
persuasive.  
 Training: imparting skills. Prescribers need to know how to implement 
recommendations in the prescribing process, and how to access the required 
data on the patient record systems. Training could help prescribers to form 
personal rules, action plans, and to remember and apply recommendations. 
 Environmental restructuring: changing the physical or social context. 
Technological solutions could be developed to make applying the 
recommendations easier in the prescribing process. Making warnings and 
prompts patient and drug specific would make them more useable, and making 
them easily available at medication review would be important. Pharmacists 
could be more involved with medication review and audit. Community 
pharmacists might have kidney function results to inform use of medicines. 
 Enablement: increasing means/ reducing barriers to increase capability 
(beyond education and training) or opportunity (beyond environmental 
restructuring). 
 Modelling: providing an example for people to aspire to or imitate. Case 
studies could be used to induce automatic imitation and change habit. 
 Persuasion: using communication to induce positive or negative feelings or 
stimulate action. Respected leaders and peers could be used to persuade of 
the need to assess kidney function in the prescribing process. Pharmacists 
have been suggested as being respected in this area. GPs were motivated by 
not doing harm which can be used to persuade prescribers of the importance of 
applying recommendations. 
 Incentivisation: creating an expectation of reward. The Quality Outcomes 
Framework has previously incentivised GP practices in care for patients with 
CKD including regular kidney function monitoring, but now it is only to keep a 
register. The data is available to provide reports and so kidney function as 
creatinine clearance could be reported if it was agreed to be prioritised this 
way.  
The APEASE criteria (affordability, practicability, effectiveness/ cost-effectiveness, 
acceptability, side-effects/ safety, equity) for designing and evaluating interventions 
and intervention ideas will be used to select the most appropriate intervention 
functions (Michie et al, 2014). 
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 Policy categories 
The next step in developing an intervention strategy will be to consider what policies 
would support the delivery of the intervention functions. The 19 framework synthesis 
identified seven policy categories representing types of decisions made by authorities 
that help to support and enact the interventions. Fiscal measures, regulation, and 
legislation are not likely to be applicable, but potential policy categories that could be 
considered using the APEASE criteria are: 
 Communication/ marketing: using print, electronic, telephonic or broadcast 
media. 
 Guidelines: creating documents that recommend or mandate practice. This 
includes all changes to service provision. 
 Environmental/ social planning: designing and/ or controlling the physical or 
social environment. 
 Service provision: delivering a service. 
 
 Content and implementation options 
The final stage in intervention development will be to identify content and 
implementation options i.e. which behaviour change techniques (BCTs) and the mode 
of delivery. A BCT is defined as ‘an active component of an intervention designed to 
change behaviour’, with defining characteristics that are observable, replicable, an 
irreducible component of an intervention designed to change behaviour and a 
postulated active ingredient within the intervention (Michie and Johnstone, 2013). It is 
the smallest component in the proposed mechanisms of change, and can be used 
alone or in combination with other BCTs. Behaviour specific taxonomies of BCTs have 
been synthesised and refined to produce a BCT taxonomy with 93 BCTs organised 
into 16 groupings (Michie et al, 2013). All BCTs that could be considered for any 
particular intervention function, guided by the definition, will be considered, and then 
narrowed down to those most likely to be appropriate. The modes of delivery will also 
need to be considered. 
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6.5 Strengths and limitations 
These pragmatic studies using mixed methods have given a comprehensive picture of 
the extent of inappropriate prescribing in RKF, and what needs to change to help 
prescribers apply the prescribing recommendations. The application of several robust 
and reproducible research methods studying of the same problem area has given 
cross-verification, reducing the weaknesses and biases of single method studies. The 
investigation has been driven by the research questions, and derived from the 
integration of methods and results from the previous studies. It has combined data 
from both quantitative and qualitative methods to address the different research 
questions and enhance the validity of the findings. Updating of the  scoping literature 
review led to a re-analysis of the prescribing data from the cross-sectional survey to 
include a ‘cases missed’ analysis, adding strength to the quantitative analysis, giving a 
clear measure of the impact for patients, as well as a comparison to the other studies 
in the literature. 
The problem has been mapped, tested in a wide population, and explored to find what 
needs to change. There has been good participation and support from GP practices, 
interviewees and panellists throughout the project. 
The project was based in one former PCT which is not a typical population with fewer 
older people than the England & Wales average, so the findings may be an 
underestimation of the problem in the UK. The GPs interviewed were from a small 
localised area, but there was a wide range of prescribing experience, clinical interests 
and specialities, and so the findings may be more likely to be applicable in a wider 
context. Primary care studies in France and Australia (Breton et al, 2011; Khanal et al, 
2015) have also found a high prevalence of inappropriate prescribing for older people 
with RKF lending weight to the generalisability of the findings. 
Patient and public involvement in the project was considered, but the initial key aim of 
this project was to investigate whether there was a problem of prescribing 
recommendations in RKF not being applied. Having established that there is a need 
for intervention, it is planned that there should be patient and public involvement in the 
planning and participation in the subsequent stages of research. The consensus panel 
raised the issue that patients do not tend to have any awareness of kidney function 
unless they have severe disease. Raising the issues of reduced kidney function in 
those who are unaware would need sensitive consideration.  
As a single researcher, overseen by the supervision team, there was a vision and a 
consistency carried through the project. However, it may mean biases are introduced 
296 
 
 
to the methods and analysis. The reproducibility may be reduced by my professional 
involvement, which may have contributed to the rich data collected, but also could 
have meant an assumed shared language and understanding. Specialist expertise 
was sought to verify reliability, and there was an iterative process of reflection, as well 
as comparison with methods and results from similar studies from hospital and other 
countries, lending greater confidence in the conclusions. 
 
 
6.6 What this project adds to the literature 
No evidence was found in the literature on the prevalence of inappropriate prescribing 
for older people with RKF in UK primary care, or the determinants of prescriber 
behaviour in this area, suggesting that these studies are the first in the UK.   
This project has added to the body of literature on: 
 The international evidence base for prevalence of inappropriate prescribing for 
older people with RKF. 
 The necessity of using the Cockcroft Gault equation with ideal body weight, or 
actual if lower, to estimate kidney function for prescribing decisions, particularly 
for older people. 
 The UK evidence base for prescriber behaviour. 
 The use of a scoping literature review, the TDF, and consensus group methods 
in healthcare research. 
The focus for this research has been on older people. It has been previously 
highlighted that this age group are generally under-represented in medication related 
research (Avorn, 2010). Older people were not included in the kidney function 
estimation equation development studies and yet, in 2013, people aged 65 years and 
older took 60% of all dispensed medications in England & Wales (Health and Social 
Care Information Centre, 2014), emphasising the necessity of research focussed on 
this age group. 
 
 
6.7 What this project adds to practice and policy 
Highlighting the issues to both clinicians and policymakers is the first stage in 
minimising inappropriate prescribing in routine clinical practice. Further research is 
needed to ensure an intervention will be more likely to be successful in changing 
practice, and not have unintended consequences.  
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The impact of this project on practice and policy has already included: 
Locally:  
 Development of a guideline for the assessment of kidney function for use of 
new oral anticoagulants (NOACs) in the Bradford deep vein thrombosis (DVT) 
pathway, and in the anticoagulant clinics. 
 Assessment of kidney function included in pharmacy team audits. 
 Key prescribing performance indicators to review medications for people with 
chronic kidney disease. 
Regionally: 
 Involvement with the Yorkshire regional AKI forum: educational sessions, and 
resource development. 
Nationally: 
 The guideline for the assessment of kidney function for use of new oral 
anticoagulants (Wood et al, 2013) is being used widely, for example: 
- As part of a Primary Care DVT pathway in Horsham and Mid Sussex 
CCG. 
- To aid safe prescribing of NOACs in primary care in North Somerset 
CCG, Aylesbury Vale CCG, Chiltern CCG, Buckingham CCG, Bury and 
Greater Manchester. 
 Participation on a diabetes advisory board resulting in the inclusion of a 
‘reducing risk of medicines in RKF’ component on a data ‘dashboard’ for use in 
primary care. 
The requirements for education and training need to be developed and implemented. 
The consensus panel agreed that a submission should be made to the BNF Formulary 
Committee to clarify the advice and information for prescribing in RKF, particularly in 
relation to prescribing for older people. Both the front ‘prescribing in renal impairment’ 
section and the individual drug monographs could be improved to help application of 
the prescribing recommendations. The panel also highlighted that the ‘renal calculator’ 
on at least one of the national GP patient record systems needs to be corrected to use 
the best evidence-based variables, and this has since been rectified.   
Dumbreck et al (2015) have highlighted that guidelines need to consider 
recommendations for drug use in relation to level of kidney function. CKD and AKI 
guidelines could include guidance on prescribing to both reduce the risk to the kidney, 
and reduce ADRs from all renally excreted drugs. The NHS England ‘Think Kidneys’ 
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campaign resources include an ‘AKI medicines optimisation toolkit’ aimed at 
prescribers in hospitals (NHS England, 2015), but it could be usefully extended to 
primary care to help reduce the risk of AKI from drugs. The consensus panel also 
suggested that a new NICE guideline on prescribing for older people would be a focus 
for change and education. 
Having the warnings and prompts at medication review would have the added benefit 
of highlighting other parameters that might need assessment, such as liver function 
and thyroid function tests.  
 
 
6.8 Translation and impact 
 Publication and presentation 
Publication: 
 Wood, S., Petty, D., Glidewell, L., Raynor, T. 2011. Are we over-dosing our 
elderly patients with renally excreted drugs in primary care? International 
Journal of Pharmacy Practice, 19(suppl. 2), p.38. 
Publications arising from issues raised in practice: 
 Wood, S., Petty, D., Fay, M., Lewington, A. 2013. Assessing kidney function in 
oral anticoagulant prescribing: an aid for safer drug and dose choices. British 
Journal of Cardiology, 20, pp.61–64. 
 Wood S. Anticoagulant dosing in reduced renal function for stroke and 
systemic embolism prevention in non-valvular AF. Guidelines in Practice 2013, 
(suppl). 
 Howard, P. and Wood, S. 2013. Outcomes with the use of nitrofurantoin in 
renal impairment in primary care − a pilot study. European Journal of Hospital 
Pharmacy, 20, p.A114. 
Poster presentations: 
 The Royal Pharmaceutical Society Conference 2011. 
 The Renal Association Conference 2012. 
 The University of Leeds School of Healthcare Postgraduate Research 
Conference 2011 (first prize achieved). 
 The University of Leeds School of Healthcare Postgraduate Research 
Conference 2014. 
Oral presentations: 
299 
 
 
 The University of Leeds School of Healthcare Postgraduate Research 
Conference 2015. 
 The Health Services Research & Pharmacy Practice Conference 2016. 
 The International Social Pharmacy Workshop 2016. 
 The Yorkshire Regional AKI Forum. 
 Bradford primary care AKI/CKD education event. 
 The Mixed Methods module group, University of Leeds School of Healthcare. 
Plan for publication: 
 ‘A scoping literature review to identify the evidence base on prescribing for 
older people with reduced kidney function.’ 
 ‘A cross-sectional survey of prescribing data to investigate whether 
recommendations for prescribing are applied for older people across a PCT 
population.’ 
 ‘A qualitative GP interview study to explore why prescribers do not apply 
prescribing recommendations for older people with reduced kidney function.’ 
 ‘A consensus group method to identify key themes for development of an 
intervention strategy and future research into prescribing for older people with 
reduced kidney function.’ 
 
 Further research 
The next stage of research will be an application for funding for a feasibility study 
before intervention implementation research, including patient and public involvement. 
Other questions have been raised during the process that might be possible to pursue 
in the future, such as ‘does reducing the burden of drugs excreted by the kidney 
improve kidney function for older people with RKF?’ 
 
 Impact for patients and the NHS 
Implementation of better practice is likely to reduce the risk of harm from medications. 
Using recommended drugs and doses could also mean that older people can continue 
to use beneficial treatments that might have been stopped if doses were too high and 
caused ADRs. 
ADRs, and harm related to medicine given during inpatient stays, have been estimated 
to cost £770m in 2007 in England, and that £5m was spent on litigation for drug-
related medical errors between 1995 and 2007 (Frontier Economics, 2014). Helldén et 
al (2009) found a third of admissions for older people with ADRs were caused by RKF 
suggesting a high financial impact.  
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 Impact for myself 
This process has enabled me to become more confident about the evidence around 
prescribing in RKF, and presentation of the issues. The skills gained have also 
impacted on my professional life by: 
 Questioning the status quo more. 
 Having the confidence and skills to pursue clinical, professional and research 
problems. 
 Awareness of the need to explore the wider aspects of behaviour change, such 
as systems, habit or emotion, when questioning issues in prescribing. 
As a pharmacist, reducing risk from drugs is my ultimate aim. 
 
6.9  Conclusion 
At least 40% of all people aged 65 years and older are prescribed drugs that are 
excreted by the kidney and which have recommendations for altered use when kidney 
function is reduced. Older people are more likely to have RKF, but, although eGFR is 
routinely reported by pathology, and most have a recent kidney function estimate on 
their record, it is not applied to prescribing decisions by GPs. When looking at specific 
renally excreted drugs, 10.1% of ≥65 year olds, and 39.5% of ≥85 year olds, had a 
kidney function too low for the medication, or dose, they were prescribed, increasing 
the risk of ADR, harm and hospitalisation. Evidence of actual harm was found when 
reviewing case-notes. 
This research has mapped and highlighted the prevalence of inappropriate prescribing 
in RKF in primary care and explored the behaviour determinants. It has identified what 
needs to change in practice and policy, and what further research is required, to 
improve patient safety.
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8 Appendices 
8.1 Appendix 1: case-note review patient details form 
Practice...................................... Pt Number................... M/F……… Age……… 
diabetic?..................other current problems……………………………………… 
 
eGFR  ……………………   CKD stage ………………..   date ………….. 
 
CrCl calculated by Cockcroft & Gault (140-age) x IBW  (x1.2 if male) = 
      Serum creatinine                     ....................... 
Potentially nephrotoxic drugs 
Drug recommendation Comment 
   
   
   
 
Other renally cleared drugs  
Drug recommendation Comment 
   
   
   
   
   
   
Other drugs 
 
 
 
Other comments 
 
 
 
Pharmacist…………………………………         date……………… 
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8.2 Appendix 2: the 70 different drugs encountered in the case-note review not used according to 
recommendations in RKF with patient numbers and BNF/SPC recommendations. 
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Appendix 3: literature search term categories 
#NAME? Subject heading keywords (‘OR’)
Adverse Drug 
Reactions - ADR
Drug toxicity   explode
Medication errors
(drug adj2 (problem* or event* or error* or adverse))
(adverse adj3 (reaction* or event*))
ADR
(medication adj2 (error* or safety or adverse))
(renal risk adj (drug* or medication*))
nephrotoxic
Hospital admission*
Hospitali*
Decision support 
tools - DS
Decision Support Systems, Clinical
Decision Making, Computer-Assisted     
Therapy, Computer-Assisted
Decision Support Techniques
alert*
drug dos* service
dos* guid*
(compute* adj3 (support or tool* or service*))
(decision adj3 (support or tool* or service*))
Elderly - E Aged explode elder*
over 65*
old* person*
old* patient*
Guidelines/ 
recommendations - 
GR
guideline  or practice guideline
guideline adherence
guideline*
guidance
guideance
recommendation*
((guid* or recommendation*) adj4 (adher* or comply or complia* or complie* or follow* or observ*))
Kidney function 
Equations/ diagnostic 
tests - KFT
Kidney Function Tests explode (kidney adj4 (test* or check* or formula* or equation*))
Glomerular filtration rate
GFR
eGFR
MDRD
Cockcroft adj Gault
Cockcroft-Gault
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Prescribers - P Physicians explode prescriber*
doctor*
GP*
general practitioner*
MD*
physician*
phycisian*
Prescriber Behaviour 
- PB
((prescrib* or MD* or physician* or GP* or general practitioner* or doctor*) adj (behavi* or performance or error))
((prescrib* or MD* or physician* or GP* or general practitioner* or doctor*) adj4 (knowledge or attitude* or belief* or 
barrier* or adhere* or implement* or compli*))
Prescribing - Pg Drug Therapy  explode
Drug Prescriptions explode
prescrip*
prescrib*
'drug use'
'medication use'
drug dos*
medication dos*
medication order*
dos* adjustment
Primary Care - PC Primary Health Care
general practice  or family practice
(primary adj (healthcare or health care or care))
general practice
GP*
Renal impairment - RI Renal Insufficiency  or renal 
insufficiency, chronic
(renal adj (impairment or failure or dysfunction or insufficiency))
(impaired adj (renal function or kidney function))
(reduced adj (renal function or kidney function or GFR or glomerular filtration rate or eGFR or creatinine clearance))
(kidney adj (failure or dysfunction))
(poor adj (renal function or kidney function))
(chronic adj (renal failure or kidney disease))
CKD
eGFR decline
Additions English only
Reviews only
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8.3 Appendix 4: Medline search strategy for the literature  
review key review area 4 
Medline  
1. exp Physicians/  
2. prescriber*.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier]  
3. doctor*.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier]  
4. GP*.mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier]  
5. general practitioner*.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, 
rare disease supplementary concept word, unique identifier] 
6. MD*.mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier]  
7. physician*.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] 
8. phycisian*.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier]1  
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8  
10. Guideline Adherence/ or Guideline/ or Practice Guideline/  
11. guideline*.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier]  
12. guidance.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier]  
13. guideance.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier]2  
14. recommendation*.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, 
rare disease supplementary concept word, unique identifier] 
15. ((guid* or recommendation*) adj4 (adher* or comply or complia* or complie* or 
follow* or observ*)).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, 
rare disease supplementary concept word, unique identifier] 
16. 10 or 11 or 12 or 13 or 14 or 15  
17. exp Drug Therapy/  
18. exp Drug Prescriptions/  
19. prescrip*.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier]  
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20. prescrib*.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier]  
21. 'drug use'.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier]  
22. 'medication use'.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, 
rare disease supplementary concept word, unique identifier] 
23. drug dos*.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier]  
24. medication dos*.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, 
rare disease supplementary concept word, unique identifier] 
25. medication order*.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, 
rare disease supplementary concept word, unique identifier] 
26. dos* adjustment.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, 
rare disease supplementary concept word, unique identifier] 
27. 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26  
28. ((prescrib* or MD* or physician* or GP* or general practitioner* or doctor*) adj 
(behavi* or performance or error)).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier]  
29. ((prescrib* or MD* or physician* or GP* or general practitioner* or doctor*) adj4 
(knowledge or attitude* or belief* or barrier* or adhere* or implement* or 
compli*)).mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier]  
30. 28 or 29  
31. exp Kidney Function Tests/  
32. (kidney adj4 (test* or check* or formula* or equation*)).mp. [mp=title, abstract, 
original title, name of substance word, subject heading word, keyword heading word, 
protocol supplementary concept word, rare disease supplementary concept word, 
unique identifier]  
33. Glomerular filtration rate.mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary concept 
word, rare disease supplementary concept word, unique identifier]  
34. GFR.mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier]  
35. eGFR.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier]  
36. MDRD.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier]  
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37. (Cockcroft adj Gault).mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary concept 
word, rare disease supplementary concept word, unique identifier]  
38. Cockcroft-Gault.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, 
rare disease supplementary concept word, unique identifier] 
39. 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38  
40. Primary Health Care/  
41. Family Practice/ or General Practice/  
42. (primary adj (healthcare or health care or care)).mp. [mp=title, abstract, original 
title, name of substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, unique 
identifier]  
43. general practice.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, 
rare disease supplementary concept word, unique identifier] 
44. GP*.mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier]  
45. 40 or 41 or 42 or 43 or 44  
46. 9 and 16 and 27 and 30 and 39 and 45  
47. limit 46 to english language  
48. 9 and 16 and 27 and 30 and 39  
49. limit 48 to english language  
50. 9 and 16 and 27 and 30  
51. limit 50 to english language  
52. limit 51 to ("review articles" and "qualitative (best balance of sensitivity and 
specificity)") 
 
 
 
Footnotes: 
1. ‘phycisian’ has been deliberately added in search term 8, as well as the 
correctly spelt ‘physician’ in term 7. The University of Leeds Library adviser 
suggested that as this term is frequently mis-spelt, it can increase the number 
of studies found. 
2. ‘guideance’ has been deliberately added in search term 13, as well as the 
correctly spelt ‘guidance’ in term 12, on the advice of the University of Leeds 
Library adviser as in footnote 1. 
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8.4 Appendix 5: letter of access for the PCT-wide 
prescribing survey (Chapter 3) 
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8.5 Appendix 6: email reply from the National Research 
Ethics Service re PCT-wide prescribing survey 4/12/2011 
(Chapter 3) 
Thank you for your further email enquiry.  As you are aware, our leaflet “Defining 
Research”, explains how we differentiate research from other activities, and is 
published at: http://www.nres.npsa.nhs.uk/applications/is-your-project-research/. 
Based on the additional information you have provided, our advice is that the project is 
not considered to be research according to this guidance and therefore does not 
require ethical review by an NHS Research Ethics Committee.  
If you are undertaking the project within the NHS, you should check with the relevant 
NHS care organisation(s) what other review arrangements or sources of advice apply 
to projects of this type.  Guidance may also be available from the clinical governance 
office.  
Although ethical review by an NHS REC is not necessary in this case, all types of 
study involving human participants should be conducted in accordance with basic 
ethical principles, such as informed consent and respect for the confidentiality of 
participants.  Also, in processing identifiable data there are legal requirements under 
the Data Protection Act 2000.  When undertaking an audit or service/therapy 
evaluation, the investigator and his/her team are responsible for considering the ethics 
of their project with advice from within their organisation.   
This response should not be interpreted as giving a form of ethical approval or any 
endorsement to your project, but it may be provided to a journal or other body as 
evidence that ethical approval is not required under NHS research governance 
arrangements. 
However, if you, your sponsor/funder or any NHS organisation feel that the project 
should be managed as research, and/or that ethical review by an NHS REC is 
essential, then please write setting out your reasons and we will be pleased to 
consider your request further.   
Where NHS organisations have clarified that a project is not to be managed as 
research, the Research Governance Framework states that it should not be presented 
as research within the NHS. 
Regards  
Queries Line 
National Research Ethics Service 
National Patient Safety Agency 
4-8 Maple Street 
London 
W1T 5HD  
 
Website: www.nres.npsa.nhs.uk 
Email:  queries@nres.npsa.nhs.uk  
 
Ref:  04/31 
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8.6 Appendix 7: participant invitation letter for the GP 
interview study (Chapter 4). 
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8.7 Appendix 8: participant consent form for the GP 
interview study (Chapter 4) 
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8.8  Appendix 9: participant information sheet for the GP 
interview study (Chapter 4) 
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8.9  Appendix 10: certificate of attendance for the GP 
interview study (Chapter 4) 
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8.10  Appendix 11: participant pre-interview reading for the 
GP interview study (Chapter 4) 
Pre discussion reading 
 
Thank you very much for agreeing to discuss your experience and views on drug use 
and prescribing for older patients with reduced kidney function (RKF). If you could 
possibly read the following now, it might help you to think about the subject before our 
discussion.  
 
In a case note study in 5 GP practices in Bradford1 25% of all patients aged 65 years 
or older were on a drug that needed stopping or the dose reducing because of their 
level of kidney function based on the recommendations given in the drug licence 
(Summary of Product Characteristics2 - SPC). The study highlighted four main 
categories: 
 Drugs to avoid at specified reduced levels of kidney function e.g. metformin, 
alendronic acid. 
 Drugs that need reduced dosing e.g. gabapentin, pregabalin, simvastatin, 
ramipril. 
 Drugs that are ineffective at reduced levels of kidney function e.g. 
nitrofurantoin, thiazides. 
 Drugs that do not have specific recommendations other than ‘caution’ but are 
well known to be problematic in reduced kidney function (RKF e.g. NSAIDs, 
ACEIs, ARBs. 
A cross-sectional survey of the PCT-wide prescribing database corroborated the 
practice level findings suggesting that recommendations for prescribing for patients 
with RKF are often not followed. For example, 73% of nitrofurantoin prescribed for 
patients aged 65 years and older was at a kidney function too low for an adequate 
urine concentration for effectiveness.  
 
A pilot study3 in a Bradford GP practice showed that patients with a reduced kidney 
function given nitrofurantoin were more likely to need further antibiotic treatment and a 
recent MHRA Drug Safety Update has highlighted this problem4. 
 
Thank you for taking time to read this and I shall look forward to discussing the issues 
around prescribing for older patients with RKF. 
 
 
References 
1. Wood SI, Petty D, Glidewell L, Raynor T. Are we over-dosing our elderly patients with renally excreted drugs 
in primary care? IJPP 2011;19 (suppl. 2):38 
2. Summary of Product Characteristics. www.medicines.org.uk 
3. Howard P and Wood S. Outcomes with the use of nitrofurantoin in renal impairment in primary care − a pilot 
study. Eur J Hosp Pharm 2013 20: A114 
4. Nitrofurantoin: reminder on precautions for use, especially renal impairment in (elderly) patients. Drug Safety 
Update August 2013 
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8.11  Appendix 12: the topic guide for the GP interview study 
(Chapter 4) 
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8.12  Appendix 13: University of Leeds School of Healthcare 
Ethics approval letter for the GP interview study 
(Chapter 4) 
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8.13  Appendix 14: WSYB CSU NHS research governance 
assurance letter for the GP interview study (Chapter 4) 
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8.14  Appendix 15: WSYBCSU letter of access for the GP 
interview study (Chapter 4) 
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8.15  Appendix 16: participant invitation letter for the 
consensus group study (Chapter 5). 
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8.16  Appendix 17: participant consent form for the 
consensus group study (Chapter 5) 
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8.17  Appendix 18: participant information sheet for the 
consensus group study (Chapter 5) 
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8.18  Appendix 19: certificate of attendance for the 
consensus group study (Chapter 5) 
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8.19  Appendix 20: University of Leeds School of Healthcare 
ethics approval letter for the consensus panel study 
(Chapter 5) 
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8.20  Appendix 21: NHS research governance assurance 
letters for the consensus panel study (Chapter 5)  
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Email from Mark Baker, Director of the NICE Centre for Clinical Practice 
confirming governance approval for panel member. 
 
 
Please see below for confirmation from my employer that I am able to participate. 
Mark Baker is Director of the NICE Centre for Clinical Practice 
Best wishes 
 
From: Mark Baker  
Sent: 19 May 2015 17:03 
To:  
Subject: RE: Consensus panel for PhD student 
Yes of course. Sounds really interesting and worthwhile. 
M 
 
Sent from my Windows Phone 
Sent: 19/05/2015 16:34 
To: Mark Baker 
Subject: FW: Consensus panel for PhD student 
Hi Mark, 
I have been asked to take part in a consensus panel for a PhD student at Leeds 
University (please see email below). It’s 12.30-2.30pm on 4/6/15 
Johanna and Paul have approved me to do this, but I’ve just been made aware that 
the Research Governance Policy also requires approval from a SMT-level Director 
Would you be able to approve this please? 
Many thanks 
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8.21  Appendix 22: presentation slides for the consensus 
group discussion meeting. 
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